<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002252.pub2" GROUP_ID="PREG" ID="272900051816053096" MERGED_FROM="" MODIFIED="2014-01-29 14:14:09 +0000" MODIFIED_BY="Leanne Jones" REVIEW_NO="0163" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.4">
<COVER_SHEET MODIFIED="2014-01-29 14:14:09 +0000" MODIFIED_BY="Leanne Jones">
<TITLE>Antihypertensive drug therapy for mild to moderate hypertension during pregnancy</TITLE>
<CONTACT MODIFIED="2014-01-29 14:14:09 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="15818" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Edgardo</FIRST_NAME><LAST_NAME>Abalos</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>edgardoabalos@crep.org.ar</EMAIL_1><EMAIL_2>crep@crep.org.ar</EMAIL_2><URL>www.crep.com.ar</URL><ADDRESS><ORGANISATION>Centro Rosarino de Estudios Perinatales (CREP)</ORGANISATION><ADDRESS_1>Moreno 878, 6th floor</ADDRESS_1><CITY>Rosario</CITY><ZIP>S2000DKR</ZIP><REGION>Santa Fe</REGION><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+54 341 4483887</PHONE_1><PHONE_2>+54 341 4472625</PHONE_2><FAX_1>+54 341 4483887</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-01-29 14:14:09 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="15818" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Edgardo</FIRST_NAME><LAST_NAME>Abalos</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>edgardoabalos@crep.org.ar</EMAIL_1><EMAIL_2>crep@crep.org.ar</EMAIL_2><URL>www.crep.com.ar</URL><ADDRESS><ORGANISATION>Centro Rosarino de Estudios Perinatales (CREP)</ORGANISATION><ADDRESS_1>Moreno 878, 6th floor</ADDRESS_1><CITY>Rosario</CITY><ZIP>S2000DKR</ZIP><REGION>Santa Fe</REGION><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+54 341 4483887</PHONE_1><PHONE_2>+54 341 4472625</PHONE_2><FAX_1>+54 341 4483887</FAX_1></ADDRESS></PERSON><PERSON ID="7397" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lelia</FIRST_NAME><LAST_NAME>Duley</LAST_NAME><POSITION>Director/Professor of Clinical Trials Research</POSITION><EMAIL_1>lelia.duley@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07979744934</MOBILE_PHONE><ADDRESS><DEPARTMENT>Nottingham Clinical Trials Unit</DEPARTMENT><ORGANISATION>Nottingham Health Science Partners</ORGANISATION><ADDRESS_1>C Floor, South Block</ADDRESS_1><ADDRESS_2>Queen's Medical Centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 115 8844919</PHONE_1><FAX_1>44 115 9194430</FAX_1></ADDRESS></PERSON><PERSON ID="16029" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>D Wilhelm</FIRST_NAME><LAST_NAME>Steyn</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>dws@sun.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>Department of Obstetrics &amp; Gynaecology</ADDRESS_1><ADDRESS_2>PO Box 19063</ADDRESS_2><CITY>Tygerberg</CITY><ZIP>7505</ZIP><REGION>Stellenbosch</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 9389377</PHONE_1><PHONE_2>+27 21 9386143</PHONE_2><FAX_1>+27 21 9316595</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-11-29 12:31:21 +0000" MODIFIED_BY="Sonja L  Henderson">
<UP_TO_DATE>
<DATE DAY="30" MONTH="4" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="4" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="4" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2014-01-05 12:06:25 +0000" MODIFIED_BY="Sonja L  Henderson">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-06-19 09:40:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>Three new trials were added for this update: one of beta blockers versus methyldopa; one of calcium channel blockers versus methyldopa; and a three-arm trial of labetalol versus methyldopa versus no treatment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-01-05 12:06:25 +0000" MODIFIED_BY="Denise Atherton">
<DATE DAY="31" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Review authors updated. April 2013: search updated.</P>
<P>Nineteen trials added to excluded studies (not all are new studies as, for some, new information has become available leading them to be reclassified as excluded).</P>
<P>Four figures added: 'Risk of bias' graph, 'Risk of bias' summary, and two funnel plots.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-05-25 23:58:58 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-08-29 10:13:33 +0100" MODIFIED_BY="Denise Atherton">
<DATE DAY="6" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Search updated. Nineteen new reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-17 21:56:42 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-05-25 23:58:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>March 2006: Search updated. Six new trials were added to included studies. Twenty-seven new trials added to excluded studies (not all are new studies as, for some, new information has become available leading them to be reclassified as excluded).</P>
<P>Changes in the outcome tree (calcium channel blockers versus beta blockers are no longer referred to the beta blockers review (Magee 2000) as this comparison is now part of the group 'any antihypertensive versus calcium channel blockers').  Changes in the text to reflect new data.   An entire section describing the general characteristics of the excluded trials has been added in the text.</P>
<P>Acknowledgements to authors for unpublished data.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-01-28 09:51:53 +0000" MODIFIED_BY="Leanne V Jones">
<INTERNAL_SOURCES MODIFIED="2014-01-28 09:51:53 +0000" MODIFIED_BY="Leanne V Jones">
<SOURCE>
<NAME>Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Centro Rosarino de Estudios Perinatales. Rosario</NAME>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-01-28 09:51:53 +0000" MODIFIED_BY="Leanne V Jones">
<NAME>Nottingham Clinical Trials Unit, University of Nottingham</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-01-28 09:51:06 +0000" MODIFIED_BY="Leanne V Jones">
<SOURCE>
<NAME>Human Reproduction Programme. World Health Organization. Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-01-29 14:09:42 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-01-05 11:45:32 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-08 10:57:05 +0100" MODIFIED_BY="[Empty name]">Antihypertensive drug therapy for mild to moderate hypertension during pregnancy</TITLE>
<SUMMARY_BODY MODIFIED="2014-01-05 11:45:32 +0000" MODIFIED_BY="[Empty name]">
<P>There is not enough evidence to show whether antihypertensive drug treatment for mild to moderate hypertension during pregnancy is worthwhile.</P>
<P>During the early weeks of normal pregnancy, blood pressure falls and climbs slowly in later pregnancy to reach pre-pregnancy levels at term. Mild to moderate hypertension (high blood pressure) is common during pregnancy. In some women, it can become more serious, resulting in hospital admission, pre-eclampsia (a complication of pregnancy that includes high blood pressure) and possible premature delivery. Antihypertensive drugs are often used to lower blood pressure in the belief that they will prevent this progression. This review of 49 trials, involving 4723 women, found there was not enough evidence to show the benefit of antihypertensive drugs for mild to moderate hypertension during pregnancy. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-01-05 11:45:20 +0000" MODIFIED_BY="Sonja L  Henderson">
<ABS_BACKGROUND MODIFIED="2014-01-05 11:45:20 +0000" MODIFIED_BY="Heather Maxwell">
<P>Mild to moderate hypertension during pregnancy is common. Antihypertensive drugs are often used in the belief that lowering blood pressure will prevent progression to more severe disease, and thereby improve the outcome.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of antihypertensive drug treatments for women with mild to moderate hypertension during pregnancy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-06-17 11:21:12 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2013) and reference lists of retrieved studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised trials evaluating any antihypertensive drug treatment for mild to moderate hypertension during pregnancy defined, whenever possible, as systolic blood pressure 140 to 169 mmHg and diastolic blood pressure 90 to 109 mmHg. Comparisons were of one or more antihypertensive drug(s) with placebo, with no antihypertensive drug, or with another antihypertensive drug, and where treatment was planned to continue for at least seven days. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-01-05 11:45:20 +0000" MODIFIED_BY="Denise Atherton">
<P>Forty-nine trials (4723 women) were included. Twenty-nine trials compared an antihypertensive drug with placebo/no antihypertensive drug (3350 women). There is a halving in the risk of developing severe hypertension associated with the use of antihypertensive drug(s) (20 trials, 2558 women; risk ratio (RR) 0.49; 95% confidence interval (CI) 0.40 to 0.60; risk difference (RD) -0.10 (-0.13 to -0.07); number needed to treat to harm (NNTH) 10 (8 to 13)) but little evidence of a difference in the risk of pre-eclampsia (23 trials, 2851 women; RR 0.93; 95% CI 0.80 to 1.08). Similarly, there is no clear effect on the risk of the baby dying (27 trials, 3230 women; RR 0.71; 95% CI 0.49 to 1.02), preterm birth (15 trials, 2141 women; RR 0.96; 95% CI 0.85 to 1.10), or small-for-gestational-age babies (20 trials, 2586 women; RR 0.97; 95% CI 0.80 to 1.17). There were no clear differences in any other outcomes.</P>
<P>Twenty-two trials (1723 women) compared one antihypertensive drug with another. Alternative drugs seem better than methyldopa for reducing the risk of severe hypertension (11 trials, 638 women; RR (random-effects) 0.54; 95% CI 0.30 to 0.95; RD -0.11 (-0.20 to -0.02); NNTH 7 (5 to 69)). There is also a reduction in the overall risk of developing proteinuria/pre-eclampsia when beta blockers and calcium channel blockers considered together are compared with methyldopa (11 trials, 997 women; RR 0.73; 95% CI 0.54 to 0.99). However, the effect on both severe hypertension and proteinuria is not seen in the individual drugs. Other outcomes were only reported by a small proportion of studies, and there were no clear differences.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-05-26 02:51:48 +0100" MODIFIED_BY="[Empty name]">
<P>It remains unclear whether antihypertensive drug therapy for mild to moderate hypertension during pregnancy is worthwhile.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-01-07 12:28:51 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-01-05 11:47:25 +0000" MODIFIED_BY="Denise Atherton">
<CONDITION MODIFIED="2014-01-05 11:45:46 +0000" MODIFIED_BY="Denise Atherton">
<P>During the early weeks of normal pregnancy blood pressure falls, climbing slowly in later pregnancy to reach pre-pregnancy levels at term (<LINK REF="REF-Hytten-1980" TYPE="REFERENCE">Hytten 1980</LINK>; <LINK REF="REF-Villar-1989" TYPE="REFERENCE">Villar 1989</LINK>). These changes are related to multiple physiological and environmental factors, and complicate the diagnosis of hypertension during pregnancy. There is no consensus about the definition of hypertensive disorders during pregnancy (<LINK REF="REF-Chappell-1999" TYPE="REFERENCE">Chappell 1999</LINK>), and several classifications have been suggested (<LINK REF="REF-ASSHP-1993" TYPE="REFERENCE">ASSHP 1993</LINK>; <LINK REF="REF-Davey-1988" TYPE="REFERENCE">Davey 1988</LINK>; <LINK REF="REF-Gifford-1990" TYPE="REFERENCE">Gifford 1990</LINK>; <LINK REF="REF-North-1999" TYPE="REFERENCE">North 1999</LINK>; <LINK REF="REF-Roberts-1993" TYPE="REFERENCE">Roberts 1993</LINK>). Nevertheless, there is now general agreement about the broad categories. These are: (a) gestational hypertension or pregnancy-induced hypertension, which is hypertension without proteinuria; (b) pre-eclampsia, which is hypertension with proteinuria; (c) chronic hypertension, or essential hypertension, which is pre-existing hypertension; and (d) chronic hypertension with superimposed pre-eclampsia.</P>
<P>Variations in the systems for classification are largely to do with how high blood pressure is defined. The system suggested by the International Society for the Study of Hypertension in Pregnancy defines hypertension as a diastolic blood pressure of 90 mmHg or above on two consecutive occasions at least four hours apart, or a single diastolic blood pressure of 110 mmHg or more (<LINK REF="REF-Davey-1988" TYPE="REFERENCE">Davey 1988</LINK>). In the past there was disagreement about which auscultatory sound to use for measuring diastolic blood pressure. However, Korotkoff phase V (disappearance of sounds) is now widely recommended as more reliable than phase IV (muffling) (<LINK REF="REF-Brown-2001" TYPE="REFERENCE">Brown 2001</LINK>; <LINK REF="REF-Rubin-1996" TYPE="REFERENCE">Rubin 1996</LINK>).</P>
<P>The suggestion that a change in blood pressure is more important than any absolute level (<LINK REF="REF-Redman-1988" TYPE="REFERENCE">Redman 1988</LINK>) is no longer included in the definition of gestational hypertension due to lack of evidence that it is related to outcome (<LINK REF="REF-Brown-2000" TYPE="REFERENCE">Brown 2000</LINK>; <LINK REF="REF-Brown-2001" TYPE="REFERENCE">Brown 2001</LINK>; <LINK REF="REF-NHBPEP-2000" TYPE="REFERENCE">NHBPEP 2000</LINK>). Pre-eclampsia is defined as high blood pressure (using the criteria above) plus significant proteinuria, usually taken as at least 300 mg/24 hour or 1+ on dipsticks (<LINK REF="REF-Davey-1988" TYPE="REFERENCE">Davey 1988</LINK>).</P>
<P>For this review we have accepted broad and pragmatic criteria for identifying women with mild to moderate hypertension during pregnancy. This reflects clinical practice, and is justifiable in the context of randomised trials as within each study the same criteria will have been used for women in both groups.</P>
<P>Hypertension during pregnancy is common. One in 10 women will have high blood pressure at some time before delivery, and pre-eclampsia complicates between 2% to 8% of pregnancies (<LINK REF="REF-WHO-1988" TYPE="REFERENCE">WHO 1988</LINK>). Pre-eclampsia is discussed in more detail in the generic protocol of interventions for prevention of pre-eclampsia (<LINK REF="REF-Meher-2005" TYPE="REFERENCE">Meher 2005</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-01-05 11:46:25 +0000" MODIFIED_BY="Denise Atherton">
<P>A wide variety of drugs have been advocated for lowering blood pressure in hypertensive pregnant women, and each group has different potential side-effects and adverse events. In this review we evaluate individual agents within the class or family to which they belong, as each class has a similar mechanism of action. Alpha agonists inhibit vasoconstriction via a centrally mediated effect (<LINK REF="REF-Ingenito-1970" TYPE="REFERENCE">Ingenito 1970</LINK>). Methyldopa is the most widely used alpha agonist, and became available in 1963. Clonidine is also an alpha agonist, although it has the disadvantage that sudden withdrawal may cause a hypertensive crisis (<LINK REF="REF-Isaac-1980" TYPE="REFERENCE">Isaac 1980</LINK>). Beta-adrenoceptor blocking drugs block adrenoceptors in the heart, peripheral blood vessels, airways, pancreas and liver (<LINK REF="REF-Frishman-1979" TYPE="REFERENCE">Frishman 1979</LINK>). Labetalol has an additional arteriolar vasodilating action that lowers peripheral resistance, but is usually classified with the beta blockers. Calcium channel blockers include isradipine, nifedipine, nicardipine, nimodipine and verapamil. These drugs inhibit influx of calcium ions to vascular smooth muscle resulting in arterial vasodilatation (<LINK REF="REF-Robinson-1980" TYPE="REFERENCE">Robinson 1980</LINK>). Hydralazine is a vasodilator with a direct relaxing effect on smooth muscle in the blood vessels, predominantly in the arterioles (<LINK REF="REF-Stunkard-1954" TYPE="REFERENCE">Stunkard 1954</LINK>). Ketanserin, is a selective serotonin receptor antagonist with weak adrenergic receptor blocking properties (<LINK REF="REF-Frishman-1995" TYPE="REFERENCE">Frishman 1995</LINK>). The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. Glyceryl trinitrate is a nitric oxide donor with vasodilator effect in perivascular smooth-muscle cells (<LINK REF="REF-Seligman-1994" TYPE="REFERENCE">Seligman 1994</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-05-25 23:32:36 +0100" MODIFIED_BY="Denise Atherton">
<P>The role of antihypertensive therapy for pregnant women with mild to moderate hypertension is unclear. As there is no immediate need to lower blood pressure, the rationale for treatment is that it will prevent or delay progression to more severe disease, thereby benefiting the woman or her baby, or both, and reducing consumption of health service resources. As well as reducing blood pressure, the belief has been that these drugs reduce the risk of preterm delivery and placental abruption and improve fetal growth.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-01-05 11:47:25 +0000" MODIFIED_BY="Denise Atherton">
<P>The aim of this review is to assess the potential benefits and hazards, to the woman and baby, of antihypertensive drugs for the treatment of mild to moderate hypertension during pregnancy. If antihypertensive agents are overall beneficial, a secondary aim will be to assess the comparative effects of alternative agents.</P>
<P>There are other types of interventions for women with mild to moderate hypertension during pregnancy that are not considered in this review. Interventions covered by other reviews include salt restriction (<LINK REF="REF-Duley-1999" TYPE="REFERENCE">Duley 1999</LINK>), antiplatelet agents (<LINK REF="REF-Duley-2007" TYPE="REFERENCE">Duley 2007</LINK>), abdominal decompression (<LINK REF="REF-Hofmeyr-2012" TYPE="REFERENCE">Hofmeyr 2012</LINK>) and bed rest, with or without hospitalisation (<LINK REF="REF-Meher-2005a" TYPE="REFERENCE">Meher 2005a</LINK>). Diuretics are no longer widely used in pregnancy, and are usually reserved for women with renal or cardiac problems (<LINK REF="REF-ASSHP-1993" TYPE="REFERENCE">ASSHP 1993</LINK>; <LINK REF="REF-CHSCC-1997" TYPE="REFERENCE">CHSCC 1997</LINK>). The role of diuretics for women with hypertension during pregnancy is covered by a separate Cochrane review (<LINK REF="REF-Churchill-2007" TYPE="REFERENCE">Churchill 2007</LINK>), as is prevention and treatment of postpartum hypertension (<LINK REF="REF-Magee-2013" TYPE="REFERENCE">Magee 2013</LINK>).</P>
<P>For women with severe hypertension, usually defined as 160 to 170 mmHg or more systolic blood pressure or 110 mmHg or more diastolic blood pressure, there is a risk of direct arterial damage and so antihypertensive drugs are used to lower blood pressure (<LINK REF="REF-Gifford-1990" TYPE="REFERENCE">Gifford 1990</LINK>; <LINK REF="REF-Redman-1993" TYPE="REFERENCE">Redman 1993</LINK>). The question of which drug is best in this situation is considered in another Cochrane review and not discussed further here (<LINK REF="REF-Duley-2013" TYPE="REFERENCE">Duley 2013</LINK>).</P>
<P>A separate review assessing the effect of oral beta blockers in mild to moderate hypertension during pregnancy is available (<LINK REF="REF-Magee-2003" TYPE="REFERENCE">Magee 2003</LINK>). However, beta blockers are included in this review as part of all the spectrum of antihypertensive drugs.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-05-08 10:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the possible benefits, risks and side-effects of antihypertensive drug treatments for women with mild to moderate hypertension during pregnancy (defined whenever possible as a systolic blood pressure of 140 to 169 mmHg or diastolic blood pressure of 90 to 109 mmHg, or both). Also, to compare the differential effects of alternative drug regimens.</P>
<P>The comparisons are of:</P>
<OL>
<LI>any antihypertensive drug with either no drug or placebo;</LI>
<LI>one antihypertensive drug compared with another. For this review, the commonly used drugs are regarded as control and compared with all other agents (for example, any antihypertensive versus methyldopa, any antihypertensive versus calcium channel blockers).</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2014-01-07 12:28:51 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-01-05 11:49:33 +0000" MODIFIED_BY="Denise Atherton">
<CRIT_STUDIES>
<P>All randomised trials evaluating any antihypertensive drug treatment for mild to moderate hypertension during pregnancy. Quasi-randomised designs were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-01-05 11:47:45 +0000" MODIFIED_BY="Heather Maxwell">
<P>The review includes women with mild to moderate hypertension during pregnancy, defined whenever possible as those with systolic blood pressure 140 to 169 mmHg and diastolic blood pressure 90 to 109 mmHg. Studies in which participants were described as having 'mild to moderate' hypertension but the range of blood pressures was not clearly specified were also included. Women were included regardless of whether they had proteinuria or not, and irrespective of previous antihypertensive treatment or whether the pregnancy was singleton or multiple.</P>
<P>Women who had given birth before trial entry were excluded, as were women with severe hypertension (defined whenever possible as either systolic blood pressure of 170 mmHg or more, or diastolic blood pressure 110 mmHg or more). Studies that included a substantial proportion of women who did not have mild to moderate hypertension were excluded, unless data were available on outcomes for those with mild to moderate hypertension only.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-01-05 11:47:56 +0000" MODIFIED_BY="Heather Maxwell">
<P>Any comparison of one or more antihypertensive drug with either placebo or no antihypertensive drug was included, as were comparisons of one antihypertensive drug with another. Studies were excluded if the intention was to treat for less than seven days, as a longer period of treatment would be necessary for any substantive clinical effect. Comparisons of two drugs of the same class were also excluded, although these may be included in future updates if clinically relevant.<BR/>
<BR/>Drugs that aimed to reduce the risk of pregnancy-induced hypertension progressing to pre-eclampsia but are not antihypertensive agents were also excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-01-05 11:49:33 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-06-19 09:48:09 +0100" MODIFIED_BY="Denise Atherton">
<P>Main outcomes were prespecified as follows.</P>
<UL>
<LI>Severe hypertension: defined whenever possible as either systolic blood pressure 170 mmHg or more, or diastolic blood pressure 110 mmHg or more. Trials where the definition of severe hypertension was not clear, or where the cut-off was up to 10 mmHg lower were also included and were clearly documented.</LI>
<LI>Proteinuria: defined whenever possible as new proteinuria (1+ or more or 300 mg/24 hour).</LI>
<LI>Any reported baby death: fetal deaths included miscarriage (fetal losses before viability, usually taken as 20 or 24 weeks) and stillbirths (after 24 weeks, or however defined). Perinatal deaths are stillbirths plus deaths in the first week of life. Neonatal deaths are deaths in the first 28 days.</LI>
<LI>Small-for-gestational age: low birthweight for gestational age, below the third, fifth or 10th percentile, using the most severe reported.</LI>
<LI>Preterm birth: all births before 37 completed weeks.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-01-05 11:49:33 +0000" MODIFIED_BY="Denise Atherton">
<SUBSECTION>
<HEADING LEVEL="5">(i) For the woman</HEADING>
<UL>
<LI>Severe pre-eclampsia: defined whenever possible as severe hypertension with proteinuria 2+ or more, or 2 g or more/24 hours, with or without other signs of symptoms, or as moderate hypertension with proteinuria 3+ or more. Haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome is a form of severe pre-eclampsia and was therefore included here as well as a separate measure. Trials reporting imminent eclampsia, or where the definition of severe pre-eclampsia was not clear were also included.</LI>
<LI>Eclampsia.</LI>
<LI>HELLP syndrome.</LI>
<LI>Severe maternal morbidity: such as liver or renal failure, disseminated intravascular coagulation and cerebrovascular accident (stroke).</LI>
<LI>Need for another drug to control blood pressure.</LI>
<LI>Miscarriage (fetal losses before viability, usually taken as before 20 or 24 weeks).</LI>
<LI>Elective delivery: combines elective caesarean sections and elective induction of labour at term or before term.</LI>
<LI>Caesarean section.</LI>
<LI>Antenatal hospital admission and length of stay more than seven days: hospital and day care unit were to be reported separately.</LI>
<LI>Placental abruption.</LI>
<LI>Side-effects: any reported side-effects or severe adverse events.</LI>
<LI>Drug stopped because of side-effects.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(ii) For the baby</HEADING>
<UL>
<LI>Very low, less than four, five-minute Apgar score.</LI>
<LI>Severe prematurity, all births less than 32 or less than 34 weeks' gestation.</LI>
<LI>Admission to neonatal or intensive care nursery.</LI>
<LI>Respiratory distress syndrome.</LI>
<LI>Other morbidity possibly related to maternal drug therapy, such as hypo or hypertension, hypoglycaemia and bradycardia (with beta blockers).</LI>
<LI>Impaired long-term growth and development in infancy and childhood.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-01-05 11:49:40 +0000" MODIFIED_BY="Sonja L  Henderson">
<ELECTRONIC_SEARCHES MODIFIED="2014-01-05 11:49:40 +0000" MODIFIED_BY="Sonja L  Henderson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (30 April 2013). </P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of Embase;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.</P>
<P>For detail of additional searching carried out for the previous version (<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>), see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-06-17 11:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>We searched reference lists of retrieved studies.</P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-01-07 12:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>For the methods used when assessing the trials identified in the previous version of this review, <I>see </I>
<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>.</P>
<P>For this update we used the following methods when assessing the reports identified by the updated search.</P>
<STUDY_SELECTION MODIFIED="2014-01-05 11:49:50 +0000" MODIFIED_BY="Denise Atherton">
<P>Two authors (E Abalos (EA), L Duley (LD)) assessed for inclusion all potential studies identified as a result of the search strategy. Disagreements were resolved through discussion. If agreement could not be reached, a third review author (DW Steyn (DWS)) was consulted.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-01-07 12:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>Data were extracted in an <I>ad-hoc </I>form and entered into Review Manager (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) by EA, and checked by LD. Review authors were not blinded to the authors, sources of the articles, or results. Discrepancies were resolved by discussion between the two review authors and, when necessary, the third review author (DWS) was consulted. When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-01-05 11:52:03 +0000" MODIFIED_BY="[Empty name]">
<P>One review author (EA) assessed the risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions (</I>
<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Results were checked and agreed by a second review author (LD). Disagreements were resolved by discussion or by involving the third review author.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>The method used to generate the allocation sequence was described for each included study in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>The method used to conceal allocation to interventions prior to assignment was described (when information was available) for each included study and whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment was assessed.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We evaluated for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we re-included missing data in the analyses.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data less tan 10% of randomised women);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomisation, missing outcome data more than 10% of randomised patients);</LI>
<LI>unclear risk of bias.</LI>
</UL>
<P>Trials were excluded if it was not possible to enter data on an intention-to-treat basis or if 20% or more participants were excluded, or both.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias</HEADING>
<P>For each included study the possibility of selective outcome reporting bias was sought.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported either in the paper or through personal communication);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>low risk of other bias;</LI>
<LI>high risk of other bias;</LI>
<LI>unclear whether there is risk of other bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-05-24 16:56:44 +0100" MODIFIED_BY="Denise Atherton">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>We only collected dichotomous data, presenting the results as summary risk ratio with 95% confidence intervals. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>Continuous data were not collected.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-06-19 10:38:11 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was individual randomised women.</P>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>No cluster-randomised trials were found for this review. If we had identified cluster-randomised trials, they would have been eligible for inclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>Given the objectives of this review, cross-over trials were not included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other unit of analysis issues</HEADING>
<P>No other units of analyses were used in this review.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-01-05 11:52:17 +0000" MODIFIED_BY="Denise Atherton">
<P>For all outcomes, we conducted the analyses on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. Trials were excluded if it was not possible to enter data on an intention-to-treat basis, or if 20% or more participants were excluded, or both.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-01-05 11:52:42 +0000" MODIFIED_BY="Denise Atherton">
<P>Statistical heterogeneity in each meta-analysis was assessed using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if the I² was greater than 30% and either the Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.<B> </B>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-01-05 11:52:58 +0000" MODIFIED_BY="Denise Atherton">
<P>We investigated reporting biases (such as publication bias) using funnel plots. We assessed funnel plot asymmetry visually, and used formal tests for funnel plot asymmetry. As all outcomes were dichotomous, we used the test proposed by <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-01-05 11:53:15 +0000" MODIFIED_BY="Denise Atherton">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average of the range of possible treatment effects as an input to discuss the clinical implications of treatment effects differing between trials. Trials were not combined if the average treatment effect was not clinically meaningful.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-11-25 12:00:36 +0000" MODIFIED_BY="Denise Atherton">
<P>For the comparison of antihypertensive drug/s with placebo or no treatment the following subgroup analyses were prespecified:</P>
<OL>
<LI>by class of drug (such as alpha agonists, beta blockers and calcium channel blockers);</LI>
<LI>by type of hypertensive disorder at trial entry: mild to moderate hypertension alone; mild to moderate hypertension with proteinuria; chronic hypertension; unspecified;</LI>
<LI>by gestational age at trial entry: less than about 32 weeks' gestation; about 32 weeks or more gestation; or unclassified/mixed;</LI>
<LI>by whether a placebo was used: placebo, no placebo.</LI>
</OL>
<P>The subgroup analysis by type of drug is presented for all outcomes. The remaining subgroups are presented for the prespecified primary outcomes only.</P>
<P>We assessed subgroup differences by interaction tests available within RevMan (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We reported the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value.<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-05-24 17:17:32 +0100" MODIFIED_BY="Denise Atherton">
<P>Sensitivity analyses were not conducted.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-01-05 12:03:52 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-01-05 11:56:40 +0000" MODIFIED_BY="Sonja L  Henderson">
<P>Details for each trial can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-01-05 11:55:49 +0000" MODIFIED_BY="Denise Atherton">
<P>Forty-nine trials (4723 women) were included in this review. Of these, 34 (3480 women) were conducted in industrialised countries (Australia, France, Hong Kong, Ireland, Israel, Italy, Sweden, UK and USA), and 15 (1243 women) were performed in middle- or low-income countries (Argentina, Brazil, Caribbean Islands, India, South Africa, Sudan and Venezuela). Three trials were published in the 1960s and 1970s, 22 in the 1980s, 17 in the 1990s, and seven after the year 2000. All included trials are small. The largest study recruited 300 women. Two three-arm trials of methyldopa versus labetalol versus no treatment (<LINK REF="STD-India-2012" TYPE="STUDY">India 2012</LINK>; <LINK REF="STD-USA-1990" TYPE="STUDY">USA 1990</LINK>) were included in the comparison of any antihypertensive with placebo/no antihypertensive, and in the comparison of one drug with another. Only five studies had comparison arms containing more than 100 women.</P>
<P>(One report from an updated search in April 2013 has been added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.)</P>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The antihypertensive drugs used in these trials include: alpha agonists (methyldopa), beta blockers (acebutolol, atenolol, labetalol, mepindolol, metoprolol, pindolol, oxprenolol and propranolol), calcium channel blockers (isradipine, nicardipine, nifedipine, nimodipine and verapamil), vasodilators (hydralazine and prazozin), ketanserin and glyceryl trinitrate (GTN). All drugs were given orally, except glyceryl trinitrate, which was given transdermally. The dose for several agents varied considerably between studies, in both amount and duration of therapy.</P>
<P>The antihypertensive drug was compared with placebo, or no antihypertensive drug, in 29 trials (3350 women). Of these trials, 16 evaluated beta blockers (1602 women), seven using a placebo for the control group and nine comparing with no treatment. Methyldopa was evaluated in eight trials (986 women), one comparison with placebo, and seven with no antihypertensive treatment. One trial (118 women) compared isradipine with placebo, another trial (199 women) compared verapamil with placebo, and three studies (583 women) compared nifedipine with no drug treatment. Prazozin was compared with placebo in one trial (32 women), and GTN was compared with placebo patches in another (16 women).</P>
<P>Alternative drug regimens were compared in 22 trials (1723 women). Twenty of these studies compared methyldopa with another agents. In 16 trials (1507 women) the comparison was with beta blockers, in two it was nifedipine (49 women), in one (111 women) it was nimodipine and in another ketanserin (20 women). One small trial (36 women) compared nifedipine with glyceryl trinitrate. In one study (100 women), metoprolol was compared with nicardipine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Gestation at trial entry</HEADING>
<P>Twenty of the 49 included studies recruited women during the second and third trimester of pregnancy, and 19 recruited only during the third trimester. Two studies recruited women during the first trimester (<LINK REF="STD-Argentina-1988" TYPE="STUDY">Argentina 1988</LINK>; <LINK REF="STD-USA-1990" TYPE="STUDY">USA 1990</LINK>). Gestational age at trial entry was not reported in eight studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severity and type of hypertension disease at trial entry</HEADING>
<P>Mild to moderate hypertension was defined as a diastolic blood pressure of 90 mmHg or more in 35 studies. In seven trials, the definition was 95 mmHg or more. In two trials, the cut-off was 85 mmHg, In five studies, authors merely stated 'mild to moderate hypertension', or 'pregnancy-induced hypertension', or 'diagnosed hypertension'. Women with proteinuria were excluded from trial entry in 17 studies whilst in six trials all women had proteinuria at recruitment. Twelve trials included women regardless of whether or not they had proteinuria, and the proportion of women with proteinuria ranged from 4% to 47%. In the remaining 14 trials the presence of proteinuria at trial entry was not reported.</P>
<P>Eight studies only recruited women with chronic hypertension. Women with chronic hypertension were excluded from 16 trials (16/49). Nine trials included women regardless of whether or not they had chronic hypertension, although outcomes were often not reported separately. In the remaining 16 trials, chronic hypertension at trial entry was not mentioned.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Methods for measuring blood pressure</HEADING>
<P>Only four trials masked the assessment of blood pressure by using a random zero sphygmomanometer (<LINK REF="STD-Australia-1983" TYPE="STUDY">Australia 1983</LINK>; <LINK REF="STD-UK-1976" TYPE="STUDY">UK 1976</LINK>; <LINK REF="STD-UK-1983" TYPE="STUDY">UK 1983</LINK>; <LINK REF="STD-UK-1983a" TYPE="STUDY">UK 1983a</LINK>). For assessment of diastolic blood pressure, Korotkoff phase IV sound was used in 14 trials and Korotkoff phase V was used for eight studies. Criteria for blood pressure measurement were not mentioned in 27 trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Definition of small-for-gestational age</HEADING>
<P>Small-for-gestational age was defined in a variety of ways in the 29 trials reporting this outcome. Four studies used birthweight below the fifth centile and 11 below the 10th centile. Five trials used other definitions, and in the remaining nine trials, small-for-gestational age was not defined.</P>
<P>One outcome specified in our protocol, very low (less than four) five-minute Apgar score, is not included in this review as it was not reported by any trial.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-01-05 11:56:40 +0000" MODIFIED_BY="Denise Atherton">
<P>Eighty studies were excluded from the review. Of these, 36 were conducted in high-income countries (Australia, Belgium, Denmark, Finland, France, Germany, Hong Kong, Israel, Italy, Japan, Spain, Sweden, UK and USA), and 44 in low- and middle-income countries (Argentina, Brazil, China, Cuba, Czech Republic, Dominican Republic, Egypt, Hungary, India, Iran, Kuwait, Mexico, Pakistan, Panama, Philippines, Russia, Singapore, Slovakia, South Africa, Sri Lanka, Uganda and Venezuela). The oldest excluded study was published 1957, one was published in 1978, 54 were published in the 1980s and 1990s, and 24 have been published since the millennium.</P>
<P>The language of publication was English (for 63 papers), Chinese (five), Spanish (five), Portuguese (three), Czech (two), French (one), and Russian (one). Language was not a reason for exclusion. Twenty-two papers (22/80) were published only as congress abstracts. Authors of 11 papers provided additional information about methods and/or clinical outcomes.<BR/>
<BR/>The reasons for exclusions were as follows.<BR/>
</P>
<UL>
<LI>Methodological problems (22 studies): either they were not randomised trials (11 studies) or they used quasi-random methods for treatment allocation (seven), or more than 20% of women were excluded after randomisation (four).</LI>
<LI>Participants were not eligible for the review (nine studies): either some or all of the women had severe hypertension (six), or some women had normal blood pressure (three), and data were not presented separately for the women with mild to moderate hypertension.</LI>
<LI>Intervention was not eligible for the review (38 studies): either the comparison was of drugs within the same class (eight), or the allocated intervention was for less than seven days (13), or it was not an antihypertensive drug (16) or mixed control group (1).</LI>
<LI>No clinical outcomes reported (11 studies): there are no data on relevant clinical outcomes (eight congress abstracts, of which four authors were contacted but with no responses to date). Two reports were personal communications of planned randomised controlled trials, but no information could be found about their completion.</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-01-05 12:03:52 +0000" MODIFIED_BY="[Empty name]">
<P>Overall, the quality of the studies included in this review is moderate to poor (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2014-01-05 11:57:31 +0000" MODIFIED_BY="Denise Atherton">
<P>Methods for generating the random sequence were described in 14 trials (29%). These included: computer generation (<LINK REF="STD-France-1994" TYPE="STUDY">France 1994</LINK>; <LINK REF="STD-Italy-1998" TYPE="STUDY">Italy 1998</LINK>; <LINK REF="STD-USA-1987" TYPE="STUDY">USA 1987</LINK>; <LINK REF="STD-USA-1990" TYPE="STUDY">USA 1990</LINK>; <LINK REF="STD-USA-1992" TYPE="STUDY">USA 1992</LINK>), random-number tables (<LINK REF="STD-UK-1980" TYPE="STUDY">UK 1980</LINK>; <LINK REF="STD-UK-1989" TYPE="STUDY">UK 1989</LINK>; <LINK REF="STD-Venezuela-1988" TYPE="STUDY">Venezuela 1988</LINK>), series of random numbers (<LINK REF="STD-Israel-1992" TYPE="STUDY">Israel 1992</LINK>). Although three studies did not describe the method used for allocation, the authors mentioned that it was in blocks of six (<LINK REF="STD-Sweden-1995" TYPE="STUDY">Sweden 1995</LINK>),10 (<LINK REF="STD-Caribbean-Is.1990" TYPE="STUDY">Caribbean Is.1990</LINK>), or nine at each centre (<LINK REF="STD-France-1987" TYPE="STUDY">France 1987</LINK>). Inadequate methods were used in two trials, namely "mixed-up opaque envelopes" (<LINK REF="STD-India-2012" TYPE="STUDY">India 2012</LINK>) and "cards shuffled into a random order and numbered in sequence" (<LINK REF="STD-Ireland-1991" TYPE="STUDY">Ireland 1991</LINK>).</P>
<P>Concealment of allocation was adequate for only 17 of the 49 trials (35%), being unclear whether concealment was adequate in the remaining 32 trials. Methods for concealing the allocation included telephone randomisation (<LINK REF="STD-Italy-1998" TYPE="STUDY">Italy 1998</LINK>; <LINK REF="STD-Sweden-1984" TYPE="STUDY">Sweden 1984</LINK>), blinded treatment packs (<LINK REF="STD-Brazil-1988" TYPE="STUDY">Brazil 1988</LINK>; <LINK REF="STD-Brazil-2000a" TYPE="STUDY">Brazil 2000a</LINK>; <LINK REF="STD-Caribbean-Is.1990" TYPE="STUDY">Caribbean Is.1990</LINK>; <LINK REF="STD-Israel-1992" TYPE="STUDY">Israel 1992</LINK>; <LINK REF="STD-Italy-1999" TYPE="STUDY">Italy 1999</LINK>; <LINK REF="STD-Italy-2000" TYPE="STUDY">Italy 2000</LINK>; <LINK REF="STD-UK-1989" TYPE="STUDY">UK 1989</LINK>), consecutive, sealed identical envelopes (<LINK REF="STD-UK-1992" TYPE="STUDY">UK 1992</LINK>) or blinded or sealed envelopes (<LINK REF="STD-France-1987" TYPE="STUDY">France 1987</LINK>; <LINK REF="STD-France-1994" TYPE="STUDY">France 1994</LINK>; <LINK REF="STD-India-2012" TYPE="STUDY">India 2012</LINK>; <LINK REF="STD-Ireland-1991" TYPE="STUDY">Ireland 1991</LINK>; <LINK REF="STD-USA-1987" TYPE="STUDY">USA 1987</LINK>; <LINK REF="STD-USA-1990" TYPE="STUDY">USA 1990</LINK>; <LINK REF="STD-USA-1992" TYPE="STUDY">USA 1992</LINK>). Most trials with unclear concealment of allocation were described as 'randomised' with no details on how this was achieved. Some of these studies were stated to be double blind, but with no information about how this was achieved. Three trials with unclear concealment used random-number tables without mentioning any attempt to conceal the allocation (<LINK REF="STD-Sweden-1995" TYPE="STUDY">Sweden 1995</LINK>; <LINK REF="STD-UK-1980" TYPE="STUDY">UK 1980</LINK>; <LINK REF="STD-Venezuela-1988" TYPE="STUDY">Venezuela 1988</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-01-05 11:57:52 +0000" MODIFIED_BY="Denise Atherton">
<P>All trials evaluating alternative treatments for mild/moderate hypertension during pregnancy were open label trials, and no attempts were made to blind outcome assessment in order to prevent performance or detection bias. From 29 trials evaluating whether or not hypertension should be treated with antihypertensives, only 12 (41%) compared the active drug with placebo, 10 of them were described by authors as double blind (<LINK REF="STD-Brazil-2000a" TYPE="STUDY">Brazil 2000a</LINK>; <LINK REF="STD-Caribbean-Is.1990" TYPE="STUDY">Caribbean Is.1990</LINK>; <LINK REF="STD-Hong-Kong-1990" TYPE="STUDY">Hong Kong 1990</LINK>; <LINK REF="STD-Israel-1992" TYPE="STUDY">Israel 1992</LINK>; <LINK REF="STD-Sweden-1984" TYPE="STUDY">Sweden 1984</LINK>; <LINK REF="STD-Sweden-1995" TYPE="STUDY">Sweden 1995</LINK>; <LINK REF="STD-UK-1983" TYPE="STUDY">UK 1983</LINK>; <LINK REF="STD-UK-1989" TYPE="STUDY">UK 1989</LINK>; <LINK REF="STD-UK-1990" TYPE="STUDY">UK 1990</LINK>; <LINK REF="STD-USA-1987a" TYPE="STUDY">USA 1987a</LINK>). One placebo-controlled trial was reported as single blind (<LINK REF="STD-Australia-2001" TYPE="STUDY">Australia 2001</LINK>), and another, even though placebo controlled, did not mention whether it was single or double blinded (<LINK REF="STD-South-Africa-1991" TYPE="STUDY">South Africa 1991</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-01-05 11:58:34 +0000" MODIFIED_BY="Denise Atherton">
<P>As per protocol, trials were excluded from the review (or a particular outcome was excluded from the analysis) if it was not possible to enter data on an intention-to-treat basis, or lf 20% or more participants were excluded or withdrawn. We also downgraded the score of a trial to a high risk of bias status if more than 10% of randomised women were withdrawn from the analysis. Most trials reported the outcomes for all (or nearly all) women randomised, although only four trials described the women who met the study eligibility criteria, but were not randomised (<LINK REF="STD-Sweden-1984" TYPE="STUDY">Sweden 1984</LINK>; <LINK REF="STD-Sweden-1985" TYPE="STUDY">Sweden 1985</LINK>; <LINK REF="STD-UK-1976" TYPE="STUDY">UK 1976</LINK>; <LINK REF="STD-UK-1983" TYPE="STUDY">UK 1983</LINK>). Four trials reported losses greater than 10%: <LINK REF="STD-Italy-1999" TYPE="STUDY">Italy 1999</LINK> (17%), <LINK REF="STD-South-Africa-1993" TYPE="STUDY">South Africa 1993</LINK> (10%), <LINK REF="STD-UK-1990" TYPE="STUDY">UK 1990</LINK> (12%) and <LINK REF="STD-USA-1990" TYPE="STUDY">USA 1990</LINK> (12%).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-01-05 11:58:49 +0000" MODIFIED_BY="Denise Atherton">
<P>Thirty-three trials (67%) reported on the risk of a woman for developing severe hypertension (one of the primary outcomes of this review). However, all trials evaluated the effect that the antihypertensive under scrutiny may have on blood pressure (mean blood pressure after treatment, % fall in blood pressure, etc.). Proteinuria (either new proteinuria or the aggravation of previously existing) was reported in 46 (46/49) trials. Fetal or neonatal deaths were evaluated in 48 trials, preterm birth in 25 and small-for-gestational-age babies in 28. Most analyses were carried out using data from published reports. Authors were contacted for unpublished information related to the main outcomes; we obtained data from <LINK REF="STD-Brazil-1988" TYPE="STUDY">Brazil 1988</LINK>; <LINK REF="STD-Caribbean-Is.1990" TYPE="STUDY">Caribbean Is.1990</LINK>; <LINK REF="STD-Italy-1999" TYPE="STUDY">Italy 1999</LINK>; <LINK REF="STD-Italy-2000" TYPE="STUDY">Italy 2000</LINK>; <LINK REF="STD-Sweden-1984" TYPE="STUDY">Sweden 1984</LINK>; <LINK REF="STD-UK-1982" TYPE="STUDY">UK 1982</LINK>; <LINK REF="STD-UK-1990" TYPE="STUDY">UK 1990</LINK>; <LINK REF="STD-USA-1990" TYPE="STUDY">USA 1990</LINK>.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-01-05 12:03:52 +0000" MODIFIED_BY="Denise Atherton">
<P>Baseline characteristics were similar between groups in 23 trials, thus in the absence of other potential sources of bias they were scored as at low risk. In one trial (<LINK REF="STD-Australia-1985" TYPE="STUDY">Australia 1985</LINK>) co-interventions were unevenly distributed: 48% of oxprenolol group and 35% of methyldopa group received a second or third antihypertensive. In another study (<LINK REF="STD-Caribbean-Is.1990" TYPE="STUDY">Caribbean Is.1990</LINK>), treatment was unblinded in 23 women (15%) and other treatment started, 16 for uncontrolled BP (five experimental, 11 control) and seven for poor compliance/side-effects (four experimental, three control).</P>
<P>Informed consent was mentioned in the majority of trials. In one study, informed consent was obtained only from women allocated to the treatment arm (<LINK REF="STD-Ireland-1991" TYPE="STUDY">Ireland 1991</LINK>).</P>
<P>Sample size and power calculations were reported for five trials (<LINK REF="STD-Caribbean-Is.1990" TYPE="STUDY">Caribbean Is.1990</LINK>; <LINK REF="STD-France-1987" TYPE="STUDY">France 1987</LINK>; <LINK REF="STD-Ireland-1991" TYPE="STUDY">Ireland 1991</LINK>; <LINK REF="STD-Italy-1998" TYPE="STUDY">Italy 1998</LINK>; <LINK REF="STD-UK-1989" TYPE="STUDY">UK 1989</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-01-05 12:01:09 +0000" MODIFIED_BY="[Empty name]">
<P>This review includes 49 trials, involving 4723 women.</P>
<SUBSECTION>
<HEADING LEVEL="3">(1) Any antihypertensive drug versus none</HEADING>
<P>Overall, 29 trials with a total of 3350 women compared an antihypertensive drug with placebo or no antihypertensive drug.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severe hypertension</HEADING>
<P>There is a halving in the risk of developing severe hypertension associated with the use of antihypertensive drug/s (20 trials, 2558 women; risk ratio (RR) 0.49; (95% confidence interval (CI) 0.40 to 0.60); risk difference (RD) -0.10 (-0.13 to -0.07); number needed to treat to harm (NNTH) 10 (8 to 13)), <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>. This effect is strikingly consistent regardless of the gestation at trial entry, or whether a placebo was used for the control group. Although the magnitude of this reduction varies when the class of drug (Test for subgroup differences: Chi² = 17.03, df = 6 (P = 0.009), I² = 64.8%, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and hypertensive disorder at trial entry (Test for subgroup differences: Chi² = 10.20, df = 3 (P = 0.02), I² = 70.6%, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) are considered, a beneficial trend is still observed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pre-eclampsia</HEADING>
<P>There is no clear evidence of an overall difference in the risk of pre-eclampsia/proteinuria in the 23 trials (2851 women) reporting this outcome (RR 0.93; 95% CI 0.80 to 1.08), <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>. These results are consistent regardless of the use of placebo. However, when other subgroups are considered, there is evidence of a difference between subgroups: class of drug (Test for subgroup differences: Chi² = 18.28, df = 8 (P = 0.02), I² = 56.2%), <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; type of hypertensive disorder (Test for subgroup differences: Chi² = 8.27, df = 3 (P = 0.04), I² = 63.7%), <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.</P>
<P>There is a reduction in the risk of developing proteinuria in women treated with beta blockers versus none (eight trials, 883 women; RR 0.73; 95% CI 0.57 to 0.94) <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.1, in those with hypertension alone at trial entry (eight trials, 684 women; RR 0.72; 95% CI 0.57 to 0.92), <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.1, and in two trials of 120 women recruited after 32 weeks' gestation (RR 0.34; 95% CI 0.12 to 0.96), <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.2. However, in trials evaluating calcium channel blockers versus none (four trials, 725 women), the risk of pre-eclampsia appears to increase (RR 1.40; 95% CI 1.06 to 1.86), <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.6.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fetal or neonatal deaths</HEADING>
<P>Although there is no statistically significant difference in the overall risk of the baby dying, the point estimate is for a 29% reduction associated with the use of antihypertensive drugs (27 trials, 3230 women; RR 0.71; 95% CI 0.49 to 1.02), <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>. The only subgroup in which this reduction reaches statistical significance is for methyldopa versus none (three trials, 337 women; RR 0.35; 95% CI 0.13 to 0.94). Assessing by time of death of the baby, the only statistically significant difference was for miscarriage (seven trials, 1058 women; RR 0.39; 95% CI 0.17 to 0.93). This was also seen in 12 trials (1422 babies) with unclassified/mixed hypertensive disorders at trial entry (RR 0.55; 95% CI 0.31 to 0.96). However, no differences were observed between any of the subgroups as indicated by subgroup interaction tests.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Preterm birth (less than 37 weeks)</HEADING>
<P>There is no overall difference in the 15 trials (2141 women) reporting this outcome (RR 0.96; 95% CI 0.85 to 1.10), <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>. No differences were found between any of the subgroups considered.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Small-for-gestational age</HEADING>
<P>There is no overall difference in the 20 trials (2586 women) reporting small-for-gestational-age babies (RR 0.97; 95% CI 0.80 to 1.17), <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>. This result remains consistent across all the subgroups. However, for the comparison of beta blockers versus none, there is a strong trend towards an increase (nine trials, 904 women; RR 1.38; 95% CI 0.99 to 1.92), <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>.1. Three of these beta blocker trials (287 women) are the only studies in the subgroup for birthweight less than fifth centile (RR 3.04; 95 % CI 1.25 to 7.40), <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>.2.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Of the remaining outcomes, use of additional antihypertensives was reported in 10 trials (1285 women) (RR 0.42; 95% CI 0.30 to 0.58) <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; changed drugs due to side-effects in 15 trials (1403 women) (RR 2.59; 95% CI 1.33 to 5.04) <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; caesarean section in 20 trials (2624 women) (RR 0.92; 95% CI 0.83 to 1.02) <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; placental abruption in 11 trials (1433 women) (RR 1.41; 95% CI 0.65 to 3.07) <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>; and admission to special care nursery was reported in nine trials (1470 babies) (average RR 1.04; 95% CI 0.83 to 1.30; Heterogeneity: Tau² = 0.04; Chi² = 12.46, df = 8 (P = 0.13); I² = 36%), <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>. Remaining outcomes were only reported for less than half the women in the comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) One hypertensive drug versus another</HEADING>
<P>Overall, 22 trials with a total of 1723 women compared one antihypertensive drug with another.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severe hypertension</HEADING>
<P>Beta blockers and calcium channel blockers together appear to be more effective than methyldopa in avoiding an episode of severe hypertension (11 trials, 638 women; RR (random-effects) 0.54; 95% CI 0.30 to 0.95; RD -0.11 (-0.20 to -0.02); NNTH 7 (5 to 69)), <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>. There is no clear difference between any class of antihypertensive drugs: beta blockers versus methyldopa (nine trials, 592 women); RR 0.59; 95% CI 0.33 to 1.05, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.1; calcium channel blockers versus methyldopa (two trials, 46 women) RR 0.23; 95% CI 0.04 to 1.22, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.2; beta blockers versus calcium channel blockers (one trial, 100 women) 2.14; 95% CI 0.96 to 4.80, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.2; and for the comparison of glyceryl trinitrate with nifedipine (one trial, 36 women), it is 1.56; 95% CI 1.07 to 35.67, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.1.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pre-eclampsia</HEADING>
<P>There is a reduction in the overall risk of developing proteinuria/pre-eclampsia when either beta blockers or calcium channel blockers are compared with methyldopa (11 trials, 997 women; RR 0.73; 95% CI 0.54 to 0.99) <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>. However, this effect is not seen in the subgroup analysis for beta blockers versus methyldopa (10 trials, 903 women; RR 0.75; 95% CI 0.53 to 1.05), <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>.1, or for calcium channel blockers versus methyldopa (one trial, 94 women; RR 0.66; 95% CI 0.34 to 1.27), <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>.2.</P>
<P>One trial (92 women) compared beta blockers with calcium channel blockers (RR 2.67; 95% CI 0.75 to 9.42), <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.2. One trial compared glyceryl trinitrate with calcium channel blockers, but was too small for any reliable conclusion (one trial, 36 women; RR 1.00; 95% CI 0.10 to 9.96), <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.1.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Total reported fetal deaths or deaths before discharge from hospital</HEADING>
<P>There is no difference in the risk of the baby dying (19 trials, 1339 women; RR 0.73; 95% CI 0.42 to 1.27), <LINK REF="CMP-005.10" TYPE="ANALYSIS">Analysis 5.10</LINK>, when any antihypertensive drug was compared with methyldopa. No differences were found when metoprolol or glyceryl trinitrate were compared with calcium channel blockers (two trials, 136 women; RR 1.00; 95% CI 0.06 to 15.55), <LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Preterm birth (less than 37 weeks)</HEADING>
<P>Only nine trials comparing any antihypertensive with methyldopa (623 women, RR 0.76; 95% CI 0.55 to 1.05), <LINK REF="CMP-005.11" TYPE="ANALYSIS">Analysis 5.11</LINK>, and the small trial (36 women) of glyceryl trinitrate versus nifedipine (RR 0.63; 95% CI 0.20 to 1.91), <LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>, reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Small-for-gestational age</HEADING>
<P>Only seven small trials reported this outcome. Six trials (577 women) compared beta blockers with methyldopa (RR 0.85; 95% CI 0.55 to 1.32), <LINK REF="CMP-005.12" TYPE="ANALYSIS">Analysis 5.12</LINK>.1, and one trial (20 women) compared nifedipine versus methyldopa (RR 0.40; 95% CI 0.10 to 1.60), <LINK REF="CMP-005.12" TYPE="ANALYSIS">Analysis 5.12</LINK>.2.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Of the remaining outcomes, use of additional antihypertensives was reported in 12 trials (989 women) comparing any antihypertensive with methyldopa (RR 0.84; 95% CI 0.66 to 1.06), <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>, and in one trial (100 women) comparing metoprolol with nicardipine (RR 2.14; 95% CI 0.96 to 4.80), <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>. In the comparison of any antihypertensive versus methyldopa changed drugs due to side-effects was reported by four trials (272 women) (RR 2.80; 95% CI 0.12 to 67.91), <LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>; caesarean section by 10 trials (878 women) (RR 0.93; 95% CI 0.78 to 1.12) <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>; placental abruption by one trial (173 women) (RR 2.02; 95% CI 0.19 to 21.90) <LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>; and admission to special care nursery was reported by four trials (478 babies) (RR 0.92; 95% CI 0.67 to 1.26), <LINK REF="CMP-005.13" TYPE="ANALYSIS">Analysis 5.13</LINK>. Similarly, there were no clear differences in the other comparisons where these outcomes were reported.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-01-05 12:02:24 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-01-05 12:01:34 +0000" MODIFIED_BY="[Empty name]">
<P>Antihypertensive drugs half the risk that a pregnant woman with mild or moderate hypertension will have one or more episodes of severe hypertension. This is unsurprising, as the antihypertensive effects of these agents have been well demonstrated in non-pregnant people. Also unsurprising is that women allocated an antihypertensive were less likely to need another agent, and more likely to experience side-effects than those allocated placebo or no antihypertensive treatment. Between eight to 13 women need to be treated with an antihypertensive drug to prevent an episode of severe hypertension. Whether this reduction in risk would, alone, be worthwhile is likely to depend on whether there are associated reductions in the consequences of severe hypertension, such as admission to hospital and stroke. There are insufficient data for any firm conclusions about these more substantive outcomes. However, if the reduction in severe hypertension was clinically important, you might expect to see an impact in terms of fewer preterm births and fewer caesarean sections. There is no clear evidence of such an effect in this review.</P>
<P>Beta blockers and calcium channel blockers considered together seem to be more effective than methyldopa for preventing severe hypertension, although the comparative effects on other outcomes are unclear.<BR/>
</P>
<P>One of the main objectives in treating women with mild to moderate hypertension with antihypertensive drugs is to prevent or delay progression to pre-eclampsia. Although this review excludes a large reduction in the overall risk of pre-eclampsia associated with antihypertensive therapy in general, a moderate but clinically important effect remains possible. The confidence intervals suggest the true effect is somewhere between a 20% reduction in the risk of pre-eclampsia and a 8% increase. Although with beta blockers, or in the subgroup of women with hypertension alone at trial entry (independently of the antihypertensive drug used) this effect is likely, this should be interpreted with caution as asymmetric funnel plots in these comparisons cannot exclude the possibility of publication bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Similarly, a moderate but clinically important reduction in the risk of fetal or neonatal death (point estimate 29%, confidence intervals consistent with everything from a 51% reduction in risk to a 2% increase) is possible. Although many studies did not define stillbirths and miscarriages, these data suggest that antihypertensive treatment for mild to moderate hypertension may have a greater potential for reducing early pregnancy loss than later stillbirths or neonatal deaths.</P>
<P>For small-for-gestational-age babies, the confidence intervals include everything from a 20% reduction in the risk of a small-for-gestational-age baby to a 17% increase, and the point estimate is for a 3% reduction in risk. It has been argued that lowering maternal blood pressure may cause fetal growth restriction (<LINK REF="REF-von-Dadelszen-2000" TYPE="REFERENCE">von Dadelszen 2000</LINK>). This hypothesis is based on meta-regression, however. So, although the included studies were randomised trials, the analysis is prone to all the biases of observational studies. Also, combining data from all trials there is no overall effect on the relative risk of having a small-for-gestational-age baby (RR 0.97; 95% CI 0.80 to 1.17) for women allocated antihypertensive drugs rather than placebo. Yet amongst the trials of beta blockers an increase appears likely (nine trials, 904 women; RR 1.38; 95% CI 0.99 to 1.92). It therefore remains plausible that the observed association with fetal growth restriction is related to beta blockers, rather than any general effect of reducing blood pressure.</P>
<P>Being small-for-gestational age is an important marker for neurodevelopmental delay. The ideal timing of delivery for such babies is unclear, regardless of whether the woman has raised blood pressure or not (<LINK REF="REF-Thornton-2004" TYPE="REFERENCE">Thornton 2004</LINK>).</P>
<P>Few children exposed to antihypertensive drugs in utero have been followed up beyond the perinatal period. Two trials (<LINK REF="STD-Italy-1998" TYPE="STUDY">Italy 1998</LINK>; <LINK REF="STD-UK-1983" TYPE="STUDY">UK 1983</LINK>) have reported follow-up of a total of 110 children at age one year, and of 190 children at age 18 months, respectively. Another (<LINK REF="STD-UK-1976" TYPE="STUDY">UK 1976</LINK>) reported follow-up at 7½ years of age for children randomised before 28 weeks' gestation. All studies were too small to provide reliable estimates of the benefits and adverse effects for surviving children.</P>
<P>The question of which antihypertensive drug to use is less relevant until it becomes clearer whether attempting to control mild to moderate hypertension during pregnancy is worthwhile. However, beta blockers seem to be better tolerated by women than methyldopa (RR 0.69; 95% CI 0.52 to 0.91), although there is potential for reporting or detection bias as this outcome was only reported by half the trials, all of them open label studies. Beta blockers also seem to be more effective than methyldopa in avoiding an episode of severe hypertension. However, concerns remain about their possible role in the risk of having small-for-gestational-age babies (<I>see</I> above).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-01-05 12:01:55 +0000" MODIFIED_BY="[Empty name]">
<P>We believe that this is a comprehensive review that covers the most up to date evidence from randomised controlled trials conducted around the world. We have not applied language restrictions for selecting studies.</P>
<P>Surprisingly, only four eligible trials (recruiting 511 women) were published since this review was first available in 2001. Twenty-five (out of 49) trials included in this review were published before 1990, more than 20 years ago. Evidence from these trials account for 48% of the total number of women recruited. Maternal and perinatal survival, availability of resources, technologies for diagnosis and treatment of complications, as well as indications for termination of pregnancy for maternal or perinatal conditions could have changed substantially since then. On the other hand, only a quarter of women considered in this review were recruited in low- and middle-income countries, where keeping the woman in a stable condition aiming at prolonging pregnancy may have major impact on neonatal survival.</P>
<P>These considerations, amongst others, may lead to a different response to the uncertainties presented in this review in different settings.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-06-19 10:03:11 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, the quality of the studies included in this review is moderate to poor. Concealment of allocation was adequate for only 17 of the 49 trials (35%). Most trials with unclear concealment of allocation were described as 'randomised' with no further details. Some of these studies were stated to be double blind, but with no information about how this was achieved. Only 12 of the studies evaluating a single agent used a placebo for the control group. All trials comparing alternative antihypertensive drugs were open label trials. None of the trials comparing a single drug against no treatment, or those comparing one agent with another, mentioned blinding in the assessment of outcome. The primary outcome reported by trials usually was mean blood pressure, or a fall in blood pressure, thus sample size to test the hypothesis was in general small for other clinically important outcomes, such as maternal or perinatal morbidity. The largest trial in this review recruited only 300 women, and only five studies had comparison arms of more than 100 women. Five trials (out of 49) reported sample size and power calculations.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-06-19 10:03:39 +0100" MODIFIED_BY="Denise Atherton">
<P>A large number of outcomes are reported in these trials, and for many, data are only available from a small number of studies. There is therefore considerable potential to be misled by reporting bias. For example, in the comparison of any antihypertensive with none, only five of the 29 trials reported respiratory distress syndrome, and all had results favouring antihypertensive treatment. Without further information, it is impossible to know whether the other 24 trials did not collect these data, or whether they did not report it because it did not favour antihypertensive therapy.</P>
<P>We also report data from a large number of subgroups. Although these subgroups were all prespecified, the numbers in many cells are small, and for one in 20 the difference will be statistically significant purely by chance. Results from these subgroups should therefore be interpreted with caution, as there is considerable potential to be misled by random errors.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-01-05 12:02:24 +0000" MODIFIED_BY="Denise Atherton">
<P>The review of Magee and Duley on beta blockers for non-severe hypertension also concludes that the effect of beta blockers on perinatal outcome is uncertain and large randomised trials are needed to determine whether antihypertensive therapy in general (rather than beta blocker therapy specifically) results in greater benefit than risk, for treatment of non-severe pregnancy hypertension (<LINK REF="REF-Magee-2003" TYPE="REFERENCE">Magee 2003</LINK>).</P>
<P>In the National Institute for Health and Clinical Excellence (NICE) guideline CG107<I> Hypertension in pregnancy: The management of hypertensive disorders during pregnancy,</I> the authors do not recommend antihypertensive drugs in mild pregnancy-induced hypertension or pre-eclampsia. Only when blood pressure is greater than 150/100 mmHg, labetalol, methyldopa or nifedipine are advised as the drugs of choice (<LINK REF="REF-NICE-2011" TYPE="REFERENCE">NICE 2011</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-01-05 12:02:43 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE>
<P>It remains unclear whether antihypertensive drug therapy for mild to moderate hypertension during pregnancy is worthwhile. Whether the reduction in the risk of severe hypertension is considered sufficient to warrant treatment is a decision that should be made by women in consultation with their obstetrician. If an antihypertensive is used, there is insufficient evidence to conclude that one antihypertensive is better than another. The choice should therefore depend on the previous experience of the clinician and the woman's preference.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-01-05 12:02:43 +0000" MODIFIED_BY="[Empty name]">
<P>Large simple trials are required in order to provide reliable estimates of the benefits and adverse effects of antihypertensive treatment for mild to moderate hypertension. We need to know the effects for both mother and baby, as well as the costs to the health services, to women and to their families. Outcomes relevant to women should be included in such studies, such as admission to hospital, clinic visits, and disruption to their family and working life. Trials should also assess the level of blood pressure at which antihypertensive treatment becomes worthwhile. Long-term follow-up of children entered into such trials as fetuses is needed in order to assess whether there are any effects on infant and child development.</P>
<P>[Note: The one citation in the awaiting classification section of the review may alter the conclusions of the review once assessed (<LINK REF="STD-Canada-2008" TYPE="STUDY">Canada 2008</LINK>).]</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-01-05 12:02:51 +0000" MODIFIED_BY="[Empty name]">
<P>Thanks to Rory Collins and David Henderson Smart for their contribution to earlier versions of this review.</P>
<P>Thanks to Marta Roqué i Figuls from the Iberoamerican Cochrane Centre, Barcelona, (Spain), and to Zulma Ortiz from the Centro de Investigaciones Epidemiologicas, Academia Nacional de Medicina, Buenos Aires, (Argentina) for their help in locating original papers in Spanish and Portuguese.</P>
<P>Special thanks to Greg Davis (<LINK REF="STD-Australia-2001" TYPE="STUDY">Australia 2001</LINK>), Salvio Freire (<LINK REF="STD-Brazil-1988" TYPE="STUDY">Brazil 1988</LINK>), Soubhi Kahhale and Silvana Darcie (<LINK REF="STD-Brazil-2000" TYPE="STUDY">Brazil 2000</LINK>), Denis J Nascimento (<LINK REF="STD-Brazil-2000a" TYPE="STUDY">Brazil 2000a</LINK>), Pierre-Francois Plouin (<LINK REF="STD-Caribbean-Is.1990" TYPE="STUDY">Caribbean Is.1990</LINK>), Elba Gomez Sosa (<LINK REF="STD-Cuba-1994" TYPE="STUDY">Cuba 1994</LINK>), Fakhrolmolouk Yassaee (<LINK REF="STD-Iran-2000" TYPE="STUDY">Iran 2000</LINK>), Sean Blake and Dermot MacDonald (<LINK REF="STD-Ireland-1991" TYPE="STUDY">Ireland 1991</LINK>), Isabella Neri and Fabio Facchinetti (<LINK REF="STD-Italy-1999" TYPE="STUDY">Italy 1999</LINK>), Claudio Borghi (<LINK REF="STD-Italy-2000" TYPE="STUDY">Italy 2000</LINK>), Klas Wichman and Orvar Finnström (<LINK REF="STD-Sweden-1984" TYPE="STUDY">Sweden 1984</LINK>), Stellan Högstedt (<LINK REF="STD-Sweden-1985" TYPE="STUDY">Sweden 1985</LINK>), James Walker (<LINK REF="STD-UK-1982" TYPE="STUDY">UK 1982</LINK>), Peter C Rubin (<LINK REF="STD-UK-1990" TYPE="STUDY">UK 1990</LINK>), DJ Cruickshank (<LINK REF="STD-UK-1992" TYPE="STUDY">UK 1992</LINK>), Baha Sibai (<LINK REF="STD-USA-1990" TYPE="STUDY">USA 1990</LINK>), and Silvia Sanchez (<LINK REF="STD-Venezuela-1985" TYPE="STUDY">Venezuela 1985</LINK>), who kindly provided unpublished data for this review.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Pregnancy and Childbirth Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-01-29 14:09:42 +0000" MODIFIED_BY="Leanne V Jones">
<P>E Abalos updated this systematic review in order to compile the new evidence for the update of the WHO recommendations for Prevention and treatment of pre-eclampsia and eclampsia. L Duley has been awarded an NIHR research grant for a programme of work on care at very preterm birth.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-09-10 11:30:49 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>For this update, all changes on the text of the review were drafted by E Abalos with input by L Duley. E Abalos and L Duley performed the methodological assessment of all new studies, and extracted the data when appropriate. E Abalos, L Duley and W Steyn have commented on and agreed the final version. </P>
<P>E Abalos is the guarantor of the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-11-25 12:02:44 +0000" MODIFIED_BY="Leanne V Jones">
<P>Methods updated. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-01-01 18:08:25 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-01-01 18:08:25 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-01-01 18:08:25 +0000" MODIFIED_BY="Edgardo J Abalos">
<STUDY DATA_SOURCE="PUB" ID="STD-Argentina-1985" NAME="Argentina 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Voto L, Lapidus A, Neira J, Margulies M</AU>
<TI>Atenolol vs alpha methyldopa in the treatment of hypertension in pregnancy</TI>
<SO>5th International Congress for the International Society for the study of Hypertension in Pregnancy; 1986 July 7-10; Nottingham, UK</SO>
<YR>1986</YR>
<PG>138</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Voto LS, Lapidus AM, Neira J, Margulies M</AU>
<TI>Treatment of hypertension during pregnancy: Atenolol versus Methyldopa</TI>
<TO>Tratamiento de la hipertensión en el embarazo: Atenolol versus Alfa Metildopa</TO>
<SO>Obstetricia y Ginecología Latino-Americanas</SO>
<YR>1985</YR>
<VL>43</VL>
<NO>9-10</NO>
<PG>335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argentina-1987" NAME="Argentina 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Voto LS, Zin C, Neira J, Lapidus AM, Margulies M</AU>
<TI>Ketanserin versus alpha methyldopa in the treatment of hypertension during pregnancy: a preliminary report</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>S101-S103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argentina-1988" NAME="Argentina 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Casavilla F, Vega HR</AU>
<TI>Prospective and randomized study on mepindolol and alpha-methydopa efficacy in arterial hypertension (AH) treatment during pregnancy</TI>
<SO>World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil</SO>
<YR>1988</YR>
<PG>182</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Australia-1983" NAME="Australia 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Livingstone I, Craswell PW, Bevan EB, Smith MT, Eadie MJ</AU>
<TI>Propranolol in pregnancy - three-year prospective study</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1983</YR>
<VL>2</VL>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Australia-1985" MODIFIED="2013-05-19 20:53:45 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Australia 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-05-19 20:53:45 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallery EDM, Gyory AZ</AU>
<TI>Antihypertensive therapy in pregnancy [abstract]</TI>
<SO>Kidney International</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>2</NO>
<PG>232</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gallery EDM, Hunyor SN, Saunders DM, Gyory AZ</AU>
<TI>A randomized trial of oxyprenolol and a-methyl dopa in therapy of hypertension in pregnancy</TI>
<SO>1st Congress of the International Society of Hypertension in Pregnancy; 1978 September 27-29; Dublin, Ireland</SO>
<YR>1978</YR>
<PG>88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gallery EDM, Ross MR, Gyory AZ</AU>
<TI>Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa</TI>
<SO>BMJ</SO>
<YR>1985</YR>
<VL>291</VL>
<PG>563-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallery EDM, Saunders DM, Hunyor SN, Gyory AZ</AU>
<TI>Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy</TI>
<SO>BMJ</SO>
<YR>1979</YR>
<VL>1</VL>
<PG>1591-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Australia-2001" NAME="Australia 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Davis G, Brown M</AU>
<TI>Re: glyceryl trinitrate (GTN) patches are unsuitable in hypertensive pregnancy</TI>
<SO>Australian Journal of Obstetrics and Gynaecology</SO>
<YR>2001</YR>
<VL>41</VL>
<NO>4</NO>
<PG>474</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brazil-1985" NAME="Brazil 1985" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kahhale S, Carrara W, Barros ACSD, Zugaib M, Neme B</AU>
<TI>A comparative study between treated (beta-blocker pindolol) and untreated chronic hypertension</TI>
<SO>4th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kahhale S, Zugaib M, Carrara W, Paula FJ, Sabbaga E, Neme B</AU>
<TI>Comparative study of chronic hypertensive pregnant women treated and non-treated with pindolol</TI>
<TO>Estudio comparativo de gestantes hipertensas crônicas tratadas e näo tratadas com betabloqueador pindolol</TO>
<SO>Ginecologia e Obstetrícia Brasileiras</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>2</NO>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brazil-1988" NAME="Brazil 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freire S, de França LA, Rau de Almeida Callou M, Alves de Oliveira JE, Barbosa Filho J</AU>
<TI>Comparative study with pindolol and methyldopa in pregnant women with chronic hypertension</TI>
<TO>Estudo comparativo com pindolol e metildopa em gestantes com hipertensão arterial crônica</TO>
<SO>Jornal Brasileiro de Ginecologia</SO>
<YR>1988</YR>
<VL>98</VL>
<NO>3</NO>
<PG>157-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brazil-2000a" NAME="Brazil 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Nascimento DJ</AU>
<SO>Avaliaçäo do uso do verapamil em gestantes com formas näo graves de doença hipertensiva vascular crônica [Evaluation of the use of Verapamil with non-serious form of chronic vascular hypertension disease during pregnancy] [Doctoral thesis]</SO>
<YR>2000</YR>
<PB>Facultade Evangélica de Medicina do Paraná</PB>
<CY>Brazil</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Caribbean-Is.1990" NAME="Caribbean Is.1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plouin PF, Breart G, Llado J, Dalle M, Keller ME, Goujon H, et al</AU>
<TI>A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1990</YR>
<VL>97</VL>
<PG>134-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-France-1987" NAME="France 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plouin PF, Breart G, Maillard F, Papiernik E, Relier JP, Labetolol Methyldopa Study Group</AU>
<TI>Antihypertensive efficacy and perinatal safety of labetalol in the treatment of hypertension in pregnancy: a randomised comparison to methyldopa</TI>
<TO>Effets maternels et securite perinatale du labetalol dans le traitement des hypertensions de la grossesse. Comparaison a la methyldopa par un essai cooperatif randomise</TO>
<SO>Archives des Maladies du Coeur</SO>
<YR>1987</YR>
<VL>80</VL>
<PG>952-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Plouin PF, Breart G, Maillard F, Papiernik E, Relier JP, the Labetolol Methyldopa Study Group</AU>
<TI>Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1988</YR>
<VL>95</VL>
<PG>868-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-France-1988" NAME="France 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Blazquez, Lardoux H, Leperlier E</AU>
<TI>Randomized and comparative study of methyl dopa (MD), acebutolol (ACE) and labetalol for the treatment of moderate hypertension during pregnancy (HDP)</TI>
<SO>6th International Congress, International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lardoux H, Blazquez G, Leperlier E, Gerard J</AU>
<TI>Randomized and comparative study of methyldopa (MD), acebutolol (ACE) and labetalol for the treatment of moderate hypertension during pregnancy (HDP)</TI>
<TO>Essai ouvert, comparatif, avec tirage au sort pour le traitement de l'HTA gravidique moderee: methyldopa, acetbutolol, labetalol</TO>
<SO>Archives des Maladies du Coeur</SO>
<YR>1988</YR>
<VL>91</VL>
<PG>137-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-France-1994" NAME="France 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jannet D, Carbonne B, Sebban E, Milliez J</AU>
<TI>Nicardipine vs metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1995</YR>
<VL>49</VL>
<PG>225</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jannet D, Carbonne B, Sebban E, Milliez J</AU>
<TI>Nicardipine vs metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1994</YR>
<VL>84</VL>
<PG>354-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-Kong-1990" NAME="Hong Kong 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Li CY, Lao TT, Yu KM, Wong SP, Leung CF</AU>
<TI>The effect of labetalol on mild pre-eclampsia</TI>
<SO>Proceedings of the 7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<PG>191</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-1992" NAME="India 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oumachigui A, Verghese M, Balachander J</AU>
<TI>A comparative evaluation of metoprolol and methyldopa in the management of pregnancy induced hypertension</TI>
<SO>Indian Heart Journal</SO>
<YR>1992</YR>
<VL>44</VL>
<PG>39-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-2002" MODIFIED="2013-05-19 22:30:21 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="India 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-05-19 22:30:21 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banerjee G, Chatterjee D, Chatterjee A, Mukherjee P, Das A</AU>
<TI>A randomized controlled trial on use of nimodipine in mild P.I.H</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>2002</YR>
<VL>52</VL>
<NO>4</NO>
<PG>44-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-2012" MODIFIED="2014-01-01 18:08:25 +0000" MODIFIED_BY="Edgardo J Abalos" NAME="India 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-01-01 18:08:25 +0000" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molvi SN, Mir S, Rana VS, Jabeen F, Rauoof A</AU>
<TI>Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: A prospective randomized study comparing labetalol with alpha methyldopa</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>2012</YR>
<VL>285</VL>
<NO>6</NO>
<PG>1553-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-2013" MODIFIED="2014-01-01 15:46:58 +0000" MODIFIED_BY="Edgardo J Abalos" NAME="India 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-01-01 15:46:58 +0000" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subhedar V, Inamdar S, Hariharan C, Subhedar S</AU>
<TI>Comparison of efficacy of labetalol and methyldopa in patients with pregnancy-induced hypertension</TI>
<SO>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</SO>
<YR>2013</YR>
<VL>2</VL>
<NO>1</NO>
<PG>27-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ireland-1991" NAME="Ireland 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blake S, MacDonald D</AU>
<TI>The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1991</YR>
<VL>98</VL>
<PG>244-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Israel-1986" NAME="Israel 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ellenbogen A, Jaschevatzky O, Davidson A, Anderman S, Grunstein S</AU>
<TI>Management of pregnancy-induced hypertension with pindolol - comparative study with methyldopa</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1986</YR>
<VL>24</VL>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jaschevatzky OE, Davidson A, Ellenbogen A, Anderman S, Grunstein S</AU>
<TI>Comparative study of pindolol and methyldopa and transplacental cross of pindolol in PIH</TI>
<SO>5th International Congress of the International Society for the study of Hypertension in Pregnancy; 1986 7-10 July; Nottingham, England</SO>
<YR>1986</YR>
<PG>137</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Israel-1986a" MODIFIED="2014-01-01 15:47:45 +0000" MODIFIED_BY="Heather Maxwell" NAME="Israel 1986a" YEAR="1986">
<REFERENCE MODIFIED="2014-01-01 15:47:45 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenfeld J, Bott-Kanner G, Boner G, Nissenkorn A, Friedman S, Ovadia J, et al</AU>
<TI>Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1986</YR>
<VL>22</VL>
<PG>197-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Israel-1992" NAME="Israel 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bar J, Hirsch M, Friedman S, Fuchs J, Ovadia J, Bott-Kanner G</AU>
<TI>The effect of beta-adrenergic blocker pindolol on platelet function in chronic hypertensive pregnancies</TI>
<SO>Proceedings of 9th International Congress, International Society for the Study of Hypertension in Pregnancy; 1994 March 15-18; Sydney, Australia</SO>
<YR>1994</YR>
<PG>155</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bott-Kanner G, Hirsch M, Boner G, Ovadia J, Modan M, Friedmann S, et al</AU>
<TI>Evaluation of antihypertensive therapy (AHT) in the management of hypertension in pregnancy (HP)</TI>
<SO>6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bott-Kanner G, Hirsch M, Friedman S, Boner G, Ovadia J, Merlob P, et al</AU>
<TI>Antihypertensive therapy in the management of hypertension in pregnancy - a clinical double-blind study of pindolol</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1992</YR>
<VL>B11</VL>
<PG>207-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch M, Bar J, Bott-Kanner G, Kaplan B, Fuchs J, Ovadia J</AU>
<TI>Effect of the beta-adrenergic blocker pindolol on platelet function in chronic hypertensive pregnancy</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>193-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Israel-1995" NAME="Israel 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Paran E, Baile Y, Holzberg G, Masor M, Zmora E, Insler V</AU>
<TI>Treatment of hypertension in pregnancy: different regime, different outcome</TI>
<SO>6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Paran E, Holzberg G, Mazor M, Zmora E, Insler V</AU>
<TI>Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>33</VL>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Paran E, Maisner I, Holzberg G, Mazor M, Zmora E, Biale Y, et al</AU>
<TI>Beta-blocker treatment of PIH correlated with uteroplacental blood flow measurement</TI>
<SO>6th International Congress, International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>109</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-1997" NAME="Italy 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catalano D, Ercolano S, Pollio F, Ascione L, Russo C, De Santi B, et al</AU>
<TI>Evaluation of nifedipine monotherapy in the management of pregnancy hypertension</TI>
<TO>Valuazione della monoterapia con nifedipina nel management della gestosi EPH</TO>
<SO>Giornale Italiano Di Ostetricia e Ginecologia</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>373-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-1998" NAME="Italy 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bortolus R, Ricci E, Chatenoud L, Parazzini F</AU>
<TI>Nifedipine administered in pregnancy: effect on the development of children at 18 months</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2000</YR>
<VL>107</VL>
<PG>792-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gruppo di Studio Ipertensione in Gravidanza</AU>
<TI>Nifedipine versus expectant management in mild to moderate hypertension in pregnancy</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>105</VL>
<PG>718-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luchini L, Bortolus R, Parazzini F</AU>
<TI>Multicentric, randomized, clinical trial on the efficacy of long-acting nifedipine in improving the prognosis of pregnancy in women with mild or moderate chronic or pregnancy-induced hypertension</TI>
<SO>Journal of Nephrology</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Italy-1999" NAME="Italy 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neri I, Ternelli G, Facchinetti F, Volpe A</AU>
<TI>Effectiveness of oral nifedipine and transdermal glyceryltrinitrate on 24-hours blood pressure values in pregnancy-induced hypertension</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>O65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neri I, Valensise H, Fachinetti F, Menghini S, Romanini C, Volpe A</AU>
<TI>24-hour ambulatory blood pressure monitoring: a comparison between transdermal glyceryl-trinitrate and oral nifedipine</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1999</YR>
<VL>18</VL>
<PG>107-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Italy-2000" NAME="Italy 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borghi C, Degli Esposti D, Cassani A, Immordino V, Bovicelli L, Ambrosioni E</AU>
<TI>The treatment of hypertension in pregnancy</TI>
<SO>Journal of Hypertension</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>Suppl 2</NO>
<PG>S52-S56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Borghi C, Immordino V, Degli Esposti D, Boschi S, Cassani A, Bentivenga C, et al</AU>
<TI>Comparison between nifedipine-gits and methyldopa on blood pressure control, utero-placental hemodynamic and fetal outcome in patients with pre-eclampsia</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>P8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1991" NAME="South Africa 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Odendaal HJ, Schabort I, and Pattinson RC. 2840. Prazosin for the treatment of hypertension in pregnancy: a randomized control trial. In: Oxford Database of Perinatal Trials, Version 1.2, Disk Issue 6, Autumn. Chalmers I (ed). Oxford: Oxford University Press.1991&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Odendaal HJ, Schabort I, Pattinson RC</AU>
<TI>Prazosin for the treatment of hypertension in pregnancy: a randomized control trial</TI>
<SO>In: Oxford Database of Perinatal Trials, Version 1.2, Disk Issue 6, Autumn. Chalmers I (ed). Oxford: Oxford University Press.1991</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1993" NAME="South Africa 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Eloff WJ</AU>
<TI>The use of nifedipine vs methyldopa in mild to moderate pregnancy associated hypertension</TI>
<SO>Proceedings of the 12th Conference on Priorities in Perinatal Care; 1993; South Africa</SO>
<YR>1993</YR>
<PG>130-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sudan-2002" NAME="Sudan 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elhassan EM, Mirghani OA, Habour AB, Adam I</AU>
<TI>Methyldopa versus no drug treatment in the management of mild pre-eclampsia</TI>
<SO>East African Medical Journal</SO>
<YR>2002</YR>
<VL>71</VL>
<NO>4</NO>
<PG>172-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sweden-1984" NAME="Sweden 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjorksten B, Finnstrom O, Wichman K</AU>
<TI>Intrauterine exposure to the beta-adrenergic receptor-blocking agent metoprolol and allergy</TI>
<SO>International Archives of Allergy and Immunology</SO>
<YR>1988</YR>
<VL>87</VL>
<PG>59-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finnstrom O, Ezitis J, Ryden G, Wichman K</AU>
<TI>Neonatal effects of beta-blocking drugs in pregnancy</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica Supplement</SO>
<YR>1984</YR>
<VL>118</VL>
<PG>91-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ryden G, Karlberg BE, Wichman K</AU>
<TI>Metoprolol in the treatment of hypertension in pregnancy - effect on the mother and foetus</TI>
<SO>4th World Congress of the International Society for the study of Hypertension in Pregnancy; 1984 Jun 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wichman K, Ezitis J, Finnstrom O, Ryden G</AU>
<TI>Metoprolol in the treatment of hypertension in pregnancy - effect on the newborn baby</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1984</YR>
<VL>B3</VL>
<PG>153</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wichman K, Ezitis J, Finnstrom O, Ryden G</AU>
<TI>Metoprolol in the treatment of hypertension in pregnancy - effects on the newborn baby</TI>
<SO>4th World Congress of the International Society for the study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Wichman K, Karlberg BE, and Ryden G. 2886. Metoprolol in the treatment of mild to moderate hypertension in pregnancy - effects on the mother. Clin-Exp-Hypertens. 1985, B4, 141-156.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wichman K, Karlberg BE, Ryden G</AU>
<TI>Metoprolol in the treatment of mild to moderate hypertension in pregnancy - effects on the mother</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1985</YR>
<VL>B4</VL>
<PG>141-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wichman K, Ryden G, Karlberg BE</AU>
<TI>A placebo controlled trial of metoprolol in the treatment of hypertension in pregnancy</TI>
<SO>Scandinavian Journal of Clinical and Laboratory Investigation</SO>
<YR>1984</YR>
<VL>106</VL>
<PG>90-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wichman K</AU>
<TI>Metoprolol in the treatment of mild to moderate hypertension in pregnancy - effects on fetal heart activity</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1986</YR>
<VL>5</VL>
<PG>195-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sweden-1985" MODIFIED="2014-01-01 15:55:29 +0000" MODIFIED_BY="Heather Maxwell" NAME="Sweden 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Högstedt S, Lindberg B, Lindberg S, Ludviksson K, Sandström B</AU>
<TI>Effect of metoprolol on fetal heart rate patterns during pregnancy and delivery</TI>
<SO>4th World Congress of the International Society for the study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Högstedt S, Lindeberg S, Axelsson O, Lindmark G, Rane A, Sandström B, et al</AU>
<TI>A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1985</YR>
<VL>64</VL>
<PG>505-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogstedt S, Lindberg B, Lindeberg S, Ludviksson K, Sandstrom B</AU>
<TI>Effect of metoprolol on fetal heart rate patterns during pregnancy and delivery</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1984</YR>
<VL>B3</VL>
<PG>152</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-01 15:55:29 +0000" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Rest of authors not given on paper.&lt;/p&gt;" NOTES_MODIFIED="2014-01-01 15:55:29 +0000" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindeberg S, Axelsson O, Lindeberg BS, Lindmark G, Ludviksson K, Sandström B</AU>
<TI>Effect of metoprolol in combination with hydralazine on fetal heart rate patterns during hypertensive pregnancy and delivery</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>1</NO>
<PG>87-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sweden-1995" NAME="Sweden 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wide-Swensson D, Ingemarsson I, Lunell NO, Lindberg B, Lindeberg S, Marsal K, et al</AU>
<TI>Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study</TI>
<SO>International Journal of Obstetrics &amp; Gynecology</SO>
<YR>1994</YR>
<VL>46</VL>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wide-Swensson DH, Ingemarsson I, Lunell NO, Forman A, Skajaa K, Lindberg B</AU>
<TI>Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>872-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1968" NAME="UK 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leather HM, Humphreys DM, Baker P, Chadd MA</AU>
<TI>A controlled trial of hypotensive agents in hypertension in pregnancy</TI>
<SO>Lancet</SO>
<YR>1968</YR>
<VL>2</VL>
<PG>488-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1976" MODIFIED="2014-01-01 15:57:22 +0000" MODIFIED_BY="Heather Maxwell" NAME="UK 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cockburn J, Moar VA, Ounsted MK, Redman CWG</AU>
<TI>Final report on study of hypertension during pregnancy: the effects of specific treatment on the growth and development of the children</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>1</VL>
<PG>647-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moar VA, Jefferies MA, Mutch LMM, Ounsted MK, Redman CWG</AU>
<TI>Neonatal head circumference and the treatment of maternal hypertension</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1978</YR>
<VL>85</VL>
<PG>933-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mutch LMM, Moar VA, Ounsted MK, Redman CWG</AU>
<TI>Hypertension during pregnancy, with and without specific hypotensive treatment. I. Perinatal factors and neonatal morbidity</TI>
<SO>Early Human Development</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>47-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mutch LMM, Moar VA, Ounsted MK, Redman CWG</AU>
<TI>Hypertension during pregnancy, with and without specific hypotensive treatment. II The growth and development of the infant in the first year of life</TI>
<SO>Early Human Development</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>59-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-01 15:57:22 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Ounsted M</AU>
<TI>The children of women who had hypertension during pregnancy</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1988</YR>
<PG>341-62</PG>
<ED>Rubin PC</ED>
<PB>Elsevier Science Publishers B.V</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ounsted MK, Moar VA, Good FJ, Redman CWG</AU>
<TI>Hypertension during pregnancy with and without specific treatment: the development of the children at the age of four years</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1980</YR>
<VL>87</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Redman CWG, Beilin LJ, Bonnar J, Ounsted MK</AU>
<TI>Fetal outcome in trial of antihypertensive treatment in pregnancy</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>753-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redman CWG, Beilin LJ, Bonnar J</AU>
<TI>Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1977</YR>
<VL>84</VL>
<PG>419-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1980" NAME="UK 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lamming GD, Pipkin FB, Symonds EM</AU>
<TI>Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1980</YR>
<VL>2</VL>
<PG>865-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lamming GD, Symonds EM</AU>
<TI>Comparison of the alpha and beta blocking drug labetalol and aldomet in the treatment of pregnancy induced hypertension</TI>
<SO>Proceedings of the 2nd Congress of the International Society for the Study of Hypertension in Pregnancy; 1980 December 1-4; Cairo, Egypt</SO>
<YR>1980</YR>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamming GD, Symonds EM</AU>
<TI>Use of labetalol and methyldopa in pregnancy-induced hypertension</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1979</YR>
<VL>8</VL>
<PG>217S-222S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-UK-1982" NAME="UK 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cameron AD, Walker JJ, Bonduelle M, Calder AA</AU>
<TI>A randomised trial of the antihypertensive agent, labetalol, against bed rest in pregnancy hypertension</TI>
<SO>Archives of Gynecology</SO>
<YR>1985</YR>
<VL>237</VL>
<NO>Suppl 1</NO>
<PG>295</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lang GD, Lowe GDO, Walker JJ, Forbes CD, Calder AA</AU>
<TI>Increased blood viscosity in pre-eclampsia: effect of treatment with labetalol</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1983</YR>
<VL>50</VL>
<PG>156</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lang GD, Lowe GDO, Walker JJ, Forbes CD, Prentice CRM, Calder AA</AU>
<TI>Blood rheology in pre-eclampsia and intrauterine growth retardation: effects of blood pressure reduction with labetalol</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1984</YR>
<VL>91</VL>
<PG>438-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Walker J</AU>
<SO>Intrauterine growth retardation and maternal labetalol treatment in a random allocation controlled study [MD thesis]</SO>
<YR>1992</YR>
<PG>141-55</PG>
<PB>University of Glasgow</PB>
<CY>Scotland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Walker JJ, Crooks A, Erwin L, Calder AA</AU>
<TI>Labetalol in pregnancy-induced hypertension: fetal and maternal effects</TI>
<SO>International Congress Series 591</SO>
<YR>1982</YR>
<PG>148-60</PG>
<ED>Reilly A, Symonds EM</ED>
<PB>Excerpta Medica</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1983" NAME="UK 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds B, Butters L, Evans J, Adams T, Rubin PC</AU>
<TI>First year of life after the use of atenolol in pregnancy associated hypertension</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1984</YR>
<VL>59</VL>
<PG>1061-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubin PC, Butters L, Clark D, Sumner D, Belfield A, Pledger D, et al</AU>
<TI>Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1984</YR>
<VL>150</VL>
<PG>389-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubin PC, Butters L, Clark DM, Low RA, Reid JL</AU>
<TI>Atenolol in the management of hypertension during pregnancy</TI>
<SO>Drugs</SO>
<YR>1983</YR>
<VL>25</VL>
<PG>212-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rubin PC, Butters L, Clark DM, Reynolds B, Sumner DJ, Steedman D</AU>
<TI>Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<PG>431-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rubin PC, Butters L, Reynolds B, Low RAL</AU>
<TI>Atenolol in the management of pregnancy associated hypertension: obstetric and paediatric aspects</TI>
<SO>4th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1983a" MODIFIED="2014-01-01 15:59:52 +0000" MODIFIED_BY="Heather Maxwell" NAME="UK 1983a" YEAR="1983">
<REFERENCE MODIFIED="2014-01-01 15:59:52 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fidler J, Smith V, Fayers P, de Swiet M</AU>
<TI>Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy</TI>
<SO>British Medical Journal</SO>
<YR>1983</YR>
<VL>286</VL>
<PG>1927-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fidler J, Smith V, Fayers P, de Swiet M</AU>
<TI>Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy</TI>
<SO>Obstetrical and Gynecological Survey</SO>
<YR>1983</YR>
<VL>286</VL>
<PG>202-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1984" MODIFIED="2014-01-01 16:00:24 +0000" MODIFIED_BY="Heather Maxwell" NAME="UK 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-01-01 16:00:24 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorley KJ</AU>
<TI>Atenolol: side effects in the newborn infant</TI>
<SO>British Medical Journal</SO>
<YR>1982</YR>
<VL>285</VL>
<PG>1116</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thorley KJ</AU>
<TI>Randomised trial of atenolol and methyl dopa in pregnancy related hypertension</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1984</YR>
<VL>133</VL>
<PG>168</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Thorley KJ</AU>
<TI>Randomised trial of atenolol and methyl dopa in pregnancy related hypertension</TI>
<SO>4th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1989" NAME="UK 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pickles C, Symonds E, Brinkman C</AU>
<TI>Effects of labetalol (L) vs placebo (P) on arterial pressure (AP) and forearm venous distensibility (FVD) in women with pregnancy induced hypertension (PIH)</TI>
<SO>5th International Congress of the International Society for the study of Hypertension in Pregnancy; 1986 7-10 July; Nottingham, England</SO>
<YR>1986</YR>
<PG>92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pickles CJ, Broughton Pipkin F, Symonds EM</AU>
<TI>A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension</TI>
<SO>Britisth Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>99</VL>
<PG>964-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pickles CJ, Symonds EM, Broughton Pipkin F</AU>
<TI>The fetal outcome in a randomized double-blind controlled trial of labetalol vs placebo in pregnancy-induced hypertension</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<VL>96</VL>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pickles CJ, Symonds EM, Broughton Pipkin F</AU>
<TI>The fetal outcome of early intervention therapy in pregnancy induced hypertension. A randomised, double-blind controlled trial of labetalol vs placebo</TI>
<SO>6th International Congress, International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-UK-1990" NAME="UK 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butters L, Kennedy S, Rubin PC</AU>
<TI>Atenolol in essential hypertension during pregnancy</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>301</VL>
<PG>587-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-UK-1992" NAME="UK 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruickshank DJ, Campbell D, Robertson AA, MacGillivray I</AU>
<TI>Intra-uterine growth retardation and maternal labetalol treatment in a random allocation controlled study</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>12</VL>
<PG>223-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruickshank DJ, Campbell DM</AU>
<TI>Atenolol in essential hypertension during pregnancy</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>301</VL>
<PG>1103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruickshank DJ, Robertson AA, Campbell DM, MacGillivray I</AU>
<TI>Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cruickshank DJ, Robertson AA, Campbell DM, MacGillivray I</AU>
<TI>Maternal obstetric outcome measures in a randomised controlled study of labetalol in the treatment of hypertension in pregnancy</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1991</YR>
<VL>B10</VL>
<PG>333-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-1979" NAME="USA 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arias F, Zamora J</AU>
<TI>Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1979</YR>
<VL>53</VL>
<PG>489-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-1987" NAME="USA 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sibai BM, Gonzalez AR, Mabie WC, Moretti M</AU>
<TI>A comparison of labetalol plus hospitalization vs hospitalization alone in the management of preeclampsia remote from term</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1987</YR>
<VL>70</VL>
<PG>323-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-1987a" NAME="USA 1987a" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weitz C, Khouzami V, Maxwell K, Johnson JWC</AU>
<TI>Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1987</YR>
<VL>25</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-USA-1990" NAME="USA 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD</AU>
<TI>A comparison of no medication vs methyldopa or labetalol in chronic hypertension during pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>162</VL>
<PG>960-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sibai BM</AU>
<TI>The need of hypertensive drugs in management of mild to moderate pregnant hypertension</TI>
<SO>Proceedings of the 7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-1992" NAME="USA 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barton JR, Mercer BM, Sibai BM</AU>
<TI>The effect of nifedipine on urinary excretion of calcium in preeclampsia</TI>
<SO>American Journal of Perinatology</SO>
<YR>1997</YR>
<VL>14</VL>
<PG>609-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sibai BM, Barton JR, Akl S, Sarinoglu C, Mercer BM</AU>
<TI>A randomized prospective comparison of nifedipine and bed rest vs bed rest alone in the management of preeclampsia remote from term</TI>
<SO>Amercian Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>167</VL>
<PG>879-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sibai BM, Barton JR, Akl S, Sarinoglu C, Mercer BM</AU>
<TI>A randomized prospective comparison of nifedipine and bed rest vs bed rest alone in the management of preeclampsia remote from term</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>166</VL>
<PG>280</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venezuela-1988" MODIFIED="2014-01-01 16:03:52 +0000" MODIFIED_BY="Heather Maxwell" NAME="Venezuela 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-01-01 16:03:52 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faneite PJ, Gonzalez X, Salazar G</AU>
<TI>Evaluation of antihypertensives in pregnancy: prospective randomized study of mepindolol and alpha methyldopa</TI>
<TO>Evaluación de antihipertensivos en embarazadas: Mepindolol y alfametildopa. Estudio prospectivo y randomizado</TO>
<SO>Revista de Obstetricia y Ginecologia de Venezuela</SO>
<YR>1988</YR>
<VL>48</VL>
<PG>139-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-01-01 16:19:07 +0000" MODIFIED_BY="Edgardo J Abalos">
<STUDY DATA_SOURCE="PUB" ID="STD-Argentina-1990" MODIFIED="2013-05-20 19:22:42 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Argentina 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-05-20 19:22:42 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Voto LS, Quiroga CA, Lapidus AM, Catuzzi P, Uranga IF, Margulies M</AU>
<TI>Effectiveness of antihypertensive drugs in the treatment of hypertension in pregnancy</TI>
<SO>Clinical and Experimental Hypertension - Part B Hypertension in Pregnancy</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>3</NO>
<PG>339-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argentina-1994" NAME="Argentina 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fabregues G, Sure P, Knaudt S, Gonzalez Pena J, Esper R</AU>
<TI>The use of atenolol to prevent preeclampsia and superimposed preeclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1994</YR>
<VL>46</VL>
<PG>95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Australia-1985a" MODIFIED="2013-05-19 21:04:26 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Australia 1985a" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson-Smart DJ, Horvath JS, Phippard A, Korda A, Child A, Duggin GG, et al</AU>
<TI>Effect of antihypertensive drugs on neonatal blood pressure</TI>
<SO>Clinical and Experimental Pharmacology and Physiology</SO>
<YR>1984</YR>
<VL>11</VL>
<PG>351-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Horvath JS, Henderson-Smart DJ, Phippard A, Korda A, Child A, Duggin GG et al. The effect of antihypertensive drugs on neonatal blood pressure . 4th World Congress of the International Society for the study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands 1984:42&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Horvath JS, Henderson-Smart DJ, Phippard A, Korda A, Child A, Duggin GG, et al</AU>
<TI>The effect of antihypertensive drugs on neonatal blood pressure</TI>
<SO>4th World Congress of the International Society for the study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Horvath JS, Phippard A, Korda A, Henderson-Smart D, Child A, Duggin GG, et al</AU>
<TI>A controlled trial comparing clonidine hydrochloride and alpha methyl dopa in pregnant women with hypertension</TI>
<SO>4th World Congress of the International Society for the study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>246</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Horvath JS, Phippard A, Korda A, Henderson-Smart DJ, Child A, Tiller DJ</AU>
<TI>Clonidine hydrochloride - a safe and effective antihypertensive agent in pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1985</YR>
<VL>66</VL>
<PG>634-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-19 21:04:26 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horvath JS, Phipparel A, Korda A, Henderson-Smart D, Child A, Duggin GG, et al</AU>
<TI>A controlled trial comparing clonidine hydrochloride and alpha methyl dopa in pregnant women [abstract]</TI>
<SO>Kidney International</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>2</NO>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Australia-1991" NAME="Australia 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Phippard A, Fisher W, Child A, Henderson-Smart D, Horvarth J, Korda A, et al</AU>
<TI>A randomized, placebo-controlled study on the effect of therapy for mild to moderate hypertension in primigravidae</TI>
<SO>6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Phippard AF, Fischer WE, Horvath JS, Child AG, Korda AR, Henderson-Smart DJ, et al</AU>
<TI>Early blood pressure control improves pregnancy outcome in primigravid women with mild hypertension</TI>
<SO>Medical Journal of Australia</SO>
<YR>1991</YR>
<VL>154</VL>
<PG>378-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belgium-1988" NAME="Belgium 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Loquet P, Buytaert P, Renier M</AU>
<TI>The influence of pindolol and atenolol on serial feto-placental blood flow measurements in non-proteinuric hypertension in pregnancy</TI>
<SO>6th International Congress, International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>111</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Renier M, Loquet P, Buytaert P</AU>
<TI>The influence of pindolol and atenolol on serial feto-placental blood flow measurements in non-proteinuric hypertension in pregnancy</TI>
<SO>Proceedings of the 11th European Congress of Perinatal Medicine;1988 April 10-13; Rome, Italy</SO>
<YR>1988</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brazil-1997" MODIFIED="2013-05-19 21:33:58 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Brazil 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-05-19 21:33:58 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pereira TS, Pereira CIGS, Junior JA, Netto HC</AU>
<TI>Influence of nifedipine on the fetal placental flow</TI>
<SO>Jornal Brasileiro de Ginecologia</SO>
<YR>1997</YR>
<VL>107</VL>
<NO>10</NO>
<PG>371-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brazil-2000" MODIFIED="2014-01-01 16:09:20 +0000" MODIFIED_BY="Heather Maxwell" NAME="Brazil 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-01-01 16:09:20 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="BOOK">
<AU>Alves EA</AU>
<SO>Estudo prospectivo, comparativo da Isradipina e Atenolol no tratamento de gestantes hipertensas [Prospective, comparative study of isradipine and atenolol for the treatment of hypertensive pregnant women] [Doctoral Thesis]</SO>
<YR>1998</YR>
<PB>Faculty of Medicine, University of São Paulo</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Darcie S, Leone CR, Calil VMLT, Prescinotti EP, Kahhale S, Zugaib M</AU>
<TI>Glycemia in newborns of hypertensive mothers according to maternal treatment</TI>
<TO>Glicemia no recém-nascido de mäe hipertensas de acordo com a terapêutica materna</TO>
<SO>Revista do Hospital das Clínicas</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>5</NO>
<PG>244-0</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahhale S, Alves EA, Takiuti NH, Zugaib M</AU>
<TI>Efficacy and safety of isradipina and atenolol in hypertensive disorders in pregnancy [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>1</NO>
<PG>98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leone CR, Calil VMLT, Darcie S, Prescinotti EP, Kahhale S, Zugaib M</AU>
<TI>Growth of newborn of the mothers with hypertension during the first year of life: therapeutics in pregnancy on the newborn</TI>
<TO>Crescimento de recém-nascidos de mäes hipertensas durante o primeiro ano de vida: influência da terapêutica materna</TO>
<SO>Revista Paulista de Pediatría</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>1</NO>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brazil-2000b" NAME="Brazil 2000b" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vasconcellos MJ, Chaves Netto H, Kahhale S, Almeida PJ</AU>
<TI>Verapamil use in chronic hypertension pregnant women</TI>
<SO>XVI FIGO World Congress of Obstetrics and Gynaecology; 2000 Sept 3-8; Washington DC. Book 2</SO>
<YR>2000</YR>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vasconcellos MJA, Chaves Netto H, Kahhale S, Almeida PJ</AU>
<TI>Use of verapamil in chronic hypertensive pregnant women: flow analysis of uterine and umbilical artery</TI>
<TO>Uso do verapamil em gestantes hipertensas crônicas: análise do fluxo das artérias uterinas e umbilical</TO>
<SO>Revista Brasileira de Ginecologia é Obstetrícia</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>5</NO>
<PG>265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vasconcellos MJA, Chaves Netto H, Kahhale S</AU>
<TI>Incidence of small fetuses for the gestational age among chronic hypertensive women in use of verapamil (chronico oral use)</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>P166</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vasconcellos MJA, Chaves Netto H, Kahhale S</AU>
<TI>Verapamil: its effect on placental circulation in mild to moderate chronic hypertensive pregnant women</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>P163</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-China-1991" NAME="China 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qian XH, Huang YL, Wu SP</AU>
<TI>Treatment of hypertension syndrome of pregnancy with ligustrazine</TI>
<SO>Chung Hsi I Chieh Ho Tsa Chih</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>9</NO>
<PG>533-4, 516</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-China-1993" NAME="China 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong YJ, Lin CF, Chen JC, Pan P, Wong KL, Wei TT</AU>
<TI>Nifedipine in preeclampsia for cesarean section</TI>
<SO>Ma Tsui Hsueh Tsa Chi (Acta Anaesthesiologica Sinica)</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>1</NO>
<PG>43-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-China-1998" NAME="China 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li M, Yang M, Qiu X</AU>
<TI>The effect of nimodipine on retinal blood flow in pregnancy induced hypertension</TI>
<SO>Chung-Hua Fu Chan Ko Tsa Chih</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>7</NO>
<PG>397-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-China-1999" NAME="China 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Z, Song H</AU>
<TI>Clinical observation on therapeutical effect of prepared rhubarb in treating pregnancy induced hypertension</TI>
<SO>Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih</SO>
<YR>1999</YR>
<VL>19</VL>
<PG>725-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-China-2000" NAME="China 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang X, Liu Y</AU>
<TI>The effect of nifedipine on postpartum blood loss in patients with pregnancy induced hypertension</TI>
<SO>Zhonghua Fu Chan Ke Za Zhi</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>3</NO>
<PG>151-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cuba-1994" NAME="Cuba 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gómez Sosa E, Miró Maceo M, Alcade MT</AU>
<TI>Mild chronic hypertension: antihypertensive medication and maternal and perinatal results</TI>
<TO>Hipertensión Crónica Moderada: Medicación Antihipertensiva y resultados maternos y perinatales</TO>
<SO>Revista Cubana de Medicina General Integral</SO>
<YR>1994</YR>
<VL>10</VL>
<NO>4</NO>
<PG>340-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czech-Republic-1993" NAME="Czech Republic 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soucek M, Prasek J, Spinarova L</AU>
<TI>Atenolol and bisoprolol in the treatment of mild and moderately severe hypertension</TI>
<TO>Atenolol a bisoprolol v lécbe mírné a stredne tezké hypertenze</TO>
<SO>Vnitrni Lekarstvi</SO>
<YR>1993</YR>
<VL>39</VL>
<NO>6</NO>
<PG>541-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denmark-1991" NAME="Denmark 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicki M, Frölich A, Fischer Rasmussen W, McNair P</AU>
<TI>The effect of magnesium on maternal blood pressure in pregnancy-induced hypertension</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1991</YR>
<VL>70</VL>
<PG>445-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicki M, Frölich A, Fischer-Rasmussen W</AU>
<TI>Magnesium supplement in pregnancy-induced hypertension: effects on maternal and neonatal magnesium and calcium homeostasis</TI>
<SO>Mineral and Electrolyte Metabolism</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>6</NO>
<PG>399-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicki M, Junge J, Frölich A, Ornvold K, Fischer-Rasmussen W</AU>
<TI>Magnesium supplement in pregnancy-induced hypertension. A clinicopathological study</TI>
<SO>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</SO>
<YR>1990</YR>
<VL>98</VL>
<NO>12</NO>
<PG>1123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denmark-2000" NAME="Denmark 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicki M, Frølich A, Pilsgaard K, Nyrnberg L, Møller M, Sanchez M, et al</AU>
<TI>Comparison of magnesium and methyldopa for the control of blood pressure in pregnancies complicated with hypertension</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>2000</YR>
<VL>49</VL>
<PG>231-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominican-Rep-1992" NAME="Dominican Rep 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cid-Troncoso J, Pérez-Pérez M, Jiménez JA, Núñez-Diplan AM, Balbi M, Santana E</AU>
<TI>Nifedipine retard vs methyldopa in chronic hypertension with superimposed toxemia</TI>
<TO>Nifedipina retard vs. alfa-metil-dopa en la hipertensión arterial crónica mas toxemia agregada</TO>
<SO>Revista Médica Dominicana</SO>
<YR>1992</YR>
<VL>53</VL>
<NO>2/3</NO>
<PG>76-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominican-Rep-1992a" MODIFIED="2014-01-01 16:12:17 +0000" MODIFIED_BY="Heather Maxwell" NAME="Dominican Rep 1992a" YEAR="1992">
<REFERENCE MODIFIED="2014-01-01 16:12:17 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deschamps C, Guzman P, Mejia M, Sanchez Ramirez PB, Sanchez Beltre JE, Gomez Hernandez J</AU>
<TI>Comparison of hydralazine and alpha methyldopa in hypertension in pregnancy</TI>
<TO>Comparacion de hidralazina y alfametildopa en la hipertension durante el embarazo</TO>
<SO>Acta Medica Dominicana</SO>
<YR>1992</YR>
<VL>14</VL>
<NO>6</NO>
<PG>222-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egypt-1988" NAME="Egypt 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Salem HT, Ghanemah S, Seleem S, Sayed EH, Abdel-Latif A, Chard T</AU>
<TI>Bromocriptine therapy in pre-eclamptic toxaemia of pregnancy (PET)</TI>
<SO>World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil</SO>
<YR>1988</YR>
<PG>184</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egypt-1993" NAME="Egypt 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ismail AAA, Medhat I, Tawfic TAS, Kholeif A</AU>
<TI>Evaluation of calcium-antagonist (Nifedipine) in the treatment of pre-eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1993</YR>
<VL>40</VL>
<PG>39-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egypt-1997" NAME="Egypt 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Salem HT, Salah M, Kotb HI, Makarem MH, Mostafa SAM, Mohamed SA</AU>
<TI>The use of specific opioid receptor antagonist (Naltrexone) in hypertensive pregnancy</TI>
<SO>Research Activities on Reproductive Health</SO>
<YR>1997</YR>
<PG>74</PG>
<PB>Assiut University, Faculty of Medicine</PB>
<CY>Assiut</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egypt-2009" MODIFIED="2013-05-19 21:48:00 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Egypt 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-19 21:48:00 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanbouli T, Mawsouf MN, Re L, Martinez-Sanchez G, Saaed G, El SM, et al</AU>
<TI>Effect of ozone therapy on foetoplacental blood flow in hypertensive pregnant women</TI>
<SO>International Journal of Ozone Therapy</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>2</NO>
<PG>211-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finland-1988" MODIFIED="2014-01-01 16:14:02 +0000" MODIFIED_BY="Heather Maxwell" NAME="Finland 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-01-01 16:14:02 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tuimala R, Hartikainen-Sorri AL</AU>
<TI>Randomised comparison of atenolol and pindolol for treatment of hypertension in pregnancy</TI>
<SO>Current Therapeutic Research</SO>
<YR>1988</YR>
<VL>44</VL>
<NO>4</NO>
<PG>579-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tuimala R, Hartikainen-Sorri AL</AU>
<TI>Treatment of hypertension during pregnancy by beta blocking agents</TI>
<SO>4th World Congress of the International Society for the study of Hypertension in Pregnancy; 1984 June 18-21; Amsterdam, The Netherlands</SO>
<YR>1984</YR>
<PG>52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finland-1988a" NAME="Finland 1988a" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yla-Outinen A, Tuimala R</AU>
<TI>Management of pregnancy induced hypertension by using nifedipine - a prospective randomized trial</TI>
<SO>6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finland-1995" NAME="Finland 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Räsänen J, Joupilla P</AU>
<TI>Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1995</YR>
<VL>62</VL>
<PG>195-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finland-1999" NAME="Finland 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laivuori HM, Laakso M, Tikkanen MJ, Cacciatore B, Ylikorkala RO, Kaaja Rj</AU>
<TI>Short-term metabolic effects of isradipine and metoprolol in pre-eclampsia</TI>
<SO>Journal of Hypertension</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>8</NO>
<PG>1189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-France-1988a" NAME="France 1988a" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Madonna O, M'Pio I, Labeeuw M, Pozet N, Zech P</AU>
<TI>Evaluation of renal function in pregnant hypertensives under treatment. A comparison between methyldopa, pindolol and atenolol</TI>
<SO>6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>260</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-France-1990" NAME="France 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonnin P, Mintz P, Kedra AW, Pruna A, Ciraru-Vigneron N, Savin E, et al</AU>
<TI>Effects of nifedipine and atenolol on the fetal-maternal circulation in moderate hypertension in pregnancy</TI>
<TO>Effets de la nifedipine et de l'atenolol sur les circulations foeto-maternelles en cas d'hypertension arterielle gravidique moderee</TO>
<SO>Therapie</SO>
<YR>1990</YR>
<VL>45</VL>
<NO>6</NO>
<PG>525</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciraru-Vigneron N, Pruna A, Akposso K, Bonnin P, Kedra W, Mintz P, et al</AU>
<TI>Comparison of the effects of nefedipine and atenolol in the treatment of uncomplicated hypertension in pregnancy</TI>
<TO>Comparaison des effets de la nifedipine et de l'atenolol dans le traitement de l'hypertension arterielle gravidique non compliquée</TO>
<SO>Therapie</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>3</NO>
<PG>221</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Ciraru-Vigneron N, Pruna A, Mintz P, Bonnin P, Lefevre V, Beaufils M, et al</AU>
<TI>Comparison of nifedipine and atenolol in treatment of moderate pregnancy hypertension</TI>
<SO>Proceedings of the 7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<PG>340</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mintz P, Ciraru-Vigneron N, Ravina JH, Pruna A, Idatte JH, Bonnin P, et al</AU>
<TI>Comparison of the effects of nifedipine and atenolol in the treatment of non-complicated hypertension in pregnancy</TI>
<TO>Comparaison des effets de la nifedipine et de l'atenolol dans le traitement de l'hypertension arterielle gravidique non compliquée</TO>
<SO>Therapie</SO>
<YR>1989</YR>
<VL>44</VL>
<NO>6</NO>
<PG>461</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Germany-2012" MODIFIED="2013-05-19 21:01:33 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Germany 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-05-19 21:01:33 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groten T, Fitzgerald J, Lehmann T, Schneider U, Kahler C, Schleussner E</AU>
<TI>Reduction of preeclampsia related complications with with the NO-donor penterythriltetranitrat (petn) in risk pregnancies - A prospective randomized double-blind placebo pilot study</TI>
<SO>Pregnancy Hypertension</SO>
<YR>2012</YR>
<VL>2</VL>
<NO>3</NO>
<PG>181</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-Kong-1993" NAME="Hong Kong 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yuen FT, Mo YP, Yin LC, Terence L</AU>
<TI>A double-blind randomised placebo controlled trial of labetalol in the treatment of mild pregnancy induced hypertension</TI>
<SO>Proceedings of the 2nd International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1993; Hong Kong, Singapore</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hungary-1999" NAME="Hungary 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tamás P, Csermely T, Ertl T, Vizer M, Szabó I, Prievara FT</AU>
<TI>Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension: a pilot study</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1999</YR>
<VL>47</VL>
<PG>210-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tamás P, Csermely T, Szabó EI</AU>
<TI>Doxium - a novel drug in the management of gestational hypertension?</TI>
<SO>16th European Congress of Perinatal Medicine; 1998 June 10-13; Zagreb</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamás P, Szabó I, Szekely J, Csermely T, Prievara FT, Nemeth L, et al</AU>
<TI>Effects of doxium 500(tm) in gestational hypertension</TI>
<TO>A Doxium 500 (R) hatasanak vizgalata terhessegi hypertoniaban (kettos vak, placebo-kontrollalt tanulmany)</TO>
<SO>Magyar Noorvosok Lapja</SO>
<YR>1997</YR>
<VL>60</VL>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-1999" NAME="India 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shenoy S, Chandrika D, Pisharody R</AU>
<TI>RCT of low dose aspirin to prevent the progression of pregnancy induced hypertension grade A to B</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>Suppl 1</NO>
<PG>28S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-2011" MODIFIED="2013-05-20 15:45:15 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="India 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-20 15:45:15 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pandey K, Gupta N, Gupta R, Gupta S</AU>
<TI>Comparing obstetric outcome using labetalol/methyldopa in pregnancy induced hypertension</TI>
<SO>54th All India Congress of Obstetrics and Gynaecology; 2011 January 5-9; Hyderabad, Andhra Pradesh, India</SO>
<YR>2011</YR>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-2012a" MODIFIED="2014-01-01 16:16:14 +0000" MODIFIED_BY="Edgardo J Abalos" NAME="India 2012a" YEAR="2012">
<REFERENCE MODIFIED="2014-01-01 16:16:14 +0000" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verma R, Lahon K, TonpaY SD, Kale VJ</AU>
<TI>A comparative randomised controlled parallel group study of maternal, fetal and neonatal outcomes of labetalol versus methyldopa in the treatment of new onset hypertension during pregnancy</TI>
<SO>International Journal of Pharma &amp; Bio Sciences</SO>
<YR>2012</YR>
<VL>3</VL>
<NO>1</NO>
<PG>201-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-2012b" MODIFIED="2013-05-19 22:32:16 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="India 2012b" YEAR="2012">
<REFERENCE MODIFIED="2013-05-19 20:45:15 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dasgupta S, Ghosh D, Seal SL, Kamilya G, Karmakar M, Saha D</AU>
<TI>Randomized controlled study comparing effect of magnesium sulfate with placebo on fetal umbilical artery and middle cerebral artery blood flow in mild preeclampsia at &gt;= 34 weeks gestational age</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2012</YR>
<VL>38</VL>
<NO>5</NO>
<PG>763-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-19 20:45:15 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="OTHER">
<AU>Dasgupta S</AU>
<TI>Does prophylactic magnesium sulphate in mild preeclampsia reduce umbilical artery pulsatility index? A randomized placebo controlled trial</TI>
<SO>Clinical Trials Registry - India (http://www.ctri.nic.in) (accessed 8 July 2011)</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Iran-2000" NAME="Iran 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yassae F</AU>
<TI>A comparison of the effect of nifedipine and hydralazine in treatment of pregnancy induced hypertension</TI>
<SO>XVI FIGO World Congress of Obstetric and Gynecology (Book 3); 2000 Sept 3-8; Washington DC, USA</SO>
<YR>2000</YR>
<PG>93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iran-2005" MODIFIED="2013-05-19 20:50:22 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Iran 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-19 20:50:22 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghahiri A, Berjis K</AU>
<TI>A comparison between intravenous magnesium sulfate and oral magnesium chloride in mild preeclampsia</TI>
<SO>Journal of Research in Medical Sciences</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>1</NO>
<PG>6-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Israel-1988" NAME="Israel 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Davidson A, Ellenbogen A, Jaschevatzky O, Attias Y, Anderman S, Grunstein S</AU>
<TI>Randomized comparison of pindolol and atenolol for treatment of hypertension during pregnancy</TI>
<SO>6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Israel-1992a" NAME="Israel 1992a" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meizner I, Paran E, Katz M, Holcberg G, Insler V</AU>
<TI>Flow velocity analysis of umbilical and uterine artery flow in pre-eclampsia treated with propranolol or pindolol</TI>
<SO>Journal of Clinical Ultrasound</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>115-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Israel-1999" NAME="Israel 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thaler I, Amit A, Kamil D, Itskovitz-Eldor J</AU>
<TI>The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension</TI>
<SO>American Journal of Hypertension</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>4</NO>
<PG>341-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-1986" NAME="Italy 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Martinelli P, Ferrara LA, Pasanisi F, Arpaia F, Paladini D, Mancini M</AU>
<TI>Nifedipine and atenolol in the treatment of pregnancy associated hypertension</TI>
<SO>5th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1986 July 7-10; Nottingham, England</SO>
<YR>1986</YR>
<PG>128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-1990" NAME="Italy 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marlettini MG, Crippa S, Morselli-Labate AM, Contarini A, Orlandi C</AU>
<TI>Randomised comparison of calcium antagonists and beta-blockers in the treatment of pregnancy-induced hypertension</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1990</YR>
<VL>48</VL>
<NO>4</NO>
<PG>684-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Orlandi C, Marlettini MG, Cassani A, Crippa S</AU>
<TI>Antihypertensive therapy in pregnancy</TI>
<SO>Proceedings of the 11th European Congress of Perinatal Medicine; 1988; Rome, Italy</SO>
<YR>1988</YR>
<PG>271</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-1990a" NAME="Italy 1990a" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Di Iorio R, Horvath S, Marinoni E, Manzari G, Martinico E, Bresadola M</AU>
<TI>Use of a thromboxane receptor inhibitor in pregnancy-induced hypertension</TI>
<SO>Proceedings of the 7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<EN>75</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-2000a" NAME="Italy 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Picciolo C, Roncaglia N, Neri I, Pasta F, Arreghini A, Facchinetti F</AU>
<TI>Nitric oxide in the prevention of pre-eclampsia</TI>
<SO>Prenatal and Neonatal Medicine</SO>
<YR>2000</YR>
<VL>5</VL>
<PG>212-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-2001" NAME="Italy 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scarpellini F, Sbracia M, Lecchini S, Bolis P</AU>
<TI>Nitric oxide donor treatment reduces apoptosis in placental vessels of pregnancy induced hypertension [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2001</YR>
<VL>185</VL>
<NO>6 Suppl</NO>
<PG>S177</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-2004" MODIFIED="2013-05-19 21:12:46 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Italy 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-19 21:12:46 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neri I, Venturini P, Battista Allais G, Facchinetti F</AU>
<TI>Acupuncture plus alfa-metildopa in the treatment of chronic hypertension: a protocol design [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>Suppl 1</NO>
<PG>54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-2006" MODIFIED="2013-05-19 21:21:35 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Italy 2006" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Facchinetti F, Piccinini F, Pizzi C, Bukowski R, Volpe A, Saade G</AU>
<TI>Effect of arginine supplementation in patients with gestational hypertension</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>6</NO>
<PG>S213</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-19 21:21:02 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neri I, Blasi I, Facchinetti F</AU>
<TI>Effects of acute L-arginine infusion on non-stress test in hypertensive pregnant women</TI>
<SO>Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-19 21:20:56 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neri I, Jasonni VM, Gori GF, Blasi I, Facchinetti F</AU>
<TI>Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial</TI>
<SO>Journal of Maternal-Fetal and Neonatal Medicine</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>5</NO>
<PG>277-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-2008" MODIFIED="2013-05-19 21:25:15 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Italy 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-19 21:25:15 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noris M, Fratelli N, Rampello S, Gherardi G, Platto C, Todeschini M, et al</AU>
<TI>A double-blind, randomized, pilot study on L-arginine oral supplementation in pre-eclamptic pregnancies</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>4</NO>
<PG>505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Italy-2010" MODIFIED="2013-05-19 22:08:04 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Italy 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-19 22:08:04 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neri I, Monari F, Sgarbi L, Berardi A, Masellis G, Facchinetti F</AU>
<TI>L-Arginine supplementation in women with chronic hypertension: Impact on blood pressure and maternal and neonatal complications</TI>
<SO>Journal of Maternal-Fetal and Neonatal Medicine</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>12</NO>
<PG>1456-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Japan-1997" NAME="Japan 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Makino Y, Izumi H, Makino I, Shirakawa K</AU>
<TI>The effect of nitric oxide on uterine and umbilical artery flow velocity waveform in pre-eclampsia</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1997</YR>
<VL>73</VL>
<NO>2</NO>
<PG>139-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuwait-1995" NAME="Kuwait 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Qarmalawi AM, Morsy AH, Al-Fadly A, Obeid A, Hashem M</AU>
<TI>Labetalol vs methyldopa in the treatment of pregnancy-induced hypertension</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1995</YR>
<VL>49</VL>
<PG>125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mexico-2008" MODIFIED="2013-05-19 21:09:45 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Mexico 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-19 21:09:45 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="OTHER">
<AU>Lopez-Molina K, Gonzalez-Altamirano JC, Valdivia-Silva JE</AU>
<TI>Early L-arginine therapy improves notably the fetal growth in preeclamptic women. A randomized controlled trial</TI>
<SO>55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26-29; San Diego, USA</SO>
<YR>2008</YR>
<PG>Abstract no: 801</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pakistan-1994" NAME="Pakistan 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilani A, Khan Z</AU>
<TI>Role of aspirin in management of pregnancy induced hypertension. A study in Pakistani population</TI>
<SO>Specialist</SO>
<YR>1994</YR>
<VL>10</VL>
<NO>4</NO>
<PG>323-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panama-2012" MODIFIED="2013-06-17 12:16:14 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Panama 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-06-17 12:16:14 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="OTHER">
<AU>Reyes OA</AU>
<TI>Hydralazine vs. Labetalol for the management of hypertensive crisis in patients with hypertensive disorders of pregnancy. a randomized controlled trial</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT01538875"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Philippines-2000" NAME="Philippines 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Decano MB, Cabrera LT</AU>
<TI>The effects of transdermal nitroglicerin (nitrol patch) on the uterine and umbilical artery blood flow in preeclampsia: a randomized double blind placebo controlled study</TI>
<SO>XVI Figo World Congress of Obstetric and Gynecology (Book 1); 2000 Sept 3-8; Washington DC, USA</SO>
<YR>2000</YR>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russia-1993" NAME="Russia 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osadchaia OV, Nazarenko LG, Bobritskaia VV</AU>
<TI>The clinical and hemodynamic aspects of using peripheral vasodilators in hypertension in pregnant women</TI>
<TO>Klinicheskie i gemodinamicheskie aspekty primeneniia perifericheskikh vazodilatorov pri gipertenzii beremennykh</TO>
<SO>Akusherstvo i Ginekologia</SO>
<YR>1993</YR>
<VL>1993</VL>
<NO>2</NO>
<PG>16-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singapore-1996" NAME="Singapore 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam SS</AU>
<TI>Randomised controlled trial of methyldopa and isradipine in preeclampsia - effects on uteroplacental and fetal hemodynamics</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1996</YR>
<VL>24</VL>
<PG>177-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wide-Swensson D, Montan S, Arulkumaran S, Ingemarsson I, Ratnam SS</AU>
<TI>Effect of methyldopa and isradipine on fetal heart rate pattern assessed by computerized cardiotocography in human pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>169</VL>
<PG>1581-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singapore-1998" NAME="Singapore 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yin KH, Koh SCL, Malcus P, Montan S, Biswas A, Arulkumaran S, et al</AU>
<TI>Preeclampsia: haemostatic status and the short-term effects of methyldopa and isradipine therapy</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>1998</YR>
<VL>24</VL>
<NO>3</NO>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slovakia-2002" MODIFIED="2014-01-01 16:19:07 +0000" MODIFIED_BY="Edgardo J Abalos" NAME="Slovakia 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-01-01 16:19:07 +0000" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirotiaková J, Mlyncek M, Kriska M, Letkovicová M</AU>
<TI>Acebutolol in the treatment of arterial hypertension in pregnancy--comparison with commonly used hypertensive agents</TI>
<TO>Acebutolol v liecbe arteriovej hypertenzie v gravidite--porovnanie s bezne uzivanymi antihypertenzivami</TO>
<SO>Ceska Gynekologie</SO>
<YR>2002</YR>
<VL>67</VL>
<NO>1</NO>
<PG>8-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1988" NAME="South Africa 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindow SW, Davies N, Davey DA, Smith JA</AU>
<TI>The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1988</YR>
<VL>95</VL>
<PG>1276-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1990" NAME="South Africa 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anthony J, Rees AE, Davey DA</AU>
<TI>Indoramin in the treatment of pregnancy hypertension</TI>
<SO>South African Medical Journal</SO>
<YR>1990</YR>
<VL>78</VL>
<PG>458-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1991a" NAME="South Africa 1991a" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puzey MS, Ackovic KL, Lindow SW, Gonin R</AU>
<TI>The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancies complicated by hypertension</TI>
<SO>South African Medical Journal</SO>
<YR>1991</YR>
<VL>79</VL>
<PG>192-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1997" MODIFIED="2013-05-19 21:28:27 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="South Africa 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steyn DW, Odendaal HJ, Kirsten GF</AU>
<TI>Mental development in children six years after in utero exposure to ketanserin - a follow-up study of a randomized controlled trial</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>131</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steyn DW, Odendaal HJ</AU>
<TI>Blood pressure patterns in pregnant patients on oral ketanserin</TI>
<SO>Cardiovascular Journal of Southern Africa</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>2</NO>
<PG>82-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Steyn DW, Odendaal HJ</AU>
<TI>Fetal heart baseline variability in patients on oral ketanserin</TI>
<SO>10th World Congress of the International Society for the Study of Hypertension in Pregnancy;1996 August 4-8; Seattle, Washington, USA</SO>
<YR>1996</YR>
<PG>171</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steyn DW, Odendaal HJ</AU>
<TI>Maternal outcome six years after presenting with mild to moderate mid-trimester hypertension during pregnancy</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-19 21:28:27 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Steyn DW, Odendaal HJ</AU>
<TI>Maternal outcome six years after presenting with mild to moderate mid-trimester hypertension during pregnancy</TI>
<SO>21st Conference on Priorities in Perinatal Care in South Africa; 2002 March 5-8; Eastern Cape, South Africa</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Steyn DW, Odendaal HJ</AU>
<TI>Oral ketanserin in mild midtrimester hypertension - a randomised controlled trial</TI>
<SO>Proceedings of the 16th Conference on Priorities in Perinatal Care; 1997; South Africa</SO>
<YR>1997</YR>
<PG>88-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Steyn DW, Odendaal HJ</AU>
<TI>Oral ketanserin plus aspirin decrease the incidence of proteinuric hypertension and perinatal mortality in patients with mild midtrimester hypertension</TI>
<SO>10th World Congress of the International Society for the Study of Hypertension in Pregnancy;1996 August 4-8; Seattle, Washington, USA</SO>
<YR>1996</YR>
<PG>131</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steyn DW, Odendaal HJ</AU>
<TI>Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>1267-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steyn DW, Odendaal HJ</AU>
<TI>The effect of oral ketanserin on fetal heart rate parameters</TI>
<SO>Journal of Maternal Fetal Investigation</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>126-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spain-1988" NAME="Spain 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Torres Pons PJ, Roca M, Codina C, Cobo E, Cararach V, Gonzalez-Merlo J</AU>
<TI>Labetalol in the treatment of mild hypertension in pregnancy. A double blind controlled trial</TI>
<SO>6th International Congress, International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada</SO>
<YR>1988</YR>
<PG>102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sri-Lanka-1994" NAME="Sri Lanka 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jayawardana J, Lekamge N</AU>
<TI>A comparison of nifedipine with methyldopa in pregnancy induced hypertension</TI>
<SO>Ceylon Medical Journal</SO>
<YR>1994</YR>
<VL>39</VL>
<PG>87-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sweden-1992" NAME="Sweden 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Montan S, Ingemarsson I, Marsál K, Sjöberg NO</AU>
<TI>Negative influence of atenolol compared with pindolol on fetal hemodynamics in pregnancies with hypertension - a controlled study</TI>
<SO>Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<PG>192</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Montan S, Ingemarsson I, Marsál K, Sjöberg NO</AU>
<TI>Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<PG>946-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sweden-1993" NAME="Sweden 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hjertberg R, Belfrage P, Faxelius G, Lagercrantz H</AU>
<TI>Neonatal outcome in infants &lt;1500g, a randomized study of labetalol vs dihydralazine-treated hypertensive pregnant women</TI>
<SO>Proceedings of the 7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<PG>361</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hjertberg R, Faxelius G, Belfrage P</AU>
<TI>Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1993</YR>
<VL>72</VL>
<PG>611-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hjertberg R, Faxelius G, Lagercrantz H</AU>
<TI>Neonatal adaptation in hypertensive pregnancy - a study of labetalol vs hydralazine treatment</TI>
<SO>Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland</SO>
<YR>1994</YR>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hjertberg R, Faxelius G, Lagercrantz H</AU>
<TI>Neonatal adaption in hypertensive pregnancy - a study of labetalol vs hydralazine treatment</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>69-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Uganda-1992" MODIFIED="2013-05-19 20:19:12 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Uganda 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-05-19 20:19:12 +0100" MODIFIED_BY="Edgardo J Abalos" NOTES="&lt;p&gt;Lule J. 7239. Aspirin and methyldopa for moderate hypertension in pregnancy . Personal communication June 6 1992;&lt;/p&gt;" NOTES_MODIFIED="2013-05-19 20:19:12 +0100" NOTES_MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lule J</AU>
<TI>Aspirin and methyldopa for moderate hypertension in pregnancy</TI>
<SO>Personal communication</SO>
<YR>June 6 1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1978" NAME="UK 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Redman CWG</AU>
<TI>A controlled trial of the treatment of hypertension in pregnancy: labetalol compared with methyldopa. The investigation of labetalol in the management of hypertension in pregnancy</TI>
<SO>International Congress Series 591</SO>
<YR>1978</YR>
<PG>101-10</PG>
<PB>Amsterdam: Excerpta Medica</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Redman CWG</AU>
<TI>Controlled trials of treatment of hypertension during pregnancy</TI>
<SO>Proceedings of the 8th International Congress of Nephrology; 1981; Athens, Greece</SO>
<YR>1981</YR>
<PG>523-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1991" NAME="UK 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Harper A, Murnaghan GA, Erskine L, Ritchie JK. Response of fetal umbilical artery time velocity waveforms to antihypertensive drugs . Proceedings of the 24th British Congress of Obstetrics and Gynaecology;1986 April 15-18; Cardiff, UK 1986:33&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harper A, Murnaghan GA, Erskine L, Ritchie JK</AU>
<TI>Response of fetal umbilical artery time velocity waveforms to antihypertensive drugs</TI>
<SO>Proceedings of the 24th British Congress of Obstetrics and Gynaecology;1986 April 15-18; Cardiff, UK</SO>
<YR>1986</YR>
<PG>33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harper A, Murnaghan GA</AU>
<TI>Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1991</YR>
<VL>98</VL>
<PG>453-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-1957" NAME="USA 1957" YEAR="1957">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landesman R, McLarn WD, Ollstein RN, Mendelsohn B</AU>
<TI>Reserpine in toxemia of pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1957</YR>
<VL>9</VL>
<PG>377-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-1981" NAME="USA 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welt SI, Dorminy JH, Jelovsek FR, Crenshaw MC, Gall SA</AU>
<TI>The effect of prophylactic management and therapeutics on hypertensive disease in pregnancy: preliminary studies</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1981</YR>
<VL>57</VL>
<PG>557-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-USA-1990a" MODIFIED="2013-05-19 20:23:00 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="USA 1990a" YEAR="1990">
<REFERENCE MODIFIED="2013-05-19 20:23:00 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Weiner CP</AU>
<TI>Trial to evaluate oral hypotensive agents in early onset preeclampsia</TI>
<SO>Personal communication</SO>
<YR>November 1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-1991" NAME="USA 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thaler I, Wiener Z, Manor D, Itskovitz J</AU>
<TI>Effect of calcium channel blocker nifedipine on uterine artery flow velocity waveforms</TI>
<SO>Journal of Ultrasound in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>6</NO>
<PG>301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-2005" MODIFIED="2013-05-19 20:28:41 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="USA 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-19 20:28:27 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="OTHER">
<AU>August P</AU>
<TI>Treatment targets for chronic hypertension in pregnancy</TI>
<SO>http://clinicaltrials.gov/ct2/show/record/NCT00194974 (accessed 17 May 2013)</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00194974"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Venezuela-1985" NAME="Venezuela 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sánchez S, Zschaeck D, Alfonso C, González I, Kalbakdij B</AU>
<TI>Labetalol in the treatment of hypertension associated with pregnancy</TI>
<TO>Labetalol en el tratamiento de la hipertensión arterial asociada al embarazo</TO>
<SO>Centro Médico</SO>
<YR>1985</YR>
<VL>24</VL>
<NO>81</NO>
<PG>101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venezuela-1997" NAME="Venezuela 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>González JC, Andolcetti R</AU>
<TI>Labetalol vs. methyldopa in the treatment of hypertension in pregnancy</TI>
<TO>Labetalol vs metildopa en el tratamiento de la hipertensión arterial asociada con el embarazo</TO>
<SO>Boletín Médico de Postgrado</SO>
<YR>1997</YR>
<VL>13</VL>
<NO>1</NO>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venezuela-2001" NAME="Venezuela 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reyna-Villasmil E, Prieto-Franchi M, Guerra-Velázquez M, Torres-Montilla M</AU>
<TI>Effect of transdermal nitroglycerin on umbilical artery blood flow in preeclampsia (abstract)</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>Suppl 1</NO>
<PG>486</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venezuela-2007" MODIFIED="2013-05-19 20:35:47 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="Venezuela 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-05-19 20:35:47 +0100" MODIFIED_BY="Edgardo J Abalos" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Centeno DMW, Urbina JCP, De Las Salas M, Fuenmayor AJ</AU>
<TI>Effect of carvedilol in the treatment of hypertension in pregnant women</TI>
<SO>XLIV ERA-EDTA Congress; 2007 June 21-24; Barcelona, Spain</SO>
<YR>2007</YR>
<PG>Poster no: FP078</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-05-22 16:15:23 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Canada-2008" MODIFIED="2013-05-19 22:34:25 +0100" MODIFIED_BY="[Empty name]" NAME="Canada 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-06 12:27:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Smith G</AU>
<TI>Use of a nitric oxide (ISMN) for the prevention and management of pre-eclampsia (pilot study)</TI>
<SO>http://www.controlled-trials.com/isrctn/pf/45790835</SO>
<YR>(accessed 20 February 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-08-06 12:27:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-06 12:27:53 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN45790835"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-01-01 16:28:03 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-25 12:04:07 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ASSHP-1993" NAME="ASSHP 1993" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Australian Society for the Study of Hypertension in Pregnancy: Consensus statement: management of hypertension in pregnancy: executive summary</TI>
<SO>Medical Journal of Australia</SO>
<YR>1993</YR>
<VL>158</VL>
<PG>700-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2000" NAME="Brown 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, et al</AU>
<TI>The detection, investigation, and management of hypertension in pregnancy: full consensus statement</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>2000</YR>
<VL>40</VL>
<NO>2</NO>
<PG>139-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2001" NAME="Brown 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brown MA, Lindheimer MD, De Swiet M, Van Assche A, Moutquin J</AU>
<TI>The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the international society for the study of hypertension in pregnancy (ISSHP)</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>1</NO>
<PG>ix-xiv</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chappell-1999" NAME="Chappell 1999" TYPE="JOURNAL_ARTICLE">
<AU>Chappell L, Poulton L, Halligan A, Shennan AH</AU>
<TI>Lack of consistency in research papers over the definition of pre-eclampsia</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1999</YR>
<VL>106</VL>
<PG>983-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CHSCC-1997" NAME="CHSCC 1997" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1997</YR>
<VL>157</VL>
<PG>1245-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Churchill-2007" MODIFIED="2013-06-14 13:18:58 +0100" MODIFIED_BY="[Empty name]" NAME="Churchill 2007" TYPE="COCHRANE_REVIEW">
<AU>Churchill D, Beevers GDG, Meher S, Rhodes C</AU>
<TI>Diuretics for preventing pre-eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-06-14 13:18:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 13:18:58 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004451.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davey-1988" NAME="Davey 1988" TYPE="JOURNAL_ARTICLE">
<AU>Davey DA, MacGilivray I</AU>
<TI>The classification and definition of the hypertensive disorders of pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>892-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duley-1999" MODIFIED="2008-05-08 11:22:33 +0100" MODIFIED_BY="[Empty name]" NAME="Duley 1999" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Henderson-Smart DJ</AU>
<TI>Reduced salt intake compared to normal dietary salt, or high intake, in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-05-08 11:22:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-08 11:22:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001687"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-2007" MODIFIED="2013-06-14 13:02:00 +0100" MODIFIED_BY="[Empty name]" NAME="Duley 2007" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Henderson-Smart DJ, Meher S, King JF</AU>
<TI>Antiplatelet agents for preventing pre-eclampsia and its complications</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-06-14 13:02:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 13:02:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004659.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-2013" MODIFIED="2013-09-06 15:04:09 +0100" MODIFIED_BY="Leanne V Jones" NAME="Duley 2013" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Meher S, Jones L</AU>
<TI>Drugs for treatment of very high blood pressure during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2013-09-06 15:04:09 +0100" MODIFIED_BY="Leanne V Jones">
<IDENTIFIER MODIFIED="2013-09-06 15:04:09 +0100" MODIFIED_BY="Leanne V Jones" TYPE="DOI" VALUE="10.1002/14651858.CD001449.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frishman-1979" NAME="Frishman 1979" TYPE="JOURNAL_ARTICLE">
<AU>Frishman W</AU>
<TI>Clinical pharmacology of the new beta-adrenergic drugs. Part 1. Pharmacodynamic and pharmacokinetic properties</TI>
<SO>American Heart Journal</SO>
<YR>1979</YR>
<VL>97</VL>
<PG>663-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frishman-1995" NAME="Frishman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Frishman WH, Huberfeld S, Okin S, Wang Y-H, Kumar A, Shareef B</AU>
<TI>Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>35</VL>
<PG>541-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gifford-1990" NAME="Gifford 1990" TYPE="JOURNAL_ARTICLE">
<AU>Gifford RW, August P, Chesley LC, Cunningham G, Ferris TF, Lindheimer MD, et al</AU>
<TI>National high blood pressure education program working group report on high blood pressure in pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>163</VL>
<PG>1691-712</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2012-08-29 10:18:46 +0100" MODIFIED_BY="Denise Atherton" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-08-29 10:18:57 +0100" MODIFIED_BY="Denise Atherton" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2012" MODIFIED="2013-06-14 13:09:12 +0100" MODIFIED_BY="[Empty name]" NAME="Hofmeyr 2012" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ</AU>
<TI>Abdominal decompression for suspected fetal compromise/pre-eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-06-14 13:09:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 13:09:04 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000004.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hytten-1980" NAME="Hytten 1980" TYPE="BOOK">
<AU>Hytten F, Chamberlain G</AU>
<SO>Clinical physiology in obstetrics</SO>
<YR>1980</YR>
<PB>Blackwell Scientific Publications</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ingenito-1970" NAME="Ingenito 1970" TYPE="JOURNAL_ARTICLE">
<AU>Ingenito AJ, Barrett JP, Procita L</AU>
<TI>A centrally mediated peripheral hypotensive effect of methyldopa</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1970</YR>
<VL>175</VL>
<PG>593-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Isaac-1980" NAME="Isaac 1980" TYPE="JOURNAL_ARTICLE">
<AU>Isaac L</AU>
<TI>Clonidine in the central nervous system: site of mechanism of hypotensive action</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>1</NO>
<PG>S5-S19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magee-2003" MODIFIED="2008-05-08 11:18:55 +0100" MODIFIED_BY="[Empty name]" NAME="Magee 2003" TYPE="COCHRANE_REVIEW">
<AU>Magee LA, Duley L</AU>
<TI>Oral beta-blockers for mild to moderate hypertension during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-05-08 11:18:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-08 11:18:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002863"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Magee-2013" MODIFIED="2013-06-14 13:28:33 +0100" MODIFIED_BY="[Empty name]" NAME="Magee 2013" TYPE="COCHRANE_REVIEW">
<AU>Magee L, von Dadelszen P</AU>
<TI>Prevention and treatment of postpartum hypertension</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-06-14 13:28:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 13:28:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004351.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meher-2005" MODIFIED="2008-05-08 11:25:12 +0100" MODIFIED_BY="[Empty name]" NAME="Meher 2005" TYPE="COCHRANE_REVIEW">
<AU>Meher S, Duley L, on behalf of the Prevention of Pre-eclampsia Cochrane Review authors</AU>
<TI>Interventions for preventing pre-eclampsia and its consequences: generic protocol</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-05-08 11:25:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-08 11:25:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005301"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meher-2005a" MODIFIED="2008-05-08 11:15:36 +0100" MODIFIED_BY="[Empty name]" NAME="Meher 2005a" TYPE="COCHRANE_REVIEW">
<AU>Meher S, Abalos E, Carroli G</AU>
<TI>Bed rest with or without hospitalisation for hypertension during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-05-08 11:15:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-08 11:15:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003514.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NHBPEP-2000" NAME="NHBPEP 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gifford RW Jr, August PA, Cunningham G, Green LA, Lindhemier MD, McNellis D, et al</AU>
<TI>Report of the national high blood pressure education program working group on high blood pressure in pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>183</VL>
<NO>Suppl 1</NO>
<PG>S1-S22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2011" MODIFIED="2013-06-17 11:36:44 +0100" MODIFIED_BY="Edgardo J Abalos" NAME="NICE 2011" TYPE="BOOK_SECTION">
<AU>NICE</AU>
<TI>Hypertension in pregnancy: The management of hypertensive disorders during pregnancy</TI>
<SO>NICE Clinical Guideline 107</SO>
<YR>2011</YR>
<PG>1-53</PG>
<PB>National Institute for Health and Clinical Excellence</PB>
<CY>Manchester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-North-1999" NAME="North 1999" TYPE="JOURNAL_ARTICLE">
<AU>North RA, Taylor RS, Schellenberg JC</AU>
<TI>Evaluation of the definition of pre-eclampsia</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1999</YR>
<VL>106</VL>
<PG>767-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redman-1988" NAME="Redman 1988" TYPE="JOURNAL_ARTICLE">
<AU>Redman CWG, Jefferies M</AU>
<TI>Revised definition of pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>1</VL>
<PG>809-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redman-1993" NAME="Redman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Redman CWG, Roberts JM</AU>
<TI>Management of pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>1451-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-09-05 16:57:31 +0100" MODIFIED_BY="Denise Atherton" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1993" NAME="Roberts 1993" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JM, Redman CWG</AU>
<TI>Pre-eclampsia: more than pregnancy-induced hypertension</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>1447-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-1980" NAME="Robinson 1980" TYPE="JOURNAL_ARTICLE">
<AU>Robinson BF, Dobbs RJ, Kelsey CR</AU>
<TI>Effects of nifedipine on resistance vessels, arteries and veins in man</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1980</YR>
<VL>10</VL>
<PG>433-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rubin-1996" NAME="Rubin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rubin P</AU>
<TI>Measuring diastolic blood pressure in pregnancy</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seligman-1994" NAME="Seligman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB</AU>
<TI>The role of nitric oxide in the pathogenesis of preeclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>171</VL>
<NO>4</NO>
<PG>944-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stunkard-1954" NAME="Stunkard 1954" TYPE="JOURNAL_ARTICLE">
<AU>Stunkard A, Wertheimer L, Redisch W</AU>
<TI>Studies on hydralazine; evidences for a peripheral site of action</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1954</YR>
<VL>33</VL>
<PG>1047-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornton-2004" NAME="Thornton 2004" TYPE="JOURNAL_ARTICLE">
<AU>Thornton JG, Hornbuckle J, Vail A, Spiegelhalter DJ, Levene M, GRIT study group</AU>
<TI>Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<NO>9433</NO>
<PG>513-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1989" NAME="Villar 1989" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Repke J, Markush L, Calvert W, Rhoads G</AU>
<TI>The measuring of blood pressure during pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>161</VL>
<PG>1019-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-von-Dadelszen-2000" NAME="von Dadelszen 2000" TYPE="JOURNAL_ARTICLE">
<AU>von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA</AU>
<TI>Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1988" NAME="WHO 1988" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization International Collaborative Study of Hypertensive Disorders in Pregnancy</AU>
<TI>Geographic variation in the incidence of hypertension in pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>80-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-01-01 16:28:03 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abalos-2001" MODIFIED="2014-01-01 16:28:03 +0000" MODIFIED_BY="[Empty name]" NAME="Abalos 2001" TYPE="COCHRANE_REVIEW">
<AU>Abalos E, Duley L, Steyn DW, Henderson-Smart DJ</AU>
<TI>Antihypertensive drug therapy for mild to moderate hypertension during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-06-14 12:45:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 12:45:38 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002252"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Abalos-2007" MODIFIED="2014-01-01 16:26:59 +0000" MODIFIED_BY="[Empty name]" NAME="Abalos 2007" TYPE="COCHRANE_REVIEW">
<AU>Abalos E, Duley L, Steyn DW, Henderson-Smart DJ</AU>
<TI>Antihypertensive drug therapy for mild to moderate hypertension during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-06-14 12:40:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 12:40:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002252.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-01-07 12:20:14 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-01-07 12:20:14 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Argentina-1985">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said '...randomly divided into two groups...'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 women with SBP &gt;/= 160 mmHg and/or DBP &gt;/= 100 mmHg x 2, 24 hr apart, with or without proteinuria at trial entry.<BR/>Excluded: &gt; 1 drug to control BP, or contraindication for beta blockers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: atenolol 50-250 mg/day.<BR/>Control: methyldopa 750-2000 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: BP (mean).<BR/>Babies: gestational age, birthweight, Apgar score, stillbirth, neonatal deaths.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Main paper in Spanish. Methods for measuring BP not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Argentina-1987">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'open randomised study'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 women with SBP &gt; 159 mmHg and/or DBP &gt; 99 mmHg x 2, 24 hr apart, +/- proteinuria.<BR/>Excluded: &gt; 1 drug to control BP, or hypertensive emergency.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: ketanserin 20-80 mg/day.<BR/>Control: methyldopa 500-2000 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: none reported.<BR/>Babies: stillbirth, neonatal death, birthweight (mean), gestation at delivery (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Interim report of study ongoing in 1987. Methods for measuring BP not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Argentina-1988">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'randomised' 'divided into 2 equal groups'.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>36 women &gt; 14 weeks' gestation with BP &gt;/= 140/90 mmHg and &lt;/= 170/110 mmHg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: mepindolol, increasing weekly doses, from 5-10 mg/day.<BR/>Control: methyldopa, increasing weekly doses from 500-2000 mg/day.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: additional antihypertensive, caesarean section, side-effects, maternal complications.<BR/>Babies: stillbirth, SGA (undefined).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Methods for measuring BP not mentioned. Available only as an abstract.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Australia-1983">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'randomly allocated'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 women in antenatal clinics with mild-moderate PIH (BP &gt;/= 140/90 mmHg x 2 at least 24 hr apart).<BR/>Excluded: impaired renal function.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: propranolol 30-160 mg/day.<BR/>Control: methyldopa 500-1000 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria (undefined), additional antihypertensive, changed drugs due to side-effects, caesarean section.<BR/>Babies: perinatal death, preterm delivery, jaundice, bradycardia, hypoglycaemia, birthweight (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>London School of Hygiene sphygmomanometer (random zero) used. No mention of which Korotkoff sound used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-01 17:38:30 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Australia-1985">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'allocated by series of random numbers'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-01 17:38:30 +0000" MODIFIED_BY="Heather Maxwell">
<P>183 women with singleton pregnancy and mild hypertension (DBP &gt;/= 90 mmHg x 2, 24 hr apart, or DBP &gt;/= 95 mmHg x 2, 12 hr apart, or DBP &gt;/= 100 mmHg x 2, 8 hr apart).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: oxprenolol 40-320 mg x 2/day.<BR/>Control: methyldopa 250 mg x 2/day-1000 mg x 3/day.</P>
<P>If blood pressure not controlled, hydralazine in both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria ('heavy and increasing requiring delivery'), additional antihypertensive, induction of labour, caesarean section, <BR/>Babies: stillbirth, neonatal death, admission to SCBU, days in SCBU, RDS, birthweight. (mean), Apgar (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-01 16:33:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Australia-2001">
<CHAR_METHODS>
<P>Allocation concealment: central telephone randomisation Although authors stated it was a placebo-controlled trial, data provided by authors suggest that they may have used a patch for the control, but not a matching placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-19 10:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>16 women with gestational hypertension, defined as "de novo" hypertension after 20 weeks' gestation of &gt; 140 and/or 90 mmHg on 2 readings, 6 hr apart; or a rise in systolic pressure of &gt; 25 mmHg or a diastolic of 15 mmHg from a BP pre-pregnancy or in the first trimester.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-01 16:33:15 +0000" MODIFIED_BY="Heather Maxwell">
<P>Exp: transdermal glyceryl trinitrate patches 10 mg.<BR/>Control: patch for the control, but not a matching placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: pre-eclampsia, side-effects.<BR/>Babies: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Trial planned to recruit 220 women and stopped early due to side-effects (headache) in the treatment group. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:24:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brazil-1985">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said '...patients were randomly divided into two groups...'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-19 10:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>100 women with chronic hypertension diagnosed before 20th week, BP &gt;/= 140/90 mmHg x 2, 5 min apart. With no proteinuria and no contraindication to beta blockers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: pindolol 10-30 mg/day.<BR/>Control: no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: MAP, severe pre-eclampsia, side-effects.<BR/>Babies: abortions, fetal deaths, neonatal deaths, gestational age, birthweight, IUGR, Apgar score, congenital malformations, hypoglycaemia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Methods for measuring blood pressure not mentioned. Main paper in Portuguese.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brazil-1988">
<CHAR_METHODS>
<P>Allocation concealment: consecutive numbered treatment boxes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 pregnant women with chronic hypertension with DBP =/&gt; 95 mmHg, without proteinuria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: pindolol 10-30 mg/day.<BR/>Control: methyldopa 500-2000 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: BP, need for additional antihypertensives, severe HT, superimposed pre-eclampsia.<BR/>Babies: birthweight, Apgar score, fetal and neonatal death, preterm birth, SGA (undefined).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Main paper in Portuguese. Methods for measuring BP not mentioned. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brazil-2000a">
<CHAR_METHODS>
<P>Allocation concealment: trial drug supplied by pharmacy in packs with serial numbers.<BR/>Withdrawals: 15 women (7.5%) excluded from the analysis (5 delivered in other hospitals, 9 dropped the study or failed to comply with treatment, 1 due to side-effects).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>199 singleton pregnant women with mild/moderate chronic hypertension (DBP &gt; 90 mmHg and =/&lt; 110 mmHg before 20 weeks' gestation, or with history of chronic hypertension), before 25 weeks' gestation and giving informed consent. Excluded: renal, cardiac or hepatic disease, IUGR diagnosed before trial entry, alcohol/drug abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: verapamil 240 mg x 3/day.<BR/>Control: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: BP, heart rate, severe hypertension, superimposed pre-eclampsia, side-effects, mode of delivery.<BR/>Babies: birthweight, gestational age, SGA, Apgar score, jaundice, hypoglycaemia, mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. Main report in Portuguese, presented as a Doctoral Thesis. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Caribbean-Is.1990">
<CHAR_METHODS>
<P>Allocation concealment: women given number corresponding to sealed envelope and treatment batch. Envelope contained unblinding, kept by investigator and only opened when necessary. Envelopes collected at end of study. 2 centres.<BR/>Withdrawals: 1 woman, from placebo group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>155 women with singleton pregnancy at 20-36 weeks' gestation, DBP &lt; 85 mmHg x 2 before 20 weeks and &gt; 84 mmHg after 20 weeks.<BR/>Excluded: type I diabetes, congestive heart failure, cardiac block, asthma, pre-pregnancy hypertension, antihypertensive treatment during current pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: oxprenolol 160-320 mg x 2/day. Hydralazine 50-100 mg added if necessary to keep DBP &lt; 86 mmHg. </P>
<P>Control: placebo, identical appearance.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: death, mean BP, severe hypertension, proteinuria (&gt; 1+ or 0.25 g/L), additional antihypertensive, eclampsia, changed drugs due to side-effects, elective delivery, caesarean section, hospital admission, days in hospital, placental abruption. <BR/>Babies: perinatal death, preterm delivery (&lt; 37 weeks), birthweight (mean), SGA (undefined, excludes stillbirth), 5 min Apgar &lt; 7, admission to SCBU, RDS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. For 23 women (15%), treatment unblinded and other treatment started. 16 for uncontrolled BP (5 exp, 11 control) and 7 for poor compliance/side-effects (4 exp, 3 control). Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:36:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-France-1987">
<CHAR_METHODS MODIFIED="2013-06-19 10:36:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: 'blinded envelopes'. Stratified in blocks of 10 at each clinic. Multicentre, 12 hospitals.<BR/>Withdrawals: 12 women (6%). 5 labetalol (3 lost to follow-up and 2 given methyldopa) and 7 methyldopa (all lost to follow-up).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>188 women with singleton pregnancy at 12-34 weeks' gestation, booked &lt; 20 weeks and DBP &gt;/= 90 mmHg.<BR/>Excluded: previous antihypertensive treatment this pregnancy, diabetes, depression, contraindication to beta blockers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: labetalol 200-600 mg x 2/day.<BR/>Control: methyldopa 250-750 mg x 2/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: proteinuria (&gt; 2+ or 0.5 g/L), admission to hospital, caesarean section, elective delivery, additional antihypertensive, side-effects, changed drugs due to side-effects.<BR/>Babies: stillbirth, neonatal death, admission to SCBU, SGA (&lt; 5th centile, excludes stillbirths), preterm delivery (&lt; 37 weeks), 5 min Apgar &lt; 8.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:08:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-France-1988">
<CHAR_METHODS MODIFIED="2013-06-19 10:08:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: not stated. Authors said 'random order'.<BR/>3-arm study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>63 women at 7-36 weeks' gestation with DBP &gt; 90 mmHg x 2, 8 days apart).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: (1) acebutolol 400-1200 mg; (2) labetalol 400-1200 mg.<BR/>Control: methyldopa 500-1500 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: PE, caesarean section. <BR/>Babies: perinatal death, preterm delivery, birthweight (mean), Apgar, admission to SCBU, hypoglycaemia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No mention about Korotkoff sound considered for DBP. Main paper in French.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-01 17:42:21 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-France-1994">
<CHAR_METHODS>
<P>Allocation concealment: sealed envelopes drawn by physician. Ordered using list of computer-generated random numbers.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 women with singleton pregnancy at &gt; 20 weeks' gestation and mild-moderate hypertension (BP &gt;/= 140/90 mmHg x 2). No other antihypertensive medication at trial entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-01 17:42:21 +0000" MODIFIED_BY="Heather Maxwell">
<P>Exp: nicardipine 20 mg x 3/day.<BR/>Control: metoprolol (slow release) 200 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria (undefined), HELLP syndrome, additional antihypertensive, changed drug due to side-effects, induction of labour, caesarean section.<BR/>Babies: perinatal death, umbilical Doppler, admission to SCBU.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:09:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hong-Kong-1990">
<CHAR_METHODS MODIFIED="2013-06-19 10:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: not stated.<BR/>Authors said: 'randomised double-blind'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>41 healthy nulliparous women admitted for PE (BP &gt;/= 140/90 mmHg x 2 within 24 hours).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: labetalol 200 mg x 3/day.<BR/>Control: placebo (character not stated).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: mean BP, severe hypertension, additional antihypertensive.<BR/>Babies: birthweight (mean), SGA (&lt; 10th centile), gestation at delivery (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Trial reported as in progress in 1990. Missing data for some babies. No description of how BP measured. Available only as an abstract.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-India-1992">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'randomly allocated'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 primigravid women at 24-37 weeks' gestation with mild-moderate PIH (BP&gt;/ = 140/90 mmHg x 2, 6 hr apart).<BR/>Excluded: UTI, heart disease or other cause of hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: metoprolol 50-150 mg x 2/day.<BR/>Control: methyldopa 250 mg x 3/day, increased to 2000 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension.<BR/>Babies: perinatal death, preterm delivery, gestation at delivery, birthweight, Apgar at 1 and 5 min (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Method for measuring BP not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-01 16:37:09 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-India-2002">
<CHAR_METHODS MODIFIED="2013-05-20 15:27:27 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Methods not stated, authors only say "...randomised by number..."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-20 15:22:59 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>118 primigravid women with hypertension (BP &gt; 140/90 x 2, 60 hours apart) during pregnancy with and without proteinuria at &gt; 20 weeks' gestation.</P>
<P>Excluded: 2nd or more pregnancies, history of chronic HT, use of anti HT drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-20 15:24:06 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Exp: Nimodipine 30 mg every 6 hours.</P>
<P>Control: Methyldopa 250 mg every 6 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-01 16:37:09 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>MAP, additional antihypertensives, serum creatinine and liver enzymes, induction of labour, serious maternal side-effects, perinatal deaths.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-20 15:26:17 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Method for measuring BP not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-07 12:20:14 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-India-2012">
<CHAR_METHODS MODIFIED="2013-06-19 10:10:03 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Mixed sealed envelopes containing the assigned intervention. 3-arm trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-07 12:20:14 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>149 women with PIH (140-159/90-109 mmHg x 2, 6 hours apart, without proteinuria) at 20-38 weeks' gestation.</P>
<P>Excluded: chronic HT, previous anti HT medication, secondary HT, UTI, diabetes, known medical/psychiatric disorders, multiple pregnancy, placenta previa, Rh isoimmunisation, congenital abnormality.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-19 10:10:27 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Exp 1: Labetalol 100 mg x 2/day (up to 2500 mg).</P>
<P>Exp 2: Methyldopa 250 mg x 2/day (up to 2000 mg).</P>
<P>Control: no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-19 10:10:48 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>BP, laboratory parameters, gestational age at delivery, birthweight, 5 min Apgar score, maternal adverse events, maternal death, major morbidity, severe HT, proteinuria, severe pre-eclampsia, antenatal hospital admission, caesarean section, perinatal death, SGA, preterm babies, Admission to NICU.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-19 10:10:52 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Korotkoff phase V for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-01 16:37:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-India-2013">
<CHAR_METHODS MODIFIED="2013-05-20 20:28:36 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>"...patients were divided into two groups randomly..."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-19 10:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>180 pregnant women at &gt; 20 weeks' gestation with BP &gt; 140/90 mmHg x 2, 6 hours apart and proteinuria 1+ on dipstick x 2, 4 hours apart.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-19 10:11:16 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Exp: Labetalol 100 mg t.i.d. (doubled every 48 hours until BP control).</P>
<P>Control: Methyldopa 250 mg t.i.d. (doubled every 48 hours until BP control).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-01 16:37:17 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Fall in BP after 7 days treatment, average dose of drug used, induction of labour, maternal side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-20 20:33:00 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Method for measuring BP not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:12:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ireland-1991">
<CHAR_METHODS>
<P>Allocation concealment: cards with 'test' or 'control' sealed in envelopes, shuffled and then numbered in sequence. Consecutive envelopes opened.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-19 10:12:19 +0100" MODIFIED_BY="[Empty name]">
<P>36 women &lt; 38 weeks' gestation with BP &gt;/= 140/90 mmHg on 2 separate days, without proteinuria.<BR/>Excluded: if lived too far from the hospital to attend for frequent examinations.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-19 10:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Exp: choice between atenolol 50-100 mg/day and methyldopa 750-2250 mg/day. If monotherapy inadequate, 2 drugs combined. Bendrofluazide 2.5-5.0 mg added as a third agent when necessary.<BR/>Control: no antihypertensive.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: MAP, proteinuria. <BR/>Babies: perinatal death, Apgar, gestation age at delivery, birthweight, birthweight &lt; 50th centile.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase V used for DBP. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Israel-1986">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'randomly allocated'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>32 women with singleton pregnancy at 27-33 weeks' gestation with PIH (DBP &gt;/= 95 mmHg x 2 at least 6 hr apart).<BR/>Excluded: history of chronic renal disease or essential hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: pindolol 15 mg/day.<BR/>Control: methyldopa up to 2000 mg/day (no other details).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, new proteinuria (&gt; 2+ or 0.5 g/L), eclampsia, side-effects, additional antihypertensive, changed drugs due to side-effects.<BR/>Babies: neonatal death, birthweight (mean), abnormal antenatal fetal heart rate, gestation at delivery (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Methods for BP measurement not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-01 17:46:15 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Israel-1986a">
<CHAR_METHODS MODIFIED="2014-01-01 17:46:15 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation concealment: not stated. Authors said 'randomly allocated'.<BR/>2 women with side-effects on hydralazine crossed over to pindolol + hydralazine, and reported in this group. Data only included if available as intention-to-treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>44 women at &lt; 37 weeks with BP &gt;/= 150/90 mmHg x 2 at least 24 hr apart.<BR/>Excluded: insulin-dependent diabetes, obstructive lung disease, contraindication to pindolol or hydralazine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: hydralazine 50-100 mg/day + pindolol 10-25 mg/day (in 2 daily doses).<BR/>Control: hydralazine 50-100 mg/day (in 2 daily doses).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria (&gt; 1 g in 24 hr), side-effects, changed drug due to side-effects, caesarean section.<BR/>Babies: preterm delivery, SGA (&lt; 250 on Usher's curve), hypoglycaemia, hypothermia, low Apgar score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No mention of which Korotkoff sound used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Israel-1992">
<CHAR_METHODS>
<P>Allocation concealment: trial drug supplied by pharmacy in packs with serial numbers, in blocks of 6.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 women &lt; 35 weeks' gestation with DBP 85-99 mmHg x 2, 12 hours apart, and no treatment for hypertension during this pregnancy.<BR/>Excluded: multiple pregnancy, contraindication to beta blockers or insulin-dependent diabetes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: pindolol 5 mg x 2/day. If DBP still &gt;/= 85 mmHg on day 3, increased to 5 mg x 3/day, if no response next day, increased to 10 mg x 2/day. <BR/>Control: identical placebo. </P>
<P>If DBP 100-109 mmHg x2 or &gt; 110 mmHg x1, hydralazine added for pindolol group. In placebo group, pindolol given first, followed by hydralazine if DBP &gt; 100 mmHg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: additional antihypertensive, days in hospital, proteinuria &gt; 2+ or &gt; 0.5 g/L, treatment stopped due to side-effects, caesarean section.<BR/>Babies: perinatal death, gestation at delivery (mean), birthweight, 5 min Apgar &gt; 7, SGA (&lt; 10th centile), hypoglycaemia, jaundice.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff IV used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:13:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Israel-1995">
<CHAR_METHODS MODIFIED="2013-06-19 10:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: not stated. Authors said 'randomly allocated'.<BR/>3-arm trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>51 women with BP 140-160/95-110 mmHg.<BR/>Excluded: proteinuria &gt; 2+, contraindication to beta blockers, or any other disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: (1) hydralazine 60-200 mg/day + propranolol 40-120 mg/day; (2) hydralazine 60-200 mg/day + pindolol 5-15 mg/day.<BR/>Control: hydralazine 60-200 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: eclampsia, severe maternal morbidity, side-effects, caesarean section.<BR/>Babies: perinatal death, preterm delivery, SGA (&lt; 10th centile), birthweight (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase V used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Italy-1997">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said: 'randomly allocated'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 primigravid women at 26-36 weeks' gestation with SBP 140-160 mmHg, and DBP 90-110 mmHg in first 24 hr after admission and proteinuria &lt; 300 mg/24 hr. <BR/>Excluded: if other medical maternal or fetal pathology (IUGR or altered biophysical profile).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: nifedipine 40-120 mg/day orally and bed rest. <BR/>Control: bed rest alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria, days in hospital before delivery. <BR/>Babies: stillbirth, neonatal death, gestation at delivery (mean), birthweight, placental weight, SGA (undefined).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Methods for measuring blood pressure not stated. Article in Italian.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:36:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Italy-1998">
<CHAR_METHODS MODIFIED="2013-06-19 10:36:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: central telephone randomisation, stratified by centre and type of hypertension (chronic, gestational or unclassified). Multicentre, 33 hospitals.<BR/>Withdrawals: 22 women (8%), 13 exp and 9 control lost to follow-up.<BR/>Follow-up of children at 18 months: 190/252 (77%) responded to postal survey.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>283 women at 12-34 weeks' gestation, with mild-moderate hypertension (DBP 90-110 mmHg x 2, 4 hours apart).<BR/>Excluded: chronic diseases (such as diabetes or renal disease), fetal malformations, previous antihypertensive treatment or contraindications to nifedipine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: slow-release nifedipine 20-80 mg x 2/day orally.<BR/>Control: no antihypertensive.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria, caesarean section, admission to intensive care.<BR/>Babies: perinatal death, birthweight, SGA (&lt; 10th centile), preterm delivery (&lt; 34 and &lt; 37 weeks), admission to SCBU, hyperglycaemia, jaundice, RDS, other serious neonatal problems.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-19 10:36:24 +0100" MODIFIED_BY="[Empty name]">
<P>Classification of hypertensive disorders using Davey and MacGillivray system. Methods for measuring blood pressure not mentioned.<BR/>Data from follow-up excluded as &gt; 20% lost.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-01 17:48:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Italy-1999">
<CHAR_METHODS MODIFIED="2013-06-19 10:14:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: consecutive-numbered, opaque, sealed envelopes. 3-arm study. 6 women (17%) left the study due to side-effects (2 women) or mother's or baby's worsening conditions (4).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-01 17:48:30 +0000" MODIFIED_BY="Heather Maxwell">
<P>36 women with singleton pregnancy, gestation &gt; 24 weeks and PIH or PE (BP 140/90 mmHg or more, PE if proteinuria &gt; 300 mg/24 hr).<BR/>Excluded: fetal abnormalities or chromosomal disorders, renal or hepatic disease, chronic hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp (1): transdermal glyceryl trinitrate 10 mg continuously 24 hr/day. Exp (2): transdermal glyceryl trinitrate 10 mg intermittently for 16 hr/day. <BR/>Control: Nifedipine 40 mg/day orally.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: caesarean section, BP (mean), stopped drug due to side-effects, severe hypertension, proteinuria/pre-eclampsia.<BR/>Babies: birthweight, fetal/neonatal deaths, preterm birth, IUGR, gestation at birth (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-19 10:22:41 +0100" MODIFIED_BY="[Empty name]">
<P>Korotkoff phase IV used for DBP. In the analysis the 2 GTN arms have been combined. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Italy-2000">
<CHAR_METHODS>
<P>Allocation concealment: consecutive-numbered treatment boxes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 women with pre-eclampsia (no further details).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: nifedipine GITS 30-60 mg/day.<BR/>Control: methyldopa 500-1000 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: BP, PE, Doppler abnormalities, need for drug adjustment, severe hypertension.<BR/>Babies: fetal and neonatal death, preterm birth, SGA (undefined), Apgar score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published as an abstract only. Method for measuring BP not stated. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-South-Africa-1991">
<CHAR_METHODS>
<P>Allocation concealment: cards labelled R and Q picked blindly from a box, these identified drug container.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>32 women at 12-30 weeks' gestation with a singleton pregnancy and BP &gt;/= 140/90 mmHg x 2 at least 6 hr apart, no proteinuria, no antihypertensive therapy and no other drug treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: prazosin 1-5 mg x 3/day.<BR/>Control: identical placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria, duration of treatment, placental abruption, caesarean section.<BR/>Babies: perinatal death, gestation at delivery (mean), birthweight, SGA (&lt; 10th centile) preterm delivery (&lt; 37 weeks).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Method for measuring blood pressure not mentioned. The trial stopped early.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:36:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-South-Africa-1993">
<CHAR_METHODS MODIFIED="2013-06-19 10:36:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: not stated. Authors said: 'randomised open study'.<BR/>Withdrawals: 3 women (10%) lost to follow-up, but outcome for babies reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>29 women at 29-36 weeks' gestation with mild-moderate hypertension (DBP 90-110 mmHg).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: nifedipine started at 30 mg/day.<BR/>Control: methyldopa started at 750 mg/day.</P>
<P>Stated that 'dose adjustments were made, when necessary, every second day until control of BP was obtained'.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: additional antihypertensive, caesarean section, induction of labour, side-effects.<BR/>Babies: stillbirth, preterm delivery, gestation at delivery (mean), admission to SCBU.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Method for measuring BP not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sudan-2002">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said: '...patients were randomly allocated...'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>70 primigravid women with pre-eclampsia (BP =/&gt; 90/109 mmHg x 2, 6 hr apart plus 2+ proteinuria in dipsticks) at 28-36 weeks' gestation. Singleton pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: methyldopa 750-4000 mg/day<BR/>Control: no drug treatment.</P>
<P>All women in both groups were admitted to hospital for bed rest.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: BP, abruptio, imminent eclampsia, eclampsia, preterm delivery, caesarean section, maternal death.<BR/>Babies: birthweight, IUGR, admission to SCBU (reported as 'referral of baby'), perinatal deaths, Apgar score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff IV sound used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sweden-1984">
<CHAR_METHODS>
<P>Allocation concealment: telephone randomisation, no further details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>52 women in antenatal clinic at &lt; 37 weeks' gestation with singleton pregnancy, BP &gt;/= 140/90 mmHg or an increase of at least 30 mmHg SBP or 15 mmHg DBP x 2 within 24 hr. <BR/>Excluded: imminent eclampsia, serious fetal distress, severe hypertension (&gt; 170/110 mm Hg), Rh disease, diabetes, contraindication to beta blockers, 'social or psychological handicaps'.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: metoprolol 100-200 mg x 2/day.<BR/>Control: identical placebo x 2/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: proteinuria (&gt;/= 2+), severe hypertension, changed drugs due to side-effects, hospital admission, placental abruption, caesarean section.<BR/>Babies: perinatal death, gestation at delivery (mean) Apgar (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase V used for DBP. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sweden-1985">
<CHAR_METHODS>
<P>Allocation concealment: 'envelope randomisation'. No further information.<BR/>Withdrawals: 7 women (4%) dropped out (4 exp, 3 control). Multicentre, not stated how many hospitals.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>168 women in antenatal ward with singleton pregnancy at &lt; 37 weeks, DBP &gt;/= 90 mmHg x 2, no proteinuria.<BR/>Excluded: diabetes, asthma, heart disease, psychiatric or psychological disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: metoprolol 50-200 mg/day + hydralazine 50-300 mg/day.<BR/>Control: no antihypertensive.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria (&gt; 1+ or 0.25 g/L), changed drugs due to side-effects, placental abruption, caesarean section.<BR/>Babies: stillbirth, neonatal death, preterm delivery (&lt; 37 and &lt; 34 weeks), SGA (undefined), bradycardia, hypoglycaemia, Apgar &lt; 7 at 1 and 5 min, RDS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase V used for DBP. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sweden-1995">
<CHAR_METHODS>
<P>Allocation concealment: authors said: 'randomised by numbers to treatment with capsules'. Randomisation in blocks of 6. Information about allocation kept in sealed envelopes, opened if severe complications or side-effects. 5 centres in Sweden, 1 in Denmark.<BR/>Withdrawals: 7 women (6%), 1 dropout, 6 not re-evaluated after 3 days (4 exp, 2 control).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>118 women at 26-37 weeks, with singleton pregnancy and DBP 95-110 mmHg.<BR/>Excluded: if delivery expected within a week, history of alcohol or drug abuse, or other medication known to be toxic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: isradipine (slow release) 5 mg x 2/day.<BR/>Control: placebo x 2/day.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: eclampsia, severe hypertension (DBP &gt;/= 110 mmHg), proteinuria &gt;/=2+, need for additional antihypertensive, MAP, caesarean section, induction of labour, side-effects.<BR/>Babies: perinatal death, gestation at delivery (mean), admission to SCBU, birthweight (mean), placental weight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. Description of BP measurements technique, and of criteria used to define hypertension and proteinuria.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:22:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-UK-1968">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'allocated at random'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 pregnant women with DBP &gt;/= 90 mmHg or more x 2, 48 hr apart.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: methyldopa 250-1,000 mg x 2/day + bendrofluazide 5-10 mg/day. <BR/>Control: no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: mean BP, proteinuria, residual hypertension, length of gestation.<BR/>Babies: birthweight (mean), perinatal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-19 10:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>Methods for measuring BP not mentioned. According with BP at entry, women were divided in 2 groups: 'moderate' for those with DBP = or &gt; 90 mmHg at entry (n = 42), and 'severe' for those with DBP = or &gt; 100 mmHg (n = 58). For the main outcomes results are presented together.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-01 17:54:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-UK-1976">
<CHAR_METHODS MODIFIED="2013-06-19 10:36:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: not stated. Authors said 'randomly allocated'.<BR/>Withdrawals: 5 women (2%) withdrawn from exp group.<BR/>Follow-up of 202 live born children. At 4 years, 34 (17%) lost to follow-up. At 7, years 7 (3%) lost to follow-up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-01 17:54:18 +0000" MODIFIED_BY="Heather Maxwell">
<P>247 women with BP &gt;/= 140/90 mmHg if &lt; 28 weeks' gestation, or &gt;/= 150/95 mmHg if &gt; 28 weeks' gestation x 2, 24 hr apart.<BR/>Excluded: diabetes, multiple pregnancy, Rh immunisation. Women &gt; 36 weeks' gestation excluded during first year of the trial, thereafter excluded if &gt; 32 weeks' gestation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: methyldopa 750-4000 mg/day. <BR/>Control: no antihypertensive.</P>
<P>Hydralazine if severe hypertension.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria, caesarean section, elective delivery, side-effects, changed drug due to side-effects.<BR/>Babies: perinatal death, birthweight (mean), gestation at delivery (mean), SGA (&lt; 2 SD below mean), babies nursed in an incubator, neurodevelopment at 4 and 7 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. Random zero sphygmomanometer.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UK-1980">
<CHAR_METHODS>
<P>Allocation concealment: randomly allocated using random-number table.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 women &lt; 38 weeks' gestation with PIH and no contraindication to beta blockers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: labetalol 400-800 mg/day.<BR/>Control: methyldopa 750-1500 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: proteinuria, severe hypertension, caesarean section, induction of labour, side-effects.<BR/>Babies: stillbirth, birthweight (mean), gestation at delivery (mean), 1 min Apgar, admission to SCBU, jaundice.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UK-1982">
<CHAR_METHODS>
<P>Allocation concealment: envelope randomisation, no further information.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>126 women with either chronic hypertension or PIH, and DBP &gt; 95 mmHg if &lt; 20 weeks or 95-109 mmHg if &gt; 20 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: labetalol 100 mg x 2/day, increased to maximum of 1200 mg/day.<BR/>Control: no antihypertensive.</P>
<P>If BP not controlled, hydralazine 25 mg x 3/day, increased to maximum of 200 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria (undefined), caesarean section, placental abruption.<BR/>Babies: perinatal death, SGA (&lt; 10th centile).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Methods for measuring BP not mentioned. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:36:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-UK-1983">
<CHAR_METHODS MODIFIED="2013-06-19 10:36:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: authors said 'allocated in double-blind and randomised manner'.<BR/>Withdrawals: some data missing for 35 women (29%). Data for each outcome only included if &lt; 20% excluded.<BR/>Follow-up: 110 children (92%) seen at 1 year.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 women with PIH in third trimester admitted for bed rest, SBP 140-170 mmHg and DBP 90-110 mmHg x 2, 24 hr apart. <BR/>Excluded: women with contraindication to beta blockers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: atenolol 100-200 mg/day. <BR/>Control: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: proteinuria (&gt; 0.5 g/24 hr), severe hypertension, additional antihypertensive, changed treatment due to side-effects, side-effects, admission to hospital prior to delivery, caesarean section.<BR/>Babies: perinatal death, SGA (&lt; 10th centile), bradycardia, hypoglycaemia, jaundice, RDS. At 1 year: cerebral palsy, IQ &lt; 1 SD below mean, weight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. Random zero sphygmomanometer used for measuring blood pressure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UK-1983a">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'allocated at random'. Stratified by gestational age.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 women with singleton pregnancy and DBP &gt;/= 95 mmHg x 2 at least 24 hr apart, or &gt; 105 mmHg x 1.<BR/>Excluded: asthma, heart failure, or heart block, diabetes, renal disease, or taking other hypertensive medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: oxprenolol 80-320 mg x 2/day. <BR/>Control: methyldopa 250-1000 mg x 3/day.</P>
<P>If BP not controlled, hydralazine added to both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria (&gt; trace on dipstick), induction of labour, caesarean section, additional antihypertensive, hospital admission. <BR/>Babies: perinatal death, birthweight (mean), 5 min Apgar &lt; 7, antenatal fetal heart rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. Random zero sphygmomanometer.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UK-1984">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'randomised trial'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 women at 18-36 weeks' gestation with undefined hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: atenolol 100 mg/day. <BR/>Control: methyldopa 250 mg x 3/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: proteinuria (undefined). <BR/>Babies: stillbirth, birthweight, SGA (&lt; 10th centile) bradycardia, hypoglycaemia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase V used for DBP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:21:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-UK-1989">
<CHAR_METHODS MODIFIED="2013-06-19 10:21:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: drug and placebo sent by manufacturer to hospital pharmacy with list of random numbers. Then dispensed by pharmacists. 5 centres.<BR/>Withdrawals: 8 (5%), 6 exp, 2 control. 2 women withdrew, 1 treated with ward stock labetalol, 1 developed rash, and 4 did not fulfil entry criteria.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>152 women from antenatal wards at 20-38 weeks' gestation with SBP 140-160 mmHg and DBP 90-105 mmHg x 2, 24 hr apart, and no proteinuria.<BR/>Excluded: history of hypertension, renal, metabolic, cardiovascular, respiratory or collagen disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: labetalol 100-200 mg x 3/day.<BR/>Control: identical placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: mean BP, severe hypertension, proteinuria (undefined), induction of labour, caesarean section, days in hospital (mean), side-effects.<BR/>Babies: perinatal death, preterm delivery (&lt; 37 weeks), SGA (&lt; 5th centile), admission to SCBU, RDS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. Conventional sphygmomanometers used to measure blood pressure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UK-1990">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'randomised' but no other information.<BR/>Withdrawals: 4 (12%), 1 exp (changed her mind), 3 control (2 severe hypertension, 1 breathlessness).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>33 women 12-24 weeks' gestation with SBP 140-170 mmHg and DBP 90-110 mmHg x 2, 24 hr apart. <BR/>Excluded: if 'usual' contraindications to beta blockers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: atenolol 50-200 mg/day.<BR/>Control: placebo (character not stated).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: mean BP, severe hypertension, stopped drug due to side-effects.<BR/>Babies: stillbirth, birthweight, SGA (&lt; 5th centile), placental weight, gestation at delivery (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase V used for DBP. The trial was stopped early when the principal investigator left Glasgow. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UK-1992">
<CHAR_METHODS>
<P>Allocation concealment: numbered, sealed opaque envelopes. Stratified by parity.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>114 women with singleton pregnancy at 24-39 weeks' gestation with DBP &gt; 90 mmHg for &gt; 24 hr and no proteinuria.<BR/>Excluded: psychoneurosis, cardiac abnormality, diabetes, asthma, contraindication to beta blockers, antenatal antihypertensive treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: labetalol 100 mg x 2/day, increased up to 400 mg x 3/day.<BR/>Control: no antihypertensive.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: proteinuria (&gt; 1+ or 0.25 g/L), duration of stay in hospital (mean), side-effects, changed drug due to side-effects, elective delivery, caesarean section.<BR/>Babies: perinatal death, gestation at delivery (mean), preterm delivery (&lt; 37 weeks), SGA (&lt;5th centile), admission to SCBU, length of stay in hospital (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-USA-1979">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'allocated randomly to treatment or no treatment'.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>58 women with hypertension before pregnancy or BP &gt;/= 140/90 mmHg x 2 more than 24 hr apart before 20 weeks' gestation. Excluded: DBP &gt; 100 mmHg, nulliparous, other major medical or obstetric problem.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: methyldopa 750-2000 mg/day, hydrochlorothiazide 50 mg/day, hydralazine 75-250 mg/day.<BR/>Control: no antihypertensive.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, proteinuria (&gt; 1+ or &gt; 300 mg/L in 24 hr), caesarean section.<BR/>Babies: perinatal death, gestation at delivery, birthweight &lt; 2500 g, fetal distress, SGA (undefined).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No information about how BP measured. In exp group, 11 women had methyldopa + hydrochlorothiazide, 10 hydralazine + hydrochlorothiazide, 8 had all 3 drugs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-USA-1987">
<CHAR_METHODS>
<P>Allocation concealment: physician drew a sealed envelope containing assignment.<BR/>Withdrawals: 14 women (7%), 8 exp and 6 control refused hospitalisation, but data reported for perinatal death.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>200 primigravid women in hospital at 26-35 weeks' gestation with SBP 140-160 mmHg and DBP 90-110 mmHg, proteinuria &gt; 0.3 g/L and uric acid &gt; 4.6 mg/dL.<BR/>Excluded: associated medical and obstetrical complications, other antihypertensive medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: hospitalisation + labetalol 300 mg/day, increased every few days to max 2400 mg/day. <BR/>Control: hospitalisation alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, increased proteinuria, eclampsia, placental abruption, caesarean section, renal function, days gained during management.<BR/>Babies: perinatal death, gestation at delivery (mean), birthweight (mean), placental weight, admission to SCBU, SGA (&lt; 10th centile).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No mention of how BP measured.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-USA-1987a">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Authors said 'randomly allocated', no further information.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>25 women at &lt; 34 weeks' gestation, singleton pregnancy with BP 140/90 mmHg x 2 at least 6 hr apart and no proteinuria. Presumed chronic hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: methyldopa 750 mg x 3/day to 2000 mg x 4/day.<BR/>Control: placebo, in the same way.<BR/>If severe pre-eclampsia, hydralazine or MgSO4 added.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: MAP, new proteinuria (2+ or greater on urine dipsticks), PE (defined as a sudden rise of 30 mmHg SBP or 15 mmHg DBP and weight gain &gt; 2 lbs/week, or proteinuria &gt; 2+), elective delivery, side-effects.<BR/>Babies: perinatal death, gestation at delivery (mean), birthweight (mean and &lt; 50th centile).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No information about how BP measured.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:38:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-USA-1990">
<CHAR_METHODS MODIFIED="2013-06-19 10:36:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: envelope randomisation, using computer-generated random numbers. 3-arm study.<BR/>Withdrawals: 37 women (12%). 27 exp (21 excluded due to poor compliance, 3 twin, 1 abortion and 2 lost to follow-up) and 10 control (8 due to poor compliance, 1 twin and 1 spontaneous abortion).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>300 women in antenatal ward with chronic mild-moderate hypertension at 6-13 weeks' gestation. All had chronic hypertension before pregnancy and no associated medical complications.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: (1) methyldopa 750-4000 mg/day (no other details). (2) labetalol 300-2400 mg/day (no other details).<BR/>Control: no antihypertensive.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-19 10:38:56 +0100" MODIFIED_BY="[Empty name]">
<P>Women: PE (defined as hypertension, proteinuria, and hyperuricaemia), additional antihypertensive, days in hospital, placental abruption, congestive heart failure, serum creatinine, uric acid.<BR/>Babies: perinatal death, gestation at delivery, birthweight &lt; 2.5 kg, preterm delivery (&lt; 37 weeks), SGA (undefined), admission to SCBU, hypoglycaemia, 5 min Apgar &lt; 7.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Korotkoff phase IV used for DBP. 36% of women were taking an antihypertensive at the time of trial entry. Additional data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-19 10:36:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-USA-1992">
<CHAR_METHODS MODIFIED="2013-06-19 10:36:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment: physician drew sealed envelope containing assignment. Computer-generated random numbers.<BR/>Withdrawals: 3 women (1.5%) lost to follow-up (2 exp, 1 control).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>200 primigravid women at 26-36 weeks' gestation with SBP 140-160 mmHg and/or DBP 90-110 mmHg 24 hr after hospitalisation, proteinuria &gt; 300 mg/24 hr, and/or uric acid &gt; 6 mg/dL.<BR/>Excluded: associated medical or obstetric complications, or fetal compromise (suspected abnormal fetal growth by US, abnormal fetal testing).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: nifedipine 40-120 mg/day.<BR/>Control: bed rest alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: MAP, severe proteinuria (&gt; 5 g/24 hr), antenatal hospital stay (mean), days gained during management, caesarean section, placental abruption, HELLP syndrome.<BR/>Babies: stillbirth, neonatal death, birthweight, preterm delivery (&lt; 37 weeks), SGA (&lt; 10th centile), admission to SCBU, days in SCBU (mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Method of measuring blood pressure not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Venezuela-1988">
<CHAR_METHODS>
<P>Allocation concealment: not stated. Treatment assigned using random-number tables.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>31 women &gt; 14 weeks' gestation with either chronic hypertension or mild-moderate PIH (BP 140-169/90-109 mmHg x 2 after 5 min rest). <BR/>Excluded: contraindication to beta blockers, Rh or haemorrhagic disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exp: mepindolol 5 mg/day, increased weekly to 10 mg/day. <BR/>Control: methyldopa 250 mg x 2/day increased weekly to 250 mg x 4/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: severe hypertension, caesarean section, induction of labour.<BR/>Babies: perinatal death, gestation at delivery, birthweight, Apgar score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Main paper in Spanish. <BR/>Method of measuring blood pressure not mentioned.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>DBP: diastolic blood pressure<BR/>exp: experimental<BR/>GITS: gastrointestinal therapeutic system<BR/>GTN: glyceryl trinitrate<BR/>HELLP: syndrome of haemolysis, elevated liver enzymes and low platelets<BR/>hr: hour(s)<BR/>HT: hypertension<BR/>IUGR: intrauterine growth restriction<BR/>IV: intravenous<BR/>MAP: mean arterial pressure<BR/>MgSO4: magnesium sulphate<BR/>min: minutes<BR/>NICU: neonatal intensive care unit<BR/>PE: pre-eclampsia<BR/>PIH: pregnancy-induced hypertension<BR/>RDS: respiratory distress syndrome<BR/>SBP: systolic blood pressure<BR/>SCBU: special care baby unit<BR/>SD: standard deviation<BR/>SGA: small-for-gestational age<BR/>t.i.d.: dosing three times daily<BR/>US: ultrasound<BR/>UTI: urinary tract infection<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-01-04 17:32:58 +0000" MODIFIED_BY="Edgardo J Abalos" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-01-01 16:35:39 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Argentina-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 16:35:39 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Most women with severe chronic hypertension. Women with mild-moderate HT not analysed separately.</P>
<P>Methods: open, prospective, randomised, comparative 3-arm trial.</P>
<P>Participants: 90 women with severe chronic hypertension.</P>
<P>Intervention: Atenolol (50-200 mg daily), vs methyldopa (500-2000 mg daily) vs ketanserin (80-120 mg daily).</P>
<P>Outcomes: BP, gestational age at delivery, birthweight, 1-min Apgar score, fetal and neonatal mortality.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Argentina-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clearly randomised. Available as abstract only.<BR/>Methods: 'divided into two groups'. No further information.<BR/>Participants: 187 women with chronic hypertension (n = 66) or gestational hypertension (n = 121).<BR/>Interventions: atenolol 40-100 mg/day versus methyldopa 250-2000 mg/day.<BR/>Outcomes: superimposed pre-eclampsia, maternal BP, birthweight.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 16:35:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Australia-1985a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 16:35:32 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 alpha agonists.<BR/>Methods: 'prospective, double blinded'. Women entered in a numerical sequence. No numbers missed or used a second time.<BR/>Participants: 100 women with BP &gt; 130/85 mmHg or a rise of 30/15 mmHg from previous values.<BR/>Intervention: clonidine 150-1200 mcg/day versus methyldopa 250-2000 mg/day. If additional treatment needed, hydralazine.<BR/>Outcomes: severe hypertension, need for additional drug, stopped treatment due to side-effects, stillbirth, neonatal death, preterm delivery, birthweight (mean), SGA, 5-min Apgar.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Australia-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Entry criteria was DBP greater than 1 SD above the reported mean for gestational age. Mean BP of recruited women was 129/84 mmHg at entry to the trial (122-136/79-89 mmHg) for the placebo group, and 126/82 mmHg (118-134/79-85) for the treatment group.<BR/>Participants: 52 nulliparous with singleton pregnancies between 28 and 34 weeks of gestation, without proteinuria.<BR/>Intervention: clonidine from 200 to 800 mcg a day plus hydralazine from 50 to 200 mg a day, and placebo.<BR/>Outcomes: severe hypertension, imminent eclampsia, eclampsia, severe proteinuria, antepartum haemorrhage, HELLP syndrome, fetal distress, fetal death, IUGR.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:25:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belgium-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:25:52 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 beta blockers. Available as abstract only.<BR/>Methods: 'randomised', no further information.<BR/>Participants: 23 women with BP at least 140/90 mmHg x 2 and no proteinuria.<BR/>Intervention: atenolol 100 mg a day vs pindolol 15 mg a day.<BR/>Outcomes: umbilical PI, maternal BP, birthweight, Apgar score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:27:23 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Brazil-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:27:23 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Single-dose intervention. No clinical outcomes studied (effect of nifedipine in placental blood flow). Article in Portuguese. Only abstract translated into English.<BR/>Methods: double blind, placebo-controlled, RCT.<BR/>Participants: 65 women with pre-eclampsia.<BR/>Intervention: nifedipine 20 mg orally (only dose) vs placebo.<BR/>Outcomes: placental blood flow prior and 30 minutes after the intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brazil-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-random design. Main paper in Portuguese.<BR/>Methods: alternated allocation (data extracted from original thesis). 11 women (10.5%) excluded after trial entry.<BR/>Participants: 105 women with singleton pregnancies diagnosed with pre-eclampsia, chronic hypertension, and pre-eclampsia superimposed to chronic hypertension.<BR/>Intervention: isradipine (slow release), 5 mg every 12 hr vs atenolol 50 mg every 12 hr. <BR/>Outcomes: BP, maternal heart rate, proteinuria, maternal side-effects, mode of delivery, gestational age, birthweight, SGA babies, Apgar score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brazil-2000b">
<CHAR_REASON_FOR_EXCLUSION>
<P>40 women (24%) excluded after randomisation. Reasons for exclusion were: missed appointment for Doppler (70%), non-compliance (20%), side-effects (7.5%), preterm delivery (2.5%). Data were not presented by treatment arm. Main paper in Portuguese.<BR/>Methods: randomised, double-blind, placebo-controlled trial.<BR/>Participants: 123 pregnant women with chronic hypertension.<BR/>Intervention: verapamil 240 mg/day vs placebo during 30 days.<BR/>Outcomes: Doppler PI, RI and S/D ratio, incidence of pre-eclampsia, birthweight, gestational age at delivery, SGA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-China-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Herbal medicine vs magnesium sulphate. No clinical data available. Article in Chinese. Only abstract translated into English.<BR/>Methods: not reported. Authors said: '...randomly designed to...'.<BR/>Participants: 75 women with 'hypertension syndrome of pregnancy'.<BR/>Intervention: Magnesium sulphate 20-25 g/day vs ligustrazine 120-160 mg/day. <BR/>Outcomes: MAP, proteinuria, haematocrit, side-effects, positive rate of NST, Apgar score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-China-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only dose intervention. Sublingual nifedipine previous to caesarean section. Article in Chinese. Only abstract translated into English.<BR/>Methods: not reported. Indexed as publication type: RCT.<BR/>Participants: 33 women with pre-eclampsia undergoing emergent caesarean section.<BR/>Intervention: sublingual nifedipine, 16 mg (only dose). Control group not reported in abstract.<BR/>Outcomes: MAP, systolic and diastolic BP, maternal heart rate, postoperative haematocrit, side-effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 16:40:59 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-China-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 16:40:59 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Single-dose intervention. No clinical outcomes studied (effect of nimodipine in retinal blood flow). Article in Chinese. Only abstract translated into English.<BR/>Methods: not stated. Indexed as publication type: RCT.<BR/>Participants: 28 women with PIH.<BR/>Intervention: nimodipine 30 mg orally (only dose) vs IV magnesium sulphate.<BR/>Outcomes: retinal PI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-China-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Herbal medicine + nifedipine vs nifedipine. No clinical outcomes studied. Article in Chinese. Only abstract translated into English.<BR/>Methods: not stated. Indexed as publication type: RCT.<BR/>Participants: 95 women with PIH.<BR/>Intervention: prepared rhubarb + nifedipine vs nifedipine.<BR/>Outcomes: serum lipids, and other blood tests.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 16:41:53 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-China-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 16:41:53 +0000" MODIFIED_BY="Heather Maxwell">
<P>Less than 7 days treatment. Treatment was given only during labour. Article in Chinese. Only abstract translated into English.<BR/>Methods: "64 cases of PIH were randomly divided into...".<BR/>Participants: 64 women with PIH.<BR/>Interventions: Nifedipine orally given every 6 hrs during labour vs no treatment.<BR/>Outcomes: postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cuba-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-random design. Article in Spanish.<BR/>Methods: alternate allocation (data provided by author).<BR/>Participants: 90 pregnant women with chronic hypertension.<BR/>Intervention: methyldopa (1-2 g/day) or hydralazine (100-200 mg/day) vs no treatment.<BR/>Outcomes: BP, superimposed pre-eclampsia, abruption, preterm delivery, LBW, Apgar score, RDS, hypoxia, fetal death.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:22:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czech-Republic-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:22:50 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 beta blockers. Article in Czech. Only abstract translated into English.<BR/>Methods: 'divided at random'. No further information.<BR/>Participants: 40 women with DBP 95-105 mmHg.<BR/>Intervention: atenolol 50-100 mg/day versus bisoprolol 5-10 mg/day.<BR/>Outcomes: BP, maternal heart rate, side-effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denmark-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention is not an antihypertensive: magnesium vs placebo.<BR/>Methods: "...patients were allocated in a double-blind and randomised manner, based in a computer-generated list of numbers...".<BR/>Participants: 61 women with PIH. Chronic HT excluded. Withdrawals: 3 women (2 from intervention group, 1 from control group) excluded after randomisation.<BR/>Intervention: 48-hr of either IV magnesium or placebo infusion followed by daily oral magnesium or placebo tablets.<BR/>Outcomes: MAP, caesarean section, induction of labour, side-effects, gestational age, birthweight, Apgar score, admission to SCBU and days of stay.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denmark-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention is not an antihypertensive: magnesium vs methyldopa.<BR/>Methods: RCT. Allocation concealment by numbered sealed opaque envelopes.<BR/>Participants: 33 women with PIH. Chronic HT excluded.<BR/>Intervention: magnesium, 48-hr IV infusion followed by daily oral magnesium vs methyldopa 250 mg x 4/day.<BR/>Outcomes: BP, gestational age, birthweight, admission to SCBU and length of stay, serum magnesium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dominican-Rep-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT. Article in Spanish. Only abstract translated into English.<BR/>Methods: not stated. Authors only says "...divided into 2 groups...". Women known as given the drugs under study were also included.<BR/>Participants: 50 pregnant women with chronic HT + superimposed pre-eclampsia.<BR/>Intervention: slow-release nifedipine 20 mg every 8 hr vs methyldopa 500 mg every 12 hr.<BR/>Outcomes: BP, Apgar score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dominican-Rep-1992a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT. Article in Spanish. Only abstract translated into English.<BR/>Methods: not stated. Authors only says "...divided into 2 groups...". <BR/>Participants: 30 pregnant women with severe pre-eclampsia.<BR/>Intervention: methyldopa 250-500 mg every 5 hr vs hydralazine 20-50 mg every 8 hr.<BR/>Outcomes: BP, maternal side-effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 16:44:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Egypt-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 16:44:06 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant clinical outcomes reported. Available as abstract only.<BR/>Methods: 'patients were randomly allocated to three treatment groups'. No further information.<BR/>Participants: 50 primigravidae with pre-eclamptic toxaemia and 20 multigravidae with essential hypertension in their late pregnancy.<BR/>Interventions: 3-arm trial: bromocriptine 5 mg, methyldopa 1 gr, and placebo, in different combinations. No further information.<BR/>Outcomes: serum prolactin and serum placental lactogen, BP. 1-year follow-up reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Egypt-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>One-week intervention. Outcomes measured at 30 min, 3 and 7 days.<BR/>Methods: 'randomly allocated' .<BR/>Participants: 30 women with PE in the third trimester. 25 women had mild PE with DBP 100-109 mmHg and 5 had severe PE with DBP &gt;/= 110 mmHg.<BR/>Intervention: nifedipine 20 mg every 8 hr for 7 days or placebo in the same time and duration.<BR/>Outcomes: BP and fetal heart rate measured at 30 min, 3 and 7 days. Renal function tests and Doppler scans of umbilical cord.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 17:34:10 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Egypt-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 17:34:10 +0000" MODIFIED_BY="Heather Maxwell">
<P>The intervention is not an antihypertensive. Naltrexone vs placebo. Available as an abstract only.<BR/>Methods: "...were randomly allocated to either naltrexone (...) or placebo".<BR/>Participants: 20 women with PIH at 30-36 weeks' gestation.<BR/>Intervention: naltrexone (opioid receptor antagonist), 50 mg every 12 hr vs placebo.<BR/>Outcomes: BP, proteinuria, oedema, prolactin levels, gestational age, status of the baby at birth.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:28:06 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Egypt-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:28:06 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>The intervention is not an antihypertensive. Ozone therapy (rectal insufflations).<BR/>Methods: "...were randomly assigned into two groups in equal numbers as follow...".<BR/>Participants: 30 hypertensive pregnant women at 24 weeks' gestation.<BR/>Intervention: ozone therapy by rectal Insufflations 3 sessions/week for 7 weeks + methyldopa vs methyldopa.<BR/>Outcomes: BP, resistance and pulsatility index, dose of methyldopa required.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:22:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Finland-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:22:55 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 beta blockers.<BR/>Methods: 'according to randomisation table'. No further information.<BR/>Participants: 51 women with BP &gt; 149/94 mmHg x 2 in sitting position after 2 days bed rest in hospital.<BR/>Intervention: atenolol 50-100 mg/day versus pindolol 10-20 mg/day. If needed, hydralazine 150 mg/day added.<BR/>Outcomes: stillbirths, side-effects, need for additional drug, caesarean section, gestation at delivery (mean), birthweight (mean), 5 min Apgar.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Finland-1988a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No relevant clinical outcomes reported, report of ongoing study. Available as abstract only.<BR/>Methods: 'randomised pilot trial'. No further information.<BR/>Participants: 25 women with PIH.<BR/>Interventions: nifedipine 30-60 mg a day versus no treatment.<BR/>Outcomes: mean DBP, birthweight (mean).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 17:34:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Finland-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 17:34:20 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 beta blockers. Less than 7 days treatment, single-dose study. Women with mild hypertension not reported separately from severe hypertension.<BR/>Methods: 'randomly chosen'. No further information.<BR/>Participants: 24 women with a singleton pregnancy at 28-40 weeks, and either mild or severe pre-eclampsia (BP &gt; 160/110 mmHg plus proteinuria &gt; 5 g/24 hr, or BP 140/90-160/110 mmHg plus proteinuria &lt; 5 g/24 hr).<BR/>Intervention: atenolol 0.15 mg/kg IV vs pindolol 0.006 mg/kg IV in 100 mL of Ringer's solution. Infusion time 15-20 min.<BR/>Outcomes: utero and umbilicoplacental vascular impedance, fetal haemodynamics and cardiac function.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Finland-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Main outcomes were assessed only at 5-7 days of inclusion. 29% of women were excluded from the analysis.<BR/>Methods: randomised, double-blind, double-dummy study.<BR/>Participants: 24 women with singleton pregnancies between 29 and 39 weeks with BP &gt; 140/90 mmHg x2, 6 hr apart, and proteinuria &gt; 0.3 g in 24 hr urine collection.<BR/>Intervention: isradipine 2.5 mg twice daily or placebo vs metoprolol 50 mg twice daily or placebo (double-dummy study).<BR/>Outcomes: insulin sensitivity, uric acid, degree of proteinuria, lipids and lipoproteins, BP, umbilical artery RI, birthweight, placental weight, caesarean section, Apgar scores.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:23:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-France-1988a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:23:46 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported. Outcomes assessed at 4 weeks after trial entry. Available as abstract only.<BR/>Methods: 'randomised' no further information. 3-arm study.<BR/>Participants: 29 women with isolated hypertension after 'a mean period of 18 weeks of pregnancy'.<BR/>Intervention: pindolol vs atenolol versus methyldopa.<BR/>Outcomes: BP, maternal heart rate, serum sodium, potasium, uric acid, creatinine, plasma renin activity and aldosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-France-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical data reported. Available as congress abstracts only (1 in English, 3 in French).<BR/>Methods: 'randomised protocol'.<BR/>Participants: 21 women with moderate hypertension (SBP 140-180 mmHg and DBP 90-120 mmHg).<BR/>Intervention: oral atenolol (n = 12) vs nifedipine (n = 9) (no doses reported).<BR/>Outcomes: BP, Doppler measures, birthweight and length, Apgar score, admission to SCBU.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:28:24 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Germany-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:28:24 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Not mild-moderate HT. Prevention study.</P>
<P>Methods: randomised, placebo-controlled, double blind study.</P>
<P>Participants: 111 pregnant women with abnormal placental perfusion at 19 - 24 weeks' gestation.</P>
<P>Intervention: NO-donor penterythriltetranitrat (n = 54) vs placebo (n = 57).</P>
<P>Outcomes: utero-placental perfusion, preterm birth, IUGR, pre-eclampsia, fetal deaths.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hong-Kong-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical data available. Abstract report.<BR/>Methods: allocated in 'randomised double manner'. No further information. 4 women (6.2%) excluded after randomisation.<BR/>Participants: 65 primigravid women with a singleton pregnancy at &gt; 20 weeks' gestation and BP 140-165/90-105 mmHg x 2, 6 hr apart but no proteinuria.<BR/>Interventions: labetalol (dose not reported) vs placebo (vitamin C).<BR/>Outcomes: BP, need for additional antihypertensives, induction of labour, proteinuria, gestational age, mode of delivery, birthweight, Apgar score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hungary-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>28% of women excluded after randomisation (7 because of treatment duration not exceeding 10 days and 2 dropped out).<BR/>Methods: allocation 'according to randomisation list'. No further information.<BR/>Participants: 32 healthy primigravidae with BP at least 140/90 mmHg x 2 at least 6 hr apart.<BR/>Interventions: calcium dobesilate 2 g a day vs placebo.<BR/>Outcomes: new proteinuria, caesarean section, placental abruption, preterm delivery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-India-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention is an antiplatelet agent. Available as abstract only.<BR/>Methods: randomised, placebo-controlled trial.<BR/>Participants: 163 women with PIH of 20-32 weeks' gestation. <BR/>Intervention: aspirin 60 mg a day vs placebo from 22 until 38 weeks of gestation. <BR/>Outcomes: prevention of PIH grade B (BP 160/110 mmHg x 2, 4 hr apart), proteinuria 2+ or more, perinatal mortality, maternal mortality, eclampsia, SGA (&lt; 10th centile).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 16:47:26 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-India-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 16:47:26 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Not possible to extract data. Available as abstract only.</P>
<P>Methods: prospective randomised comparative study.</P>
<P>Participants: 200 women with singleton pregnancy, 28-40 weeks' gestation with pregnancy-induced hypertension.</P>
<P>Intervention: oral labetalol versus oral methyldopa.</P>
<P>Outcomes: BP, control of proteinuria, mode of delivery, neonatal Apgar score, NICU admission, neonatal complications, perinatal deaths.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:29:28 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-India-2012a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:29:28 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Includes women with severe hypertension. IV labetalol given to this subgroup, not analysed separately.</P>
<P>Methods: prospective, randomised controlled parallel group study.</P>
<P>Participants: 90 women with singleton, vertex pregnancies at 20-40 weeks' gestation with BP &gt;/= 140/90, with and without proteinuria.</P>
<P>Intervention: oral or IV Labetalol versus oral methyldopa.</P>
<P>Outcomes: serum urea and creatinine, significant proteinuria, severe maternal complications, induction of labour, caesarean section, lactation, gestational age at delivery, Apgar score, admission to NICU, RDS, bradycardia, jaundice, hypoglycaemia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 16:48:01 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-India-2012b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 16:48:01 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Intervention is not an antihypertensive: magnesium sulphate vs placebo. No clinical outcomes studied. 27% women (18/66) excluded after randomisation.<BR/>Methods: women were randomly allocated by sealed envelopes containing computer-generated random numbers. Double-blind, placebo-controlled.<BR/>Participants: 66 women with mild pre-eclampsia or PIH after 34 weeks' gestation.<BR/>Intervention: 24-hr of either IV magnesium sulphate or placebo infusion.<BR/>Outcomes: umbilical artery and fetal middle cerebral artery pulsatility index.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iran-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-random design (data from personal communication). Available as abstract only.<BR/>Methods: 'patients were sequentially assigned to one of two randomised groups'. Alternate allocation (data obtained from personal communication).<BR/>Participants: 37 pregnant women over 26 weeks' gestation with blood pressure over 140/90 mmHg (after 24-48 hr resting) + proteinuria or generalised oedema.<BR/>Intervention: nifedipine 10 mg t.i.d. vs hydralazine 10 mg t.i.d.<BR/>Outcomes: BP, termination of pregnancy, side-effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:30:12 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Iran-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:30:12 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Intervention is not an antihypertensive: IV magnesium sulphate vs oral magnesium chloride. No clinical outcomes studied.<BR/>Methods: randomised controlled open clinical trial.<BR/>Participants: 68 women with mild pre-eclampsia.<BR/>Intervention: IV magnesium sulphate (2 g/h) or oral magnesium chloride (4 g/2h).<BR/>Outcomes: serum Mg levels at 3, 6 and 12 hr after administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:23:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Israel-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:23:02 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 beta blockers. Published as abstract only.<BR/>Methods: 'allocated in blind and randomised manner'. No further information.<BR/>Participants: 30 women with SBP 140-170 mmHg and DBP 90-110 mmHg x 2, 6 hr apart.<BR/>Intervention: Atenolol 100 mg plus 2 placebo tablets vs pindolol 5 mg x 3/day.<BR/>Outcomes: gestation at delivery (mean).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:23:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Israel-1992a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:23:03 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 beta blockers.<BR/>Methods: 'randomly allocated to double blind treatment'. No further information.<BR/>Participants: 20 women with mild PE, BP &gt;/= 140/90 mmHg.<BR/>Interventions: propranolol 40 mg x 3/day vs pindolol 5 mg x 3/day, for 7 days.<BR/>Outcomes: BP, umbilical artery Doppler.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Israel-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single-dose intervention.<BR/>Methods: double-blind, placebo-controlled RCT.<BR/>Participants: 23 women with PIH.<BR/>Intervention: sublingual tablet of Isosorbide dinitrate (5 mg) or placebo (single dose).<BR/>Outcomes: maternal BP and heart rate, umbilical artery Doppler.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Italy-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT (matched controls). Available as abstract only. <BR/>Methods: 'randomised protocol', no further information, for group A (nifedipine or atenolol), control group (B) was matched by age and parity with group A. Results in group A were not presented separately.<BR/>Participants: 10 women with mild-moderate hypertension in the third trimester (group A).<BR/>Interventions: atenolol 100 mg a day or slow-release nifedipine 20 mg x 2/day (group A) vs diuretics or bed rest (group B).<BR/>Outcomes: BP, gestational age, birthweight, Apgar score, serum bilirubin, preterm delivery, RDS, side-effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:22:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Italy-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:22:05 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised design. 2 trials with same methods reported in 1 paper (1) 44 women (2) 50 women.<BR/>Methods: allocation by 'order of attendance at clinic or department'.<BR/>Participants: women with BP =/&gt; 140/90 mmHg x 2 over 8 hr, normal BP before pregnancy.<BR/>Intervention: (1) slow-release verapamil 360-480 mcg/day vs pindolol 15-20 mg/day. (2) slow-release verapamil 360-480 mcg/day vs atenolol 100-150 mg/day.<BR/>Outcomes: caesarean section, baby death, Apgar (mean), gestation at delivery (mean).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Italy-1990a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention is an antiplatelet agent. No clinical outcomes reported. Available as abstract only.<BR/>Methods: '...using a random selection...'. No further information.<BR/>Participants: 20 women with PIH before 36 weeks' gestation. <BR/>Intervention: picotamide (no dose reported) vs no treatment. <BR/>Outcomes: platelet aggregation, ADP-threshold values, collagen concentration thresholds.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Italy-2000a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women had chronic hypertension or history of hypertension or IUGR (results were not presented separately).<BR/>Methods: "...patients were randomly allocated to two treatments...".<BR/>Participants: 68 women with either chronic hypertension or with previous history of PE or IUGR.<BR/>Intervention: glyceryl trinitrate transdermal patch (5 mg/24 hr) for 14-16 hr/day from 16 to 38 weeks' gestation vs observation.<BR/>Outcomes: hypertensive syndrome, preterm delivery, abruptio, birthweight, IUGR, Apgar score, admission to SCBU, RDS, neonatal death, umbilical and cerebral artery PI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Italy-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clearly randomised. No clinical data reported. Available as congress abstract only.<BR/>Methods: not stated. <BR/>Participants: 24 women with PIH.<BR/>Intervention: isosorbide dinitrate sublingual every 6 hr (n = 12) vs nifedipine 20 mg daily (n = 12).<BR/>Outcomes: apoptosis in placental tissues.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-20 00:06:25 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Italy-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-20 00:06:25 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Intervention is not an antihypertensive: acupuncture + methyldopa vs. methyldopa. Protocol for a future RCT. Available as abstract only.</P>
<P>Methods: planned RCT</P>
<P>Participants: 60 women with chronic hypertension at 16-20 weeks' gestation.</P>
<P>Intervention: acupuncture + methyldopa vs. methyldopa.</P>
<P>Outcomes:need for antihypertensives.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 17:19:13 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Italy-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 17:19:13 +0000" MODIFIED_BY="Heather Maxwell">
<P>Intervention is not an antihypertensive. Single-dose treatment.<BR/>Methods: double-blind, randomised, cross-over design.<BR/>Participants: 15 pregnant women at 30-34 weeks' gestation with mild/moderate PIH.<BR/>Intervention: L-Arginine 20 g /500 mL vs placebo infusion.<BR/>Outcomes: systolic and diastolic BP, fetal heart rate and fetal movements.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 17:19:27 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Italy-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 17:19:27 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Intervention is not an antihypertensive. Available only as an abstract.<BR/>Methods: double-blind, randomised, placebo-controlled trial.<BR/>Participants: 20 pregnant women with pre-eclampsia.<BR/>Intervention: L-Arginine 1.66g 3 times a day vs placebo.<BR/>Outcomes: Serum L-arginine levels, adverse maternal and fetal outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 17:19:40 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Italy-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 17:19:40 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Intervention is not an antihypertensive.<BR/>Methods: double-blind, randomised, placebo-controlled trial.<BR/>Participants: 80 pregnant women with mid chronic hypertension.<BR/>Intervention: L-Arginine vs placebo.<BR/>Outcomes: BP, need for additional antihypertensives, superimposed pre-eclampsia, adverse maternal and fetal outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Japan-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single-dose intervention. No clinical outcomes studied.<BR/>Methods: "...randomly allocated into two groups using sealed envelopes...".<BR/>Participants: 18 pregnant women with SBP = or &gt; 140 mmHg and DBP = or &gt; 90 mmHg, with or without proteinuria and oedema.<BR/>Intervention: isosorbide dinitrate patches (40 mg, only dose) and bed rest vs bed rest alone.<BR/>Outcomes: systolic and diastolic BP, uterine and umbilical Doppler velocimetry.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuwait-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clearly randomised.<BR/>Methods: 'randomly allocated in sequence'. No further information.<BR/>Participants: 120 primigravid women &gt; 26 weeks' gestation, with SBP 120-140 mmHg and DBP 95-105 mmHg persisting for 3 days.<BR/>Intervention: labetalol 100-300 mg x 3/day vs methyldopa 250-750 mg x 3/day.<BR/>Outcomes: maternal MAP, proteinuria (undefined), placental abruption, caesarean section, elective delivery, side-effects, 1 min Apgar score &lt; 5, days on SCBU, birthweight (mean).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 17:20:51 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Mexico-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 17:20:51 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Intervention is not an antihypertensive. Available only as an abstract.</P>
<P>Methods: randomised, placebo-controlled trial.</P>
<P>Participants: 100 pregnant women with pre-eclampsia.</P>
<P>Intervention: L-Arginine vs placebo.</P>
<P>Outcomes: birthweight, SGA babies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:22:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pakistan-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:22:12 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention is an antiplatelet agent.<BR/>Methods: 'randomly divided into two groups'. No further information.<BR/>Participants: 200 women, 1 group with previous history of PIH (100 women) and other with mild essential hypertension or those developing BP 140/90 mmHg x 2 at least 15 days apart (100 women).<BR/>Intervention: aspirin 75 mg b.i.d. vs routine antihypertensive treatment with beta blockers or calcium channel blockers when DBP exceeded 100 mmHg.<BR/>Outcomes: development of PE. No other relevant outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 18:00:06 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Panama-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 18:00:06 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Severe hypertension. Ongoing trial.</P>
<P>Methods: randomised, open label trial.</P>
<P>Participants: 284 (estimated) women with at &gt; 24 weeks' gestation with severe HT (SBP &gt; 160 mmHg/DBP &gt; 110 mmHg).</P>
<P>Intervention: 5 mg IV hydralazine every 15 min until BP controlled vs. IV labetalol ant increasing doses until BP controlled.</P>
<P>Outcomes: BP control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:23:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Philippines-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:23:56 +0100" MODIFIED_BY="[Empty name]">
<P>3 days treatment. No relevant clinical outcomes studied. Available as abstract only.<BR/>Methods: randomised, double-blind, placebo-controlled trial.<BR/>Participants: 16 pre-eclamptics (no further details).<BR/>Intervention: nitrol patch 5 mg for 16 hr for 3 consecutive days vs the same regimen using a gauze only.<BR/>Outcomes: uterine and umbilical Doppler velocimetry.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-01 17:22:57 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Russia-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-01 17:22:57 +0000" MODIFIED_BY="Heather Maxwell">
<P>Possibly not a RCT. Full text awaiting translation from Russian. Abstract only in English.<BR/>Participants: 92 women with slight and medium-severe hypertension at 24-39 weeks' gestation.<BR/>Interventions: venodilators, prazosin and cordafen are all mentioned. Not clear how the groups were constructed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singapore-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>More than 20% of women excluded, 6 women (22%) excluded because delivered in the week after trial entry.<BR/>Methods: 'by opening a sealed envelope'.<BR/>Participants: 27 women with singleton pregnancies, DBP 90 mmHg or above and proteinuria.<BR/>Interventions: isradipine (slow release) 5 mg a day vs methyldopa 750 mg a day.<BR/>Outcomes: MAP, side-effects, caesarean section, perinatal mortality, birthweight, admission to SCBU, Apgar score, maternal and fetal haemodynamics (by Doppler).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singapore-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No relevant clinical outcomes studied.<BR/>Methods: 'randomised', no further information.<BR/>Participants: 30 women with PE, DBP &gt;/= 90 mmHg and proteinuria &gt;/= 300 mg/24 hr.<BR/>Interventions: methyldopa 250-500 mg x 3/day vs isradipine 5-10 mg once/day.<BR/>Outcomes: haemostatic parameters only (thrombelastography, fibrinogen, antithrombin III, thrombin-antithrombin-complex, beta-thromboglobulin, plasminogen activators, plasminogen activators inhibitors, and plasminogen).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:32:06 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Slovakia-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:32:06 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Not a RCT.</P>
<P>Methods: cohort study.</P>
<P>Participants: women with hypertension during pregnancy.</P>
<P>Interventions: acebutolol vs other antihypertensives.</P>
<P>Outcomes: maternal and perinatal adverse events.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-South-Africa-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-random design. Less than 7 days treatment, single-dose study. No clinical outcomes reported.<BR/>Methods: quasi-random design, using last digit of the hospital number.<BR/>Participants: 18 women in the last trimester of pregnancy with hypertension +/- proteinuria.<BR/>Interventions: nifedipine 5 mg vs placebo (single dose).<BR/>Outcomes: measures of uteroplacental blood flow.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-South-Africa-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included women with severe hypertension (DBP 100-120 mmHg). <BR/>Methods: 'randomly allocated', no further information.<BR/>Participants: 60 women at 28-36 weeks' gestation with mean 24 hr DBP 100-120 mmHg +/- proteinuria.<BR/>Intervention: indoramin 50 mg twice daily vs methyldopa 1 g twice daily vs placebo 1 tablet daily.<BR/>Outcomes: MAP, need for additional antihypertensive.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-South-Africa-1991a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-random design. Single-dose intervention.<BR/>Methods: allocation 'by virtue of the last digit of their folder number'.<BR/>Participants: 19 women at &gt; 28 weeks' gestation, singleton pregnancy and hypertension (defined as mean DBP &gt;/= 90 mmHg).<BR/>Intervention: sublingual nifedipine 5 mg vs placebo (single dose).<BR/>Outcomes: DBP (mean), maternal and fetal heart rate, gestational age, side-effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-South-Africa-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Most women did not have hypertension. Eligibility criteria DBP &gt;/= 80 mmHg, before 20 weeks' gestation. Of 138 recruited women, less than half had DBP &gt;/= 90 mmHg. Results for this group were not presented separately.<BR/>Methods: sequentially-numbered sealed boxes containing drug or placebo.<BR/>Participants: 138 women between 12-20 weeks' gestation with DBP 80-109 mmHg, without antihypertensive therapy.<BR/>Intervention: ketanserin 40-80 mg a day vs placebo.<BR/>Outcomes: severe HT, proteinuria, placental abruption, other drugs needed, perinatal deaths, SGA (&lt; 10th centile), birthweight.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spain-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported. Number of women in each group not reported. Available as abstract only.<BR/>Methods: 'double-blind, placebo-controlled trial', no further information. <BR/>Participants: 31 women with mild hypertension (BP 140-160/90 110 mmHg) despite bed rest in hospital.<BR/>Intervention: labetalol 200-600 mg a day vs placebo.<BR/>Outcomes: severe HT, need for additional antihypertensives, MAP, caesarean section, perinatal deaths, fetal distress.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sri-Lanka-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-random design.<BR/>Methods: 'patients were alternately allocated'.<BR/>Participants: 126 women with PIH.<BR/>Interventions: nifedipine 30-90 mg/day vs methyldopa 750-2000 mg/day.<BR/>Outcomes: severe hypertension, gestation at delivery (mean), birthweight (mean).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:23:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sweden-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:23:07 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 beta blockers.<BR/>Methods: 'randomly allocated' using 'double-blind dummy technique'. No further information.<BR/>Participants: 32 women admitted to hospital with PIH in the third trimester (BP &gt;/= 140/90 mmHg x 2 at least 4 hr apart) and normotensive in the first trimester.<BR/>Intervention: atenolol 50 mg x 2/day vs pindolol 5 mg x 2/day, for at least 1 week.<BR/>Outcomes: side-effects, caesarean section, maternal haemodynamics, fetal haemodynamics, admission to SCBU, birthweight (mean), 5 min Apgar score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-04 17:32:58 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sweden-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-04 17:32:58 +0000" MODIFIED_BY="Heather Maxwell">
<P>It is not clear from papers whether reported data represent only a subgroup of women.<BR/>Methods: not stated. Authors said 'allocated at random'.<BR/>Participants: 20 women at 26-37 weeks' gestation with 'persistent' DBP &gt;/= 100 mmHg and proteinuria.<BR/>Intervention: labetalol 300-1000 mg/day orally (if necessary, IV 25 mg bolus followed by 25-65 mg/hr infusion), vs hydralazine 75-400 mg/day orally (if necessary, 1.5-6.0 mg/hr infusion).<BR/>Outcomes: severe hypertension, additional antihypertensive, caesarean section, neonatal death, birthweight (mean), gestation at delivery (mean), SGA (2 SD below mean), bradycardia, hypotension, hypoglycaemia, 5 min Apgar &lt; 7, RDS, cord pH (&lt; 7.20).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-20 02:26:25 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Uganda-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-20 02:26:25 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Status unknown.</P>
<P>Personal communication of a planned RCT of aspirin and methyldopa in moderate hypertension during pregnancy. No further data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-UK-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included women with severe hypertension.<BR/>Methods: 'randomly allocated'. No further information.<BR/>Participants: 74 women with singleton pregnancy with DBP &gt;or = to 170/100 mm Hg x 2 at up to 36 weeks' gestation.<BR/>Intervention: labetalol 100 mg (max 1200 mg daily) vs methyldopa 250 mg (up to 4000 mg daily).<BR/>Outcomes: severe hypertension, proteinuria ('greater than trace'), additional antihypertensive therapy, changed drugs due to maternal side-effects, caesarean section, perinatal mortality, SGA infants (&lt; 10th centile), intubated, umbilical cord pH.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-UK-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 7 days treatment, single-dose study.<BR/>Methods: sequentially-numbered, sealed envelopes.<BR/>Participants: 30 women with singleton pregnancy and hypertension, defined as BP &gt;/= 140/90 mmHg.<BR/>Intervention: 10 mg hydralazine IV vs or 100 mg labetalol IV, as single dose.<BR/>Outcomes: MAP, maternal and fetal heart rate, side-effects, umbilical artery PI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-USA-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised. Although a group of women received placebo, results are presented together with a group of matched controls. Included women with severe hypertension.<BR/>Methods: not stated.<BR/>Participants: 106 pregnant women with chronic hypertension and 28 women with severe pre-eclampsia. In addition 671 women with chronic hypertension were included as controls. <BR/>Intervention: oral reserpine 0.25 to 3 mg/day (n = 80) vs placebo (n = 26). 28 women received IV reserpine.<BR/>Outcomes: status at birth, birthweight.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-USA-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study included 63 women, but only 21 randomised. Outcomes not reported separately for randomised women. <BR/>Methods: 'randomly and blindly assigned'. No further information. <BR/>Participants: 21 women with BP 140/90 mmHg or above in a seated position or at rest, x 2, 6 or more hr apart.<BR/>Intervention: hydralazine 25 mg x 3/day vs methyldopa 250 mg x 3/day vs placebo x 3/day.<BR/>Outcomes: MAP, caesarean section, induction of labour, birthweight.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 09:44:59 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-USA-1990a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 09:44:59 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Status unknown.</P>
<P>Personal communication of a planned RCT of oral hypotensive agents in early onset pre-eclampsia. No further data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-USA-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial. No clinical outcomes reported.<BR/>Methods: placebo group were matched as controls.<BR/>Participants: 16 women at 17-22 weeks' gestation.<BR/>Intervention: 10 mg sublingual nifedipine vs placebo.<BR/>Outcomes: S/D ratio of the uterine artery, maternal BP, maternal heart rate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:32:42 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-USA-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:32:42 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Intervention is not an antihypertensive. Ongoing trial.</P>
<P>Methods: randomised controlled trial. Sequentially numbered opaque envelopes.</P>
<P>Participants: 50 pregnant women with chronic hypertension.</P>
<P>Intervention: target blood pressure of 120-130/80-85 mmHg vs target blood pressure 140-150/90-100 mmHg.</P>
<P>Outcomes: BP, superimposed pre-eclampsia, worsening hypertension, HELLP syndrome, gestational age, birthweight, serious perinatal complications.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Venezuela-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised. Included women with severe hypertension. Article in Spanish.<BR/>Methods: alternated allocation (personal communication).<BR/>Participants: 32 pregnant women at &gt; 25 weeks' gestation with severe pre-eclampsia (defined as BP 160/110 or 140/90) and symptoms as headache, epigastric pain, blurred vision or hyperreflexia.<BR/>Intervention: labetalol 200-800 mg/day vs methyldopa 750-2000 mg/day.<BR/>Outcomes: maternal MAP, maternal pulse rate, gestational age at delivery, birthweight, 1 min Apgar, fetal and neonatal death.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Venezuela-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT. Matched controls. Article in Spanish.<BR/>Methods: controls were women treated with methyldopa in the same study period, with the same characteristics than the study group.<BR/>Participants: 20 women with PIH. <BR/>Intervention: labetalol 200 to 300 mg orally given every 12 hr vs methyldopa from 500 to 1500 mg/day <BR/>Outcomes: BP, severe hypertension, gestational age, induction of labour, caesarean section, birthweight.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Venezuela-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No relevant clinical outcomes reported. Less than 7 days of treatment. Available as abstract only. <BR/>Methods: Authors said '...were randomly assigned to...'. No further information. <BR/>Participants: 30 pre-eclamptic. No further information.<BR/>Intervention: transdermal nitroglycerin (7 mg for 12 hr for 2 consecutive days) vs placebo.<BR/>Outcomes: umbilical S/D ratio, PI and RI by Doppler ultrasound.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 10:33:07 +0100" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Venezuela-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 10:33:07 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Mixed control group. Available only as an abstract.</P>
<P>Method: "...were randomly assigned to two study groups...".</P>
<P>Participants: 30 women with pre-eclampsia-eclampsia and gestational hypertension.</P>
<P>Intervention: Carvedilol vs traditional antihypertensive drugs (methyldopa and/or nifedipine).</P>
<P>Outcomes: BP control, additional antihypertensives, maternal and fetal complications, Apgar score, fetal heart rate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ADP: adenosine diphosphate<BR/>b.i.d.: twice a day<BR/>BP: blood pressure<BR/>DBP: diastolic blood pressure<BR/>HT: hypertension<BR/>IUGR: intrauterine growth retardation<BR/>IV: intravenous<BR/>LBW: low birthweight<BR/>min: minutes<BR/>MAP: mean arterial pressure<BR/>NICU: neonatal intensive care unit<BR/>NO-donor: Nitric oxide donor<BR/>NST: non-stress test<BR/>PIH: pregnancy-induced hypertension<BR/>PI: pulsatility index<BR/>PE: pre-eclampsia<BR/>RCT: randomised controlled trial<BR/>RDS: respiratory distress syndrome<BR/>RI: resistance index<BR/>SBP: systolic blood pressure<BR/>SCBU: special care baby unit<BR/>SD: standard deviation<BR/>S/D ratio: ratio between peak systolic to end-diastolic flow velocity<BR/>SGA: small-for-gestational age<BR/>t.i.d.: dosing three times daily<BR/>vs: versus<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-01-01 16:37:22 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-01-01 16:37:22 +0000" MODIFIED_BY="Edgardo J Abalos" STUDY_ID="STD-Canada-2008">
<CHAR_METHODS MODIFIED="2013-06-19 10:33:19 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Randomised, multicentre, blinded, placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-01 16:29:42 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Treatment arm: all women who have been diagnosed with pre-eclampsia, are being followed clinically and who provide informed consent. For a diagnosis of pre-eclampsia a patient must meet all 3 criteria:</P>
<P>1. Systolic blood pressure greater than 140 mmHg or an increase of 30 mmHg from the participant&#8217;s baseline (with that increase present at 2 measurements taken 6 hours apart).</P>
<P>2. Diastolic blood pressure greater than 90 mmHg or an increase of 15 mmHg from the participant&#8217;s baseline (with that increase present at 2 measurements taken 6 hours apart).</P>
<P>3. Proteinuria greater than 0.3 g in 24 hour urine or 2+ on dipstick.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-19 10:34:06 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Treatment arm: experimental intervention: daily dose of low-dose Isosorbide-5-mononitrate (ISMN) (30 mg) following diagnosis of pre-eclampsia after 24 weeks' gestation till delivery.</P>
<P>Control intervention: matching placebo containing lactose. Patients randomly assigned to either receive low dose ISMN (30 mg) as stated above or placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-01 16:37:22 +0000" MODIFIED_BY="Edgardo J Abalos">
<P>Primary outcome: randomisation-to-delivery interval between ISMN/placebo groups, measured at delivery. Secondary outcomes: serial change in biochemical markers in treatment/no treatment groups, measured at routine obstetrical visits until delivery (generally every 2 weeks), incidence of any side-effects (major or minor), measured at routine obstetrical visits until delivery (generally every 2 weeks), neonatal outcomes (composite of neonatal morbidity), measured at delivery.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-19 10:34:20 +0100" MODIFIED_BY="Edgardo J Abalos">
<P>Ongoing trial. Author contacted.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-01-05 11:44:38 +0000" MODIFIED_BY="Denise Atherton">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-06-19 10:19:37 +0100" MODIFIED_BY="Denise Atherton" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:05:44 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1985">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:05:56 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1987">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:10 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1988">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:23 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Australia-1983">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:37 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Australia-1985">
<DESCRIPTION>
<P>Not described: "...were allocated by a series of random numbers to...", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:48 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Australia-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-22 19:22:44 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Brazil-1985">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:12 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Brazil-1988">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:28 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Brazil-2000a">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-22 19:41:50 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Caribbean-Is.1990">
<DESCRIPTION>
<P>"Randomisation was in stratified blocks of ten..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-22 19:50:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-France-1987">
<DESCRIPTION>
<P>"...stratified blocks of ten at each clinic..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 22:13:54 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>"Apres tirage au sort, effectué par groupe de 9 patientes..." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:06 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-France-1994">
<DESCRIPTION>
<P>List of computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:21 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Hong-Kong-1990">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:37 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-1992">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:50 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-2002">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-22 20:23:26 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-2012">
<DESCRIPTION>
<P>"Allocation cards labelled L (labetalol), M (methyldopa) or N (no antihypertensive) were prepared by a staff clerk in equal numbers of 50 each and put into opaque envelopes that were subsequently sealed, mixed up and numbered 1-150."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:11:58 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-2013">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-22 20:30:15 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Ireland-1991">
<DESCRIPTION>
<P>"...shuffled into random order..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:02:39 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1986">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:05:08 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1986a">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:10:37 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1992">
<DESCRIPTION>
<P>"...in a random fashion, in blocks of six, using serial numbers..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:15:35 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1995">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:14:09 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Italy-1997">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:22:14 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Italy-1998">
<DESCRIPTION>
<P>Computer-generated random numbers balanced by centre and stratified by type of hypertension.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:29:14 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Italy-1999">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:15:21 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Italy-2000">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:15:35 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1991">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:42:07 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1993">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:47:37 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Sudan-2002">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:16:21 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Sweden-1984">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 21:03:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Sweden-1985">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 21:05:20 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1995">
<DESCRIPTION>
<P>"...by numbers in blocks of 6..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 13:58:30 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1968">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:00:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1976">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:17:36 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1980">
<DESCRIPTION>
<P>Random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:11:18 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1982">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:17:12 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1983">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:26:07 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1983a">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:30:14 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1984">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:18:53 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1989">
<DESCRIPTION>
<P>List of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:36:15 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1990">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:40:14 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1992">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:43:27 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-USA-1979">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:19:37 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1987">
<DESCRIPTION>
<P>Computer-generated list of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:01:13 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-USA-1987a">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:05:11 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1990">
<DESCRIPTION>
<P>Computer-generated list of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:15:33 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1992">
<DESCRIPTION>
<P>Computer-generated list of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:18:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Venezuela-1988">
<DESCRIPTION>
<P>Random-number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-06-19 10:38:44 +0100" MODIFIED_BY="Denise Atherton" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:05:46 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1985">
<DESCRIPTION>
<P>Not described: "...randomly divided into two groups..." no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:05:57 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1987">
<DESCRIPTION>
<P>Not described: "...open randomised study..." no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:11 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1988">
<DESCRIPTION>
<P>Not described: "...randomised study..." no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:24 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Australia-1983">
<DESCRIPTION>
<P>Not described: "...randomly allocated..." no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:37 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Australia-1985">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:48 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Australia-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:01 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Brazil-1985">
<DESCRIPTION>
<P>Not described: : "...patients were randomly divided into two groups...", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Brazil-1988">
<DESCRIPTION>
<P>Consecutive numbered treatment boxes (personal communication).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:29 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Brazil-2000a">
<DESCRIPTION>
<P>Consecutive numbered treatment packs containing the study drug or placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-22 19:44:53 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Caribbean-Is.1990">
<DESCRIPTION>
<P>"...sealed envelopes and individual batch of drugs containing either the maximum amount of active drug that could be used in 20 weeks of treatment or placebos of identical appearance."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:08:21 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-France-1987">
<DESCRIPTION>
<P>Blinded envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:08:53 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:07 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-France-1994">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:23 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Hong-Kong-1990">
<DESCRIPTION>
<P>Not described: authors only said: 'randomised double-blind controlled study'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:37 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-India-1992">
<DESCRIPTION>
<P>Not described: "...randomly allocated...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:51 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-2002">
<DESCRIPTION>
<P>Not described: "...randomised by number...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:10:56 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-India-2012">
<DESCRIPTION>
<P>Consecutively numbered opaque sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:12:08 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-2013">
<DESCRIPTION>
<P>Not described: "...patients were divided into two groups randomly...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:12:40 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Ireland-1991">
<DESCRIPTION>
<P>Sealed, identical numbered envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:12:59 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1986">
<DESCRIPTION>
<P>Not described: "...randomly allocated...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:13:18 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1986a">
<DESCRIPTION>
<P>Not described: "...randomly allocated...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:13:37 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Israel-1992">
<DESCRIPTION>
<P>Pindolol and placebo tablets supplied by pharmacy in numbered packets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:13:57 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1995">
<DESCRIPTION>
<P>Not described: "...randomly allocated...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:14:10 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Italy-1997">
<DESCRIPTION>
<P>Not described: "...randomly allocated...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:14:29 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Italy-1998">
<DESCRIPTION>
<P>Allocation by telephone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:14:54 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Italy-1999">
<DESCRIPTION>
<P>Consecutive opaque sealed envelopes (personal communication).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:15:22 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Italy-2000">
<DESCRIPTION>
<P>Consecutive numbered treatment boxes provided by pharmacy (personal communication).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:15:37 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1991">
<DESCRIPTION>
<P>Not described: "...in a randomised way, participants either received...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:43:10 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1993">
<DESCRIPTION>
<P>Not described: "...randomised, prospective open study...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:16:14 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Sudan-2002">
<DESCRIPTION>
<P>Not described: "...patients were randomly allocated...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:16:22 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Sweden-1984">
<DESCRIPTION>
<P>Telephone randomisation (personal communication).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:16:36 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Sweden-1985">
<DESCRIPTION>
<P>Not described "...randomly allocated...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 21:08:03 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Sweden-1995">
<DESCRIPTION>
<P>Not described: "...parallel double blind study...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 13:58:55 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-UK-1968">
<DESCRIPTION>
<P>Not described: "...allocated at random...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:03:14 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-UK-1976">
<DESCRIPTION>
<P>Not described: "Treatment was allocated randomly...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:17:37 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-UK-1980">
<DESCRIPTION>
<P>Not described: "...randomly allocated...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:12:21 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-UK-1982">
<DESCRIPTION>
<P>Envelope randomisation (personal communication). No details on whether they were opaque, sealed and consecutively numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:18:06 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-UK-1983">
<DESCRIPTION>
<P>Not described: "...allocated in double-blind, randomised manner...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:26:51 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-UK-1983a">
<DESCRIPTION>
<P>Not described "...allocated at random...". Stratified by gestational age.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:18:35 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-UK-1984">
<DESCRIPTION>
<P>Not described: "...randomised trial...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:32:50 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-UK-1989">
<DESCRIPTION>
<P>Drug and placebo sent by manufacturer to hospital pharmacy with list of random numbers. Then dispensed by pharmacists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:38:44 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-UK-1990">
<DESCRIPTION>
<P>Not described: "...randomised, placebo-controlled, double blind study...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:40:27 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-UK-1992">
<DESCRIPTION>
<P>Numbered, sealed opaque envelopes. Stratified by parity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:44:44 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-USA-1979">
<DESCRIPTION>
<P>Not described: "...allocated randomly to treatment or no treatment...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:19:38 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-USA-1987">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:19:55 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-USA-1987a">
<DESCRIPTION>
<P>Not described: "...randomly allocated...". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:20:17 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-USA-1990">
<DESCRIPTION>
<P>Sealed envelopes (personal communication).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:20:35 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-USA-1992">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:20:50 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Venezuela-1988">
<DESCRIPTION>
<P>Not described: [Estudio prospectivo randomizado] "randomised, prospective trial". No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-01-05 11:44:38 +0000" MODIFIED_BY="Denise Atherton" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-01 18:00:00 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Argentina-1985">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-22 18:56:16 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Argentina-1987">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-22 18:59:59 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Argentina-1988">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-22 19:01:29 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Australia-1983">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-22 19:05:26 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Australia-1985">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:06:50 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Australia-2001">
<DESCRIPTION>
<P>Described as "...single blind, placebo controlled trial...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-22 19:23:38 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Brazil-1985">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:07:15 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Brazil-1988">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:07:33 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Brazil-2000a">
<DESCRIPTION>
<P>Double blind, only pharmacist providing treatment packs aware of the codes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-05 11:43:52 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Caribbean-Is.1990">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:08:22 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-France-1987">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:08:54 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:09:07 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-France-1994">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-05 11:44:04 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Hong-Kong-1990">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:09:39 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-1992">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:09:52 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-2002">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:10:56 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-2012">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:12:11 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-2013">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:12:41 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Ireland-1991">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:12:59 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Israel-1986">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:13:19 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Israel-1986a">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:13:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1992">
<DESCRIPTION>
<P>Double blind : "...placebo of identical appearance...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:13:58 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Israel-1995">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:14:11 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-1997">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 20:22:45 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-1998">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 20:30:06 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-1999">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:15:22 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-2000">
<DESCRIPTION>
<P>Single blind (only for participants).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-01 17:49:51 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1991">
<DESCRIPTION>
<P>Although identical placebo tablets were used, there is no information about whether it was a double-blind or a single-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 20:43:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-South-Africa-1993">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 20:50:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Sudan-2002">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:16:23 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1984">
<DESCRIPTION>
<P>Double blind. Placebos of identical appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:16:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Sweden-1985">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:16:59 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1995">
<DESCRIPTION>
<P>Double blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:17:09 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1968">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:17:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1976">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:17:38 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1980">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:17:49 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1982">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-05 11:44:16 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1983">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:18:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1983a">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-24 14:30:45 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1984">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-05 11:44:27 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1989">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-05 11:44:38 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1990">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:19:15 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1992">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:19:26 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1979">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-24 14:48:45 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1987">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:19:57 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1987a">
<DESCRIPTION>
<P>Double blind, placebo controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:20:18 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1990">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-24 15:15:36 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1992">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-19 10:20:51 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Venezuela-1988">
<DESCRIPTION>
<P>Open label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-06-19 10:20:53 +0100" MODIFIED_BY="Denise Atherton" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:05:47 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Argentina-1985">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:05:58 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Argentina-1987">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:06:12 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Argentina-1988">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:06:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Australia-1983">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:06:38 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Australia-1985">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:06:51 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Australia-2001">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:07:02 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Brazil-1985">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:07:16 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Brazil-1988">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-22 19:34:55 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Brazil-2000a">
<DESCRIPTION>
<P>Double blind, only pharmacist providing treatment packs aware of the codes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:07:59 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Caribbean-Is.1990">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:08:23 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-France-1987">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:08:54 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:09:08 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-France-1994">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:09:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Hong-Kong-1990">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:09:39 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-1992">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:09:53 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-2002">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:10:57 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-2012">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:12:11 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-India-2013">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:12:41 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Ireland-1991">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:13:00 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Israel-1986">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:13:19 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Israel-1986a">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:13:41 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1992">
<DESCRIPTION>
<P>Codes were broken only in the presence of severe side-effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:13:58 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Israel-1995">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:14:12 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-1997">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 20:23:44 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-1998">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-24 22:17:54 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-1999">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:15:23 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-2000">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:15:39 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1991">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 20:43:28 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-South-Africa-1993">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 20:50:09 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Sudan-2002">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:16:24 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1984">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:16:41 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Sweden-1985">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:17:00 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1995">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:17:09 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1968">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:17:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1976">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:17:38 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1980">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:17:50 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1982">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-24 14:18:24 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1983">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:18:26 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1983a">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:18:36 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1984">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-24 14:33:18 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1989">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-24 14:37:22 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1990">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:19:16 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1992">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-24 14:45:07 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1979">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-24 14:48:52 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1987">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:19:58 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1987a">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:20:18 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1990">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:20:38 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1992">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-19 10:20:53 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Venezuela-1988">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-01-01 16:37:01 +0000" MODIFIED_BY="Denise Atherton" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:05:47 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Argentina-1985">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:05:59 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Argentina-1987">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:06:13 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Argentina-1988">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:06:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Australia-1983">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:06:39 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Australia-1985">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:06:52 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Australia-2001">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:07:03 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Brazil-1985">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:07:17 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Brazil-1988">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-01 16:37:01 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Brazil-2000a">
<DESCRIPTION>
<P>15 withdrawals (7.5%): 5 women delivered in other hospitals, 10 withdrew consent (1 due to side-effects).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:08:00 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Caribbean-Is.1990">
<DESCRIPTION>
<P>1 women (0.6%) lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-22 19:53:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-France-1987">
<DESCRIPTION>
<P>12 women (6.4%) excluded from analysis: 10 lost to follow-up (3 from labetalol and 7 from methyldopa group), and 2 "protocol violation". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:08:55 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:09:09 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-France-1994">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:09:26 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Hong-Kong-1990">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:09:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-India-1992">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:09:54 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-India-2002">
<DESCRIPTION>
<P>7 dropouts (6%), not specified in which group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:10:58 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-India-2012">
<DESCRIPTION>
<P>1 woman withdrew consent in methyldopa group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:12:12 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-India-2013">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:12:42 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Ireland-1991">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:13:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1986">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:13:20 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1986a">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:13:42 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1992">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:13:59 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1995">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:14:13 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Italy-1997">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 20:27:10 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Italy-1998">
<DESCRIPTION>
<P>22 women (7.8%) lost to follow-up.13 in nifedipine group and 9 in control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:15:09 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Italy-1999">
<DESCRIPTION>
<P>6 withdrawals (16.6%). 3 in group 1, 1 in group 2 and 2 in group 3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:15:23 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Italy-2000">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:15:39 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-South-Africa-1991">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:16:05 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-South-Africa-1993">
<DESCRIPTION>
<P>3 women (10.3%) did not complete the trial. 2 from one group and 1 from the other, not clear from the report in which group they were.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:16:15 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sudan-2002">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:16:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1984">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:16:41 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1985">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:17:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1995">
<DESCRIPTION>
<P>7 withdrawals (6%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:17:10 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1968">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:17:26 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1976">
<DESCRIPTION>
<P>5 withdrawals (2%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:17:39 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1980">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:17:51 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1982">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:36:54 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1983">
<DESCRIPTION>
<P>Withdrawals: some data missing for 35 women (29%). Data for each outcome only included if &lt; 20% excluded. Follow-up: 110 children (92%) seen at 1 year.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 14:28:41 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1983a">
<DESCRIPTION>
<P>4 women (4%) excluded, 2 lost to follow-up, 2 abortions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:18:37 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1984">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:18:50 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1989">
<DESCRIPTION>
<P>8 women excluded after randomisation (5.3%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 14:38:06 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-UK-1990">
<DESCRIPTION>
<P>4 withdrawals (12.1%). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:19:16 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1992">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:19:27 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1979">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:19:42 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1987">
<DESCRIPTION>
<P>14 withdrawals (7%). 8 in treatment group and 6 in control group refused hospitalisation, but data reported for perinatal death.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:20:00 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1987a">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:36:58 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-USA-1990">
<DESCRIPTION>
<P>Withdrawals: 37 women (12%). 27 exp (21 excluded due to poor compliance, 3 twin, 1 abortion and 2 lost to follow-up) and 10 control (8 due to poor compliance, 1 twin and 1 spontaneous abortion).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 15:16:21 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1992">
<DESCRIPTION>
<P>3 women lost to follow-up (1.5%). 2 in treatment group and 1 in control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-19 10:20:53 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Venezuela-1988">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-06-19 10:16:25 +0100" MODIFIED_BY="Denise Atherton" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:05:48 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1985">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:00 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1987">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:13 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1988">
<DESCRIPTION>
<P>Assessment from published study abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:26 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Australia-1983">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Australia-1985">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:53 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Australia-2001">
<DESCRIPTION>
<P>Assessment from published study letter to editor.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:03 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Brazil-1985">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:18 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Brazil-1988">
<DESCRIPTION>
<P>Published and unpublished data provided by author.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:38 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Brazil-2000a">
<DESCRIPTION>
<P>Assessment from published study thesis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:08:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Caribbean-Is.1990">
<DESCRIPTION>
<P>Published and unpublished data provided by author.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:08:27 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-France-1987">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:08:56 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:10 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-France-1994">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:27 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Hong-Kong-1990">
<DESCRIPTION>
<P>Assessment from published study abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-22 20:13:11 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-1992">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:54 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-2002">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:10:59 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-2012">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:12:13 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-2013">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:12:43 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Ireland-1991">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:13:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1986">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:13:21 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1986a">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:14:14 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1992">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:14:00 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1995">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:14:14 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Italy-1997">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:14:33 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Italy-1998">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:33:27 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Italy-1999">
<DESCRIPTION>
<P>Additional data provided by authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:15:24 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Italy-2000">
<DESCRIPTION>
<P>Additional data provided by authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:15:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1991">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:47:08 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1993">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:56:23 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Sudan-2002">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:16:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1984">
<DESCRIPTION>
<P>Unpublished data provided by author.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 21:04:20 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Sweden-1985">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 21:10:06 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Sweden-1995">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:00:11 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1968">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:04:12 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1976">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:09:03 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1980">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:13:36 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1982">
<DESCRIPTION>
<P>Additional data provided by author.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:24:23 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1983">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:29:04 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1983a">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:31:19 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1984">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:35:20 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1989">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:38:55 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1990">
<DESCRIPTION>
<P>Additional data provided by authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:41:19 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1992">
<DESCRIPTION>
<P>Additional data provided by authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:46:07 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-USA-1979">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:51:07 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-USA-1987">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:03:27 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-USA-1987a">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:10:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1990">
<DESCRIPTION>
<P>Additional data provided by authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:17:17 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-USA-1992">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:22:56 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Venezuela-1988">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-01-01 17:46:40 +0000" MODIFIED_BY="Denise Atherton" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-01 17:37:37 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1985">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:06:00 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Argentina-1987">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:26:08 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Argentina-1988">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:26:15 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Australia-1983">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-22 19:10:24 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Australia-1985">
<DESCRIPTION>
<P>Cointerventions: 48% of oxprenolol group and 35% of methyldopa group received a second or third antihypertensive.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:26:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Australia-2001">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:04 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Brazil-1985">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:26:33 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Brazil-1988">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:07:38 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Brazil-2000a">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 22:13:11 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="NO" STUDY_ID="STD-Caribbean-Is.1990">
<DESCRIPTION>
<P>For 23 women (15%), treatment unblinded and other treatment started. 16 for uncontrolled BP (5 exp, 11 control) and 7 for poor compliance/side-effects (4 exp, 3 control).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:08:28 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-France-1987">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:08:56 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:10 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-France-1994">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:26:51 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Hong-Kong-1990">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:26:58 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-India-1992">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:09:55 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-India-2002">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:10:59 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-India-2012">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:12:13 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-India-2013">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:12:44 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Ireland-1991">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-19 10:13:02 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1986">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-01 17:46:40 +0000" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1986a">
<DESCRIPTION>
<P>Groups appear comparable at baseline. 2 women with side-effects on hydralazine crossed over to pindolol + hydralazine, and reported in this group. Data only included if available as intention-to-treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:14:18 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Israel-1992">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:27:29 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Israel-1995">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:28:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Italy-1997">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 20:28:26 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Italy-1998">
<DESCRIPTION>
<P>Groups appear comparable at baseline. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:28:11 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Italy-1999">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:28:18 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Italy-2000">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:28:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1991">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:28:32 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1993">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 22:19:08 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sudan-2002">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:28:42 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Sweden-1984">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 22:19:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1985">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 22:20:04 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-Sweden-1995">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:28:51 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1968">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:04:18 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1976">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:42:23 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1980">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:01 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1982">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:07 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1983">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:14 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1983a">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:20 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1984">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:25 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1989">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:31 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-UK-1990">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:42:51 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-UK-1992">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:46:22 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1979">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:40 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-USA-1987">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:46 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-USA-1987a">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:10:56 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1990">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:17:02 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="YES" STUDY_ID="STD-USA-1992">
<DESCRIPTION>
<P>Groups appear comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:29:55 +0100" MODIFIED_BY="Edgardo J Abalos" RESULT="UNKNOWN" STUDY_ID="STD-Venezuela-1988">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-09-09 17:12:36 +0100" MODIFIED_BY="Edgardo J Abalos">
<COMPARISON ID="CMP-001" MODIFIED="2013-09-06 12:30:26 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1">
<NAME>Any antihypertensive drug versus none (subgrouped by class of drug)</NAME>
<DICH_OUTCOME CHI2="2.010413792170532" CI_END="4.827101650300116" CI_START="0.24251264793228194" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0819580412624923" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.5179924755335504" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.6836864443955721" LOG_CI_START="-0.6152656064062256" LOG_EFFECT_SIZE="0.03421041899467324" METHOD="MH" MODIFIED="2013-05-20 18:12:54 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.3659690262513262" P_Q="1.0" P_Z="0.9177733687202707" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="289" TOTAL_2="236" WEIGHT="100.0" Z="0.10323889797809883">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.67913399058472" CI_START="0.12097024427277908" EFFECT_SIZE="2.9240506329113924" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8492912195923035" LOG_CI_START="-0.9173214423888976" LOG_EFFECT_SIZE="0.4659848886017029" ORDER="6761" O_E="0.0" SE="1.6251219726013035" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="2.641021425831552" WEIGHT="16.808775345615437"/>
<DICH_DATA CI_END="4.09936985144744" CI_START="0.007049864015025569" EFFECT_SIZE="0.17" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6127171027997018" LOG_CI_START="-2.151819260043154" LOG_EFFECT_SIZE="-0.769551078621726" MODIFIED="2013-05-20 18:12:54 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="724" O_E="0.0" SE="1.6239023442095932" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="2.637058823529412" WEIGHT="65.94439485076724"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6762" O_E="0.0" SE="0.0" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6763" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="66.49261543937459" CI_START="0.11569364775432935" EFFECT_SIZE="2.7735849056603774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8227734159495634" LOG_CI_START="-0.9366904856547894" LOG_EFFECT_SIZE="0.44304146514738707" ORDER="6764" O_E="0.0" SE="1.6209227553690084" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="2.6273905788730585" WEIGHT="17.24682980361733"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.154462404710548" CI_START="0.014091610588022437" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3389830508474576" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.9113953347982906" LOG_CI_START="-1.8510393667546166" LOG_EFFECT_SIZE="-0.46982201597816303" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5049745963119479" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="298" TOTAL_2="280" WEIGHT="100.00000000000001" Z="0.6666830748567941">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6765" O_E="0.0" SE="0.0" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6766" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6767" O_E="0.0" SE="0.0" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.154462404710548" CI_START="0.014091610588022437" EFFECT_SIZE="0.3389830508474576" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9113953347982906" LOG_CI_START="-1.8510393667546166" LOG_EFFECT_SIZE="-0.46982201597816303" ORDER="6768" O_E="0.0" SE="1.6226678179644862" STUDY_ID="STD-Sweden-1995" TOTAL_1="58" TOTAL_2="59" VAR="2.633050847457627" WEIGHT="100.00000000000001"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6769" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="26.964593099503514" CI_END="0.5957844050099788" CI_START="0.4010480940553339" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4888130522982617" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="242" I2="29.53722709670765" I2_Q="64.76403009497591" ID="CMP-001.03" LOG_CI_END="-0.2249108688731604" LOG_CI_START="-0.3968035432641051" LOG_EFFECT_SIZE="-0.31085720606863276" METHOD="MH" MODIFIED="2013-05-25 03:05:30 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.10548055639747878" P_Q="0.009180700986266888" P_Z="1.351374102176785E-12" Q="17.028054048668306" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1336" TOTAL_2="1222" WEIGHT="100.0" Z="7.088945824922977">
<NAME>Severe hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.203038470662835" CI_END="0.5671828515603462" CI_START="0.2599320353448457" DF="7" EFFECT_SIZE="0.38396483304955714" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="76" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.24627690826451515" LOG_CI_START="-0.585140192541632" LOG_EFFECT_SIZE="-0.41570855040307353" NO="1" P_CHI2="0.7561170695787863" P_Z="1.5179014765553709E-6" STUDIES="8" TAU2="0.0" TOTAL_1="378" TOTAL_2="384" WEIGHT="30.81488165467885" Z="4.80886436896521">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.4103128933907758" CI_START="0.28142691019844857" EFFECT_SIZE="0.63" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.14931547634177364" LOG_CI_START="-0.5506343774346102" LOG_EFFECT_SIZE="-0.2006594505464183" ORDER="6770" O_E="0.0" SE="0.41115400891590376" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="20" TOTAL_2="21" VAR="0.16904761904761906" WEIGHT="3.938914690076358"/>
<DICH_DATA CI_END="0.890351646543475" CI_START="0.1797042782154134" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="6771" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.16666666666666669" WEIGHT="6.056081335992401"/>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="6772" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="0.20186937786641335"/>
<DICH_DATA CI_END="0.7465699182036291" CI_START="0.06694355152990397" EFFECT_SIZE="0.22355769230769232" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.1269295132328718" LOG_CI_START="-1.1742912509127434" LOG_EFFECT_SIZE="-0.6506103820728076" ORDER="6773" O_E="0.0" SE="0.615225469237373" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.37850237799834574" WEIGHT="5.331914996344632"/>
<DICH_DATA CI_END="1.3197208380365462" CI_START="0.061856000684717444" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12048207414354972" LOG_CI_START="-1.208618162844101" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="6774" O_E="0.0" SE="0.7807200583588264" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="0.6095238095238094" WEIGHT="2.826171290129787"/>
<DICH_DATA CI_END="0.9183944157552488" CI_START="0.13520589135855415" EFFECT_SIZE="0.3523809523809524" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.03697076564084711" LOG_CI_START="-0.8690043843650392" LOG_EFFECT_SIZE="-0.45298757500294307" ORDER="6775" O_E="0.0" SE="0.4887406662714275" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.23886743886743886" WEIGHT="5.887856854437056"/>
<DICH_DATA CI_END="4.099426132832591" CI_START="0.010939162996078491" EFFECT_SIZE="0.21176470588235294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6127230653081122" LOG_CI_START="-1.9610159065300856" LOG_EFFECT_SIZE="-0.6741464206109866" ORDER="6776" O_E="0.0" SE="1.5118270122711395" STUDY_ID="STD-UK-1990" TOTAL_1="16" TOTAL_2="17" VAR="2.28562091503268" WEIGHT="0.9805084067797218"/>
<DICH_DATA CI_END="0.97210968055073" CI_START="0.13697733797118744" EFFECT_SIZE="0.36490683229813664" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.012284732017487168" LOG_CI_START="-0.8633512781586645" LOG_EFFECT_SIZE="-0.43781800508807583" ORDER="6777" O_E="0.0" SE="0.49992070205067496" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.24992070833883975" WEIGHT="5.591564703052482"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4790277477874878" CI_END="0.7684089667401461" CI_START="0.1208648228895664" DF="1" EFFECT_SIZE="0.3047517246412274" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" I2="32.38801628326964" ID="CMP-001.03.02" LOG_CI_END="-0.11440757589904145" LOG_CI_START="-0.9177000800152864" LOG_EFFECT_SIZE="-0.5160538279571639" NO="2" P_CHI2="0.22392703570958183" P_Z="0.011793853989049795" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="158" WEIGHT="7.184853470717706" Z="2.5182530938536023">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="1.214567931047986" CI_START="0.16149936071047388" EFFECT_SIZE="0.4428904428904429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.08442181000508182" LOG_CI_START="-0.7918291924688724" LOG_EFFECT_SIZE="-0.35370369123189527" ORDER="6778" O_E="0.0" SE="0.5147141763656174" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.264930683351736" WEIGHT="4.4988032781657825"/>
<DICH_DATA CI_END="1.2823063840978146" CI_START="0.00419990213254197" EFFECT_SIZE="0.07338638373121131" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10799180445385774" LOG_CI_START="-2.376760829552621" LOG_EFFECT_SIZE="-1.1343845125493814" ORDER="6779" O_E="0.0" SE="1.459555996939311" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="2.130303708201506" WEIGHT="2.6860501925519236"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7017805940216553" CI_END="0.5786464588187521" CI_START="0.17276545638438584" DF="1" EFFECT_SIZE="0.31618051733626856" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="40" I2="41.23801837246271" ID="CMP-001.03.03" LOG_CI_END="-0.23758670031366255" LOG_CI_START="-0.7625430882537981" LOG_EFFECT_SIZE="-0.5000648942837304" NO="3" P_CHI2="0.19205536717554206" P_Z="1.8841798169475478E-4" STUDIES="2" TAU2="0.0" TOTAL_1="151" TOTAL_2="159" WEIGHT="15.719856839283128" Z="3.734059458061913">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="0.5456419852342921" CI_START="0.05707381278355769" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.2630922196308351" LOG_CI_START="-1.2435631136863878" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="6780" O_E="0.0" SE="0.575933456577432" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3316993464052287" WEIGHT="7.059660528813997"/>
<DICH_DATA CI_END="0.8951643039341957" CI_START="0.20662144808217364" EFFECT_SIZE="0.43006993006993005" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.04809724430085871" LOG_CI_START="-0.6848245990784315" LOG_EFFECT_SIZE="-0.3664609216896451" ORDER="6781" O_E="0.0" SE="0.3740168000475848" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="123" VAR="0.13988856671783503" WEIGHT="8.660196310469132"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.699119357300525" CI_START="0.1201487169013067" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.5680983446651372" LOG_CI_START="-0.9202808627764997" LOG_EFFECT_SIZE="-0.17609125905568127" NO="4" P_CHI2="1.0" P_Z="0.6428128167691762" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="1.21121626719848" Z="0.46376961464638244">
<NAME>Methyldopa + other drug versus none</NAME>
<DICH_DATA CI_END="3.699119357300525" CI_START="0.1201487169013067" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5680983446651372" LOG_CI_START="-0.9202808627764997" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="6782" O_E="0.0" SE="0.8742813140471173" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.764367816091954" WEIGHT="1.21121626719848"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.41403131030320717" CI_END="0.7411598956461858" CI_START="0.24578839710048994" DF="1" EFFECT_SIZE="0.42681202272902574" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="-0.13008808850421288" LOG_CI_START="-0.6094386226463462" LOG_EFFECT_SIZE="-0.36976335557527956" MODIFIED="2013-05-20 18:14:20 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.5199304468136214" P_Z="0.0024964623037105377" STUDIES="2" TAU2="0.0" TOTAL_1="272" TOTAL_2="140" WEIGHT="12.822710737105124" Z="3.023769905783965">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="0.7537090344788961" CI_START="0.17266719228262" EFFECT_SIZE="0.36075036075036077" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="-0.12279627894233291" LOG_CI_START="-0.7627901729372053" LOG_EFFECT_SIZE="-0.4427932259397691" MODIFIED="2013-05-20 18:14:20 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="725" O_E="0.0" SE="0.3759355813534565" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.14132756132756133" WEIGHT="7.511166650277823"/>
<DICH_DATA CI_END="1.2034709849825036" CI_START="0.22488329113438102" EFFECT_SIZE="0.5202312138728323" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.08043562413835074" LOG_CI_START="-0.6480428115172918" LOG_EFFECT_SIZE="-0.28380359368947056" ORDER="6783" O_E="0.0" SE="0.42791183913053826" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18310854206807967" WEIGHT="5.311544086827301"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7108924571327537" CI_END="1.1061704882267052" CI_START="0.5990678683234675" DF="3" EFFECT_SIZE="0.8140461881148401" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="71" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="0.04382206764674036" LOG_CI_START="-0.22252397365624033" LOG_EFFECT_SIZE="-0.08935095300474996" NO="6" P_CHI2="0.43837947772890373" P_Z="0.18850453294580355" STUDIES="4" TAU2="0.0" TOTAL_1="330" TOTAL_2="332" WEIGHT="28.695954914425084" Z="1.3150159770869556">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="1.4733985973056012" CI_START="0.30597037852147974" EFFECT_SIZE="0.6714285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.16832025206513437" LOG_CI_START="-0.5143206162222133" LOG_EFFECT_SIZE="-0.1730001820785394" ORDER="6784" O_E="0.0" SE="0.40098662515878386" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.16079027355623102" WEIGHT="5.529465567645235"/>
<DICH_DATA CI_END="1.191211707520663" CI_START="0.13431701433913634" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.07598895311772173" LOG_CI_START="-0.871868970461797" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="6785" O_E="0.0" SE="0.5567764362830021" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.30999999999999994" WEIGHT="4.037387557328267"/>
<DICH_DATA CI_END="1.3224589374430262" CI_START="0.6153541723895645" EFFECT_SIZE="0.9020979020979021" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" LOG_CI_END="0.12138219600494272" LOG_CI_START="-0.2108748503365684" LOG_EFFECT_SIZE="-0.04474632716581285" ORDER="6786" O_E="0.0" SE="0.1951694337199084" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.038091107858549716" WEIGHT="15.926797812357027"/>
<DICH_DATA CI_END="2.761015458222625" CI_START="0.4743339859607909" EFFECT_SIZE="1.144396551724138" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4410688381503073" LOG_CI_START="-0.32391575709713094" LOG_EFFECT_SIZE="0.058576540526588186" ORDER="6787" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-Sweden-1995" TOTAL_1="58" TOTAL_2="59" VAR="0.20192057925839338" WEIGHT="3.202303977094557"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0938657367258307" CI_START="0.004509539483088448" DF="0" EFFECT_SIZE="0.07023411371237458" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" I2="0.0" ID="CMP-001.03.07" LOG_CI_END="0.0389640190929527" LOG_CI_START="-2.345867806273973" LOG_EFFECT_SIZE="-1.1534518935905105" NO="7" P_CHI2="1.0" P_Z="0.057970735649096085" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="20" WEIGHT="3.550526116591623" Z="1.8959191547933125">
<NAME>Alpha blocker versus none</NAME>
<DICH_DATA CI_END="1.0938657367258307" CI_START="0.004509539483088448" EFFECT_SIZE="0.07023411371237458" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="0.0389640190929527" LOG_CI_START="-2.345867806273973" LOG_EFFECT_SIZE="-1.1534518935905105" ORDER="6788" O_E="0.0" SE="1.4008620193284582" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.9624143971970056" WEIGHT="3.550526116591623"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.76131289125791" CI_END="1.0814358835551694" CI_START="0.7966725673334996" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9281973398790089" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="255" I2="34.83665735731314" I2_Q="56.24803497570265" ID="CMP-001.04" LOG_CI_END="0.034000775977028004" LOG_CI_START="-0.09872013709676974" LOG_EFFECT_SIZE="-0.03235968055987086" METHOD="MH" MODIFIED="2013-05-25 22:59:22 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" P_CHI2="0.05193747831007811" P_Q="0.01918916860140707" P_Z="0.3392000735954732" Q="18.284893022649968" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1476" TOTAL_2="1375" WEIGHT="100.0" Z="0.9557470180046432">
<NAME>Proteinuria/pre-eclampsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.730712249211084" CI_END="0.9374060632374022" CI_START="0.5714739855635762" DF="7" EFFECT_SIZE="0.7319174673757555" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="106" I2="9.452068912352198" ID="CMP-001.04.01" LOG_CI_END="-0.028072241746008975" LOG_CI_START="-0.24300353461836677" LOG_EFFECT_SIZE="-0.13553788818218784" NO="1" P_CHI2="0.35693738575260014" P_Z="0.013437944727637022" STUDIES="8" TAU2="0.0" TOTAL_1="433" TOTAL_2="450" WEIGHT="39.720316456122404" Z="2.471946972705065">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.3583113580225423" CI_START="0.184052057375089" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13299933222130308" LOG_CI_START="-0.7350593235492654" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6789" O_E="0.0" SE="0.5099019513592785" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.26" WEIGHT="3.8601194029451373"/>
<DICH_DATA CI_END="2.9127186917646344" CI_START="0.03556141346709918" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4642985428103939" LOG_CI_START="-1.4490209853631926" LOG_EFFECT_SIZE="-0.4923612212763993" ORDER="6790" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Israel-1992" TOTAL_1="29" TOTAL_2="28" VAR="1.2631362889983577" WEIGHT="1.1783522387937788"/>
<DICH_DATA CI_END="2.6978801705038147" CI_START="0.37066138479132504" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.43102265606802675" LOG_CI_START="-0.43102265606802675" LOG_EFFECT_SIZE="0.0" ORDER="6791" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.2564102564102564" WEIGHT="2.3160716417670826"/>
<DICH_DATA CI_END="1.325960843975488" CI_START="0.139806606855715" EFFECT_SIZE="0.4305555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.12253069941078948" LOG_CI_START="-0.854472304604781" LOG_EFFECT_SIZE="-0.36597080259699577" ORDER="6792" O_E="0.0" SE="0.5738964008016139" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.3293570788530466" WEIGHT="3.5292520255498396"/>
<DICH_DATA CI_END="1.06832246368607" CI_START="0.09098117388503381" EFFECT_SIZE="0.31176470588235294" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.028702360428301738" LOG_CI_START="-1.0410484639832713" LOG_EFFECT_SIZE="-0.5061730517774848" ORDER="6793" O_E="0.0" SE="0.6283769296113413" STUDY_ID="STD-UK-1983" TOTAL_1="51" TOTAL_2="53" VAR="0.3948575656677766" WEIGHT="3.785886337503885"/>
<DICH_DATA CI_END="1.0030463333503243" CI_START="0.5287431144942136" EFFECT_SIZE="0.7282539682539683" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="45" LOG_CI_END="0.0013209946890276583" LOG_CI_START="-0.276755275137731" LOG_EFFECT_SIZE="-0.13771714022435164" ORDER="6794" O_E="0.0" SE="0.1633433773959736" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.02668105893912346" WEIGHT="16.888022387884977"/>
<DICH_DATA CI_END="1.7570972141948125" CI_START="0.5078480840975841" EFFECT_SIZE="0.9446366782006921" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.24479579019217332" LOG_CI_START="-0.29426618162375695" LOG_EFFECT_SIZE="-0.024735195715791802" ORDER="6795" O_E="0.0" SE="0.31664767064447336" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.10026574732457087" WEIGHT="5.871444776058657"/>
<DICH_DATA CI_END="4.49416039642105" CI_START="0.6452514414860213" EFFECT_SIZE="1.7028985507246377" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6526485683139724" LOG_CI_START="-0.190271016572973" LOG_EFFECT_SIZE="0.23118877587049977" ORDER="6796" O_E="0.0" SE="0.49513513668183046" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.24515880357693495" WEIGHT="2.2911676456190495"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4762560179574197" CI_END="2.509778782766206" CI_START="0.6322964103559457" DF="1" EFFECT_SIZE="1.2597317631665033" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.39963544352969466" LOG_CI_START="-0.19907928373641004" LOG_EFFECT_SIZE="0.10027807989664232" NO="2" P_CHI2="0.4901231375623857" P_Z="0.5114738613469818" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="158" WEIGHT="5.108391781300124" Z="0.65654448132155">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="2.645622079552134" CI_START="0.35884770476159167" EFFECT_SIZE="0.9743589743589743" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42252780640959303" LOG_CI_START="-0.44508982722897117" LOG_EFFECT_SIZE="-0.011281010409689058" ORDER="6797" O_E="0.0" SE="0.5096428927758443" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.2597358781569308" WEIGHT="2.737175576633825"/>
<DICH_DATA CI_END="4.174737638310471" CI_START="0.6049216305326484" EFFECT_SIZE="1.5891472868217054" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6206291874090091" LOG_CI_START="-0.21830088589599841" LOG_EFFECT_SIZE="0.20116415075650532" ORDER="6798" O_E="0.0" SE="0.4927916778301993" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.24284363773870293" WEIGHT="2.371216204666299"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01801766625912571" CI_END="2.707824342587548" CI_START="0.5521536562709335" DF="1" EFFECT_SIZE="1.2227571759344336" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.4326204881079139" LOG_CI_START="-0.2579400476613153" LOG_EFFECT_SIZE="0.08734022022329929" NO="3" P_CHI2="0.8932207883934247" P_Z="0.62004834153447" STUDIES="2" TAU2="0.0" TOTAL_1="130" TOTAL_2="137" WEIGHT="3.4720657466027847" Z="0.49578183858647107">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="4.0885479522838075" CI_START="0.40201448264565726" EFFECT_SIZE="1.2820512820512822" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6115690957141797" LOG_CI_START="-0.3957583010951405" LOG_EFFECT_SIZE="0.10790539730951963" ORDER="6799" O_E="0.0" SE="0.5917090992368278" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="0.3501196581196581" WEIGHT="1.8662560749776076"/>
<DICH_DATA CI_END="3.3138380098347344" CI_START="0.40175800470462913" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5203312750083746" LOG_CI_START="-0.3960354615106857" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="6800" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.28974358974358977" WEIGHT="1.6058096716251773"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6049827814707158" CI_END="1.2972665385323219" CI_START="0.4274754288879957" DF="1" EFFECT_SIZE="0.7446808510638299" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.11302921611588866" LOG_CI_START="-0.3690888432867723" LOG_EFFECT_SIZE="-0.1280298135854418" NO="4" P_CHI2="0.4366833332080583" P_Z="0.29789217178222305" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="77" WEIGHT="7.982726925290544" Z="1.04096421480559">
<NAME>Methyldopa + other drug versus none</NAME>
<DICH_DATA CI_END="1.44433264431343" CI_START="0.4592966054898607" EFFECT_SIZE="0.8144796380090498" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.15966722713427386" LOG_CI_START="-0.3379067642978832" LOG_EFFECT_SIZE="-0.08911976858180463" ORDER="6801" O_E="0.0" SE="0.2922774255982299" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="0.08542609351432881" WEIGHT="6.824691104407003"/>
<DICH_DATA CI_END="3.0199847904557613" CI_START="0.03679194394033447" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48000475572610146" LOG_CI_START="-1.4342472651654263" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="6802" O_E="0.0" SE="1.124441112772009" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="1.2643678160919538" WEIGHT="1.1580358208835413"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.220918400047208" CI_END="1.1917999434371787" CI_START="0.5002389129870893" DF="1" EFFECT_SIZE="0.7721299814170466" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="28" I2="76.30847353057534" ID="CMP-001.04.05" LOG_CI_END="0.07620336047715379" LOG_CI_START="-0.300822528042848" LOG_EFFECT_SIZE="-0.11230958378284715" MODIFIED="2013-05-20 18:16:12 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.03992869021332002" P_Z="0.24293600605638266" STUDIES="2" TAU2="0.0" TOTAL_1="272" TOTAL_2="140" WEIGHT="14.291041286236716" Z="1.167679706012476">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="0.8648180115377374" CI_START="0.21669620926622504" EFFECT_SIZE="0.4329004329004329" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="-0.06307527392293309" LOG_CI_START="-0.6641486858613557" LOG_EFFECT_SIZE="-0.36361197989214433" MODIFIED="2013-05-20 18:16:12 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="726" O_E="0.0" SE="0.35307349753400447" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.12466089466089465" WEIGHT="7.181376499975786"/>
<DICH_DATA CI_END="1.9930163928537483" CI_START="0.6235458309350601" EFFECT_SIZE="1.1147811725846408" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.29951087085133893" LOG_CI_START="-0.2051316201474312" LOG_EFFECT_SIZE="0.04718962535195388" ORDER="6803" O_E="0.0" SE="0.2964294972332956" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.08787044682998439" WEIGHT="7.109664786260931"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5914328680316467" CI_END="1.859917544724171" CI_START="1.0584061281393966" DF="3" EFFECT_SIZE="1.4030495811517292" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="65" I2="16.467880363187543" ID="CMP-001.04.06" LOG_CI_END="0.2694936911721852" LOG_CI_START="0.024652345738608868" LOG_EFFECT_SIZE="0.14707301845539703" NO="6" P_CHI2="0.30909592993864665" P_Z="0.01854016644801603" STUDIES="4" TAU2="0.0" TOTAL_1="360" TOTAL_2="365" WEIGHT="24.77723069006767" Z="2.3546498550701283">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="1.5842961150946966" CI_START="0.6384891163205925" EFFECT_SIZE="1.005761316872428" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.1998363572614902" LOG_CI_START="-0.19484650131708134" LOG_EFFECT_SIZE="0.002494927972204436" ORDER="6804" O_E="0.0" SE="0.23183866484071194" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.05374916651512396" WEIGHT="10.195750162126831"/>
<DICH_DATA CI_END="2.5880090016834325" CI_START="0.8937770351034582" EFFECT_SIZE="1.520888888888889" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" LOG_CI_END="0.41296578257419125" LOG_CI_START="-0.048770808386753274" LOG_EFFECT_SIZE="0.182097487093719" ORDER="6805" O_E="0.0" SE="0.2712263591634463" STUDY_ID="STD-Italy-1998" TOTAL_1="125" TOTAL_2="118" VAR="0.07356373790505877" WEIGHT="7.148369264713217"/>
<DICH_DATA CI_END="4.028818448809723" CI_START="1.061595617073956" EFFECT_SIZE="2.068085106382979" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.605177697158387" LOG_CI_START="0.025959116822727186" LOG_EFFECT_SIZE="0.31556840699055716" ORDER="6806" O_E="0.0" SE="0.3402358612673805" STUDY_ID="STD-Sweden-1995" TOTAL_1="47" TOTAL_2="54" VAR="0.11576044129235619" WEIGHT="3.5925863750182465"/>
<DICH_DATA CI_END="3.384593215279071" CI_START="0.7718834398672652" EFFECT_SIZE="1.616326530612245" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5295064795276351" LOG_CI_START="-0.11244827640567534" LOG_EFFECT_SIZE="0.20852910156097987" ORDER="6807" O_E="0.0" SE="0.3770874013625181" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.14219490826633682" WEIGHT="3.8405248882093757"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5234570593395587" CI_START="0.04403130645709946" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.04.07" LOG_CI_END="0.4019959189169215" LOG_CI_START="-1.3562384283562463" LOG_EFFECT_SIZE="-0.47712125471966244" NO="7" P_CHI2="1.0" P_Z="0.2874525074776517" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="20" WEIGHT="1.4475447761044264" Z="1.0637267744876013">
<NAME>Alpha blocker versus none</NAME>
<DICH_DATA CI_END="2.5234570593395587" CI_START="0.04403130645709946" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.4019959189169215" LOG_CI_START="-1.3562384283562463" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="6808" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="1.4475447761044264"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.283656704405851" CI_START="0.055935649162505596" DF="0" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.04.08" LOG_CI_END="0.516357746749645" LOG_CI_START="-1.252311317338834" LOG_EFFECT_SIZE="-0.36797678529459443" NO="8" P_CHI2="1.0" P_Z="0.41475612857916777" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="9" WEIGHT="1.0132813432730985" Z="0.8155525089097773">
<NAME>Glyceryl trinitrate versus none</NAME>
<DICH_DATA CI_END="3.283656704405851" CI_START="0.055935649162505596" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.516357746749645" LOG_CI_START="-1.252311317338834" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="6809" O_E="0.0" SE="1.0389249632986395" STUDY_ID="STD-Australia-2001" TOTAL_1="7" TOTAL_2="9" VAR="1.0793650793650793" WEIGHT="1.0132813432730985"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3948816754667623" CI_START="0.024875366572638065" DF="0" EFFECT_SIZE="0.18627450980392157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.04.09" LOG_CI_END="0.14453736899216416" LOG_CI_START="-1.6042305106103414" LOG_EFFECT_SIZE="-0.7298465708090885" NO="9" P_CHI2="1.0" P_Z="0.10184416694925946" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="2.187400995002245" Z="1.635978118892511">
<NAME>Regular antihypertensive therapy versus none</NAME>
<DICH_DATA CI_END="1.394881675466763" CI_START="0.024875366572638044" EFFECT_SIZE="0.18627450980392157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14453736899216438" LOG_CI_START="-1.6042305106103416" LOG_EFFECT_SIZE="-0.7298465708090885" ORDER="6810" O_E="0.0" SE="1.0272349090191268" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.0552115583075337" WEIGHT="2.187400995002245"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5282660234550534" CI_END="1.2342431410418921" CI_START="0.23758578641388892" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5415151219406401" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" I2="43.31493184741493" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.09140072242919502" LOG_CI_START="-0.6241795446111259" LOG_EFFECT_SIZE="-0.2663894110909655" METHOD="MH" MODIFIED="2013-05-20 18:17:27 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.17133531817268755" P_Q="1.0" P_Z="0.14448985284537344" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="185" WEIGHT="100.0" Z="1.459273475386955">
<NAME>Severe pre-eclampsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.718293709819352" CI_START="0.02345920270962201" EFFECT_SIZE="0.25252525252525254" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.43429638016041106" LOG_CI_START="-1.6296867520114353" LOG_EFFECT_SIZE="-0.5976951859255123" MODIFIED="2013-05-20 18:17:27 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="727" O_E="0.0" SE="1.2123939087190228" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="1.4698989898989898" WEIGHT="18.505400305800453"/>
<DICH_DATA CI_END="1.0567969075014345" CI_START="0.09547686340017206" EFFECT_SIZE="0.3176470588235294" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.023991533734946027" LOG_CI_START="-1.0201018568455569" LOG_EFFECT_SIZE="-0.49805516155530544" ORDER="6811" O_E="0.0" SE="0.6133056259726248" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3761437908496732" WEIGHT="67.63950789984493"/>
<DICH_DATA CI_END="10.778393658817608" CI_START="0.37872518627575236" EFFECT_SIZE="2.020408163265306" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.032554041268742" LOG_CI_START="-0.4216758121306695" LOG_EFFECT_SIZE="0.3054391145690362" ORDER="6812" O_E="0.0" SE="0.8542218144406855" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.7296949082663369" WEIGHT="13.855091794354621"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.778393658817608" CI_START="0.37872518627575236" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.020408163265306" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.032554041268742" LOG_CI_START="-0.4216758121306695" LOG_EFFECT_SIZE="0.3054391145690362" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.41032495432090677" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="99" WEIGHT="100.0" Z="0.8233219289587672">
<NAME>HELLP syndrome</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.778393658817608" CI_START="0.37872518627575236" DF="0" EFFECT_SIZE="2.020408163265306" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="1.032554041268742" LOG_CI_START="-0.4216758121306695" LOG_EFFECT_SIZE="0.3054391145690362" NO="1" P_CHI2="1.0" P_Z="0.41032495432090677" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="99" WEIGHT="100.0" Z="0.8233219289587672">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="10.778393658817608" CI_START="0.37872518627575236" EFFECT_SIZE="2.020408163265306" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.032554041268742" LOG_CI_START="-0.4216758121306695" LOG_EFFECT_SIZE="0.3054391145690362" ORDER="6813" O_E="0.0" SE="0.8542218144406855" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.7296949082663369" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7025911574319412" CI_END="5.121166153071373" CI_START="0.29975547084055165" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2389905453499659" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="41.26599356310978" I2_Q="38.73512364028833" ID="CMP-001.07" LOG_CI_END="0.7093688664790851" LOG_CI_START="-0.5232328818431887" LOG_EFFECT_SIZE="0.09306799231794821" METHOD="MH" MODIFIED="2013-05-20 18:19:22 +0100" MODIFIED_BY="Edgardo J Abalos" NO="7" P_CHI2="0.1919495473354409" P_Q="0.2013912715938745" P_Z="0.7672488495537547" Q="1.6322566198103174" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="185" TOTAL_2="140" WEIGHT="100.0" Z="0.295975424835981">
<NAME>Pulmonary oedema</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="107.39317339384971" CI_START="0.2546874894370857" DF="0" EFFECT_SIZE="5.2298850574712645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="2.0309766756688554" LOG_CI_START="-0.5939923875918675" LOG_EFFECT_SIZE="0.7184921440384939" NO="1" P_CHI2="1.0" P_Z="0.28329751625861166" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="90" WEIGHT="15.533666462954308" Z="1.0729411978220658">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="107.39317339384971" CI_START="0.2546874894370857" EFFECT_SIZE="5.2298850574712645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0309766756688554" LOG_CI_START="-0.5939923875918675" LOG_EFFECT_SIZE="0.7184921440384939" ORDER="6814" O_E="0.0" SE="1.5419198215657732" STUDY_ID="STD-USA-1990" TOTAL_1="86" TOTAL_2="90" VAR="2.3775167361374256" WEIGHT="15.533666462954308"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4803863354103397" CI_START="0.07328956847593662" DF="0" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.5416274548730903" LOG_CI_START="-1.1349578353961525" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:19:22 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="1.0" P_Z="0.4879231388717511" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="50" WEIGHT="84.4663335370457" Z="0.6936158771689429">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="3.4803863354103406" CI_START="0.07328956847593662" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5416274548730904" LOG_CI_START="-1.1349578353961525" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:19:22 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="728" O_E="0.0" SE="0.9848344987351885" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.9698989898989899" WEIGHT="84.4663335370457"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.734650295852136" CI_END="0.5757126249621294" CI_START="0.3009961954445267" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41627792372762534" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="103" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.2397942466760663" LOG_CI_START="-0.5214389938011418" LOG_EFFECT_SIZE="-0.38061662023860393" METHOD="MH" NO="8" P_CHI2="0.5610925208557246" P_Q="0.4790771539718697" P_Z="1.1745211788714099E-7" Q="4.50602958262205" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="680" TOTAL_2="605" WEIGHT="100.00000000000001" Z="5.297417226487343">
<NAME>Additional antihypertensive</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2994903503044957" CI_END="0.7027510049558021" CI_START="0.23332974595410605" DF="2" EFFECT_SIZE="0.40493544356518113" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="33" I2="13.024205570805615" ID="CMP-001.08.01" LOG_CI_END="-0.15319852466545608" LOG_CI_START="-0.6320298918096038" LOG_EFFECT_SIZE="-0.39261420823753" NO="1" P_CHI2="0.3167178595792033" P_Z="0.001308469363646576" STUDIES="3" TAU2="0.0" TOTAL_1="120" TOTAL_2="125" WEIGHT="31.307088963016867" Z="3.214115702376758">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.4103128933907758" CI_START="0.28142691019844857" EFFECT_SIZE="0.63" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.14931547634177364" LOG_CI_START="-0.5506343774346102" LOG_EFFECT_SIZE="-0.2006594505464183" ORDER="6815" O_E="0.0" SE="0.41115400891590376" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="20" TOTAL_2="21" VAR="0.16904761904761906" WEIGHT="9.388214932683107"/>
<DICH_DATA CI_END="0.890351646543475" CI_START="0.1797042782154134" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="6816" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.16666666666666669" WEIGHT="14.434380459000279"/>
<DICH_DATA CI_END="1.0295673657195177" CI_START="0.016960264354993745" EFFECT_SIZE="0.13214285714285715" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.012654768246998906" LOG_CI_START="-1.7705673827974475" LOG_EFFECT_SIZE="-0.8789563072752242" ORDER="6817" O_E="0.0" SE="1.047473518615517" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="1.0972007722007722" WEIGHT="7.484493571333478"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1613342870396033" CI_END="0.8221240027870234" CI_START="0.12772544997764307" DF="1" EFFECT_SIZE="0.32404653707977443" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" I2="13.892148784383693" ID="CMP-001.08.02" LOG_CI_END="-0.0850626719191927" LOG_CI_START="-0.8937225586205423" LOG_EFFECT_SIZE="-0.48939261526986755" NO="2" P_CHI2="0.2811890420360674" P_Z="0.017677733646148743" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="155" WEIGHT="16.11269872446394" Z="2.372299939697767">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="1.214567931047986" CI_START="0.16149936071047388" EFFECT_SIZE="0.4428904428904429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.08442181000508182" LOG_CI_START="-0.7918291924688724" LOG_EFFECT_SIZE="-0.35370369123189527" ORDER="6818" O_E="0.0" SE="0.5147141763656174" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.264930683351736" WEIGHT="10.72268262668592"/>
<DICH_DATA CI_END="1.5589567247698681" CI_START="0.004924978729716949" EFFECT_SIZE="0.08762322015334063" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.19283405973374107" LOG_CI_START="-2.3075956408184517" LOG_EFFECT_SIZE="-1.0573807905423553" ORDER="6819" O_E="0.0" SE="1.4687647834309947" STUDY_ID="STD-Sweden-1985" TOTAL_1="82" TOTAL_2="79" VAR="2.157269989047097" WEIGHT="5.390016097778018"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8326027450866853" CI_START="0.11370915694394067" DF="0" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="-0.07956216158035542" LOG_CI_START="-0.9442045603773934" LOG_EFFECT_SIZE="-0.5118833609788743" NO="3" P_CHI2="1.0" P_Z="0.020304896670665616" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="12.50979639780024" Z="2.3206656374930166">
<NAME>Methyldopa + other drug versus none</NAME>
<DICH_DATA CI_END="0.8326027450866853" CI_START="0.11370915694394067" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.07956216158035542" LOG_CI_START="-0.9442045603773934" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="6820" O_E="0.0" SE="0.5078952251022819" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.2579575596816976" WEIGHT="12.50979639780024"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2034709849825036" CI_START="0.22488329113438102" DF="0" EFFECT_SIZE="0.5202312138728323" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.08043562413835074" LOG_CI_START="-0.6480428115172918" LOG_EFFECT_SIZE="-0.28380359368947056" NO="4" P_CHI2="1.0" P_Z="0.12672583147881158" STUDIES="1" TAU2="0.0" TOTAL_1="173" TOTAL_2="90" WEIGHT="12.659811505232183" Z="1.5271414913298613">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="1.2034709849825036" CI_START="0.22488329113438102" EFFECT_SIZE="0.5202312138728323" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.08043562413835074" LOG_CI_START="-0.6480428115172918" LOG_EFFECT_SIZE="-0.28380359368947056" ORDER="6821" O_E="0.0" SE="0.42791183913053826" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18310854206807967" WEIGHT="12.659811505232183"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.003042759258186916" CI_END="1.276440905016626" CI_START="0.35192483053627127" DF="1" EFFECT_SIZE="0.67023223526442" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="0.10600071321056147" LOG_CI_START="-0.45355008984441975" LOG_EFFECT_SIZE="-0.17377468831692916" NO="5" P_CHI2="0.956010057707303" P_Z="0.22346084399720878" STUDIES="2" TAU2="0.0" TOTAL_1="186" TOTAL_2="186" WEIGHT="18.948095081563086" Z="1.2173769697633265">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="2.2551318110349756" CI_START="0.18822491464878172" EFFECT_SIZE="0.6515151515151515" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3531719311949771" LOG_CI_START="-0.7253228911195414" LOG_EFFECT_SIZE="-0.18607547996228216" ORDER="6822" O_E="0.0" SE="0.633513197263019" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.4013389711064129" WEIGHT="5.840117151227698"/>
<DICH_DATA CI_END="1.4367143626514058" CI_START="0.32049459213570347" EFFECT_SIZE="0.6785714285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.15737043337086803" LOG_CI_START="-0.49417929414964845" LOG_EFFECT_SIZE="-0.16840443038939024" ORDER="6823" O_E="0.0" SE="0.3827235351687184" STUDY_ID="STD-Sweden-1995" TOTAL_1="54" TOTAL_2="57" VAR="0.1464773043720412" WEIGHT="13.107977930335387"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0938657367258307" CI_START="0.004509539483088448" DF="0" EFFECT_SIZE="0.07023411371237458" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" I2="0.0" ID="CMP-001.08.06" LOG_CI_END="0.0389640190929527" LOG_CI_START="-2.345867806273973" LOG_EFFECT_SIZE="-1.1534518935905105" NO="6" P_CHI2="1.0" P_Z="0.057970735649096085" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="20" WEIGHT="8.462509327923692" Z="1.8959191547933125">
<NAME>Alpha blocker versus none</NAME>
<DICH_DATA CI_END="1.0938657367258307" CI_START="0.004509539483088448" EFFECT_SIZE="0.07023411371237458" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="0.0389640190929527" LOG_CI_START="-2.345867806273973" LOG_EFFECT_SIZE="-1.1534518935905105" ORDER="6824" O_E="0.0" SE="1.4008620193284582" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.9624143971970056" WEIGHT="8.462509327923692"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.241107194624636" CI_END="5.037981844991754" CI_START="1.3325173035285223" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5909839797486325" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="7" I2="0.0" I2_Q="9.50611594598981" ID="CMP-001.09" LOG_CI_END="0.7022565981295205" LOG_CI_START="0.12467285730698677" LOG_EFFECT_SIZE="0.4134647277182536" METHOD="MH" NO="9" P_CHI2="0.605298887207963" P_Q="0.3455409006992425" P_Z="0.005014668628921433" Q="3.315141162699444" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="704" TOTAL_2="699" WEIGHT="100.00000000000001" Z="2.806089984636289">
<NAME>Changed/stopped drugs due to maternal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.772443351290372" CI_END="4.752244680683837" CI_START="0.7583356255377847" DF="6" EFFECT_SIZE="1.898366782957126" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.6768987932389531" LOG_CI_START="-0.1201385409921487" LOG_EFFECT_SIZE="0.27838012612340224" NO="1" P_CHI2="0.5733129175481034" P_Z="0.17096557609615645" STUDIES="9" TAU2="0.0" TOTAL_1="375" TOTAL_2="370" WEIGHT="60.49228267306446" Z="1.369107814102431">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="4.298716239345831" CI_START="0.011073842313529432" EFFECT_SIZE="0.21818181818181817" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6333387780424254" LOG_CI_START="-1.9557016649356633" LOG_EFFECT_SIZE="-0.661181443446619" ORDER="6825" O_E="0.0" SE="1.5208151721622152" STUDY_ID="STD-Israel-1986a" TOTAL_1="21" TOTAL_2="23" VAR="2.312878787878788" WEIGHT="21.12975215581563"/>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="6826" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="4.418039087125086"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6827" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="6828" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="4.418039087125086"/>
<DICH_DATA CI_END="158.71220818712067" CI_START="0.4794342658014378" EFFECT_SIZE="8.723076923076922" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.200610334091847" LOG_CI_START="-0.31927092959174475" LOG_EFFECT_SIZE="0.940669702250051" ORDER="6829" O_E="0.0" SE="1.4801907279011686" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="2.190964590964591" WEIGHT="4.487070947861415"/>
<DICH_DATA CI_END="21.472680254365798" CI_START="0.18628321907726103" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3318862571530974" LOG_CI_START="-0.7298262658251348" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6830" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="8.836078174250172"/>
<DICH_DATA CI_END="75.46460404625083" CI_START="0.12940669501180752" EFFECT_SIZE="3.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.877743297696218" LOG_CI_START="-0.88804325433603" LOG_EFFECT_SIZE="0.494850021680094" ORDER="6831" O_E="0.0" SE="1.6246367115279787" STUDY_ID="STD-UK-1989" TOTAL_1="71" TOTAL_2="74" VAR="2.6394444444444445" WEIGHT="4.327875024122533"/>
<DICH_DATA CI_END="8.082984457423786" CI_START="0.015411074301155481" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9075717437049503" LOG_CI_START="-1.812167085694211" LOG_EFFECT_SIZE="-0.45229767099463025" ORDER="6832" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-UK-1990" TOTAL_1="16" TOTAL_2="17" VAR="2.5522875816993467" WEIGHT="12.875428196764537"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6833" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.612191906110192" CI_START="0.30073428288398063" DF="0" EFFECT_SIZE="1.2991452991452992" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.7491325130939799" LOG_CI_START="-0.521817060696758" LOG_EFFECT_SIZE="0.11365772619861092" NO="2" P_CHI2="1.0" P_Z="0.7259267253738361" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="155" WEIGHT="26.852497308760263" Z="0.3505489981786961">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="5.612191906110192" CI_START="0.30073428288398063" EFFECT_SIZE="1.2991452991452992" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7491325130939799" LOG_CI_START="-0.521817060696758" LOG_EFFECT_SIZE="0.11365772619861092" ORDER="6834" O_E="0.0" SE="0.7465620709465345" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.5573549257759783" WEIGHT="26.852497308760263"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6835" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1985" TOTAL_1="82" TOTAL_2="79" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6836" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04924487152327843" CI_END="36.21145056431566" CI_START="0.4631151164217801" DF="1" EFFECT_SIZE="4.095127610208817" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="1.5588459222061308" LOG_CI_START="-0.3343110430799111" LOG_EFFECT_SIZE="0.6122674395631098" NO="4" P_CHI2="0.8243825025009012" P_Z="0.20488830249862955" STUDIES="2" TAU2="0.0" TOTAL_1="149" TOTAL_2="153" WEIGHT="8.728074162952996" Z="1.2677471043917747">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="75.07161777092338" CI_START="0.12783161932531675" EFFECT_SIZE="3.097826086956522" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8754757748834985" LOG_CI_START="-0.8933617095575883" LOG_EFFECT_SIZE="0.491057032662955" ORDER="6837" O_E="0.0" SE="1.6264288443272892" STUDY_ID="STD-Brazil-2000a" TOTAL_1="91" TOTAL_2="94" VAR="2.6452707856598017" WEIGHT="4.347161454711315"/>
<DICH_DATA CI_END="103.67579179014075" CI_START="0.2493797156017954" EFFECT_SIZE="5.084745762711864" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0156773608315786" LOG_CI_START="-0.6031388746765421" LOG_EFFECT_SIZE="0.7062692430775183" ORDER="6838" O_E="0.0" SE="1.538305620086906" STUDY_ID="STD-Sweden-1995" TOTAL_1="58" TOTAL_2="59" VAR="2.3663841807909605" WEIGHT="4.3809127082416826"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="281.10711692066735" CI_START="1.2506353586886105" DF="0" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.09.05" LOG_CI_END="2.4488718409836325" LOG_CI_START="0.09713070314384276" LOG_EFFECT_SIZE="1.2730012720637376" NO="5" P_CHI2="1.0" P_Z="0.03384921628209717" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="9" WEIGHT="3.9271458552222986" Z="2.121863333828005">
<NAME>Glyceryl trinitrate versus none</NAME>
<DICH_DATA CI_END="281.10711692066735" CI_START="1.2506353586886105" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4488718409836325" LOG_CI_START="0.09713070314384276" LOG_EFFECT_SIZE="1.2730012720637376" ORDER="6839" O_E="0.0" SE="1.3814243856734734" STUDY_ID="STD-Australia-2001" TOTAL_1="7" TOTAL_2="9" VAR="1.9083333333333332" WEIGHT="3.9271458552222986"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.65908830922371" CI_END="2.119243256296012" CI_START="1.1028669241109057" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5288045301849293" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="39" I2="58.44700445601271" I2_Q="63.459277915011356" ID="CMP-001.10" LOG_CI_END="0.32618080985077436" LOG_CI_START="0.04252311206757843" LOG_EFFECT_SIZE="0.1843519609591764" METHOD="MH" NO="10" P_CHI2="0.010024553493501287" P_Q="0.041864960353005465" P_Z="0.01084666983392284" Q="8.210018381745213" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="468" TOTAL_2="466" WEIGHT="100.00000000000001" Z="2.5476002011091907">
<NAME>Maternal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.111239241576065" CI_END="3.539970068941964" CI_START="1.2126300228393838" DF="6" EFFECT_SIZE="2.071876923360031" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="9" I2="66.87140001868877" ID="CMP-001.10.01" LOG_CI_END="0.5489995900064951" LOG_CI_START="0.0837283164901273" LOG_EFFECT_SIZE="0.3163639532483112" NO="1" P_CHI2="0.0059601425166168065" P_Z="0.00769017836934258" STUDIES="7" TAU2="0.0" TOTAL_1="279" TOTAL_2="275" WEIGHT="33.57365885048799" Z="2.665378198345144">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="162.8894181229835" CI_START="0.49726987138504036" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2118928719078457" LOG_CI_START="-0.30340785302919543" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="6840" O_E="0.0" SE="1.4775000967674123" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="2.1830065359477127" WEIGHT="1.1054266295300181"/>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="6841" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="1.1054266295300181"/>
<DICH_DATA CI_END="1.28735841223412" CI_START="0.35611049411032647" EFFECT_SIZE="0.6770833333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.1096994752535947" LOG_CI_START="-0.44841522804702033" LOG_EFFECT_SIZE="-0.16935787639671282" ORDER="6842" O_E="0.0" SE="0.32783933943111904" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.10747863247863247" WEIGHT="24.96963680820747"/>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="6843" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="1.1054266295300181"/>
<DICH_DATA CI_END="305.4127128839295" CI_START="1.0558848567709795" EFFECT_SIZE="17.95774647887324" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4848871107178767" LOG_CI_START="0.023616561383920452" LOG_EFFECT_SIZE="1.2542518360508987" ORDER="6844" O_E="0.0" SE="1.4457625041644782" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="2.0902292184479427" WEIGHT="1.075140968447004"/>
<DICH_DATA CI_END="8.082984457423786" CI_START="0.015411074301155481" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9075717437049503" LOG_CI_START="-1.812167085694211" LOG_EFFECT_SIZE="-0.45229767099463025" ORDER="6845" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-UK-1990" TOTAL_1="16" TOTAL_2="17" VAR="2.5522875816993467" WEIGHT="3.2215290346303385"/>
<DICH_DATA CI_END="239.2179616424993" CI_START="0.7662047597509472" EFFECT_SIZE="13.538461538461538" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3787937854725647" LOG_CI_START="-0.11565515445793856" LOG_EFFECT_SIZE="1.131569315507313" ORDER="6846" O_E="0.0" SE="1.4652516550365717" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="2.1469624125874125" WEIGHT="0.9910721506131197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.612191906110192" CI_START="0.30073428288398063" DF="0" EFFECT_SIZE="1.2991452991452992" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.7491325130939799" LOG_CI_START="-0.521817060696758" LOG_EFFECT_SIZE="0.11365772619861092" NO="2" P_CHI2="1.0" P_Z="0.7259267253738361" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="76" WEIGHT="6.718696917143487" Z="0.3505489981786961">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="5.612191906110192" CI_START="0.30073428288398063" EFFECT_SIZE="1.2991452991452992" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7491325130939799" LOG_CI_START="-0.521817060696758" LOG_EFFECT_SIZE="0.11365772619861092" ORDER="6847" O_E="0.0" SE="0.7465620709465345" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.5573549257759783" WEIGHT="6.718696917143487"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6848" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.517152874478077" CI_START="0.6029705031608324" DF="0" EFFECT_SIZE="0.9564509564509565" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="0.18102934426540507" LOG_CI_START="-0.2197039326820944" LOG_EFFECT_SIZE="-0.019337294208344638" NO="4" P_CHI2="1.0" P_Z="0.8499711452814805" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="94" WEIGHT="58.7250427838974" Z="0.18915524308591844">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="1.517152874478077" CI_START="0.6029705031608324" EFFECT_SIZE="0.9564509564509565" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.18102934426540507" LOG_CI_START="-0.2197039326820944" LOG_EFFECT_SIZE="-0.019337294208344638" ORDER="6849" O_E="0.0" SE="0.23539271054067418" STUDY_ID="STD-Brazil-2000a" TOTAL_1="91" TOTAL_2="94" VAR="0.055409728175685624" WEIGHT="58.7250427838974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="281.10711692066735" CI_START="1.2506353586886105" DF="0" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="2.4488718409836325" LOG_CI_START="0.09713070314384276" LOG_EFFECT_SIZE="1.2730012720637376" NO="5" P_CHI2="1.0" P_Z="0.03384921628209717" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="9" WEIGHT="0.9826014484711272" Z="2.121863333828005">
<NAME>Glyceryl trinitrate versus none</NAME>
<DICH_DATA CI_END="281.10711692066735" CI_START="1.2506353586886105" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4488718409836325" LOG_CI_START="0.09713070314384276" LOG_EFFECT_SIZE="1.2730012720637376" ORDER="6850" O_E="0.0" SE="1.3814243856734734" STUDY_ID="STD-Australia-2001" TOTAL_1="7" TOTAL_2="9" VAR="1.9083333333333332" WEIGHT="0.9826014484711272"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.151102288258022" CI_END="1.0325360418105587" CI_START="0.7264430837337523" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8660708205909635" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="110" I2="27.73003911549173" I2_Q="41.920152466684186" ID="CMP-001.11" LOG_CI_END="0.01390522012141862" LOG_CI_START="-0.13879840667727608" LOG_EFFECT_SIZE="-0.06244659327792872" METHOD="MH" MODIFIED="2013-05-20 18:21:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="11" P_CHI2="0.24560341871666336" P_Q="0.1787502007081314" P_Z="0.1089314244983687" Q="3.443535210475128" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="202" WEIGHT="100.00000000000001" Z="1.6030146283730249">
<NAME>Antenatal hospital admission</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2352381784113677" CI_START="0.5740927431098749" DF="0" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.09175070625683798" LOG_CI_START="-0.24101794285064634" LOG_EFFECT_SIZE="-0.07463361829690421" NO="1" P_CHI2="1.0" P_Z="0.3793120586455312" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="16.492850906328638" Z="0.8791645744884679">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.2352381784113675" CI_START="0.5740927431098749" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.0917507062568379" LOG_CI_START="-0.24101794285064634" LOG_EFFECT_SIZE="-0.07463361829690421" ORDER="6851" O_E="0.0" SE="0.19546995171711556" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.03820850202429149" WEIGHT="16.492850906328638"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5226143268606528" CI_END="1.1727592461141607" CI_START="0.7833749524488558" DF="1" EFFECT_SIZE="0.9584937238493723" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="77" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.0692088656401123" LOG_CI_START="-0.10603031865380459" LOG_EFFECT_SIZE="-0.018410726506846133" NO="2" P_CHI2="0.4697286795572069" P_Z="0.6804641637225446" STUDIES="2" TAU2="0.0" TOTAL_1="128" TOTAL_2="126" WEIGHT="67.35802061880631" Z="0.4118298202314554">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="1.3087370778275673" CI_START="0.7898641159457724" EFFECT_SIZE="1.0167224080267558" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="46" LOG_CI_END="0.11685240658306871" LOG_CI_START="-0.10244761601442051" LOG_EFFECT_SIZE="0.00720239528432409" ORDER="6852" O_E="0.0" SE="0.1288179188263846" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.016594056210761012" WEIGHT="40.44863229795431"/>
<DICH_DATA CI_END="1.2181257531700753" CI_START="0.6227475328536803" EFFECT_SIZE="0.8709677419354839" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="31" LOG_CI_END="0.08569212498709965" LOG_CI_START="-0.2056879843376704" LOG_EFFECT_SIZE="-0.05999792967528537" ORDER="6853" O_E="0.0" SE="0.17115811857217308" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.029295101553166062" WEIGHT="26.90938832085199"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9753518405660897" CI_START="0.26152204983150007" DF="0" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="-0.010838692144856504" LOG_CI_START="-0.5824916883782058" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:21:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="1.0" P_Z="0.04192268158808363" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="50" WEIGHT="16.149128474865062" Z="2.034286856573998">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="0.9753518405660896" CI_START="0.2615220498315001" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="-0.010838692144856553" LOG_CI_START="-0.5824916883782056" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:21:03 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="729" O_E="0.0" SE="0.3357917997154379" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.11275613275613273" WEIGHT="16.149128474865062"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.96048105302784" CI_END="1.071616765147699" CI_START="0.7697113026566836" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.908204567402398" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="144" I2="32.89132262289372" I2_Q="62.00014216089618" ID="CMP-001.12" LOG_CI_END="0.03003949940628978" LOG_CI_START="-0.11367213609169849" LOG_EFFECT_SIZE="-0.04181631834270437" METHOD="MH" NO="12" P_CHI2="0.20211918866413314" P_Q="0.07196416757813484" P_Z="0.25403798802182775" Q="5.263177584685321" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="287" WEIGHT="100.0" Z="1.1405962729985006">
<NAME>Induction of labour</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.42034243456027615" CI_END="1.1626660795220525" CI_START="0.828787300164199" DF="2" EFFECT_SIZE="0.9816327628189555" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="117" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.0654550022228651" LOG_CI_START="-0.08155691241407759" LOG_EFFECT_SIZE="-0.008050955095606244" NO="1" P_CHI2="0.8104455718251709" P_Z="0.830023996910507" STUDIES="3" TAU2="0.0" TOTAL_1="185" TOTAL_2="199" WEIGHT="80.41306443625666" Z="0.21467079137777878">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.3413435067161654" CI_START="0.7752400648604729" EFFECT_SIZE="1.019736842105263" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.12754001123521988" LOG_CI_START="-0.11056379078418205" LOG_EFFECT_SIZE="0.008488110225518892" ORDER="6854" O_E="0.0" SE="0.13986335193902547" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.019561757215619695" WEIGHT="27.563665966055087"/>
<DICH_DATA CI_END="1.2203957210954153" CI_START="0.6780055050757163" EFFECT_SIZE="0.9096345514950166" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="43" LOG_CI_END="0.08650067626641376" LOG_CI_START="-0.16876677985815808" LOG_EFFECT_SIZE="-0.04113305179587218" ORDER="6855" O_E="0.0" SE="0.14994536732186028" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.022483613181287603" WEIGHT="29.85024886434934"/>
<DICH_DATA CI_END="1.4088404785110547" CI_START="0.7521707371971735" EFFECT_SIZE="1.0294117647058822" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" LOG_CI_END="0.14886182119703825" LOG_CI_START="-0.12368356658099731" LOG_EFFECT_SIZE="0.012589127308020467" ORDER="6856" O_E="0.0" SE="0.16009450990224597" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.025630252100840335" WEIGHT="22.99914960585223"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2447741285535983E-31" CI_END="0.9026980667060964" CI_START="0.2629271751899556" DF="0" EFFECT_SIZE="0.4871794871794871" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" I2="100.0" ID="CMP-001.12.02" LOG_CI_END="-0.04445748766075475" LOG_CI_START="-0.5801645244865858" LOG_EFFECT_SIZE="-0.3123110060736703" NO="2" P_CHI2="0.0" P_Z="0.022296844707564677" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="76" WEIGHT="17.359174798000005" Z="2.2852726650998822">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="0.9026980667060964" CI_START="0.2629271751899557" EFFECT_SIZE="0.48717948717948717" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="-0.04445748766075475" LOG_CI_START="-0.5801645244865857" LOG_EFFECT_SIZE="-0.31231100607367024" ORDER="6857" O_E="0.0" SE="0.31467696522409305" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.09902159244264508" WEIGHT="17.359174798000005"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.093317426646381" CI_START="0.4646998620079861" DF="0" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="0.7070007431985775" LOG_CI_START="-0.33282745648428863" LOG_EFFECT_SIZE="0.18708664335714445" NO="3" P_CHI2="1.0" P_Z="0.4806383230423361" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="2.227760765743334" Z="0.7052762813709542">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="5.093317426646381" CI_START="0.4646998620079861" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7070007431985775" LOG_CI_START="-0.33282745648428863" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="6858" O_E="0.0" SE="0.6108002317263175" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.3730769230769231" WEIGHT="2.227760765743334"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.2106922211839475" CI_END="0.9984905487535644" CI_START="0.8258339400304286" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9080679401676401" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="262" I2="23.234767470277873" I2_Q="18.903950611153714" ID="CMP-001.13" LOG_CI_END="-6.560416030936251E-4" LOG_CI_START="-0.08310727250874236" LOG_EFFECT_SIZE="-0.04188165705591799" METHOD="MH" NO="13" P_CHI2="0.2663543007781479" P_Q="0.26680398360457513" P_Z="0.046463985054119555" Q="1.2331056907656677" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="366" WEIGHT="100.0" Z="1.9911537654638791">
<NAME>Elective delivery (induction of labour + elective caesarean section)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.13674481912895106" CI_END="1.131268521853194" CI_START="0.8378244030377696" DF="1" EFFECT_SIZE="0.9735524505629228" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="93" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.053565702819037525" LOG_CI_START="-0.07684699423703405" LOG_EFFECT_SIZE="-0.011640645708998244" NO="1" P_CHI2="0.7115388936598228" P_Z="0.7264189846553808" STUDIES="2" TAU2="0.0" TOTAL_1="115" TOTAL_2="125" WEIGHT="35.23294677817593" Z="0.3498930220976528">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.139260428100474" CI_START="0.7911385916631796" EFFECT_SIZE="0.949375" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="50" LOG_CI_END="0.0566230125415307" LOG_CI_START="-0.1017474301278076" LOG_EFFECT_SIZE="-0.022562208793138454" ORDER="6859" O_E="0.0" SE="0.09302758197030386" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.008654131007241606" WEIGHT="20.047758735020043"/>
<DICH_DATA CI_END="1.2918099126001377" CI_START="0.782602645244258" EFFECT_SIZE="1.0054719562243501" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="43" LOG_CI_END="0.11119861274391986" LOG_CI_START="-0.106458688491251" LOG_EFFECT_SIZE="0.0023699621263344245" ORDER="6860" O_E="0.0" SE="0.1278529761665569" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.016346383514646165" WEIGHT="15.18518804315589"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.047658556266309" CI_END="0.9857690267576504" CI_START="0.7721481751795074" DF="2" EFFECT_SIZE="0.8724447003446114" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="169" I2="60.37766862187732" ID="CMP-001.13.02" LOG_CI_END="-0.006224831666750758" LOG_CI_START="-0.11229935058669864" LOG_EFFECT_SIZE="-0.059262091126724696" NO="2" P_CHI2="0.08015217167408795" P_Z="0.02852428325950463" STUDIES="3" TAU2="0.0" TOTAL_1="229" TOTAL_2="241" WEIGHT="64.76705322182407" Z="2.1899993596872807">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="0.919601028575775" CI_START="0.41180709142809135" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" LOG_CI_END="-0.03640055164315279" LOG_CI_START="-0.38530617898663355" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="6861" O_E="0.0" SE="0.2049488926122704" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.042004048582995945" WEIGHT="15.193011704982805"/>
<DICH_DATA CI_END="1.0506124707005864" CI_START="0.8184128160694997" EFFECT_SIZE="0.9272727272727272" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="88" LOG_CI_END="0.02144255154448029" LOG_CI_START="-0.08702757833709526" LOG_EFFECT_SIZE="-0.03279251339630749" ORDER="6862" O_E="0.0" SE="0.06371589122824002" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.004059714795008914" WEIGHT="34.38885347368537"/>
<DICH_DATA CI_END="1.2918099126001377" CI_START="0.782602645244258" EFFECT_SIZE="1.0054719562243501" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="43" LOG_CI_END="0.11119861274391986" LOG_CI_START="-0.106458688491251" LOG_EFFECT_SIZE="0.0023699621263344245" ORDER="6863" O_E="0.0" SE="0.1278529761665569" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.016346383514646165" WEIGHT="15.18518804315589"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.712621399477815" CI_END="1.0224912282200458" CI_START="0.8346471457982321" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9238070064886875" ESTIMABLE="YES" EVENTS_1="459" EVENTS_2="453" I2="17.098909114525906" I2_Q="39.8915431177238" ID="CMP-001.14" LOG_CI_END="0.009659590956180178" LOG_CI_START="-0.0784970874151951" LOG_EFFECT_SIZE="-0.034418748229507454" METHOD="MH" MODIFIED="2013-05-20 18:22:01 +0100" MODIFIED_BY="Edgardo J Abalos" NO="14" P_CHI2="0.24499425663785845" P_Q="0.12541400990901796" P_Z="0.12590643174066046" Q="9.981956468706455" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1376" TOTAL_2="1248" WEIGHT="100.0" Z="1.530445751111482">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.537761096495731" CI_END="1.2971904176385212" CI_START="0.8561204111391539" DF="7" EFFECT_SIZE="1.0538269277611299" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="123" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.11300373187413545" LOG_CI_START="-0.06746514862235511" LOG_EFFECT_SIZE="0.022769291625890177" NO="1" P_CHI2="0.8312098549204319" P_Z="0.6209056846071224" STUDIES="8" TAU2="0.0" TOTAL_1="428" TOTAL_2="422" WEIGHT="26.277310905580265" Z="0.4945671676741191">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="2.68663946815498" CI_START="0.6617105863477272" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4292093904762475" LOG_CI_START="-0.1793319172596476" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="6864" O_E="0.0" SE="0.35746017649212025" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.12777777777777777" WEIGHT="1.9350333255885037"/>
<DICH_DATA CI_END="3.7101672473114045" CI_START="0.5732183940366202" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.5693934872288778" LOG_CI_START="-0.24167988195153864" LOG_EFFECT_SIZE="0.16385680263866959" ORDER="6865" O_E="0.0" SE="0.4764285119345052" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.22698412698412695" WEIGHT="1.2141385572320025"/>
<DICH_DATA CI_END="2.444625074608031" CI_START="0.6110659569068464" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3882122620222314" LOG_CI_START="-0.21391191058443107" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="6866" O_E="0.0" SE="0.3536907195518778" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.1250971250971251" WEIGHT="1.9350333255885037"/>
<DICH_DATA CI_END="1.5073460588881646" CI_START="0.49842647425485126" EFFECT_SIZE="0.8667763157894737" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.17821296977458342" LOG_CI_START="-0.30239889789496016" LOG_EFFECT_SIZE="-0.062092964060188334" ORDER="6867" O_E="0.0" SE="0.28231379013620395" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.07970107610106861" WEIGHT="4.149912740591923"/>
<DICH_DATA CI_END="2.2962216942166913" CI_START="0.6957081434841075" EFFECT_SIZE="1.2639225181598064" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.361013815749895" LOG_CI_START="-0.15757291305817264" LOG_EFFECT_SIZE="0.10172045134586116" ORDER="6868" O_E="0.0" SE="0.3046204115475673" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="0.09279359513140928" WEIGHT="3.0357787786060855"/>
<DICH_DATA CI_END="1.6673424225310431" CI_START="0.5365784172923451" EFFECT_SIZE="0.9458646616541353" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.22202480015442008" LOG_CI_START="-0.27036679987009155" LOG_EFFECT_SIZE="-0.02417099985783569" ORDER="6869" O_E="0.0" SE="0.2892332632321278" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.08365588055990532" WEIGHT="3.971596177519614"/>
<DICH_DATA CI_END="1.362135392229722" CI_START="0.3754902268632695" EFFECT_SIZE="0.7151702786377709" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.13422027730942865" LOG_CI_START="-0.4254013621873458" LOG_EFFECT_SIZE="-0.14559054243895855" ORDER="6870" O_E="0.0" SE="0.3287245212121976" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.10805981084618856" WEIGHT="3.6550629483338404"/>
<DICH_DATA CI_END="1.6805203399209745" CI_START="0.7516603633372076" EFFECT_SIZE="1.123913043478261" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" LOG_CI_END="0.2254437732541626" LOG_CI_START="-0.12397835042942563" LOG_EFFECT_SIZE="0.05073271141236845" ORDER="6871" O_E="0.0" SE="0.2052522851191477" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.0421285005466319" WEIGHT="6.380755052119797"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8072584116238111" CI_END="0.8414828309357816" CI_START="0.3817025700997496" DF="1" EFFECT_SIZE="0.566741704185426" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="51" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="-0.07495474065775573" LOG_CI_START="-0.41827491582669" LOG_EFFECT_SIZE="-0.24661482824222286" NO="2" P_CHI2="0.36893210090258977" P_Z="0.0048659733611314876" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="158" WEIGHT="11.163439012558207" Z="2.8157749900392415">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="0.839033911945249" CI_START="0.2623116873167837" EFFECT_SIZE="0.4691358024691358" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.07622048556813424" LOG_CI_START="-0.5811823589555449" LOG_EFFECT_SIZE="-0.3287014222618396" ORDER="6872" O_E="0.0" SE="0.2966171040293514" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.08798170640275904" WEIGHT="5.880490885554674"/>
<DICH_DATA CI_END="1.1620929998823464" CI_START="0.39252315097973356" EFFECT_SIZE="0.6753875968992248" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.0652408851279267" LOG_CI_START="-0.406134723514293" LOG_EFFECT_SIZE="-0.17044691919318314" ORDER="6873" O_E="0.0" SE="0.2768883658633343" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.07666716715046769" WEIGHT="5.282948127003534"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7468661635811651" CI_END="1.3041440952352923" CI_START="0.5719617184358325" DF="1" EFFECT_SIZE="0.8636668905305575" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="0.1153255793623132" LOG_CI_START="-0.24263303769025898" LOG_EFFECT_SIZE="-0.06365372916397287" NO="3" P_CHI2="0.3874702710717679" P_Z="0.4857662998822305" STUDIES="2" TAU2="0.0" TOTAL_1="134" TOTAL_2="138" WEIGHT="7.607299331488534" Z="0.6970583229442457">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="1.8791523969549517" CI_START="0.5966026322573251" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.27396200227868117" LOG_CI_START="-0.22431483482861692" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="6874" O_E="0.0" SE="0.29269028062694996" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.08566760037348271" WEIGHT="2.9240503586670723"/>
<DICH_DATA CI_END="1.327457621024143" CI_START="0.4145474824661273" EFFECT_SIZE="0.7418181818181818" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.12302066515904447" LOG_CI_START="-0.38242571796777225" LOG_EFFECT_SIZE="-0.1297025264043639" ORDER="6875" O_E="0.0" SE="0.29690170744864036" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.08815062388591802" WEIGHT="4.6832489728214615"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.722089786508345" CI_START="0.6861368899119882" DF="0" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-001.14.04" LOG_CI_END="0.6741342405602441" LOG_CI_START="-0.16358923035363193" LOG_EFFECT_SIZE="0.25527250510330607" NO="4" P_CHI2="1.0" P_Z="0.23228752729336632" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="1.0750185142158355" Z="1.19448704403612">
<NAME>Methyldopa + other drug versus none</NAME>
<DICH_DATA CI_END="4.722089786508345" CI_START="0.6861368899119882" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6741342405602441" LOG_CI_START="-0.16358923035363193" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="6876" O_E="0.0" SE="0.4920829136128705" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.24214559386973178" WEIGHT="1.0750185142158355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.850920902130736" CI_END="1.1935418714068398" CI_START="0.6657214688453255" DF="1" EFFECT_SIZE="0.8913845678276913" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="48" I2="74.03218540669857" ID="CMP-001.14.05" LOG_CI_END="0.07683765937290732" LOG_CI_START="-0.17670743726387006" LOG_EFFECT_SIZE="-0.049934888945481364" MODIFIED="2013-05-20 18:22:01 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.04971873564787366" P_Z="0.44010426509754186" STUDIES="2" TAU2="0.0" TOTAL_1="272" TOTAL_2="140" WEIGHT="13.631323643304388" Z="0.7720171693586944">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="0.9748679646437978" CI_START="0.35080193483840444" EFFECT_SIZE="0.5847953216374269" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="-0.011054200824163354" LOG_CI_START="-0.45493801996014444" LOG_EFFECT_SIZE="-0.23299611039215387" MODIFIED="2013-05-20 18:22:01 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="730" O_E="0.0" SE="0.26073955262081694" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.06798511430090377" WEIGHT="5.428482752322111"/>
<DICH_DATA CI_END="1.5705321610731209" CI_START="0.7624469871349568" EFFECT_SIZE="1.0942794498704405" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.19604683422931937" LOG_CI_START="-0.11779034738463862" LOG_EFFECT_SIZE="0.03912824342234039" ORDER="6877" O_E="0.0" SE="0.18434951399914273" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.03398474331172012" WEIGHT="8.202840890982277"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1606032961797417" CI_END="1.0860342874488993" CI_START="0.8261685265988864" DF="2" EFFECT_SIZE="0.9472314115872259" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="182" I2="36.720941776608804" ID="CMP-001.14.06" LOG_CI_END="0.035843536684496406" LOG_CI_START="-0.08293135376125588" LOG_EFFECT_SIZE="-0.023543908538379742" NO="6" P_CHI2="0.20591309414151415" P_Z="0.43714717499788536" STUDIES="3" TAU2="0.0" TOTAL_1="320" TOTAL_2="322" WEIGHT="38.95558637579376" Z="0.7770196649704364">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="1.0354349397653844" CI_START="0.6985564450150636" EFFECT_SIZE="0.8504761904761905" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="70" LOG_CI_END="0.015122815746555692" LOG_CI_START="-0.15579849610933896" LOG_EFFECT_SIZE="-0.07033784018139164" ORDER="6878" O_E="0.0" SE="0.10040002465829155" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.010080164951385551" WEIGHT="14.723079651216876"/>
<DICH_DATA CI_END="1.128053935833129" CI_START="0.7402616238581039" EFFECT_SIZE="0.9138134592680047" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="77" LOG_CI_END="0.05232986513908517" LOG_CI_START="-0.13061476443471376" LOG_EFFECT_SIZE="-0.03914244964781431" ORDER="6879" O_E="0.0" SE="0.10746258100217106" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.011548206315648176" WEIGHT="16.745575752474714"/>
<DICH_DATA CI_END="1.722020452778896" CI_START="0.8533799295221016" EFFECT_SIZE="1.2122448979591838" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="35" LOG_CI_END="0.2360383053500774" LOG_CI_START="-0.06885757544471756" LOG_EFFECT_SIZE="0.08359036495267992" ORDER="6880" O_E="0.0" SE="0.17909734963781349" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.03207586064728921" WEIGHT="7.486930972102163"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9104670775454693" CI_START="0.2044657061046387" DF="0" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-001.14.07" LOG_CI_END="0.28113955803409557" LOG_CI_START="-0.6893795233459452" LOG_EFFECT_SIZE="-0.2041199826559248" NO="7" P_CHI2="1.0" P_Z="0.40968908890474953" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="20" WEIGHT="1.2900222170590026" Z="0.8244409042667603">
<NAME>Alpha blocker versus none</NAME>
<DICH_DATA CI_END="1.9104670775454693" CI_START="0.2044657061046387" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.28113955803409557" LOG_CI_START="-0.6893795233459452" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="6881" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.325" WEIGHT="1.2900222170590026"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Regular antihypertensive therapy versus none</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6882" O_E="0.0" SE="0.0" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.949173537542894" CI_END="3.068691949526955" CI_START="0.6500344268547315" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.412358103529159" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.4869532939921526" LOG_CI_START="-0.187063641823133" LOG_EFFECT_SIZE="0.14994482608450976" METHOD="MH" MODIFIED="2013-05-20 18:22:55 +0100" MODIFIED_BY="Edgardo J Abalos" NO="15" P_CHI2="0.6835548370586505" P_Q="0.4726587963970482" P_Z="0.3831839846836882" Q="3.53445511487386" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="779" TOTAL_2="654" WEIGHT="100.0" Z="0.872044731155838">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="104.96090109443645" CI_START="0.24853855650520487" DF="0" EFFECT_SIZE="5.10752688172043" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="2.021027550486821" LOG_CI_START="-0.6046062283449584" LOG_EFFECT_SIZE="0.7082106610709314" NO="1" P_CHI2="1.0" P_Z="0.29036564123975694" STUDIES="3" TAU2="0.0" TOTAL_1="182" TOTAL_2="182" WEIGHT="4.920412869667458" Z="1.0573198748105077">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6883" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6884" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="104.96090109443645" CI_START="0.24853855650520487" EFFECT_SIZE="5.10752688172043" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.021027550486821" LOG_CI_START="-0.6046062283449584" LOG_EFFECT_SIZE="0.7082106610709314" ORDER="6885" O_E="0.0" SE="1.542310278782607" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="2.378720996038483" WEIGHT="4.920412869667458"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04446940683755507" CI_END="14.983464907345656" CI_START="0.33594310043999787" DF="1" EFFECT_SIZE="2.2435667265110713" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="1.175612255028114" LOG_CI_START="-0.47373427397179513" LOG_EFFECT_SIZE="0.35093899052815936" NO="2" P_CHI2="0.8329828395723631" P_Z="0.40424663608884137" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="158" WEIGHT="15.22054691185447" Z="0.8340609691319434">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="70.67913399058472" CI_START="0.12097024427277908" EFFECT_SIZE="2.9240506329113924" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8492912195923035" LOG_CI_START="-0.9173214423888976" LOG_EFFECT_SIZE="0.4659848886017029" ORDER="6886" O_E="0.0" SE="1.6251219726013035" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="2.641021425831552" WEIGHT="5.037081054611323"/>
<DICH_DATA CI_END="20.631863111721366" CI_START="0.17625942374542086" EFFECT_SIZE="1.9069767441860466" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3145384476825532" LOG_CI_START="-0.7538476540742931" LOG_EFFECT_SIZE="0.2803453968041302" ORDER="6887" O_E="0.0" SE="1.2149802348483025" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="1.4761769710720363" WEIGHT="10.183465857243146"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6888" O_E="0.0" SE="0.0" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5570359032852881" CI_END="2.025678448939627" CI_START="0.13098826759105406" DF="1" EFFECT_SIZE="0.5151117458601921" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="0.30657050769047256" LOG_CI_START="-0.882767601662157" LOG_EFFECT_SIZE="-0.2880985469858422" MODIFIED="2013-05-20 18:22:55 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" P_CHI2="0.45545709703843273" P_Z="0.342345432536712" STUDIES="2" TAU2="0.0" TOTAL_1="272" TOTAL_2="140" WEIGHT="52.60675840396108" Z="0.9495412139747608">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="2.718293709819352" CI_START="0.02345920270962201" EFFECT_SIZE="0.25252525252525254" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.43429638016041106" LOG_CI_START="-1.6296867520114353" LOG_EFFECT_SIZE="-0.5976951859255123" MODIFIED="2013-05-20 18:22:55 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="731" O_E="0.0" SE="1.2123939087190228" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="1.4698989898989898" WEIGHT="26.435368212528175"/>
<DICH_DATA CI_END="4.585738845056184" CI_START="0.13279019615423404" EFFECT_SIZE="0.7803468208092486" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6614093183004822" LOG_CI_START="-0.8768339875680609" LOG_EFFECT_SIZE="-0.10771233463378929" ORDER="6889" O_E="0.0" SE="0.9035717322943502" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.8164418754014129" WEIGHT="26.17139019143291"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.871814555371994" CI_START="0.2588143192579485" DF="0" EFFECT_SIZE="1.5153061224489797" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.15.05" LOG_CI_END="0.9480124553209548" LOG_CI_START="-0.5870116993994822" LOG_EFFECT_SIZE="0.1805003779607363" NO="5" P_CHI2="1.0" P_Z="0.6448442500601916" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="99" WEIGHT="19.79230101211795" Z="0.4609363818947083">
<NAME>Calcium blocker versus none</NAME>
<DICH_DATA CI_END="8.871814555371994" CI_START="0.2588143192579486" EFFECT_SIZE="1.5153061224489797" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9480124553209548" LOG_CI_START="-0.587011699399482" LOG_EFFECT_SIZE="0.1805003779607363" ORDER="6890" O_E="0.0" SE="0.9016807869748973" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.8130282415996701" WEIGHT="19.79230101211795"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="32.958832468919105" CI_START="0.33712089533478257" DF="0" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.15.06" LOG_CI_END="1.5179718188840992" LOG_CI_START="-0.4722143283234241" LOG_EFFECT_SIZE="0.5228787452803376" NO="6" P_CHI2="1.0" P_Z="0.3030677446189918" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="20" WEIGHT="7.459980802399048" Z="1.0298770398627368">
<NAME>Alpha blocker versus none</NAME>
<DICH_DATA CI_END="32.958832468919105" CI_START="0.33712089533478257" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.5179718188840992" LOG_CI_START="-0.4722143283234241" LOG_EFFECT_SIZE="0.5228787452803376" ORDER="6891" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.3666666666666667" WEIGHT="7.459980802399048"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.15.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Regular antihypertensive therapy versus none</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6892" O_E="0.0" SE="0.0" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.239345396230442" CI_END="1.0218516327002856" CI_START="0.49463043485945163" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7109422743404579" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.009387843179175827" LOG_CI_START="-0.30571916479464994" LOG_EFFECT_SIZE="-0.14816566080773708" METHOD="MH" MODIFIED="2013-05-20 18:23:44 +0100" MODIFIED_BY="Edgardo J Abalos" NO="16" P_CHI2="0.9238133124655088" P_Q="0.6864655201245905" P_Z="0.06530283454220234" Q="4.7826680568746065" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1682" TOTAL_2="1548" WEIGHT="100.0" Z="1.843179311028617">
<NAME>Total reported fetal or neonatal death (including miscarriage)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.0835268809261307" CI_END="2.286889416033467" CI_START="0.4573527994797277" DF="6" EFFECT_SIZE="1.0226999934112966" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.35924516453346594" LOG_CI_START="-0.3397486582322081" LOG_EFFECT_SIZE="0.009748253150628943" NO="1" P_CHI2="0.7982927914439639" P_Z="0.9564031277949314" STUDIES="11" TAU2="0.0" TOTAL_1="525" TOTAL_2="520" WEIGHT="17.586380255373495" Z="0.05466779380628913">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="4.384751004320472" CI_START="0.35634862697115655" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6419449362379852" LOG_CI_START="-0.44812491022187245" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="6893" O_E="0.0" SE="0.6403124237432849" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.41" WEIGHT="6.2501057742122335"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6894" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1986a" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="6895" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.7812632217765292"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6896" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.824262991946792" CI_START="0.01420084054248603" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8934434396874849" LOG_CI_START="-1.84768594912681" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="6897" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="2.3437896653295875"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6898" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.368170063591449" CI_START="0.046570804769315244" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7298262658251348" LOG_CI_START="-1.3318862571530974" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6899" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="3.1250528871061167"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6900" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="63.82881484401465" CI_START="0.12392766917779852" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050167806434498" LOG_CI_START="-0.9068317184046119" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="6901" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.5374999999999996" WEIGHT="0.8064652611886752"/>
<DICH_DATA CI_END="5.0150081559399045" CI_START="0.012082077255360984" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7002716436529105" LOG_CI_START="-1.9178583916267722" LOG_EFFECT_SIZE="-0.6087933739869308" ORDER="6902" O_E="0.0" SE="1.5379025426759756" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="2.3651442307692307" WEIGHT="3.50221444244651"/>
<DICH_DATA CI_END="73.49844303024413" CI_START="0.1248408162074388" EFFECT_SIZE="3.029126213592233" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8662781392129644" LOG_CI_START="-0.9036434005864231" LOG_EFFECT_SIZE="0.48131736931327057" ORDER="6903" O_E="0.0" SE="1.6270656238109158" STUDY_ID="STD-USA-1987" TOTAL_1="102" TOTAL_2="103" VAR="2.6473425441872043" WEIGHT="0.7774890033138406"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0439600564015739" CI_END="4.430051843108152" CI_START="0.3286995116348077" DF="1" EFFECT_SIZE="1.2067128396377198" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="4.210894481260115" ID="CMP-001.16.02" LOG_CI_END="0.64640880862579" LOG_CI_START="-0.4832009411707812" LOG_EFFECT_SIZE="0.08160393372750438" NO="2" P_CHI2="0.3069025962164482" P_Z="0.7770397730400054" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="158" WEIGHT="6.348186438417945" Z="0.2831788077811923">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="3.7796994558212216" CI_START="0.11163443866495346" EFFECT_SIZE="0.6495726495726496" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5774572681262113" LOG_CI_START="-0.952201807056952" LOG_EFFECT_SIZE="-0.18737226946537028" ORDER="6904" O_E="0.0" SE="0.8985293126971309" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.8073549257759783" WEIGHT="4.7484569843041"/>
<DICH_DATA CI_END="26.946306300069608" CI_START="0.30365054825448545" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.430499242122451" LOG_CI_START="-0.517625930402828" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="6905" O_E="0.0" SE="1.1443383697164793" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="1.3095103044053695" WEIGHT="1.5997294541138454"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.414499051143059" CI_END="0.9379196431768769" CI_START="0.13378475933796133" DF="1" EFFECT_SIZE="0.35423065048180835" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" I2="58.58354139644058" ID="CMP-001.16.03" LOG_CI_END="-0.027834368465070793" LOG_CI_START="-0.8735933582604362" LOG_EFFECT_SIZE="-0.45071386336275343" NO="3" P_CHI2="0.1202166239602468" P_Z="0.03671034691471669" STUDIES="3" TAU2="0.0" TOTAL_1="164" TOTAL_2="173" WEIGHT="22.705151076696964" Z="2.088970853830692">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="2.286031560619402" CI_START="0.21796282465092698" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.359082221907135" LOG_CI_START="-0.6616175725684332" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="6906" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="9.107296985280682"/>
<DICH_DATA CI_END="0.9226155353964339" CI_START="0.015273638959593142" EFFECT_SIZE="0.11870845204178537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.034979236829268255" LOG_CI_START="-1.816057479525592" LOG_EFFECT_SIZE="-0.9255183581774301" ORDER="6907" O_E="0.0" SE="1.0462141762393122" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="1.0945641025641026" WEIGHT="13.597854091416284"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6908" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1333696853800662" CI_END="1.4369580879619441" CI_START="0.23123039163512765" DF="1" EFFECT_SIZE="0.576427255985267" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-001.16.04" LOG_CI_END="0.1574441011667215" LOG_CI_START="-0.6359550852515184" LOG_EFFECT_SIZE="-0.2392554920423985" NO="4" P_CHI2="0.7149635949978435" P_Z="0.23717248775286803" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="77" WEIGHT="16.969037176986213" Z="1.1820837619546367">
<NAME>Methyldopa + other drug versus none</NAME>
<DICH_DATA CI_END="1.6001382903696388" CI_START="0.23666593514526177" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.20415751774911287" LOG_CI_START="-0.6258642483788992" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="6909" O_E="0.0" SE="0.4875588940976005" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="0.23771367521367523" WEIGHT="14.625247511656625"/>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="6910" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="2.3437896653295875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1421878096301208" CI_END="1.5489295532937004" CI_START="0.21586693148450858" DF="1" EFFECT_SIZE="0.5782410135533294" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-001.16.05" LOG_CI_END="0.19003166610553338" LOG_CI_START="-0.6658138818610398" LOG_EFFECT_SIZE="-0.23789110787775328" MODIFIED="2013-05-20 18:23:44 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.7061157710949089" P_Z="0.27589624937995594" STUDIES="2" TAU2="0.0" TOTAL_1="294" TOTAL_2="149" WEIGHT="14.52736542780189" Z="1.0895844578277571">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="1.6635268505992704" CI_START="0.15333447281592205" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.22102981510744976" LOG_CI_START="-0.8143601956305119" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:23:44 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="732" O_E="0.0" SE="0.608193217570691" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.3698989898989899" WEIGHT="10.381887108171327"/>
<DICH_DATA CI_END="4.483281901280379" CI_START="0.12935631556800872" EFFECT_SIZE="0.7615384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6515960474362559" LOG_CI_START="-0.8882123628548295" LOG_EFFECT_SIZE="-0.11830815770928688" ORDER="6911" O_E="0.0" SE="0.9044910823795435" STUDY_ID="STD-USA-1990" TOTAL_1="195" TOTAL_2="99" VAR="0.8181041181041181" WEIGHT="4.145478319630563"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2637390060207349" CI_END="2.048665702330036" CI_START="0.27719929719091757" DF="1" EFFECT_SIZE="0.7535838990218829" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-001.16.06" LOG_CI_END="0.31147109677203966" LOG_CI_START="-0.5572078751659064" LOG_EFFECT_SIZE="-0.12286838919693341" NO="6" P_CHI2="0.6075630107132673" P_Z="0.5792739272252987" STUDIES="5" TAU2="0.0" TOTAL_1="425" TOTAL_2="432" WEIGHT="13.356791209823502" Z="0.5544456017559559">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="8.432346492507785" CI_START="0.014360629336101962" EFFECT_SIZE="0.34798534798534797" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9259484437760184" LOG_CI_START="-1.8428265272798348" LOG_EFFECT_SIZE="-0.4584390417519083" ORDER="6912" O_E="0.0" SE="1.626392123655357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="2.645151339888182" WEIGHT="2.2933855865052952"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6913" O_E="0.0" SE="0.0" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.425266203926439" CI_START="0.28932007166963136" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.38475941491815685" LOG_CI_START="-0.5386214359925852" LOG_EFFECT_SIZE="-0.0769310105372141" ORDER="6914" O_E="0.0" SE="0.5423984826338988" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.2941961139635558" WEIGHT="11.063405623318207"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6915" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1995" TOTAL_1="54" TOTAL_2="57" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6916" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7305295740914657" CI_START="0.2543259194237104" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-001.16.07" LOG_CI_END="0.4362468846969331" LOG_CI_START="-0.5946093767921828" LOG_EFFECT_SIZE="-0.0791812460476248" NO="7" P_CHI2="1.0" P_Z="0.7633427087301341" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="20" WEIGHT="7.031368995988762" Z="0.3010941414473578">
<NAME>Alpha blocker versus none</NAME>
<DICH_DATA CI_END="2.730529574091466" CI_START="0.25432591942371036" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.4362468846969332" LOG_CI_START="-0.5946093767921828" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="6917" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.3666666666666667" WEIGHT="7.031368995988762"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.509252726006434" CI_START="0.22197715105018606" DF="0" EFFECT_SIZE="2.235294117647059" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.16.08" LOG_CI_END="1.3523610773035457" LOG_CI_START="-0.6536917268264734" LOG_EFFECT_SIZE="0.34933467523853623" NO="8" P_CHI2="1.0" P_Z="0.4948485731953328" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="1.4757194189112217" Z="0.6826175069857738">
<NAME>Regular antihypertensive therapy versus none</NAME>
<DICH_DATA CI_END="22.509252726006434" CI_START="0.22197715105018606" EFFECT_SIZE="2.235294117647059" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3523610773035457" LOG_CI_START="-0.6536917268264734" LOG_EFFECT_SIZE="0.34933467523853623" ORDER="6918" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.388544891640867" WEIGHT="1.4757194189112217"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.408489552099162" CI_END="1.196643570604431" CI_START="0.6102668154376673" CI_STUDY="95" CI_TOTAL="95" DF="32" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8545594543662397" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="66" I2="0.0" I2_Q="27.429755354511595" ID="CMP-001.17" LOG_CI_END="0.07796481175070699" LOG_CI_START="-0.21448024509196756" LOG_EFFECT_SIZE="-0.06825771667063031" METHOD="MH" NO="17" P_CHI2="0.989753873531905" P_Q="0.24736110950619306" P_Z="0.36023094502600483" Q="4.133925708333003" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3361" TOTAL_2="3116" WEIGHT="400.0" Z="0.9149251335326565">
<NAME>Fetal or neonatal death (subgrouped by time of death)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.732893184800312" CI_END="0.9312319148765431" CI_START="0.16545550647837706" DF="5" EFFECT_SIZE="0.3925270030516721" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="-0.030942148440256226" LOG_CI_START="-0.7813187746305764" LOG_EFFECT_SIZE="-0.40613046153541627" NO="1" P_CHI2="0.7410832325663035" P_Z="0.033870994604060525" STUDIES="7" TAU2="0.0" TOTAL_1="573" TOTAL_2="485" WEIGHT="99.99999999999999" Z="2.1216041381122492">
<NAME>Miscarriage</NAME>
<DICH_DATA CI_END="4.718788952018382" CI_START="0.21191878046850707" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6738305539431859" LOG_CI_START="-0.6738305539431859" LOG_EFFECT_SIZE="0.0" ORDER="6919" O_E="0.0" SE="0.7916228058025278" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.6266666666666666" WEIGHT="17.044750200961612"/>
<DICH_DATA CI_END="3.0910894699646243" CI_START="0.03433029007881391" EFFECT_SIZE="0.32575757575757575" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4901115756713894" LOG_CI_START="-1.4643225269239162" LOG_EFFECT_SIZE="-0.4871054756262634" ORDER="6920" O_E="0.0" SE="1.1480442664693202" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="1.3180056377730796" WEIGHT="17.24066686993818"/>
<DICH_DATA CI_END="4.755235908824961" CI_START="0.06490571261372155" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.677172067300664" LOG_CI_START="-1.1877170775072763" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="6921" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.2" WEIGHT="12.783562650721208"/>
<DICH_DATA CI_END="2.4923755439591804" CI_START="0.0069989172645183026" EFFECT_SIZE="0.1320754716981132" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3966134811577175" LOG_CI_START="-2.154969140330782" LOG_EFFECT_SIZE="-0.8791778295865322" ORDER="6922" O_E="0.0" SE="1.4988122624000237" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="2.2464381979206776" WEIGHT="20.665367073714897"/>
<DICH_DATA CI_END="2.1799588511499546" CI_START="0.0064571929033895095" EFFECT_SIZE="0.11864406779661017" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.33844829594993786" LOG_CI_START="-2.1899562392057126" LOG_EFFECT_SIZE="-0.9257539716278873" ORDER="6923" O_E="0.0" SE="1.4851973397547305" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="2.205811138014528" WEIGHT="24.72885889811644"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6924" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.031366277703903" CI_START="0.03209310475672013" EFFECT_SIZE="0.5076923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9047894327498617" LOG_CI_START="-1.493588266279798" LOG_EFFECT_SIZE="-0.2943994167649681" ORDER="6925" O_E="0.0" SE="1.408818932571104" STUDY_ID="STD-USA-1990" TOTAL_1="195" TOTAL_2="99" VAR="1.9847707847707847" WEIGHT="7.536794306547651"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.930655010373166" CI_END="2.172499400759051" CI_START="0.6014697036510855" DF="11" EFFECT_SIZE="1.1431065439217412" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.33695966532918586" LOG_CI_START="-0.22078624341728004" LOG_EFFECT_SIZE="0.058086710955952935" NO="2" P_CHI2="0.9344783272830454" P_Z="0.6830954674347709" STUDIES="18" TAU2="0.0" TOTAL_1="1274" TOTAL_2="1206" WEIGHT="100.00000000000001" Z="0.4082427487811754">
<NAME>Stillbirth</NAME>
<DICH_DATA CI_END="21.31282555224412" CI_START="0.18768041760557758" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3286410302116867" LOG_CI_START="-0.726581038883724" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6926" O_E="0.0" SE="1.2072476168999624" STUDY_ID="STD-Brazil-1985" TOTAL_1="47" TOTAL_2="47" VAR="1.4574468085106385" WEIGHT="5.893552763079904"/>
<DICH_DATA CI_END="8.432346492507785" CI_START="0.014360629336101962" EFFECT_SIZE="0.34798534798534797" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9259484437760184" LOG_CI_START="-1.8428265272798348" LOG_EFFECT_SIZE="-0.4584390417519083" ORDER="6927" O_E="0.0" SE="1.626392123655357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="2.645151339888182" WEIGHT="8.650214539359213"/>
<DICH_DATA CI_END="21.046832427345088" CI_START="0.18043102955110663" EFFECT_SIZE="1.9487179487179487" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3231867432672204" LOG_CI_START="-0.743688772758636" LOG_EFFECT_SIZE="0.28974898525429216" ORDER="6928" O_E="0.0" SE="1.214092909312399" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="1.4740215924426452" WEIGHT="5.9700924093536685"/>
<DICH_DATA CI_END="22.509252726006434" CI_START="0.22197715105018606" EFFECT_SIZE="2.235294117647059" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3523610773035457" LOG_CI_START="-0.6536917268264734" LOG_EFFECT_SIZE="0.34933467523853623" ORDER="6929" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.388544891640867" WEIGHT="5.56613316513102"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="6930" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="2.946776381539952"/>
<DICH_DATA CI_END="8.629088095819784" CI_START="0.24902856929353992" EFFECT_SIZE="1.4659090909090908" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.935964902797616" LOG_CI_START="-0.6037508264994553" LOG_EFFECT_SIZE="0.16610703814908032" ORDER="6931" O_E="0.0" SE="0.9044366411048811" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.8180056377730796" WEIGHT="11.922589497724864"/>
<DICH_DATA CI_END="4.755235908824961" CI_START="0.06490571261372155" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.677172067300664" LOG_CI_START="-1.1877170775072763" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="6932" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.2" WEIGHT="13.260493716929783"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6933" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="26.946306300069608" CI_START="0.30365054825448545" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.430499242122451" LOG_CI_START="-0.517625930402828" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="6934" O_E="0.0" SE="1.1443383697164793" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="1.3095103044053695" WEIGHT="6.033875447915139"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6935" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1995" TOTAL_1="54" TOTAL_2="57" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.375730921676513" CI_START="0.03756972111166537" EFFECT_SIZE="0.3561253561253561" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.528367821872939" LOG_CI_START="-1.4251620287884743" LOG_EFFECT_SIZE="-0.4483971034577677" ORDER="6936" O_E="0.0" SE="1.1475131044072329" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="1.3167863247863247" WEIGHT="17.096173717694597"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6937" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.368170063591449" CI_START="0.046570804769315244" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7298262658251348" LOG_CI_START="-1.3318862571530974" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6938" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="11.787105526159808"/>
<DICH_DATA CI_END="63.82881484401465" CI_START="0.12392766917779852" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050167806434498" LOG_CI_START="-0.9068317184046119" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="6939" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.5374999999999996" WEIGHT="3.041833684170273"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6940" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6941" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987" TOTAL_1="102" TOTAL_2="103" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.990502124660544" CI_START="0.03193556618835459" EFFECT_SIZE="0.5051546391752577" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9025740713186696" LOG_CI_START="-1.4957253797941321" LOG_EFFECT_SIZE="-0.2965756542377312" ORDER="6942" O_E="0.0" SE="1.4087729693574083" STUDY_ID="STD-USA-1990" TOTAL_1="194" TOTAL_2="98" VAR="1.9846412791920893" WEIGHT="7.83115915094179"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6943" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.429628859698126" CI_END="1.5441233004953387" CI_START="0.5975186276407715" DF="12" EFFECT_SIZE="0.9605427816709224" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" I2="0.0" ID="CMP-001.17.03" LOG_CI_END="0.18868197643152615" LOG_CI_START="-0.22364855104008313" LOG_EFFECT_SIZE="-0.01748328730427848" NO="3" P_CHI2="0.9743786355807488" P_Z="0.8679921292141781" STUDIES="20" TAU2="0.0" TOTAL_1="1243" TOTAL_2="1139" WEIGHT="100.00000000000001" Z="0.1662094420118413">
<NAME>Perinatal death</NAME>
<DICH_DATA CI_END="21.31282555224412" CI_START="0.18768041760557758" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3286410302116867" LOG_CI_START="-0.726581038883724" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6944" O_E="0.0" SE="1.2072476168999624" STUDY_ID="STD-Brazil-1985" TOTAL_1="47" TOTAL_2="47" VAR="1.4574468085106385" WEIGHT="3.101772861502025"/>
<DICH_DATA CI_END="3.7796994558212216" CI_START="0.11163443866495346" EFFECT_SIZE="0.6495726495726496" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5774572681262113" LOG_CI_START="-0.952201807056952" LOG_EFFECT_SIZE="-0.18737226946537028" ORDER="6945" O_E="0.0" SE="0.8985293126971309" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.8073549257759783" WEIGHT="9.426166877811347"/>
<DICH_DATA CI_END="22.509252726006434" CI_START="0.22197715105018606" EFFECT_SIZE="2.235294117647059" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3523610773035457" LOG_CI_START="-0.6536917268264734" LOG_EFFECT_SIZE="0.34933467523853623" ORDER="6946" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.388544891640867" WEIGHT="2.9294521469741346"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6947" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1986a" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6948" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6949" O_E="0.0" SE="0.0" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.44754414662391" CI_START="0.3355299688944815" EFFECT_SIZE="1.2215909090909092" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6481202676137489" LOG_CI_START="-0.4742686834108378" LOG_EFFECT_SIZE="0.08692579210145554" ORDER="6950" O_E="0.0" SE="0.6592968257467544" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.4346723044397463" WEIGHT="12.54970169251394"/>
<DICH_DATA CI_END="5.208824032489768" CI_START="0.20379347192963407" EFFECT_SIZE="1.0303030303030303" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.716739686092798" LOG_CI_START="-0.6908097317640628" LOG_EFFECT_SIZE="0.012964977164367635" ORDER="6951" O_E="0.0" SE="0.8268014955311085" STUDY_ID="STD-South-Africa-1991" TOTAL_1="11" TOTAL_2="17" VAR="0.6836007130124776" WEIGHT="7.311321744969058"/>
<DICH_DATA CI_END="2.286031560619402" CI_START="0.21796282465092698" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.359082221907135" LOG_CI_START="-0.6616175725684332" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="6952" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="18.078904678468945"/>
<DICH_DATA CI_END="7.824262991946792" CI_START="0.01420084054248603" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8934434396874849" LOG_CI_START="-1.84768594912681" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="6953" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="4.652659292253038"/>
<DICH_DATA CI_END="26.946306300069608" CI_START="0.30365054825448545" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.430499242122451" LOG_CI_START="-0.517625930402828" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="6954" O_E="0.0" SE="1.1443383697164793" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="1.3095103044053695" WEIGHT="3.175624596299692"/>
<DICH_DATA CI_END="2.495047980971631" CI_START="0.3001507539156594" EFFECT_SIZE="0.8653846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.3970789017312938" LOG_CI_START="-0.5226605614502047" LOG_EFFECT_SIZE="-0.06279082985945546" ORDER="6955" O_E="0.0" SE="0.5402595134565813" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="45" VAR="0.2918803418803419" WEIGHT="19.953672841002717"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6956" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.368170063591449" CI_START="0.046570804769315244" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7298262658251348" LOG_CI_START="-1.3318862571530974" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6957" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="6.20354572300405"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6958" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.0150081559399045" CI_START="0.012082077255360984" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7002716436529105" LOG_CI_START="-1.9178583916267722" LOG_EFFECT_SIZE="-0.6087933739869308" ORDER="6959" O_E="0.0" SE="1.5379025426759756" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="2.3651442307692307" WEIGHT="6.95224951715971"/>
<DICH_DATA CI_END="73.49844303024413" CI_START="0.1248408162074388" EFFECT_SIZE="3.029126213592233" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8662781392129644" LOG_CI_START="-0.9036434005864231" LOG_EFFECT_SIZE="0.48131736931327057" ORDER="6960" O_E="0.0" SE="1.6270656238109158" STUDY_ID="STD-USA-1987" TOTAL_1="102" TOTAL_2="103" VAR="2.6473425441872043" WEIGHT="1.543394225771539"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6961" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.005458840137244" CI_START="0.09274714055524197" EFFECT_SIZE="1.0103092783505154" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0416081538939646" LOG_CI_START="-1.0326994710414648" LOG_EFFECT_SIZE="0.004454341426249989" ORDER="6962" O_E="0.0" SE="1.2184585668754147" STUDY_ID="STD-USA-1990" TOTAL_1="194" TOTAL_2="98" VAR="1.4846412791920893" WEIGHT="4.121533802269814"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6963" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7954630685344157" CI_END="4.337590476422231" CI_START="0.14422630233790829" DF="1" EFFECT_SIZE="0.7909454061251664" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="44.3040618587454" ID="CMP-001.17.04" LOG_CI_END="0.6372485467040852" LOG_CI_START="-0.8409555307500349" LOG_EFFECT_SIZE="-0.10185349202297488" NO="4" P_CHI2="0.18026209791933234" P_Z="0.7870857003631815" STUDIES="4" TAU2="0.0" TOTAL_1="271" TOTAL_2="286" WEIGHT="100.00000000000001" Z="0.27009690895791005">
<NAME>Neonatal death</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6964" O_E="0.0" SE="0.0" STUDY_ID="STD-Brazil-1985" TOTAL_1="45" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="91.22890300691435" CI_START="0.18344555988812275" EFFECT_SIZE="4.090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9601324526681556" LOG_CI_START="-0.7364927954339182" LOG_EFFECT_SIZE="0.6118198286171186" ORDER="6965" O_E="0.0" SE="1.5840110192454182" STUDY_ID="STD-South-Africa-1991" TOTAL_1="10" TOTAL_2="14" VAR="2.509090909090909" WEIGHT="14.891256102973815"/>
<DICH_DATA CI_END="4.402283830496914" CI_START="0.010359982632566938" EFFECT_SIZE="0.2135593220338983" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6436780395905292" LOG_CI_START="-1.9846409726396916" LOG_EFFECT_SIZE="-0.6704814665245813" ORDER="6966" O_E="0.0" SE="1.5438875981729712" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="2.3835889157923056" WEIGHT="85.1087438970262"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6967" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.533687521022626" CI_END="1.1005465123782894" CI_START="0.8456150020125109" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9646961393514691" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="279" I2="9.873299684617702" I2_Q="9.279950365717664" ID="CMP-001.18" LOG_CI_END="0.0416084018574428" LOG_CI_START="-0.07282732083608795" LOG_EFFECT_SIZE="-0.015609459489322554" METHOD="MH" MODIFIED="2013-05-20 18:24:35 +0100" MODIFIED_BY="Edgardo J Abalos" NO="18" P_CHI2="0.34267231643694807" P_Q="0.35669089368714413" P_Z="0.5928623042363097" Q="5.511460829393707" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1135" TOTAL_2="1006" WEIGHT="100.0" Z="0.5346927986664206">
<NAME>Preterm birth (&lt; 37 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8834038366606447" CI_END="1.3241820664037631" CI_START="0.6153311734241953" DF="3" EFFECT_SIZE="0.9026685464485308" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="43" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="0.12194770186985215" LOG_CI_START="-0.21089108246898866" LOG_EFFECT_SIZE="-0.044471690299568226" NO="1" P_CHI2="0.8294309908557845" P_Z="0.6004492817266369" STUDIES="4" TAU2="0.0" TOTAL_1="183" TOTAL_2="178" WEIGHT="14.850422313789515" Z="0.5237545347481999">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="4.346977235005655" CI_START="0.44375947730871956" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.6381873658091225" LOG_CI_START="-0.3528523586716594" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="6968" O_E="0.0" SE="0.5821416398857661" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.3388888888888889" WEIGHT="1.4835811834704409"/>
<DICH_DATA CI_END="1.8452362465144543" CI_START="0.4389681817328505" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.26605197699335337" LOG_CI_START="-0.3575669581147036" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="6969" O_E="0.0" SE="0.36631684944598736" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.13418803418803418" WEIGHT="3.50290001652743"/>
<DICH_DATA CI_END="1.4478220167842517" CI_START="0.38460668816655885" EFFECT_SIZE="0.746218487394958" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.16071517658529264" LOG_CI_START="-0.41498316781315214" LOG_EFFECT_SIZE="-0.12713399561392974" ORDER="6970" O_E="0.0" SE="0.33816805725241145" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.11435763494587023" WEIGHT="5.789515305093947"/>
<DICH_DATA CI_END="1.9858834006540402" CI_START="0.45467418436677676" EFFECT_SIZE="0.9502262443438914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2979537457005959" LOG_CI_START="-0.34229970360297884" LOG_EFFECT_SIZE="-0.02217297895119145" ORDER="6971" O_E="0.0" SE="0.37608804542660773" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.14144221791280615" WEIGHT="4.074425808697695"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6288602856044958" CI_END="1.4627851324520873" CI_START="0.6314647307076033" DF="1" EFFECT_SIZE="0.9610916812390706" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="34" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.1651805375787554" LOG_CI_START="-0.1996509011447852" LOG_EFFECT_SIZE="-0.017235181783014874" NO="2" P_CHI2="0.42777389766607876" P_Z="0.8530853073905311" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="158" WEIGHT="12.140353910094632" Z="0.18518324889926943">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="1.5787217430117375" CI_START="0.3712459185862139" EFFECT_SIZE="0.7655677655677655" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.19830559034793077" LOG_CI_START="-0.43033831220733487" LOG_EFFECT_SIZE="-0.11601636092970206" ORDER="6972" O_E="0.0" SE="0.3692685401984678" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.13635925478030742" WEIGHT="4.967749114347991"/>
<DICH_DATA CI_END="1.839351437699459" CI_START="0.6536748364081058" EFFECT_SIZE="1.0965116279069766" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.2646647161177475" LOG_CI_START="-0.1846382331302263" LOG_EFFECT_SIZE="0.040013241493760614" ORDER="6973" O_E="0.0" SE="0.26392277647372825" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.06965523194160152" WEIGHT="7.172604795746642"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0011139952368271048" CI_END="3.5788513870876306" CI_START="0.7267630983179354" DF="1" EFFECT_SIZE="1.612754514022282" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="0.5537436645515518" LOG_CI_START="-0.13860713227725996" LOG_EFFECT_SIZE="0.20756826613714593" NO="3" P_CHI2="0.9733742981318928" P_Z="0.239913578087792" STUDIES="2" TAU2="0.0" TOTAL_1="134" TOTAL_2="138" WEIGHT="3.0952357826379293" Z="1.1752028821967873">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="5.143571011393654" CI_START="0.49041635546458573" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7112647400184975" LOG_CI_START="-0.3094350544570707" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="6974" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="1.3611268635649443"/>
<DICH_DATA CI_END="4.819063550418095" CI_START="0.5526849712884415" EFFECT_SIZE="1.632" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6829626535089109" LOG_CI_START="-0.2575223446732263" LOG_EFFECT_SIZE="0.2127201544178423" ORDER="6975" O_E="0.0" SE="0.552445543408011" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.30519607843137253" WEIGHT="1.734108919072985"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.412632201952985" CI_END="1.0481904801588677" CI_START="0.4214805188890782" DF="1" EFFECT_SIZE="0.6646742566640833" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" I2="81.52470068741822" ID="CMP-001.18.04" LOG_CI_END="0.020440211049414674" LOG_CI_START="-0.3752224939561963" LOG_EFFECT_SIZE="-0.17739114145339074" MODIFIED="2013-05-20 18:24:35 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" P_CHI2="0.019991626780302862" P_Z="0.07883981317279164" STUDIES="2" TAU2="0.0" TOTAL_1="272" TOTAL_2="140" WEIGHT="12.526288936025175" Z="1.757457774142072">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="0.722995814123863" CI_START="0.21342480718015033" EFFECT_SIZE="0.39281705948372614" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="-0.14086421710127925" LOG_CI_START="-0.6707551022719189" LOG_EFFECT_SIZE="-0.40580965968659916" MODIFIED="2013-05-20 18:24:35 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="733" O_E="0.0" SE="0.3112605289514186" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.09688311688311688" WEIGHT="8.37874876436494"/>
<DICH_DATA CI_END="2.5395003843815207" CI_START="0.5802272219481015" EFFECT_SIZE="1.2138728323699421" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.4047482828999033" LOG_CI_START="-0.23640189968965558" LOG_EFFECT_SIZE="0.08417319160512383" ORDER="6976" O_E="0.0" SE="0.3766147909976962" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.14183870079823838" WEIGHT="4.147540171660235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6699041372804024" CI_END="1.2058338653613225" CI_START="0.8774387503026457" DF="3" EFFECT_SIZE="1.0286133189373194" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="156" I2="0.0" ID="CMP-001.18.05" LOG_CI_END="0.08128747668725421" LOG_CI_START="-0.05678318977265632" LOG_EFFECT_SIZE="0.012252143457298954" NO="5" P_CHI2="0.445366082514705" P_Z="0.727954804232436" STUDIES="4" TAU2="0.0" TOTAL_1="370" TOTAL_2="372" WEIGHT="54.760524045057174" Z="0.34784738171299423">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="2.059747840257095" CI_START="0.5978806659848787" EFFECT_SIZE="1.1097222222222223" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.31381405615168917" LOG_CI_START="-0.22338549038624325" LOG_EFFECT_SIZE="0.04521428288272295" ORDER="6977" O_E="0.0" SE="0.31555367281702357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.09957412042831316" WEIGHT="5.482800025869021"/>
<DICH_DATA CI_END="1.6694078925301565" CI_START="0.7128770925027845" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22256246240243016" LOG_CI_START="-0.14698534062363067" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="6978" O_E="0.0" SE="0.2170742087886355" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.04712121212121212" WEIGHT="7.706380036360346"/>
<DICH_DATA CI_END="1.1143643270860302" CI_START="0.7286846217729761" EFFECT_SIZE="0.9011216056670602" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" LOG_CI_END="0.047027201049018336" LOG_CI_START="-0.13746039576903324" LOG_EFFECT_SIZE="-0.04521659736000748" ORDER="6979" O_E="0.0" SE="0.10836892759925609" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.011743824469012808" WEIGHT="27.28235691033318"/>
<DICH_DATA CI_END="1.640730612375623" CI_START="0.8883935633157071" EFFECT_SIZE="1.2073170731707317" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="41" LOG_CI_END="0.2150372811367737" LOG_CI_START="-0.0513945967091073" LOG_EFFECT_SIZE="0.0818213422138332" ORDER="6980" O_E="0.0" SE="0.15650340390573614" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.024493315434081987" WEIGHT="14.288987072494633"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6600512529016966" CI_START="0.26772935092671085" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-001.18.06" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" NO="6" P_CHI2="1.0" P_Z="0.3837111463596513" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="20" WEIGHT="2.6271750123955724" Z="0.8710787844607897">
<NAME>Alpha blocker versus none</NAME>
<DICH_DATA CI_END="1.6600512529016966" CI_START="0.26772935092671085" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="6981" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.21666666666666667" WEIGHT="2.6271750123955724"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.608547018434285" CI_END="1.1631987288761478" CI_START="0.8996666776630524" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0229814934151495" ESTIMABLE="YES" EVENTS_1="325" EVENTS_2="311" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.06565391892557434" LOG_CI_START="-0.0459183648548802" LOG_EFFECT_SIZE="0.009867777035347084" METHOD="MH" NO="19" P_CHI2="0.7405931362832774" P_Q="0.4556265260322373" P_Z="0.7288243581169409" Q="2.6106445290991416" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1580" TOTAL_2="1508" WEIGHT="400.0" Z="0.34668982190610714">
<NAME>Preterm birth (subgrouped by gestational age)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.877169304065546" CI_END="1.1337538145930648" CI_START="0.8464356238806722" DF="9" EFFECT_SIZE="0.9796170769143282" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="227" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.05451876128440902" LOG_CI_START="-0.07240606680082413" LOG_EFFECT_SIZE="-0.008943652758207535" NO="1" P_CHI2="0.8448815450084284" P_Z="0.7823833414087432" STUDIES="10" TAU2="0.0" TOTAL_1="816" TOTAL_2="753" WEIGHT="100.00000000000001" Z="0.2762144737284618">
<NAME>&lt; 37 weeks</NAME>
<DICH_DATA CI_END="2.059747840257095" CI_START="0.5978806659848787" EFFECT_SIZE="1.1097222222222223" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.31381405615168917" LOG_CI_START="-0.22338549038624325" LOG_EFFECT_SIZE="0.04521428288272295" ORDER="6982" O_E="0.0" SE="0.31555367281702357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.09957412042831316" WEIGHT="6.9108554475815405"/>
<DICH_DATA CI_END="1.5787217430117375" CI_START="0.3712459185862139" EFFECT_SIZE="0.7655677655677655" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.19830559034793077" LOG_CI_START="-0.43033831220733487" LOG_EFFECT_SIZE="-0.11601636092970206" ORDER="6983" O_E="0.0" SE="0.3692685401984678" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.13635925478030742" WEIGHT="6.261653875232971"/>
<DICH_DATA CI_END="1.1143643270860302" CI_START="0.7286846217729761" EFFECT_SIZE="0.9011216056670602" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" LOG_CI_END="0.047027201049018336" LOG_CI_START="-0.13746039576903324" LOG_EFFECT_SIZE="-0.04521659736000748" ORDER="6984" O_E="0.0" SE="0.10836892759925609" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.011743824469012808" WEIGHT="34.38834609817011"/>
<DICH_DATA CI_END="1.6600512529016966" CI_START="0.26772935092671085" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="6985" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.21666666666666667" WEIGHT="3.311451568632821"/>
<DICH_DATA CI_END="1.8452362465144543" CI_START="0.4389681817328505" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.26605197699335337" LOG_CI_START="-0.3575669581147036" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="6986" O_E="0.0" SE="0.36631684944598736" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.13418803418803418" WEIGHT="4.415268758177095"/>
<DICH_DATA CI_END="1.839351437699459" CI_START="0.6536748364081058" EFFECT_SIZE="1.0965116279069766" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.2646647161177475" LOG_CI_START="-0.1846382331302263" LOG_EFFECT_SIZE="0.040013241493760614" ORDER="6987" O_E="0.0" SE="0.26392277647372825" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.06965523194160152" WEIGHT="9.040788409600717"/>
<DICH_DATA CI_END="1.4478220167842517" CI_START="0.38460668816655885" EFFECT_SIZE="0.746218487394958" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.16071517658529264" LOG_CI_START="-0.41498316781315214" LOG_EFFECT_SIZE="-0.12713399561392974" ORDER="6988" O_E="0.0" SE="0.33816805725241145" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.11435763494587023" WEIGHT="7.297458086431588"/>
<DICH_DATA CI_END="1.9858834006540402" CI_START="0.45467418436677676" EFFECT_SIZE="0.9502262443438914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2979537457005959" LOG_CI_START="-0.34229970360297884" LOG_EFFECT_SIZE="-0.02217297895119145" ORDER="6989" O_E="0.0" SE="0.37608804542660773" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.14144221791280615" WEIGHT="5.135654713458621"/>
<DICH_DATA CI_END="2.5395003843815207" CI_START="0.5802272219481015" EFFECT_SIZE="1.2138728323699421" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.4047482828999033" LOG_CI_START="-0.23640189968965558" LOG_EFFECT_SIZE="0.08417319160512383" ORDER="6990" O_E="0.0" SE="0.3766147909976962" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.14183870079823838" WEIGHT="5.227812514434781"/>
<DICH_DATA CI_END="1.640730612375623" CI_START="0.8883935633157071" EFFECT_SIZE="1.2073170731707317" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="41" LOG_CI_END="0.2150372811367737" LOG_CI_START="-0.0513945967091073" LOG_EFFECT_SIZE="0.0818213422138332" ORDER="6991" O_E="0.0" SE="0.15650340390573614" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.024493315434081987" WEIGHT="18.010710528279763"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0773945703208" CI_END="1.5850765301282115" CI_START="0.37224308096315484" DF="1" EFFECT_SIZE="0.7681365576102418" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="67.50497938599547" ID="CMP-001.19.02" LOG_CI_END="0.20005023551907583" LOG_CI_START="-0.4291733659127867" LOG_EFFECT_SIZE="-0.11456156519685547" NO="2" P_CHI2="0.0793878591759759" P_Z="0.47541644754347" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="154" WEIGHT="100.0" Z="0.7136939596271284">
<NAME>&lt; 36 weeks</NAME>
<DICH_DATA CI_END="2.5725802870051258" CI_START="0.5130824043392492" EFFECT_SIZE="1.1488888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.41036893743221303" LOG_CI_START="-0.2898128787950153" LOG_EFFECT_SIZE="0.06027802931859881" ORDER="6992" O_E="0.0" SE="0.4112902648077625" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.1691596819256394" WEIGHT="64.01137980085349"/>
<DICH_DATA CI_END="1.6085426237362968" CI_START="0.005137857516464679" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.20643257348058153" LOG_CI_START="-2.289217943797032" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="6993" O_E="0.0" SE="1.465957467518168" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="2.1490312965722804" WEIGHT="35.98862019914652"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.617897356589214" CI_END="1.8327923184025696" CI_START="0.7687385158251058" DF="4" EFFECT_SIZE="1.1869869614551147" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="35" I2="28.798983923969125" ID="CMP-001.19.03" LOG_CI_END="0.263113255970534" LOG_CI_START="-0.11422135908779812" LOG_EFFECT_SIZE="0.07444594844136793" NO="3" P_CHI2="0.22955899140192604" P_Z="0.43929798264414566" STUDIES="5" TAU2="0.0" TOTAL_1="394" TOTAL_2="398" WEIGHT="99.99999999999999" Z="0.773379233799955">
<NAME>&lt; 34 weeks</NAME>
<DICH_DATA CI_END="17.13123339026999" CI_START="0.7800422838990042" EFFECT_SIZE="3.6555555555555554" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2337886318099458" LOG_CI_START="-0.10788185478864705" LOG_EFFECT_SIZE="0.5629533885106494" ORDER="6994" O_E="0.0" SE="0.7881038852040329" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.6211077338736913" WEIGHT="5.876204679950496"/>
<DICH_DATA CI_END="1.8781690013148065" CI_START="0.12636980621143049" EFFECT_SIZE="0.48717948717948717" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27373466835404464" LOG_CI_START="-0.8983566805013853" LOG_EFFECT_SIZE="-0.31231100607367024" ORDER="6995" O_E="0.0" SE="0.6884922602634289" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.4740215924426451" WEIGHT="18.25439168109297"/>
<DICH_DATA CI_END="2.8937027386165948" CI_START="0.7811796650221576" EFFECT_SIZE="1.5034965034965035" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.4614539153078135" LOG_CI_START="-0.10724907040672643" LOG_EFFECT_SIZE="0.17710242245054353" ORDER="6996" O_E="0.0" SE="0.3340589489339018" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.11159538136282322" WEIGHT="39.492898477358224"/>
<DICH_DATA CI_END="1.9104670775454693" CI_START="0.2044657061046387" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.28113955803409557" LOG_CI_START="-0.6893795233459452" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="6997" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.325" WEIGHT="18.020361018514855"/>
<DICH_DATA CI_END="2.861401957796932" CI_START="0.32437517377039526" EFFECT_SIZE="0.9634146341463414" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.45657886996579944" LOG_CI_START="-0.48895239215235" LOG_EFFECT_SIZE="-0.016186761093275277" ORDER="6998" O_E="0.0" SE="0.5554097438234339" STUDY_ID="STD-Sweden-1985" TOTAL_1="82" TOTAL_2="79" VAR="0.3084799835340125" WEIGHT="18.356144143083455"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8337794981784273" CI_END="1.8155984134326586" CI_START="0.8721639477194083" DF="3" EFFECT_SIZE="1.258371757364461" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="34" I2="0.0" ID="CMP-001.19.04" LOG_CI_END="0.2590197945611494" LOG_CI_START="-0.0594018695430399" LOG_EFFECT_SIZE="0.09980896250905476" NO="4" P_CHI2="0.8413715894211233" P_Z="0.21918521872336616" STUDIES="4" TAU2="0.0" TOTAL_1="220" TOTAL_2="203" WEIGHT="100.0" Z="1.2286976289907667">
<NAME>Unspecified</NAME>
<DICH_DATA CI_END="4.346977235005655" CI_START="0.44375947730871956" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.6381873658091225" LOG_CI_START="-0.3528523586716594" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="6999" O_E="0.0" SE="0.5821416398857661" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.3388888888888889" WEIGHT="12.07616925615694"/>
<DICH_DATA CI_END="1.6694078925301565" CI_START="0.7128770925027845" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22256246240243016" LOG_CI_START="-0.14698534062363067" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="7000" O_E="0.0" SE="0.2170742087886355" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.04712121212121212" WEIGHT="62.72899030281521"/>
<DICH_DATA CI_END="5.143571011393654" CI_START="0.49041635546458573" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7112647400184975" LOG_CI_START="-0.3094350544570707" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="7001" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="11.079406079458272"/>
<DICH_DATA CI_END="4.819063550418095" CI_START="0.5526849712884415" EFFECT_SIZE="1.632" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6829626535089109" LOG_CI_START="-0.2575223446732263" LOG_EFFECT_SIZE="0.2127201544178423" ORDER="7002" O_E="0.0" SE="0.552445543408011" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.30519607843137253" WEIGHT="14.11543436156958"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.442388292206317" CI_END="1.1702163995951986" CI_START="0.7986677038366341" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9667543870377162" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="165" I2="22.26618866840305" I2_Q="31.806558279921664" ID="CMP-001.20" LOG_CI_END="0.06826618008797396" LOG_CI_START="-0.09763387701628536" LOG_EFFECT_SIZE="-0.014683848464155694" METHOD="MH" MODIFIED="2013-05-20 18:25:38 +0100" MODIFIED_BY="Edgardo J Abalos" NO="20" P_CHI2="0.17972657327138897" P_Q="0.18523165102380956" P_Z="0.7286261501800338" Q="8.798500044372167" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1360" TOTAL_2="1226" WEIGHT="100.0" Z="0.34695363758798903">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.492919695070999" CI_END="1.9203063381071028" CI_START="0.9881156193356424" DF="8" EFFECT_SIZE="1.3774921729697267" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="50" I2="23.758112780011423" ID="CMP-001.20.01" LOG_CI_END="0.2833705153375212" LOG_CI_START="-0.005192235673853751" LOG_EFFECT_SIZE="0.13908913983183374" NO="1" P_CHI2="0.2321182799460677" P_Z="0.0588340992853483" STUDIES="9" TAU2="0.0" TOTAL_1="454" TOTAL_2="450" WEIGHT="29.219203874134735" Z="1.8894310076791823">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.3270725639350585" CI_START="0.105966323034376" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12289467060744537" LOG_CI_START="-0.9748321351520076" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="7003" O_E="0.0" SE="0.644810159538427" STUDY_ID="STD-Brazil-1985" TOTAL_1="47" TOTAL_2="47" VAR="0.41578014184397166" WEIGHT="4.5388890668928745"/>
<DICH_DATA CI_END="3.229845760329288" CI_START="0.21500854714921266" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5091817833102721" LOG_CI_START="-0.6675442754055219" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7004" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.4777777777777777" WEIGHT="2.150000084317677"/>
<DICH_DATA CI_END="3.4840772775713136" CI_START="0.5263279815622796" EFFECT_SIZE="1.3541666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.542087779185969" LOG_CI_START="-0.2787435406514321" LOG_EFFECT_SIZE="0.13167211926726838" ORDER="7005" O_E="0.0" SE="0.48216038045305265" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.23247863247863249" WEIGHT="3.2039216942773234"/>
<DICH_DATA CI_END="2.2146684810856616" CI_START="0.5043033207724097" EFFECT_SIZE="1.0568181818181819" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.34530872486576064" LOG_CI_START="-0.29730817205822757" LOG_EFFECT_SIZE="0.024000276403766514" ORDER="7006" O_E="0.0" SE="0.37747634625809307" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.14248839198435975" WEIGHT="6.340035522009094"/>
<DICH_DATA CI_END="2.668214881201066" CI_START="0.45839113150591804" EFFECT_SIZE="1.1059322033898304" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4262208019918935" LOG_CI_START="-0.33876379325554473" LOG_EFFECT_SIZE="0.04372850436817436" ORDER="7007" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="0.20192057925839338" WEIGHT="4.577682990541532"/>
<DICH_DATA CI_END="51.36507355693613" CI_START="0.7832527814858183" EFFECT_SIZE="6.3428571428571425" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7106679143784898" LOG_CI_START="-0.10609805417776379" LOG_EFFECT_SIZE="0.802284930100363" ORDER="7008" O_E="0.0" SE="1.0671773230665271" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="1.138867438867439" WEIGHT="0.5516011018793424"/>
<DICH_DATA CI_END="170.95704985397572" CI_START="0.6220723646134377" EFFECT_SIZE="10.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.232887014752679" LOG_CI_START="-0.20615909163671586" LOG_EFFECT_SIZE="1.0133639615579815" ORDER="7009" O_E="0.0" SE="1.4327077563660757" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.052651515151515" WEIGHT="0.29283155270276606"/>
<DICH_DATA CI_END="4.579387842528569" CI_START="0.4798392968177218" EFFECT_SIZE="1.4823529411764707" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6608074268290822" LOG_CI_START="-0.3189041880225419" LOG_EFFECT_SIZE="0.1709516194032702" ORDER="7010" O_E="0.0" SE="0.5754874522145517" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.33118580765639594" WEIGHT="2.538194543986147"/>
<DICH_DATA CI_END="4.361184783035946" CI_START="0.9766596928528737" EFFECT_SIZE="2.0638297872340425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6396044880842814" LOG_CI_START="-0.01025673542322659" LOG_EFFECT_SIZE="0.3146738763305274" ORDER="7011" O_E="0.0" SE="0.3817316995532475" STUDY_ID="STD-USA-1987" TOTAL_1="94" TOTAL_2="97" VAR="0.1457190904438108" WEIGHT="5.026047317527974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6504044475756345" CI_END="2.0170946065251494" CI_START="0.4628648678347416" DF="1" EFFECT_SIZE="0.9662516382699868" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="0.30472626813258114" LOG_CI_START="-0.3345457815946708" LOG_EFFECT_SIZE="-0.014909756731044823" NO="2" P_CHI2="0.4199683882454932" P_Z="0.927155239266563" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="158" WEIGHT="7.49604406502005" Z="0.09142457025477475">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="1.932006735256676" CI_START="0.29726269049790127" EFFECT_SIZE="0.7578347578347578" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.28600863609588756" LOG_CI_START="-0.5268595957654018" LOG_EFFECT_SIZE="-0.12042547983475708" ORDER="7012" O_E="0.0" SE="0.4774828231579635" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.22798984641089903" WEIGHT="5.1725651379201265"/>
<DICH_DATA CI_END="4.885581830333628" CI_START="0.4186942807224805" EFFECT_SIZE="1.430232558139535" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6889162918329629" LOG_CI_START="-0.3781029714413025" LOG_EFFECT_SIZE="0.15540666019583024" ORDER="7013" O_E="0.0" SE="0.626772397077841" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.3928436377387029" WEIGHT="2.3234789270999237"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.610409461199758" CI_END="3.704699929717254" CI_START="0.25585830416717564" DF="1" EFFECT_SIZE="0.9735903869008319" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="72.30231056209081" ID="CMP-001.20.03" LOG_CI_END="0.5687530371073664" LOG_CI_START="-0.5920004829503951" LOG_EFFECT_SIZE="-0.01162372292151434" NO="3" P_CHI2="0.05741915916978568" P_Z="0.968687923653709" STUDIES="2" TAU2="0.0" TOTAL_1="113" TOTAL_2="114" WEIGHT="2.340210165004067" Z="0.03925394650762226">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="136.45123367761124" CI_START="0.3734653508694201" EFFECT_SIZE="7.138613861386139" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1349774665501218" LOG_CI_START="-0.42774968467654884" LOG_EFFECT_SIZE="0.8536138909367865" ORDER="7014" O_E="0.0" SE="1.5053586143345372" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="2.266104557751198" WEIGHT="0.28089938465452224"/>
<DICH_DATA CI_END="2.328896816412874" CI_START="0.007555867021765305" EFFECT_SIZE="0.1326530612244898" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3671502472056924" LOG_CI_START="-2.1217156939770083" LOG_EFFECT_SIZE="-0.877282723385658" ORDER="7015" O_E="0.0" SE="1.4619721739358231" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="2.137362637362637" WEIGHT="2.059310780349545"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6211056113868096" CI_START="0.27615875020475317" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.20.04" LOG_CI_END="0.5588411914211685" LOG_CI_START="-0.5588411914211685" LOG_EFFECT_SIZE="0.0" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="2.2694445334464373" Z="0.0">
<NAME>Methyl dopa + other drug versus none</NAME>
<DICH_DATA CI_END="3.6211056113868096" CI_START="0.27615875020475317" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5588411914211685" LOG_CI_START="-0.5588411914211685" LOG_EFFECT_SIZE="0.0" ORDER="7016" O_E="0.0" SE="0.6565321642986127" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.43103448275862066" WEIGHT="2.2694445334464373"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5812464042886886" CI_END="1.0075842844454854" CI_START="0.42691205923048275" DF="1" EFFECT_SIZE="0.6558581262139661" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="28" I2="0.0" ID="CMP-001.20.05" LOG_CI_END="0.003281385074752978" LOG_CI_START="-0.3696615772567605" LOG_EFFECT_SIZE="-0.18319009609100376" MODIFIED="2013-05-20 18:25:38 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.4458243195679811" P_Z="0.05417008434129184" STUDIES="2" TAU2="0.0" TOTAL_1="272" TOTAL_2="140" WEIGHT="21.050173785389138" Z="1.9254740103857426">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="0.9513082570593288" CI_START="0.3546043295942168" EFFECT_SIZE="0.5808080808080808" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.02167873369607392" LOG_CI_START="-0.4502559661197649" LOG_EFFECT_SIZE="-0.23596734990791945" MODIFIED="2013-05-20 18:25:38 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="734" O_E="0.0" SE="0.2517483878171916" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.06337725076855512" WEIGHT="15.078859651758208"/>
<DICH_DATA CI_END="1.9642496501313342" CI_START="0.36383364620577213" EFFECT_SIZE="0.8453757225433526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.29319668446117586" LOG_CI_START="-0.4390971412103305" LOG_EFFECT_SIZE="-0.07295022837457736" ORDER="7017" O_E="0.0" SE="0.43015301811234175" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18503161899115658" WEIGHT="5.97131413363093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4749381746655406" CI_END="1.159789924107876" CI_START="0.6014460159776771" DF="2" EFFECT_SIZE="0.8351952042640897" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="64" I2="0.0" ID="CMP-001.20.06" LOG_CI_END="0.06437933141395737" LOG_CI_START="-0.2208033475679431" LOG_EFFECT_SIZE="-0.07821200807699287" NO="6" P_CHI2="0.47832307031008714" P_Z="0.2823526752323158" STUDIES="3" TAU2="0.0" TOTAL_1="318" TOTAL_2="322" WEIGHT="36.14485105519268" Z="1.0750492949762271">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="1.2793318917912602" CI_START="0.3401282872818949" EFFECT_SIZE="0.6596491228070176" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.10698322632013381" LOG_CI_START="-0.4683572478097944" LOG_EFFECT_SIZE="-0.18068701074483032" ORDER="7018" O_E="0.0" SE="0.33795784248519845" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.11421550329725019" WEIGHT="10.545516717916868"/>
<DICH_DATA CI_END="1.261814257395252" CI_START="0.5070833261549874" EFFECT_SIZE="0.7999031007751938" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.1009954302447171" LOG_CI_START="-0.2949206696294774" LOG_EFFECT_SIZE="-0.09696261969238013" ORDER="7019" O_E="0.0" SE="0.23256307688240377" STUDY_ID="STD-Italy-1998" TOTAL_1="129" TOTAL_2="127" VAR="0.054085584729010844" WEIGHT="18.297396550911902"/>
<DICH_DATA CI_END="2.3446304512096257" CI_START="0.5910085594521073" EFFECT_SIZE="1.1771561771561772" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.3700744011458413" LOG_CI_START="-0.228406229277967" LOG_EFFECT_SIZE="0.07083408593393713" ORDER="7020" O_E="0.0" SE="0.35155048483784457" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.12358774338972357" WEIGHT="7.301937786363911"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0658805191109848E-32" CI_END="3.5659446086028614" CI_START="0.05265863561782842" DF="0" EFFECT_SIZE="0.4333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="100.0" ID="CMP-001.20.07" LOG_CI_END="0.5521745928031724" LOG_CI_START="-1.2785303976288234" LOG_EFFECT_SIZE="-0.3631779024128256" NO="7" P_CHI2="0.0" P_Z="0.43678070346008735" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="1.4800725218128938" Z="0.7776409770336309">
<NAME>Alpha blocker versus none</NAME>
<DICH_DATA CI_END="3.565944608602859" CI_START="0.05265863561782842" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.552174592803172" LOG_CI_START="-1.2785303976288234" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="7021" O_E="0.0" SE="1.0753651735156091" STUDY_ID="STD-South-Africa-1991" TOTAL_1="10" TOTAL_2="13" VAR="1.1564102564102563" WEIGHT="1.4800725218128938"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.29250181199901" CI_END="1.1875295971445898" CI_START="0.8155850027173408" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9841398933658227" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="170" I2="24.878922056709257" I2_Q="75.15541603854095" ID="CMP-001.21" LOG_CI_END="0.07464444247913044" LOG_CI_START="-0.0885307687901531" LOG_EFFECT_SIZE="-0.006943163155511327" METHOD="MH" MODIFIED="2013-05-20 18:27:43 +0100" MODIFIED_BY="Edgardo J Abalos" NO="21" P_CHI2="0.15113786314077526" P_Q="0.017863085751972152" P_Z="0.8675318831004118" Q="8.05004423943087" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1382" TOTAL_2="1260" WEIGHT="300.0" Z="0.1667943263898117">
<NAME>Small-for-gestational age (subgrouped by severity)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.03266231330601" CI_END="1.2363817667896229" CI_START="0.7885646658683125" DF="9" EFFECT_SIZE="0.9874041598120462" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="113" I2="18.42404177325817" ID="CMP-001.21.01" LOG_CI_END="0.09215259179644164" LOG_CI_START="-0.10316268676344177" LOG_EFFECT_SIZE="-0.005505047483500062" MODIFIED="2013-05-20 18:27:43 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.27347694230185005" P_Z="0.9120248222587843" STUDIES="10" TAU2="0.0" TOTAL_1="659" TOTAL_2="606" WEIGHT="99.99999999999999" Z="0.11048490297736617">
<NAME>Birthweight &lt; 10th centile</NAME>
<DICH_DATA CI_END="3.229845760329288" CI_START="0.21500854714921266" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5091817833102721" LOG_CI_START="-0.6675442754055219" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7022" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.4777777777777777" WEIGHT="3.160616582583079"/>
<DICH_DATA CI_END="0.9513082570593288" CI_START="0.3546043295942168" EFFECT_SIZE="0.5808080808080808" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.02167873369607392" LOG_CI_START="-0.4502559661197649" LOG_EFFECT_SIZE="-0.23596734990791945" MODIFIED="2013-05-20 18:27:43 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="735" O_E="0.0" SE="0.2517483878171916" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.06337725076855512" WEIGHT="22.16674046174039"/>
<DICH_DATA CI_END="3.4840772775713136" CI_START="0.5263279815622796" EFFECT_SIZE="1.3541666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.542087779185969" LOG_CI_START="-0.2787435406514321" LOG_EFFECT_SIZE="0.13167211926726838" ORDER="7023" O_E="0.0" SE="0.48216038045305265" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.23247863247863249" WEIGHT="4.7099384367904715"/>
<DICH_DATA CI_END="1.261814257395252" CI_START="0.5070833261549874" EFFECT_SIZE="0.7999031007751938" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.1009954302447171" LOG_CI_START="-0.2949206696294774" LOG_EFFECT_SIZE="-0.09696261969238013" ORDER="7024" O_E="0.0" SE="0.23256307688240377" STUDY_ID="STD-Italy-1998" TOTAL_1="129" TOTAL_2="127" VAR="0.054085584729010844" WEIGHT="26.898164041358083"/>
<DICH_DATA CI_END="3.565944608602859" CI_START="0.05265863561782842" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.552174592803172" LOG_CI_START="-1.2785303976288234" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="7025" O_E="0.0" SE="1.0753651735156091" STUDY_ID="STD-South-Africa-1991" TOTAL_1="10" TOTAL_2="13" VAR="1.1564102564102563" WEIGHT="2.1757867778651634"/>
<DICH_DATA CI_END="2.2146684810856616" CI_START="0.5043033207724097" EFFECT_SIZE="1.0568181818181819" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.34530872486576064" LOG_CI_START="-0.29730817205822757" LOG_EFFECT_SIZE="0.024000276403766514" ORDER="7026" O_E="0.0" SE="0.37747634625809307" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.14248839198435975" WEIGHT="9.320195636823472"/>
<DICH_DATA CI_END="2.668214881201066" CI_START="0.45839113150591804" EFFECT_SIZE="1.1059322033898304" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4262208019918935" LOG_CI_START="-0.33876379325554473" LOG_EFFECT_SIZE="0.04372850436817436" ORDER="7027" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="0.20192057925839338" WEIGHT="6.729441954559605"/>
<DICH_DATA CI_END="3.12069731044987" CI_START="0.6036762376530762" EFFECT_SIZE="1.3725490196078431" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4942516466607189" LOG_CI_START="-0.21919591882807796" LOG_EFFECT_SIZE="0.13752786391632046" ORDER="7028" O_E="0.0" SE="0.4190826315905257" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.17563025210084032" WEIGHT="6.716310237989044"/>
<DICH_DATA CI_END="4.361184783035946" CI_START="0.9766596928528737" EFFECT_SIZE="2.0638297872340425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6396044880842814" LOG_CI_START="-0.01025673542322659" LOG_EFFECT_SIZE="0.3146738763305274" ORDER="7029" O_E="0.0" SE="0.3817316995532475" STUDY_ID="STD-USA-1987" TOTAL_1="94" TOTAL_2="97" VAR="0.1457190904438108" WEIGHT="7.388561801692906"/>
<DICH_DATA CI_END="2.3446304512096257" CI_START="0.5910085594521073" EFFECT_SIZE="1.1771561771561772" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.3700744011458413" LOG_CI_START="-0.228406229277967" LOG_EFFECT_SIZE="0.07083408593393713" ORDER="7030" O_E="0.0" SE="0.35155048483784457" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.12358774338972357" WEIGHT="10.734244068597784"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7590555654190156" CI_END="7.403527338505375" CI_START="1.2477517803792104" DF="2" EFFECT_SIZE="3.0393690821791024" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="27.51142727724436" ID="CMP-001.21.02" LOG_CI_END="0.8694386844148183" LOG_CI_START="0.09612819822023985" LOG_EFFECT_SIZE="0.4827834413175291" NO="2" P_CHI2="0.25169762590550804" P_Z="0.014395496635135906" STUDIES="3" TAU2="0.0" TOTAL_1="136" TOTAL_2="151" WEIGHT="100.0" Z="2.447239948784488">
<NAME>Birthweight &lt; 5th centile</NAME>
<DICH_DATA CI_END="51.36507355693613" CI_START="0.7832527814858183" EFFECT_SIZE="6.3428571428571425" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7106679143784898" LOG_CI_START="-0.10609805417776379" LOG_EFFECT_SIZE="0.802284930100363" ORDER="7031" O_E="0.0" SE="1.0671773230665271" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="1.138867438867439" WEIGHT="16.306884249994066"/>
<DICH_DATA CI_END="170.95704985397572" CI_START="0.6220723646134377" EFFECT_SIZE="10.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.232887014752679" LOG_CI_START="-0.20615909163671586" LOG_EFFECT_SIZE="1.0133639615579815" ORDER="7032" O_E="0.0" SE="1.4327077563660757" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.052651515151515" WEIGHT="8.656926569582103"/>
<DICH_DATA CI_END="4.579387842528569" CI_START="0.4798392968177218" EFFECT_SIZE="1.4823529411764707" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6608074268290822" LOG_CI_START="-0.3189041880225419" LOG_EFFECT_SIZE="0.1709516194032702" ORDER="7033" O_E="0.0" SE="0.5754874522145517" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.33118580765639594" WEIGHT="75.03618918042383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.0844158331198" CI_END="1.1020548116204876" CI_START="0.5130094273699118" DF="6" EFFECT_SIZE="0.7519072468328007" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="51" I2="1.3874106477123422" ID="CMP-001.21.03" LOG_CI_END="0.04220319505328585" LOG_CI_START="-0.28987465395814066" LOG_EFFECT_SIZE="-0.12383572945242742" NO="3" P_CHI2="0.41380071662403106" P_Z="0.14379954073364937" STUDIES="7" TAU2="0.0" TOTAL_1="587" TOTAL_2="503" WEIGHT="100.0" Z="1.4617871709814179">
<NAME>Unspecified</NAME>
<DICH_DATA CI_END="1.3270725639350585" CI_START="0.105966323034376" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12289467060744537" LOG_CI_START="-0.9748321351520076" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="7034" O_E="0.0" SE="0.644810159538427" STUDY_ID="STD-Brazil-1985" TOTAL_1="47" TOTAL_2="47" VAR="0.41578014184397166" WEIGHT="14.692777629164368"/>
<DICH_DATA CI_END="1.2793318917912602" CI_START="0.3401282872818949" EFFECT_SIZE="0.6596491228070176" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.10698322632013381" LOG_CI_START="-0.4683572478097944" LOG_EFFECT_SIZE="-0.18068701074483032" ORDER="7035" O_E="0.0" SE="0.33795784248519845" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.11421550329725019" WEIGHT="34.13675237210743"/>
<DICH_DATA CI_END="1.932006735256676" CI_START="0.29726269049790127" EFFECT_SIZE="0.7578347578347578" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.28600863609588756" LOG_CI_START="-0.5268595957654018" LOG_EFFECT_SIZE="-0.12042547983475708" ORDER="7036" O_E="0.0" SE="0.4774828231579635" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.22798984641089903" WEIGHT="16.74404203843082"/>
<DICH_DATA CI_END="4.885581830333628" CI_START="0.4186942807224805" EFFECT_SIZE="1.430232558139535" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6889162918329629" LOG_CI_START="-0.3781029714413025" LOG_EFFECT_SIZE="0.15540666019583024" ORDER="7037" O_E="0.0" SE="0.626772397077841" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.3928436377387029" WEIGHT="7.521302833976997"/>
<DICH_DATA CI_END="136.45123367761124" CI_START="0.3734653508694201" EFFECT_SIZE="7.138613861386139" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1349774665501218" LOG_CI_START="-0.42774968467654884" LOG_EFFECT_SIZE="0.8536138909367865" ORDER="7038" O_E="0.0" SE="1.5053586143345372" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="2.266104557751198" WEIGHT="0.9092956743539223"/>
<DICH_DATA CI_END="2.328896816412874" CI_START="0.007555867021765305" EFFECT_SIZE="0.1326530612244898" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3671502472056924" LOG_CI_START="-2.1217156939770083" LOG_EFFECT_SIZE="-0.877282723385658" ORDER="7039" O_E="0.0" SE="1.4619721739358231" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="2.137362637362637" WEIGHT="6.6661676280467965"/>
<DICH_DATA CI_END="1.9642496501313342" CI_START="0.36383364620577213" EFFECT_SIZE="0.8453757225433526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.29319668446117586" LOG_CI_START="-0.4390971412103305" LOG_EFFECT_SIZE="-0.07295022837457736" ORDER="7040" O_E="0.0" SE="0.43015301811234175" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18503161899115658" WEIGHT="19.32966182391966"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.459664553156195" CI_END="1.3028514377171663" CI_START="0.8303738138395438" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.04012197227226" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="183" I2="35.79281395682923" I2_Q="61.48360108298404" ID="CMP-001.22" LOG_CI_END="0.11489489655827706" LOG_CI_START="-0.08072635492469331" LOG_EFFECT_SIZE="0.01708427081679188" METHOD="MH" MODIFIED="2013-09-06 12:30:26 +0100" MODIFIED_BY="Edgardo J Abalos" NO="22" P_CHI2="0.13184291387417757" P_Q="0.03441583680811533" P_Z="0.7320945301676216" Q="10.38518686188199" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.040044963022215156" TOTALS="YES" TOTAL_1="746" TOTAL_2="724" WEIGHT="100.00000000000001" Z="0.3423406736149596">
<NAME>Admission to special care baby unit</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8168664600364377" CI_END="1.412426244409989" CI_START="0.8160546048143602" DF="2" EFFECT_SIZE="1.0735999910168705" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="66" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="0.14996577862806507" LOG_CI_START="-0.0882807802459727" LOG_EFFECT_SIZE="0.030842499191046164" NO="1" P_CHI2="0.6646911158319089" P_Z="0.6118327558586983" STUDIES="3" TAU2="0.0" TOTAL_1="215" TOTAL_2="234" WEIGHT="35.76503101812247" Z="0.5074590616825372">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="2.718520266640692" CI_START="0.5075160316876205" EFFECT_SIZE="1.1746031746031746" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.43433257502667966" LOG_CI_START="-0.29455023447189066" LOG_EFFECT_SIZE="0.0698911702773945" ORDER="7041" O_E="0.0" SE="0.42814937032755673" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.1833118833118833" WEIGHT="5.9116402983475345"/>
<DICH_DATA CI_END="2.268226889650192" CI_START="0.7542258610427557" EFFECT_SIZE="1.3079584775086506" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.35568649466293883" LOG_CI_START="-0.12249858050158369" LOG_EFFECT_SIZE="0.1165939570806775" ORDER="7042" O_E="0.0" SE="0.2808882802059379" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.07889822595704948" WEIGHT="11.101142865193067"/>
<DICH_DATA CI_END="1.379437203927906" CI_START="0.6966795088855409" EFFECT_SIZE="0.9803191489361702" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="40" LOG_CI_END="0.13970193489252422" LOG_CI_START="-0.15696696298173626" LOG_EFFECT_SIZE="-0.008632514044606035" ORDER="7043" O_E="0.0" SE="0.17426477914606933" STUDY_ID="STD-USA-1987" TOTAL_1="94" TOTAL_2="97" VAR="0.03036821325082832" WEIGHT="18.75224785458187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1360277821529805" CI_START="0.38099903150630665" DF="0" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" I2="0.0" ID="CMP-001.22.02" LOG_CI_END="0.055388952403343295" LOG_CI_START="-0.41907612829288826" LOG_EFFECT_SIZE="-0.1818435879447725" NO="2" P_CHI2="1.0" P_Z="0.13300611508724372" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="75" WEIGHT="11.216452845422976" Z="1.5023524288375596">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="1.1360277821529805" CI_START="0.38099903150630665" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.055388952403343295" LOG_CI_START="-0.41907612829288826" LOG_EFFECT_SIZE="-0.1818435879447725" ORDER="7044" O_E="0.0" SE="0.27870313704099425" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="76" TOTAL_2="75" VAR="0.07767543859649122" WEIGHT="11.216452845422976"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04317070212603502" CI_END="2.7791439899666828" CI_START="0.8794875525424161" DF="1" EFFECT_SIZE="1.5634009549372685" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" I2="0.0" ID="CMP-001.22.03" LOG_CI_END="0.44391104855066404" LOG_CI_START="-0.05577030276751715" LOG_EFFECT_SIZE="0.1940703728915735" NO="3" P_CHI2="0.8354043060589247" P_Z="0.12789535774479852" STUDIES="2" TAU2="0.0" TOTAL_1="134" TOTAL_2="138" WEIGHT="12.435158526154197" Z="1.522454021268984">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="3.7914198516766415" CI_START="0.7301878093687468" EFFECT_SIZE="1.6638655462184875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.578801879696846" LOG_CI_START="-0.13656542195884522" LOG_EFFECT_SIZE="0.22111822886900037" ORDER="7045" O_E="0.0" SE="0.42021029411780675" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.17657669128257364" WEIGHT="6.095444788001901"/>
<DICH_DATA CI_END="3.291765159972406" CI_START="0.6594368084050406" EFFECT_SIZE="1.4733333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.517428844351263" LOG_CI_START="-0.18082681509240414" LOG_EFFECT_SIZE="0.16830101462942948" ORDER="7046" O_E="0.0" SE="0.41015883077846876" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.16823026646556058" WEIGHT="6.339713738152297"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9480343101874145" CI_START="0.26905778610622744" DF="0" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-001.22.04" LOG_CI_END="-0.02317594488194555" LOG_CI_START="-0.5701544356411167" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:29:21 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" P_CHI2="1.0" P_Z="0.0334987073948694" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="50" WEIGHT="9.215733827863799" Z="2.126054673822015">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="0.9480343101874145" CI_START="0.26905778610622744" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="-0.02317594488194555" LOG_CI_START="-0.5701544356411167" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:29:21 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="736" O_E="0.0" SE="0.32129787305913377" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.10323232323232323" WEIGHT="9.215733827863799"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1644020257091712" CI_END="1.6157300784545992" CI_START="0.8674038313080681" DF="1" EFFECT_SIZE="1.1838456235553707" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="62" I2="14.119008905798083" ID="CMP-001.22.05" LOG_CI_END="0.20836880988601428" LOG_CI_START="-0.06177866391163124" LOG_EFFECT_SIZE="0.07329507298719148" MODIFIED="2013-05-20 18:28:42 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.28055451655125796" P_Z="0.28753922782831187" STUDIES="2" TAU2="0.007651562848569438" TOTAL_1="222" TOTAL_2="227" WEIGHT="31.367623782436567" Z="1.0635354184857975">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="1.4911281020410119" CI_START="0.7384936743116555" EFFECT_SIZE="1.0493753718024985" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="41" LOG_CI_END="0.17351495506917103" LOG_CI_START="-0.13165322035651117" LOG_EFFECT_SIZE="0.020930867356329937" ORDER="7047" O_E="0.0" SE="0.17925729685187683" STUDY_ID="STD-Italy-1998" TOTAL_1="123" TOTAL_2="126" VAR="0.03213317847464189" WEIGHT="18.293700922709"/>
<DICH_DATA CI_END="2.3644704479882983" CI_START="0.8983434133921958" EFFECT_SIZE="1.4574314574314575" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.37373389041496186" LOG_CI_START="-0.04655761207329017" LOG_EFFECT_SIZE="0.16358813917083587" ORDER="7048" O_E="0.0" SE="0.24688130903809008" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.06095038075236094" WEIGHT="13.073922859727565"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2908943306067187" CI_END="0.632456803263523" CI_START="0.12274794253813123" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.27862658047078187" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="-0.19896913140895112" LOG_CI_START="-0.9109857786495963" LOG_EFFECT_SIZE="-0.5549774550292738" METHOD="MH" NO="23" P_CHI2="0.8629185691573207" P_Q="0.9646248918624322" P_Z="0.002247858221151057" Q="0.0720319336312913" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="412" WEIGHT="100.0" Z="3.0553662707311515">
<NAME>Respiratory distress syndrome</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2070567662463072" CI_END="0.7071132393337507" CI_START="0.11195345702725999" DF="2" EFFECT_SIZE="0.2813605723145261" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="-0.15051103135201863" LOG_CI_START="-0.9509624912347313" LOG_EFFECT_SIZE="-0.550736761293375" NO="1" P_CHI2="0.5468788863643076" P_Z="0.006995917367367746" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="207" WEIGHT="77.91319298816637" Z="2.697038536866213">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.2035181444228498" CI_START="0.12946807261469082" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.08045264215016011" LOG_CI_START="-0.8878373172724179" LOG_EFFECT_SIZE="-0.40369233756112893" ORDER="7049" O_E="0.0" SE="0.5687783152774238" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="76" TOTAL_2="75" VAR="0.3235087719298246" WEIGHT="40.142863457124335"/>
<DICH_DATA CI_END="1.3127828342733947" CI_START="0.004358348243632464" EFFECT_SIZE="0.07564102564102564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11819288932087291" LOG_CI_START="-2.3606780714175453" LOG_EFFECT_SIZE="-1.1212425910483363" ORDER="7050" O_E="0.0" SE="1.4561010729469004" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="2.1202303346371143" WEIGHT="26.13902287693556"/>
<DICH_DATA CI_END="3.3082251922890986" CI_START="0.03753442658327228" EFFECT_SIZE="0.3523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5195950644959296" LOG_CI_START="-1.4255702145018159" LOG_EFFECT_SIZE="-0.45298757500294307" ORDER="7051" O_E="0.0" SE="1.1425997136066968" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="1.3055341055341054" WEIGHT="11.631306654106474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0959423007208584" CI_START="0.0349864320723243" DF="0" EFFECT_SIZE="0.3291139240506329" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="0.49079285811161477" LOG_CI_START="-1.4561003447508618" LOG_EFFECT_SIZE="-0.4826537433196235" NO="2" P_CHI2="1.0" P_Z="0.3311559227804418" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="78" WEIGHT="12.03983116443269" Z="0.9717882342175128">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="3.0959423007208584" CI_START="0.0349864320723243" EFFECT_SIZE="0.3291139240506329" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49079285811161477" LOG_CI_START="-1.4561003447508618" LOG_EFFECT_SIZE="-0.4826537433196235" ORDER="7052" O_E="0.0" SE="1.1436147046382008" STUDY_ID="STD-Sweden-1985" TOTAL_1="79" TOTAL_2="78" VAR="1.3078545926647192" WEIGHT="12.03983116443269"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.061682081444522" CI_START="0.009547447940844398" DF="0" EFFECT_SIZE="0.19692307692307692" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.23.03" LOG_CI_END="0.608705927026011" LOG_CI_START="-2.0201127010159854" LOG_EFFECT_SIZE="-0.7057033869949872" NO="3" P_CHI2="1.0" P_Z="0.29266184199445666" STUDIES="1" TAU2="0.0" TOTAL_1="129" TOTAL_2="127" WEIGHT="10.046975847400942" Z="1.052300229102006">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="4.061682081444522" CI_START="0.009547447940844398" EFFECT_SIZE="0.19692307692307692" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.608705927026011" LOG_CI_START="-2.0201127010159854" LOG_EFFECT_SIZE="-0.7057033869949872" ORDER="7053" O_E="0.0" SE="1.5441810749739462" STUDY_ID="STD-Italy-1998" TOTAL_1="129" TOTAL_2="127" VAR="2.3844951923076922" WEIGHT="10.046975847400942"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.687084144218705" CI_END="1.1703123134940017" CI_START="0.5056209955247601" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7692427945868081" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.0683017745045503" LOG_CI_START="-0.2961749006053562" LOG_EFFECT_SIZE="-0.11393656305040294" METHOD="MH" NO="24" P_CHI2="0.6114767953852984" P_Q="0.8120827727612007" P_Z="0.2204313868392921" Q="0.9552315420793126" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="470" TOTAL_2="392" WEIGHT="100.0" Z="1.2253818987661043">
<NAME>Neonatal hypoglycaemia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7509689655383656" CI_END="2.243640435978029" CI_START="0.2401857623542159" DF="1" EFFECT_SIZE="0.7340916077466955" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="42.88876503916032" ID="CMP-001.24.01" LOG_CI_END="0.35095325847417" LOG_CI_START="-0.6194527401232142" LOG_EFFECT_SIZE="-0.13424974082452204" NO="1" P_CHI2="0.18575507958587445" P_Z="0.5876131775694865" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="132" WEIGHT="16.18529853406836" Z="0.5422980841631599">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="2.133451314753611" CI_START="0.028310611132892353" EFFECT_SIZE="0.2457627118644068" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3290827367312557" LOG_CI_START="-1.5480507555455945" LOG_EFFECT_SIZE="-0.6094840094071693" ORDER="7054" O_E="0.0" SE="1.1026375053240673" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="1.2158094681472824" WEIGHT="9.393742278610839"/>
<DICH_DATA CI_END="6.074469268220826" CI_START="0.32706682376490515" EFFECT_SIZE="1.4095238095238096" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7835083392329835" LOG_CI_START="-0.4853635065829447" LOG_EFFECT_SIZE="0.14907241632501936" ORDER="7055" O_E="0.0" SE="0.7453416032492118" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.5555341055341055" WEIGHT="6.791556255457518"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0909221718470345E-31" CI_END="1.840624942358968" CI_START="0.3545433700518584" DF="0" EFFECT_SIZE="0.8078250863060988" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="100.0" ID="CMP-001.24.02" LOG_CI_END="0.26496530286682485" LOG_CI_START="-0.45033063150454733" LOG_EFFECT_SIZE="-0.09268266431886125" NO="2" P_CHI2="0.0" P_Z="0.611513119868087" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="78" WEIGHT="25.777014970668247" Z="0.5079147673775842">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="1.8406249423589682" CI_START="0.3545433700518584" EFFECT_SIZE="0.807825086306099" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2649653028668249" LOG_CI_START="-0.45033063150454733" LOG_EFFECT_SIZE="-0.0926826643188612" ORDER="7056" O_E="0.0" SE="0.420168372621724" STUDY_ID="STD-Sweden-1985" TOTAL_1="79" TOTAL_2="78" VAR="0.1765414613515879" WEIGHT="25.777014970668247"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.24236552067615" CI_START="0.23483452617645129" DF="0" EFFECT_SIZE="2.0697674418604652" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="1.2610811533984039" LOG_CI_START="-0.6292380512677512" LOG_EFFECT_SIZE="0.31592155106532627" NO="3" P_CHI2="1.0" P_Z="0.5123892038284114" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="89" WEIGHT="3.069025092778176" Z="0.6551220137843605">
<NAME>Beta blocker or methyldopa versus none</NAME>
<DICH_DATA CI_END="18.24236552067615" CI_START="0.23483452617645129" EFFECT_SIZE="2.0697674418604652" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2610811533984039" LOG_CI_START="-0.6292380512677512" LOG_EFFECT_SIZE="0.31592155106532627" ORDER="7057" O_E="0.0" SE="1.110382858051874" STUDY_ID="STD-USA-1990" TOTAL_1="172" TOTAL_2="89" VAR="1.232950091455448" WEIGHT="3.069025092778176"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2087762913329212" CI_START="0.3926019269547886" DF="0" EFFECT_SIZE="0.6888888888888889" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" I2="0.0" ID="CMP-001.24.04" LOG_CI_END="0.08234593325993819" LOG_CI_START="-0.40604757314208023" LOG_EFFECT_SIZE="-0.161850819941071" NO="4" P_CHI2="1.0" P_Z="0.19392960121436115" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="54.96866140248522" Z="1.2990417513522674">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="1.2087762913329212" CI_START="0.3926019269547886" EFFECT_SIZE="0.6888888888888889" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.08234593325993819" LOG_CI_START="-0.40604757314208023" LOG_EFFECT_SIZE="-0.161850819941071" ORDER="7058" O_E="0.0" SE="0.28688476324739265" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="93" VAR="0.08230286738351253" WEIGHT="54.96866140248522"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.415876753372167" CI_END="3.5328840755372277" CI_START="1.0514587986171122" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9273510437172312" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="14" I2="68.82733137059085" I2_Q="75.80223048204546" ID="CMP-001.25" LOG_CI_END="0.548129387171477" LOG_CI_START="0.02179225953892653" LOG_EFFECT_SIZE="0.28496082335520173" METHOD="MH" NO="25" P_CHI2="0.04043995492259145" P_Q="0.04206448442522748" P_Z="0.033815644358337595" Q="4.132612302377741" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="210" WEIGHT="99.99999999999999" Z="2.1222631711095556">
<NAME>Neonatal bradycardia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.315417819867416" CI_END="5.148675907827036" CI_START="1.3209605138625524" DF="1" EFFECT_SIZE="2.607910576096302" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="10" I2="56.81125059073521" ID="CMP-001.25.01" LOG_CI_END="0.7116955552818525" LOG_CI_START="0.12088983588257743" LOG_EFFECT_SIZE="0.416292695582215" NO="1" P_CHI2="0.12809701297455478" P_Z="0.005743895369054255" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="132" WEIGHT="71.17586294267838" Z="2.7620541358260895">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="8.239479970567977" CI_START="1.5768668468943248" EFFECT_SIZE="3.6045197740112993" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" LOG_CI_END="0.915899802347642" LOG_CI_START="0.1977950223710694" LOG_EFFECT_SIZE="0.5568474123593556" ORDER="7059" O_E="0.0" SE="0.42181830243422863" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="0.17793068026849437" WEIGHT="43.329760071725104"/>
<DICH_DATA CI_END="4.064926587041133" CI_START="0.27492526531005096" EFFECT_SIZE="1.0571428571428572" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6090527066014675" LOG_CI_START="-0.5607853471680287" LOG_EFFECT_SIZE="0.02413367971671937" ORDER="7060" O_E="0.0" SE="0.687168663575961" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.47220077220077217" WEIGHT="27.846102870953278"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.159388970128513" CI_START="0.028215266810465937" DF="0" EFFECT_SIZE="0.2468354430379747" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.3343308787238028" LOG_CI_START="-1.5495158385796497" LOG_EFFECT_SIZE="-0.6075924799279234" NO="2" P_CHI2="1.0" P_Z="0.20612785098598485" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="78" WEIGHT="28.82413705732161" Z="1.2642847923855585">
<NAME>Beta blocker + other drug versus none</NAME>
<DICH_DATA CI_END="2.159388970128513" CI_START="0.028215266810465937" EFFECT_SIZE="0.2468354430379747" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3343308787238028" LOG_CI_START="-1.5495158385796497" LOG_EFFECT_SIZE="-0.6075924799279234" ORDER="7061" O_E="0.0" SE="1.1065808869356935" STUDY_ID="STD-Sweden-1985" TOTAL_1="79" TOTAL_2="78" VAR="1.224521259331386" WEIGHT="28.82413705732161"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5025719866198792" CI_END="1.091174070060312" CI_START="0.5584307501326398" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7806056331266549" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="62" I2="20.08221898538401" I2_Q="19.504608566992403" ID="CMP-001.26" LOG_CI_END="0.037894037147884176" LOG_CI_START="-0.25303067518928485" LOG_EFFECT_SIZE="-0.10756831902070033" METHOD="MH" NO="26" P_CHI2="0.286136684544274" P_Q="0.28871742355472074" P_Z="0.1472318719702524" Q="2.4846142920672705" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="260" TOTAL_2="269" WEIGHT="100.0" Z="1.4493786345227677">
<NAME>Neonatal jaundice</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4696025817695455" CI_START="0.1901110943651382" DF="0" EFFECT_SIZE="0.5285714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-001.26.01" LOG_CI_END="0.16719990625861356" LOG_CI_START="-0.7209925381531372" LOG_EFFECT_SIZE="-0.27689631594726183" NO="1" P_CHI2="1.0" P_Z="0.2216895782114472" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="74" WEIGHT="15.926304788563874" Z="1.2220477895821134">
<NAME>Beta blocker versus none</NAME>
<DICH_DATA CI_END="1.4696025817695455" CI_START="0.1901110943651382" EFFECT_SIZE="0.5285714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.16719990625861356" LOG_CI_START="-0.7209925381531372" LOG_EFFECT_SIZE="-0.27689631594726183" ORDER="7062" O_E="0.0" SE="0.5217286384709701" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.2722007722007722" WEIGHT="15.926304788563874"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.610258874274182" CI_START="0.6461072915800302" DF="0" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" I2="0.0" ID="CMP-001.26.02" LOG_CI_END="0.20689570126852508" LOG_CI_START="-0.18969535774468993" LOG_EFFECT_SIZE="0.00860017176191757" NO="2" P_CHI2="1.0" P_Z="0.9322577547421076" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="102" WEIGHT="43.79170651904975" Z="0.08500457350782156">
<NAME>Methyldopa versus none</NAME>
<DICH_DATA CI_END="1.610258874274182" CI_START="0.6461072915800302" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" LOG_CI_END="0.20689570126852508" LOG_CI_START="-0.18969535774468993" LOG_EFFECT_SIZE="0.00860017176191757" ORDER="7063" O_E="0.0" SE="0.232959551221766" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.054270152505446624" WEIGHT="43.79170651904975"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0971588512499053" CI_START="0.350359475806155" DF="0" EFFECT_SIZE="0.62" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" I2="0.0" ID="CMP-001.26.03" LOG_CI_END="0.0402695110996287" LOG_CI_START="-0.45548613210312094" LOG_EFFECT_SIZE="-0.20760831050174613" NO="3" P_CHI2="1.0" P_Z="0.10068248250748398" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="40.28198869238638" Z="1.6415539270350532">
<NAME>Calcium channel blocker versus none</NAME>
<DICH_DATA CI_END="1.0971588512499053" CI_START="0.350359475806155" EFFECT_SIZE="0.62" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" LOG_CI_END="0.0402695110996287" LOG_CI_START="-0.45548613210312094" LOG_EFFECT_SIZE="-0.20760831050174613" ORDER="7064" O_E="0.0" SE="0.29120931884730705" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="93" VAR="0.08480286738351253" WEIGHT="40.28198869238638"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.008396938080814" CI_START="0.013874326156682559" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.9035455909130526" LOG_CI_START="-1.8577881003523773" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2013-06-19 10:37:17 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.49820882592826365" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="55" WEIGHT="100.0" Z="0.6773107346403724">
<NAME>Follow-up of the children at 1 year: cerebral palsy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.008396938080814" CI_START="0.013874326156682559" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9035455909130526" LOG_CI_START="-1.8577881003523773" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7065" O_E="0.0" SE="1.6220210790715333" STUDY_ID="STD-UK-1983" TOTAL_1="55" TOTAL_2="55" VAR="2.630952380952381" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4969160050770305" CI_END="1.2074719034254324" CI_START="0.3662029417059593" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.664965986394558" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.08187703397488733" LOG_CI_START="-0.4362781713354306" LOG_EFFECT_SIZE="-0.1772005686802716" METHOD="MH" MODIFIED="2013-06-19 10:37:22 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.4730956064483727" P_Q="0.4731144939824916" P_Z="0.18006628374503253" Q="1.4968361598740354" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="294" TOTAL_2="276" WEIGHT="300.0" Z="1.3405509742794155">
<NAME>Follow-up of the children at 7 1/2 years</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.061172390982919" CI_START="0.1619415315843172" DF="0" EFFECT_SIZE="0.7040816326530612" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.28.01" LOG_CI_END="0.48588778773011826" LOG_CI_START="-0.7906417576405974" LOG_EFFECT_SIZE="-0.15237698495523955" NO="1" P_CHI2="1.0" P_Z="0.6398456674159148" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="92" WEIGHT="100.0" Z="0.4679145949549324">
<NAME>Chronic ill health</NAME>
<DICH_DATA CI_END="3.061172390982919" CI_START="0.1619415315843172" EFFECT_SIZE="0.7040816326530612" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48588778773011826" LOG_CI_START="-0.7906417576405974" LOG_EFFECT_SIZE="-0.15237698495523955" ORDER="7066" O_E="0.0" SE="0.7498397738739182" STUDY_ID="STD-UK-1976" TOTAL_1="98" TOTAL_2="92" VAR="0.5622596864832888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.13810948218547" CI_START="0.38225131789391" DF="0" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-001.28.02" LOG_CI_END="0.4966680911564594" LOG_CI_START="-0.417651008589112" LOG_EFFECT_SIZE="0.039508541283673655" NO="2" P_CHI2="1.0" P_Z="0.8654949437073094" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="92" WEIGHT="100.0" Z="0.16938357302010262">
<NAME>Impaired hearing</NAME>
<DICH_DATA CI_END="3.13810948218547" CI_START="0.38225131789391" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4966680911564594" LOG_CI_START="-0.417651008589112" LOG_EFFECT_SIZE="0.039508541283673655" ORDER="7067" O_E="0.0" SE="0.537075565143086" STUDY_ID="STD-UK-1976" TOTAL_1="98" TOTAL_2="92" VAR="0.28845016267376516" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.110925689201247" CI_START="0.1983254746752202" DF="0" EFFECT_SIZE="0.46938775510204084" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" ID="CMP-001.28.03" LOG_CI_END="0.045685009571653175" LOG_CI_START="-0.7026214975934948" LOG_EFFECT_SIZE="-0.3284682440109208" NO="3" P_CHI2="1.0" P_Z="0.08531477550167316" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="92" WEIGHT="100.0" Z="1.7206476815640959">
<NAME>Impaired vision</NAME>
<DICH_DATA CI_END="1.1109256892012467" CI_START="0.19832547467522024" EFFECT_SIZE="0.46938775510204084" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.04568500957165309" LOG_CI_START="-0.7026214975934947" LOG_EFFECT_SIZE="-0.3284682440109208" ORDER="7068" O_E="0.0" SE="0.4395589464857585" STUDY_ID="STD-UK-1976" TOTAL_1="98" TOTAL_2="92" VAR="0.1932120674356699" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-05-20 18:35:18 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2">
<NAME>Any antihypertensive drug versus none (subgrouped by type of hypertensive disorder at trial entry)</NAME>
<DICH_OUTCOME CHI2="26.96459309950352" CI_END="0.5957844050099786" CI_START="0.40104809405533387" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4888130522982616" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="242" I2="29.53722709670767" I2_Q="70.58463891774535" ID="CMP-002.01" LOG_CI_END="-0.22491086887316047" LOG_CI_START="-0.3968035432641052" LOG_EFFECT_SIZE="-0.3108572060686328" METHOD="MH" MODIFIED="2013-05-20 18:30:48 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.10548055639747844" P_Q="0.016950117177323643" P_Z="1.3513741021767654E-12" Q="10.198752929161916" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1336" TOTAL_2="1222" WEIGHT="100.0" Z="7.088945824922979">
<NAME>Severe hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6639212539542925" CI_END="0.4706434785392923" CI_START="0.15079067295689247" DF="3" EFFECT_SIZE="0.2663994122585721" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="46" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.32730795472592006" LOG_CI_START="-0.8216255205924217" LOG_EFFECT_SIZE="-0.5744667376591708" MODIFIED="2013-05-20 18:30:48 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.4463934166246233" P_Z="5.225882151958858E-6" STUDIES="4" TAU2="0.0" TOTAL_1="267" TOTAL_2="226" WEIGHT="19.635599813858427" Z="4.55550922676404">
<NAME>Hypertension alone</NAME>
<DICH_DATA CI_END="0.7537090344788961" CI_START="0.17266719228262" EFFECT_SIZE="0.36075036075036077" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="-0.12279627894233291" LOG_CI_START="-0.7627901729372053" LOG_EFFECT_SIZE="-0.4427932259397691" MODIFIED="2013-05-20 18:30:48 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="737" O_E="0.0" SE="0.3759355813534565" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.14132756132756133" WEIGHT="7.511166650277823"/>
<DICH_DATA CI_END="1.0938657367258307" CI_START="0.004509539483088448" EFFECT_SIZE="0.07023411371237458" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="0.0389640190929527" LOG_CI_START="-2.345867806273973" LOG_EFFECT_SIZE="-1.1534518935905105" ORDER="7069" O_E="0.0" SE="1.4008620193284582" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.9624143971970056" WEIGHT="3.550526116591623"/>
<DICH_DATA CI_END="1.2823063840978146" CI_START="0.00419990213254197" EFFECT_SIZE="0.07338638373121131" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10799180445385774" LOG_CI_START="-2.376760829552621" LOG_EFFECT_SIZE="-1.1343845125493814" ORDER="7070" O_E="0.0" SE="1.459555996939311" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="2.130303708201506" WEIGHT="2.6860501925519236"/>
<DICH_DATA CI_END="0.9183944157552488" CI_START="0.13520589135855415" EFFECT_SIZE="0.3523809523809524" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.03697076564084711" LOG_CI_START="-0.8690043843650392" LOG_EFFECT_SIZE="-0.45298757500294307" ORDER="7071" O_E="0.0" SE="0.4887406662714275" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.23886743886743886" WEIGHT="5.887856854437056"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9128345775089857" CI_END="0.5390571260667492" CI_START="0.12516819567692877" DF="1" EFFECT_SIZE="0.25975528452096164" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="32" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.2683652084293428" LOG_CI_START="-0.9025060081597915" LOG_EFFECT_SIZE="-0.5854356082945671" NO="2" P_CHI2="0.3393635718254916" P_Z="2.959061062765769E-4" STUDIES="2" TAU2="0.0" TOTAL_1="126" TOTAL_2="130" WEIGHT="12.65122523186648" Z="3.618857856212324">
<NAME>Hypertension + proteinuria</NAME>
<DICH_DATA CI_END="0.5456419852342921" CI_START="0.05707381278355769" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.2630922196308351" LOG_CI_START="-1.2435631136863878" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="7072" O_E="0.0" SE="0.575933456577432" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3316993464052287" WEIGHT="7.059660528813997"/>
<DICH_DATA CI_END="0.97210968055073" CI_START="0.13697733797118744" EFFECT_SIZE="0.36490683229813664" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.012284732017487168" LOG_CI_START="-0.8633512781586645" LOG_EFFECT_SIZE="-0.43781800508807583" ORDER="7073" O_E="0.0" SE="0.49992070205067496" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.24992070833883975" WEIGHT="5.591564703052482"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.669518760681566" CI_END="0.9787747120630538" CI_START="0.3375392153709157" DF="3" EFFECT_SIZE="0.5747824356525321" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-0.009317259746633577" LOG_CI_START="-0.4716757634853337" LOG_EFFECT_SIZE="-0.2404965116159836" NO="3" P_CHI2="0.8803489437752683" P_Z="0.04145434203735417" STUDIES="4" TAU2="0.0" TOTAL_1="308" TOTAL_2="230" WEIGHT="13.032734328450736" Z="2.0389567721295174">
<NAME>Chronic hypertension</NAME>
<DICH_DATA CI_END="1.4733985973056012" CI_START="0.30597037852147974" EFFECT_SIZE="0.6714285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.16832025206513437" LOG_CI_START="-0.5143206162222133" LOG_EFFECT_SIZE="-0.1730001820785394" ORDER="7074" O_E="0.0" SE="0.40098662515878386" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.16079027355623102" WEIGHT="5.529465567645235"/>
<DICH_DATA CI_END="4.099426132832591" CI_START="0.010939162996078491" EFFECT_SIZE="0.21176470588235294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6127230653081122" LOG_CI_START="-1.9610159065300856" LOG_EFFECT_SIZE="-0.6741464206109866" ORDER="7075" O_E="0.0" SE="1.5118270122711395" STUDY_ID="STD-UK-1990" TOTAL_1="16" TOTAL_2="17" VAR="2.28562091503268" WEIGHT="0.9805084067797218"/>
<DICH_DATA CI_END="3.699119357300525" CI_START="0.1201487169013067" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5680983446651372" LOG_CI_START="-0.9202808627764997" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7076" O_E="0.0" SE="0.8742813140471173" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.764367816091954" WEIGHT="1.21121626719848"/>
<DICH_DATA CI_END="1.2034709849825036" CI_START="0.22488329113438102" EFFECT_SIZE="0.5202312138728323" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.08043562413835074" LOG_CI_START="-0.6480428115172918" LOG_EFFECT_SIZE="-0.28380359368947056" ORDER="7077" O_E="0.0" SE="0.42791183913053826" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18310854206807967" WEIGHT="5.311544086827301"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.564789157548967" CI_END="0.7684838758794845" CI_START="0.47031059187626373" DF="9" EFFECT_SIZE="0.6011872474630892" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="135" I2="33.65175163823765" ID="CMP-002.01.04" LOG_CI_END="-0.11436524031781889" LOG_CI_START="-0.32761524038720635" LOG_EFFECT_SIZE="-0.2209902403525126" NO="4" P_CHI2="0.13867061754548138" P_Z="4.8610765090218716E-5" STUDIES="10" TAU2="0.0" TOTAL_1="635" TOTAL_2="636" WEIGHT="54.68044062582435" Z="4.062207848861354">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="1.214567931047986" CI_START="0.16149936071047388" EFFECT_SIZE="0.4428904428904429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.08442181000508182" LOG_CI_START="-0.7918291924688724" LOG_EFFECT_SIZE="-0.35370369123189527" ORDER="7078" O_E="0.0" SE="0.5147141763656174" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.264930683351736" WEIGHT="4.4988032781657825"/>
<DICH_DATA CI_END="1.4103128933907758" CI_START="0.28142691019844857" EFFECT_SIZE="0.63" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.14931547634177364" LOG_CI_START="-0.5506343774346102" LOG_EFFECT_SIZE="-0.2006594505464183" ORDER="7079" O_E="0.0" SE="0.41115400891590376" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="20" TOTAL_2="21" VAR="0.16904761904761906" WEIGHT="3.938914690076358"/>
<DICH_DATA CI_END="0.890351646543475" CI_START="0.1797042782154134" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="7080" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.16666666666666669" WEIGHT="6.056081335992401"/>
<DICH_DATA CI_END="1.191211707520663" CI_START="0.13431701433913634" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.07598895311772173" LOG_CI_START="-0.871868970461797" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="7081" O_E="0.0" SE="0.5567764362830021" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.30999999999999994" WEIGHT="4.037387557328267"/>
<DICH_DATA CI_END="1.3224589374430262" CI_START="0.6153541723895645" EFFECT_SIZE="0.9020979020979021" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" LOG_CI_END="0.12138219600494272" LOG_CI_START="-0.2108748503365684" LOG_EFFECT_SIZE="-0.04474632716581285" ORDER="7082" O_E="0.0" SE="0.1951694337199084" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.038091107858549716" WEIGHT="15.926797812357027"/>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7083" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="0.20186937786641335"/>
<DICH_DATA CI_END="2.761015458222625" CI_START="0.4743339859607909" EFFECT_SIZE="1.144396551724138" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4410688381503073" LOG_CI_START="-0.32391575709713094" LOG_EFFECT_SIZE="0.058576540526588186" ORDER="7084" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-Sweden-1995" TOTAL_1="58" TOTAL_2="59" VAR="0.20192057925839338" WEIGHT="3.202303977094557"/>
<DICH_DATA CI_END="0.8951643039341957" CI_START="0.20662144808217364" EFFECT_SIZE="0.43006993006993005" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.04809724430085871" LOG_CI_START="-0.6848245990784315" LOG_EFFECT_SIZE="-0.3664609216896451" ORDER="7085" O_E="0.0" SE="0.3740168000475848" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="123" VAR="0.13988856671783503" WEIGHT="8.660196310469132"/>
<DICH_DATA CI_END="0.7465699182036291" CI_START="0.06694355152990397" EFFECT_SIZE="0.22355769230769232" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.1269295132328718" LOG_CI_START="-1.1742912509127434" LOG_EFFECT_SIZE="-0.6506103820728076" ORDER="7086" O_E="0.0" SE="0.615225469237373" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.37850237799834574" WEIGHT="5.331914996344632"/>
<DICH_DATA CI_END="1.3197208380365462" CI_START="0.061856000684717444" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12048207414354972" LOG_CI_START="-1.208618162844101" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="7087" O_E="0.0" SE="0.7807200583588264" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="0.6095238095238094" WEIGHT="2.826171290129787"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.761312891257916" CI_END="1.0814358835551694" CI_START="0.7966725673334996" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9281973398790089" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="255" I2="34.83665735731316" I2_Q="63.71493716316221" ID="CMP-002.02" LOG_CI_END="0.034000775977028004" LOG_CI_START="-0.09872013709676974" LOG_EFFECT_SIZE="-0.03235968055987086" METHOD="MH" MODIFIED="2013-05-20 18:31:57 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.051937478310078555" P_Q="0.04078832235533614" P_Z="0.3392000735954732" Q="8.267864971021357" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1476" TOTAL_2="1375" WEIGHT="100.00000000000001" Z="0.9557470180046432">
<NAME>Proteinuria/pre-eclampsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.690530346588446" CI_END="0.9240467343449259" CI_START="0.5663443705915339" DF="7" EFFECT_SIZE="0.7234145880197187" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="100" I2="19.45255673898061" ID="CMP-002.02.01" LOG_CI_END="-0.03430606346078766" LOG_CI_START="-0.24691941197723896" LOG_EFFECT_SIZE="-0.1406127377190133" MODIFIED="2013-05-20 18:31:57 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.27564489143571047" P_Z="0.009529199886425054" STUDIES="8" TAU2="0.0" TOTAL_1="355" TOTAL_2="329" WEIGHT="38.566096654590666" Z="2.5924609496051305">
<NAME>Hypertension alone</NAME>
<DICH_DATA CI_END="3.283656704405851" CI_START="0.055935649162505596" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.516357746749645" LOG_CI_START="-1.252311317338834" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="7088" O_E="0.0" SE="1.0389249632986395" STUDY_ID="STD-Australia-2001" TOTAL_1="7" TOTAL_2="9" VAR="1.0793650793650793" WEIGHT="1.0132813432730985"/>
<DICH_DATA CI_END="0.8648180115377374" CI_START="0.21669620926622504" EFFECT_SIZE="0.4329004329004329" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="-0.06307527392293309" LOG_CI_START="-0.6641486858613557" LOG_EFFECT_SIZE="-0.36361197989214433" MODIFIED="2013-05-20 18:31:57 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="738" O_E="0.0" SE="0.35307349753400447" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.12466089466089465" WEIGHT="7.181376499975786"/>
<DICH_DATA CI_END="1.394881675466763" CI_START="0.024875366572638044" EFFECT_SIZE="0.18627450980392157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14453736899216438" LOG_CI_START="-1.6042305106103416" LOG_EFFECT_SIZE="-0.7298465708090885" ORDER="7089" O_E="0.0" SE="1.0272349090191268" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.0552115583075337" WEIGHT="2.187400995002245"/>
<DICH_DATA CI_END="2.5234570593395587" CI_START="0.04403130645709946" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.4019959189169215" LOG_CI_START="-1.3562384283562463" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7090" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="1.4475447761044264"/>
<DICH_DATA CI_END="4.174737638310471" CI_START="0.6049216305326484" EFFECT_SIZE="1.5891472868217054" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6206291874090091" LOG_CI_START="-0.21830088589599841" LOG_EFFECT_SIZE="0.20116415075650532" ORDER="7091" O_E="0.0" SE="0.4927916778301993" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.24284363773870293" WEIGHT="2.371216204666299"/>
<DICH_DATA CI_END="1.0030463333503243" CI_START="0.5287431144942136" EFFECT_SIZE="0.7282539682539683" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="45" LOG_CI_END="0.0013209946890276583" LOG_CI_START="-0.276755275137731" LOG_EFFECT_SIZE="-0.13771714022435164" ORDER="7092" O_E="0.0" SE="0.1633433773959736" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.02668105893912346" WEIGHT="16.888022387884977"/>
<DICH_DATA CI_END="1.7570972141948125" CI_START="0.5078480840975841" EFFECT_SIZE="0.9446366782006921" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.24479579019217332" LOG_CI_START="-0.29426618162375695" LOG_EFFECT_SIZE="-0.024735195715791802" ORDER="7093" O_E="0.0" SE="0.31664767064447336" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.10026574732457087" WEIGHT="5.871444776058657"/>
<DICH_DATA CI_END="3.3138380098347344" CI_START="0.40175800470462913" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5203312750083746" LOG_CI_START="-0.3960354615106857" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="7094" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.28974358974358977" WEIGHT="1.6058096716251773"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.007032865321212505" CI_END="2.9686436048654725" CI_START="0.9156132208713884" DF="1" EFFECT_SIZE="1.6486750233657708" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="16" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.47255806228756586" LOG_CI_START="-0.03828794501667762" LOG_EFFECT_SIZE="0.21713505863544413" NO="2" P_CHI2="0.9331660093922152" P_Z="0.09568053487203616" STUDIES="2" TAU2="0.0" TOTAL_1="190" TOTAL_2="193" WEIGHT="6.131692533828425" Z="1.6661651011123726">
<NAME>Hypertension + proteinuria</NAME>
<DICH_DATA CI_END="4.49416039642105" CI_START="0.6452514414860213" EFFECT_SIZE="1.7028985507246377" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6526485683139724" LOG_CI_START="-0.190271016572973" LOG_EFFECT_SIZE="0.23118877587049977" ORDER="7095" O_E="0.0" SE="0.49513513668183046" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.24515880357693495" WEIGHT="2.2911676456190495"/>
<DICH_DATA CI_END="3.384593215279071" CI_START="0.7718834398672652" EFFECT_SIZE="1.616326530612245" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5295064795276351" LOG_CI_START="-0.11244827640567534" LOG_EFFECT_SIZE="0.20852910156097987" ORDER="7096" O_E="0.0" SE="0.3770874013625181" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.14219490826633682" WEIGHT="3.8405248882093757"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8156755310731123" CI_END="1.2787719703449092" CI_START="0.6592191489954051" DF="3" EFFECT_SIZE="0.9181453970096177" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="54" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.10679310831755215" LOG_CI_START="-0.18097018574320503" LOG_EFFECT_SIZE="-0.03708853871282643" NO="3" P_CHI2="0.4209260450895751" P_Z="0.6134027918579418" STUDIES="4" TAU2="0.0" TOTAL_1="342" TOTAL_2="263" WEIGHT="22.323570172216442" Z="0.5052221851547987">
<NAME>Chronic hypertension</NAME>
<DICH_DATA CI_END="1.3583113580225423" CI_START="0.184052057375089" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13299933222130308" LOG_CI_START="-0.7350593235492654" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7097" O_E="0.0" SE="0.5099019513592785" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.26" WEIGHT="3.8601194029451373"/>
<DICH_DATA CI_END="1.5842961150946966" CI_START="0.6384891163205925" EFFECT_SIZE="1.005761316872428" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.1998363572614902" LOG_CI_START="-0.19484650131708134" LOG_EFFECT_SIZE="0.002494927972204436" ORDER="7098" O_E="0.0" SE="0.23183866484071194" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.05374916651512396" WEIGHT="10.195750162126831"/>
<DICH_DATA CI_END="3.0199847904557613" CI_START="0.03679194394033447" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48000475572610146" LOG_CI_START="-1.4342472651654263" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7099" O_E="0.0" SE="1.124441112772009" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="1.2643678160919538" WEIGHT="1.1580358208835413"/>
<DICH_DATA CI_END="1.9930163928537483" CI_START="0.6235458309350601" EFFECT_SIZE="1.1147811725846408" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.29951087085133893" LOG_CI_START="-0.2051316201474312" LOG_EFFECT_SIZE="0.04718962535195388" ORDER="7100" O_E="0.0" SE="0.2964294972332956" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.08787044682998439" WEIGHT="7.109664786260931"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.016832031899844" CI_END="1.3587616494370758" CI_START="0.7968184205294035" DF="8" EFFECT_SIZE="1.040522134017522" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="85" I2="42.92576252755682" ID="CMP-002.02.04" LOG_CI_END="0.1331432805641218" LOG_CI_START="-0.09864063462225509" LOG_EFFECT_SIZE="0.01725132297093336" NO="4" P_CHI2="0.08132785895941697" P_Z="0.7704745240492612" STUDIES="9" TAU2="0.0" TOTAL_1="589" TOTAL_2="590" WEIGHT="32.978640639364485" Z="0.2917542546600767">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="2.645622079552134" CI_START="0.35884770476159167" EFFECT_SIZE="0.9743589743589743" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42252780640959303" LOG_CI_START="-0.44508982722897117" LOG_EFFECT_SIZE="-0.011281010409689058" ORDER="7101" O_E="0.0" SE="0.5096428927758443" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.2597358781569308" WEIGHT="2.737175576633825"/>
<DICH_DATA CI_END="2.9127186917646344" CI_START="0.03556141346709918" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4642985428103939" LOG_CI_START="-1.4490209853631926" LOG_EFFECT_SIZE="-0.4923612212763993" ORDER="7102" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Israel-1992" TOTAL_1="29" TOTAL_2="28" VAR="1.2631362889983577" WEIGHT="1.1783522387937788"/>
<DICH_DATA CI_END="2.5880090016834325" CI_START="0.8937770351034582" EFFECT_SIZE="1.520888888888889" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" LOG_CI_END="0.41296578257419125" LOG_CI_START="-0.048770808386753274" LOG_EFFECT_SIZE="0.182097487093719" ORDER="7103" O_E="0.0" SE="0.2712263591634463" STUDY_ID="STD-Italy-1998" TOTAL_1="125" TOTAL_2="118" VAR="0.07356373790505877" WEIGHT="7.148369264713217"/>
<DICH_DATA CI_END="2.6978801705038147" CI_START="0.37066138479132504" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.43102265606802675" LOG_CI_START="-0.43102265606802675" LOG_EFFECT_SIZE="0.0" ORDER="7104" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.2564102564102564" WEIGHT="2.3160716417670826"/>
<DICH_DATA CI_END="4.028818448809723" CI_START="1.061595617073956" EFFECT_SIZE="2.068085106382979" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.605177697158387" LOG_CI_START="0.025959116822727186" LOG_EFFECT_SIZE="0.31556840699055716" ORDER="7105" O_E="0.0" SE="0.3402358612673805" STUDY_ID="STD-Sweden-1995" TOTAL_1="47" TOTAL_2="54" VAR="0.11576044129235619" WEIGHT="3.5925863750182465"/>
<DICH_DATA CI_END="1.44433264431343" CI_START="0.4592966054898607" EFFECT_SIZE="0.8144796380090498" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.15966722713427386" LOG_CI_START="-0.3379067642978832" LOG_EFFECT_SIZE="-0.08911976858180463" ORDER="7106" O_E="0.0" SE="0.2922774255982299" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="0.08542609351432881" WEIGHT="6.824691104407003"/>
<DICH_DATA CI_END="4.0885479522838075" CI_START="0.40201448264565726" EFFECT_SIZE="1.2820512820512822" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6115690957141797" LOG_CI_START="-0.3957583010951405" LOG_EFFECT_SIZE="0.10790539730951963" ORDER="7107" O_E="0.0" SE="0.5917090992368278" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="0.3501196581196581" WEIGHT="1.8662560749776076"/>
<DICH_DATA CI_END="1.325960843975488" CI_START="0.139806606855715" EFFECT_SIZE="0.4305555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.12253069941078948" LOG_CI_START="-0.854472304604781" LOG_EFFECT_SIZE="-0.36597080259699577" ORDER="7108" O_E="0.0" SE="0.5738964008016139" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.3293570788530466" WEIGHT="3.5292520255498396"/>
<DICH_DATA CI_END="1.06832246368607" CI_START="0.09098117388503381" EFFECT_SIZE="0.31176470588235294" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.028702360428301738" LOG_CI_START="-1.0410484639832713" LOG_EFFECT_SIZE="-0.5061730517774848" ORDER="7109" O_E="0.0" SE="0.6283769296113413" STUDY_ID="STD-UK-1983" TOTAL_1="51" TOTAL_2="53" VAR="0.3948575656677766" WEIGHT="3.785886337503885"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.239345396230442" CI_END="1.0218516327002856" CI_START="0.49463043485945163" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7109422743404579" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.009387843179175827" LOG_CI_START="-0.30571916479464994" LOG_EFFECT_SIZE="-0.14816566080773708" METHOD="MH" MODIFIED="2013-05-20 18:33:20 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.9238133124655088" P_Q="0.6714541340917964" P_Z="0.06530283454220234" Q="1.5470519915583307" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1682" TOTAL_2="1548" WEIGHT="100.00000000000001" Z="1.843179311028617">
<NAME>Total reported fetal or neonatal death (including miscarriage)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1665023299378428" CI_END="1.6462030339889673" CI_START="0.4154200256332909" DF="4" EFFECT_SIZE="0.8269617322326941" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.2164833977676297" LOG_CI_START="-0.38151257180571446" LOG_EFFECT_SIZE="-0.08251458701904238" MODIFIED="2013-05-20 18:33:20 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.5303584449029164" P_Z="0.5885820258981895" STUDIES="7" TAU2="0.0" TOTAL_1="348" TOTAL_2="320" WEIGHT="23.990919419631673" Z="0.5408920025728826">
<NAME>Hypertension alone</NAME>
<DICH_DATA CI_END="1.6635268505992704" CI_START="0.15333447281592205" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.22102981510744976" LOG_CI_START="-0.8143601956305119" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:33:20 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="739" O_E="0.0" SE="0.608193217570691" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.3698989898989899" WEIGHT="10.381887108171329"/>
<DICH_DATA CI_END="22.509252726006434" CI_START="0.22197715105018606" EFFECT_SIZE="2.235294117647059" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3523610773035457" LOG_CI_START="-0.6536917268264734" LOG_EFFECT_SIZE="0.34933467523853623" ORDER="7110" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.388544891640867" WEIGHT="1.475719418911222"/>
<DICH_DATA CI_END="2.730529574091466" CI_START="0.25432591942371036" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.4362468846969332" LOG_CI_START="-0.5946093767921828" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7111" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.3666666666666667" WEIGHT="7.031368995988764"/>
<DICH_DATA CI_END="26.946306300069608" CI_START="0.30365054825448545" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.430499242122451" LOG_CI_START="-0.517625930402828" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="7112" O_E="0.0" SE="1.1443383697164793" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="1.3095103044053695" WEIGHT="1.5997294541138456"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7113" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.0150081559399045" CI_START="0.012082077255360984" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7002716436529105" LOG_CI_START="-1.9178583916267722" LOG_EFFECT_SIZE="-0.6087933739869308" ORDER="7114" O_E="0.0" SE="1.5379025426759756" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="2.3651442307692307" WEIGHT="3.5022144424465105"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7115" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.715541351907281" CI_END="2.5915516654741957" CI_START="0.3046980864469738" DF="1" EFFECT_SIZE="0.8886173717627038" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.4135598714069538" LOG_CI_START="-0.5161302732080112" LOG_EFFECT_SIZE="-0.05128520090052868" NO="2" P_CHI2="0.3976108245032185" P_Z="0.8288022715518061" STUDIES="3" TAU2="0.0" TOTAL_1="235" TOTAL_2="240" WEIGHT="9.884785988594524" Z="0.21623795258487324">
<NAME>Hypertension + proteinuria</NAME>
<DICH_DATA CI_END="2.286031560619402" CI_START="0.21796282465092698" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.359082221907135" LOG_CI_START="-0.6616175725684332" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="7116" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="9.107296985280684"/>
<DICH_DATA CI_END="73.49844303024413" CI_START="0.1248408162074388" EFFECT_SIZE="3.029126213592233" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8662781392129644" LOG_CI_START="-0.9036434005864231" LOG_EFFECT_SIZE="0.48131736931327057" ORDER="7117" O_E="0.0" SE="1.6270656238109158" STUDY_ID="STD-USA-1987" TOTAL_1="102" TOTAL_2="103" VAR="2.6473425441872043" WEIGHT="0.7774890033138407"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7118" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5134038641110212" CI_END="2.206143393023804" CI_START="0.3966650697775191" DF="4" EFFECT_SIZE="0.9354678096722516" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.34363373692334476" LOG_CI_START="-0.40157604170076444" LOG_EFFECT_SIZE="-0.028971152388709814" NO="3" P_CHI2="0.8242646320512601" P_Z="0.8788768966066707" STUDIES="5" TAU2="0.0" TOTAL_1="379" TOTAL_2="286" WEIGHT="15.839224606866356" Z="0.15239310299263903">
<NAME>Chronic hypertension</NAME>
<DICH_DATA CI_END="4.384751004320472" CI_START="0.35634862697115655" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6419449362379852" LOG_CI_START="-0.44812491022187245" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="7119" O_E="0.0" SE="0.6403124237432849" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.41" WEIGHT="6.250105774212234"/>
<DICH_DATA CI_END="8.432346492507785" CI_START="0.014360629336101962" EFFECT_SIZE="0.34798534798534797" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9259484437760184" LOG_CI_START="-1.8428265272798348" LOG_EFFECT_SIZE="-0.4584390417519083" ORDER="7120" O_E="0.0" SE="1.626392123655357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="2.645151339888182" WEIGHT="2.2933855865052957"/>
<DICH_DATA CI_END="63.82881484401465" CI_START="0.12392766917779852" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050167806434498" LOG_CI_START="-0.9068317184046119" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="7121" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.5374999999999996" WEIGHT="0.8064652611886753"/>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7122" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="2.343789665329588"/>
<DICH_DATA CI_END="4.483281901280379" CI_START="0.12935631556800872" EFFECT_SIZE="0.7615384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6515960474362559" LOG_CI_START="-0.8882123628548295" LOG_EFFECT_SIZE="-0.11830815770928688" ORDER="7123" O_E="0.0" SE="0.9044910823795435" STUDY_ID="STD-USA-1990" TOTAL_1="195" TOTAL_2="99" VAR="0.8181041181041181" WEIGHT="4.145478319630564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.045861221353217" CI_END="0.9638504514836933" CI_START="0.3137770435759062" DF="6" EFFECT_SIZE="0.549940128664799" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="31" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="-0.015990344866605524" LOG_CI_START="-0.5033788332570623" LOG_EFFECT_SIZE="-0.25968458906183395" NO="4" P_CHI2="0.6704700788592951" P_Z="0.03674646495454007" STUDIES="12" TAU2="0.0" TOTAL_1="720" TOTAL_2="702" WEIGHT="50.28506998490746" Z="2.08856981247998">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="3.7796994558212216" CI_START="0.11163443866495346" EFFECT_SIZE="0.6495726495726496" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5774572681262113" LOG_CI_START="-0.952201807056952" LOG_EFFECT_SIZE="-0.18737226946537028" ORDER="7124" O_E="0.0" SE="0.8985293126971309" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.8073549257759783" WEIGHT="4.7484569843041"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7125" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1986a" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7126" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.7812632217765293"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7127" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7128" O_E="0.0" SE="0.0" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.425266203926439" CI_START="0.28932007166963136" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.38475941491815685" LOG_CI_START="-0.5386214359925852" LOG_EFFECT_SIZE="-0.0769310105372141" ORDER="7129" O_E="0.0" SE="0.5423984826338988" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.2941961139635558" WEIGHT="11.063405623318209"/>
<DICH_DATA CI_END="7.824262991946792" CI_START="0.01420084054248603" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8934434396874849" LOG_CI_START="-1.84768594912681" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7130" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="2.343789665329588"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7131" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1995" TOTAL_1="54" TOTAL_2="57" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6001382903696388" CI_START="0.23666593514526177" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.20415751774911287" LOG_CI_START="-0.6258642483788992" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="7132" O_E="0.0" SE="0.4875588940976005" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="0.23771367521367523" WEIGHT="14.625247511656628"/>
<DICH_DATA CI_END="0.9226155353964339" CI_START="0.015273638959593142" EFFECT_SIZE="0.11870845204178537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.034979236829268255" LOG_CI_START="-1.816057479525592" LOG_EFFECT_SIZE="-0.9255183581774301" ORDER="7133" O_E="0.0" SE="1.0462141762393122" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="1.0945641025641026" WEIGHT="13.597854091416286"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7134" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.368170063591449" CI_START="0.046570804769315244" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7298262658251348" LOG_CI_START="-1.3318862571530974" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7135" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="3.125052887106117"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.533687521022628" CI_END="1.1005465123782894" CI_START="0.8456150020125109" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9646961393514691" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="279" I2="9.873299684617713" I2_Q="51.0252017352218" ID="CMP-002.04" LOG_CI_END="0.0416084018574428" LOG_CI_START="-0.07282732083608795" LOG_EFFECT_SIZE="-0.015609459489322554" METHOD="MH" MODIFIED="2013-05-20 18:34:20 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" P_CHI2="0.34267231643694807" P_Q="0.10565696041709083" P_Z="0.5928623042363097" Q="6.125599504832563" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1135" TOTAL_2="1006" WEIGHT="99.99999999999999" Z="0.5346927986664206">
<NAME>Preterm birth (&lt; 37 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.849673058122505" CI_END="1.0025619996707984" CI_START="0.5646765267649336" DF="4" EFFECT_SIZE="0.7524116079916717" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="78" I2="41.60305220324779" ID="CMP-002.04.01" LOG_CI_END="0.0011112394291957954" LOG_CI_START="-0.2482002652263649" LOG_EFFECT_SIZE="-0.12354451289858451" MODIFIED="2013-05-20 18:34:20 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.14404893170084376" P_Z="0.05207757319144639" STUDIES="5" TAU2="0.0" TOTAL_1="318" TOTAL_2="289" WEIGHT="28.04246968629879" Z="1.9424919528146536">
<NAME>Hypertension alone</NAME>
<DICH_DATA CI_END="0.722995814123863" CI_START="0.21342480718015033" EFFECT_SIZE="0.39281705948372614" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="-0.14086421710127925" LOG_CI_START="-0.6707551022719189" LOG_EFFECT_SIZE="-0.40580965968659916" MODIFIED="2013-05-20 18:34:20 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="740" O_E="0.0" SE="0.3112605289514186" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.09688311688311688" WEIGHT="8.378748764364937"/>
<DICH_DATA CI_END="1.6600512529016966" CI_START="0.26772935092671085" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7136" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.21666666666666667" WEIGHT="2.627175012395572"/>
<DICH_DATA CI_END="1.839351437699459" CI_START="0.6536748364081058" EFFECT_SIZE="1.0965116279069766" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.2646647161177475" LOG_CI_START="-0.1846382331302263" LOG_EFFECT_SIZE="0.040013241493760614" ORDER="7137" O_E="0.0" SE="0.26392277647372825" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.06965523194160152" WEIGHT="7.172604795746641"/>
<DICH_DATA CI_END="1.4478220167842517" CI_START="0.38460668816655885" EFFECT_SIZE="0.746218487394958" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.16071517658529264" LOG_CI_START="-0.41498316781315214" LOG_EFFECT_SIZE="-0.12713399561392974" ORDER="7138" O_E="0.0" SE="0.33816805725241145" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.11435763494587023" WEIGHT="5.789515305093946"/>
<DICH_DATA CI_END="1.9858834006540402" CI_START="0.45467418436677676" EFFECT_SIZE="0.9502262443438914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2979537457005959" LOG_CI_START="-0.34229970360297884" LOG_EFFECT_SIZE="-0.02217297895119145" ORDER="7139" O_E="0.0" SE="0.37608804542660773" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.14144221791280615" WEIGHT="4.074425808697694"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.19984451213942026" CI_END="1.6736307603216547" CI_START="0.9193827890529924" DF="1" EFFECT_SIZE="1.2404464181371975" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="45" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.22365964933057764" LOG_CI_START="-0.03650363055011655" LOG_EFFECT_SIZE="0.09357800939023052" NO="2" P_CHI2="0.6548463906650488" P_Z="0.1585523589932497" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="135" WEIGHT="15.650113936059574" Z="1.409957071835125">
<NAME>Hypertension + proteinuria</NAME>
<DICH_DATA CI_END="5.143571011393654" CI_START="0.49041635546458573" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7112647400184975" LOG_CI_START="-0.3094350544570707" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="7140" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="1.361126863564944"/>
<DICH_DATA CI_END="1.640730612375623" CI_START="0.8883935633157071" EFFECT_SIZE="1.2073170731707317" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="41" LOG_CI_END="0.2150372811367737" LOG_CI_START="-0.0513945967091073" LOG_EFFECT_SIZE="0.0818213422138332" ORDER="7141" O_E="0.0" SE="0.15650340390573614" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.024493315434081987" WEIGHT="14.28898707249463"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03345146738724446" CI_END="1.8561745983749853" CI_START="0.7181698027977523" DF="1" EFFECT_SIZE="1.1545772149463025" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="25" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.2686188250856503" LOG_CI_START="-0.1437728597975485" LOG_EFFECT_SIZE="0.06242298264405091" NO="3" P_CHI2="0.8548785561908225" P_Z="0.5529453411954868" STUDIES="2" TAU2="0.0" TOTAL_1="263" TOTAL_2="184" WEIGHT="9.630340197529254" Z="0.593352399064791">
<NAME>Chronic hypertension</NAME>
<DICH_DATA CI_END="2.059747840257095" CI_START="0.5978806659848787" EFFECT_SIZE="1.1097222222222223" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.31381405615168917" LOG_CI_START="-0.22338549038624325" LOG_EFFECT_SIZE="0.04521428288272295" ORDER="7142" O_E="0.0" SE="0.31555367281702357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.09957412042831316" WEIGHT="5.48280002586902"/>
<DICH_DATA CI_END="2.5395003843815207" CI_START="0.5802272219481015" EFFECT_SIZE="1.2138728323699421" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.4047482828999033" LOG_CI_START="-0.23640189968965558" LOG_EFFECT_SIZE="0.08417319160512383" ORDER="7143" O_E="0.0" SE="0.3766147909976962" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.14183870079823838" WEIGHT="4.147540171660234"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.422177556618528" CI_END="1.1492813049672066" CI_START="0.8028964064214648" DF="5" EFFECT_SIZE="0.9606007650036209" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="131" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="0.06042634221512442" LOG_CI_START="-0.09534048588173634" LOG_EFFECT_SIZE="-0.017457071833305957" NO="4" P_CHI2="0.788166954479829" P_Z="0.6604344241458964" STUDIES="6" TAU2="0.0" TOTAL_1="422" TOTAL_2="398" WEIGHT="46.677076180112365" Z="0.4393134595708938">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="1.5787217430117375" CI_START="0.3712459185862139" EFFECT_SIZE="0.7655677655677655" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.19830559034793077" LOG_CI_START="-0.43033831220733487" LOG_EFFECT_SIZE="-0.11601636092970206" ORDER="7144" O_E="0.0" SE="0.3692685401984678" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.13635925478030742" WEIGHT="4.967749114347991"/>
<DICH_DATA CI_END="4.346977235005655" CI_START="0.44375947730871956" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.6381873658091225" LOG_CI_START="-0.3528523586716594" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="7145" O_E="0.0" SE="0.5821416398857661" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.3388888888888889" WEIGHT="1.4835811834704407"/>
<DICH_DATA CI_END="1.6694078925301565" CI_START="0.7128770925027845" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22256246240243016" LOG_CI_START="-0.14698534062363067" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="7146" O_E="0.0" SE="0.2170742087886355" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.04712121212121212" WEIGHT="7.706380036360344"/>
<DICH_DATA CI_END="1.1143643270860302" CI_START="0.7286846217729761" EFFECT_SIZE="0.9011216056670602" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" LOG_CI_END="0.047027201049018336" LOG_CI_START="-0.13746039576903324" LOG_EFFECT_SIZE="-0.04521659736000748" ORDER="7147" O_E="0.0" SE="0.10836892759925609" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.011743824469012808" WEIGHT="27.282356910333178"/>
<DICH_DATA CI_END="1.8452362465144543" CI_START="0.4389681817328505" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.26605197699335337" LOG_CI_START="-0.3575669581147036" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="7148" O_E="0.0" SE="0.36631684944598736" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.13418803418803418" WEIGHT="3.5029000165274295"/>
<DICH_DATA CI_END="4.819063550418095" CI_START="0.5526849712884415" EFFECT_SIZE="1.632" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6829626535089109" LOG_CI_START="-0.2575223446732263" LOG_EFFECT_SIZE="0.2127201544178423" ORDER="7149" O_E="0.0" SE="0.552445543408011" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.30519607843137253" WEIGHT="1.7341089190729848"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.44238829220632" CI_END="1.170216399595199" CI_START="0.7986677038366342" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9667543870377164" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="165" I2="22.26618866840306" I2_Q="33.08809824412323" ID="CMP-002.05" LOG_CI_END="0.06826618008797412" LOG_CI_START="-0.0976338770162853" LOG_EFFECT_SIZE="-0.014683848464155594" METHOD="MH" MODIFIED="2013-05-20 18:35:18 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.17972657327138863" P_Q="0.21376641840961808" P_Z="0.7286261501800356" Q="4.483507300308521" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1360" TOTAL_2="1226" WEIGHT="100.0" Z="0.3469536375879867">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.421788253885135" CI_END="1.24232454465097" CI_START="0.5719320261259527" DF="5" EFFECT_SIZE="0.842926564967691" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="36" I2="46.93151803811534" ID="CMP-002.05.01" LOG_CI_END="0.09423506567859266" LOG_CI_START="-0.24265558385138622" LOG_EFFECT_SIZE="-0.07421025908639675" MODIFIED="2013-05-20 18:35:18 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.09337777534535652" P_Z="0.38787275190581894" STUDIES="6" TAU2="0.0" TOTAL_1="329" TOTAL_2="294" WEIGHT="24.03151752688606" Z="0.8634815795312291">
<NAME>Hypertension alone</NAME>
<DICH_DATA CI_END="0.9513082570593288" CI_START="0.3546043295942168" EFFECT_SIZE="0.5808080808080808" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.02167873369607392" LOG_CI_START="-0.4502559661197649" LOG_EFFECT_SIZE="-0.23596734990791945" MODIFIED="2013-05-20 18:35:18 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="741" O_E="0.0" SE="0.2517483878171916" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.06337725076855512" WEIGHT="15.078859651758208"/>
<DICH_DATA CI_END="3.565944608602859" CI_START="0.05265863561782842" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.552174592803172" LOG_CI_START="-1.2785303976288234" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="7150" O_E="0.0" SE="1.0753651735156091" STUDY_ID="STD-South-Africa-1991" TOTAL_1="10" TOTAL_2="13" VAR="1.1564102564102563" WEIGHT="1.4800725218128938"/>
<DICH_DATA CI_END="4.885581830333628" CI_START="0.4186942807224805" EFFECT_SIZE="1.430232558139535" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6889162918329629" LOG_CI_START="-0.3781029714413025" LOG_EFFECT_SIZE="0.15540666019583024" ORDER="7151" O_E="0.0" SE="0.626772397077841" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.3928436377387029" WEIGHT="2.3234789270999237"/>
<DICH_DATA CI_END="51.36507355693613" CI_START="0.7832527814858183" EFFECT_SIZE="6.3428571428571425" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7106679143784898" LOG_CI_START="-0.10609805417776379" LOG_EFFECT_SIZE="0.802284930100363" ORDER="7152" O_E="0.0" SE="1.0671773230665271" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="1.138867438867439" WEIGHT="0.5516011018793424"/>
<DICH_DATA CI_END="4.579387842528569" CI_START="0.4798392968177218" EFFECT_SIZE="1.4823529411764707" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6608074268290822" LOG_CI_START="-0.3189041880225419" LOG_EFFECT_SIZE="0.1709516194032702" ORDER="7153" O_E="0.0" SE="0.5754874522145517" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.33118580765639594" WEIGHT="2.538194543986147"/>
<DICH_DATA CI_END="2.328896816412874" CI_START="0.007555867021765305" EFFECT_SIZE="0.1326530612244898" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3671502472056924" LOG_CI_START="-2.1217156939770083" LOG_EFFECT_SIZE="-0.877282723385658" ORDER="7154" O_E="0.0" SE="1.4619721739358231" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="2.137362637362637" WEIGHT="2.059310780349545"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1720966661176508" CI_END="2.542443577813326" CI_START="0.9311660315690337" DF="1" EFFECT_SIZE="1.5386478144268787" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="14.682804848143505" ID="CMP-002.05.02" LOG_CI_END="0.40525132379095785" LOG_CI_START="-0.030972875231989896" LOG_EFFECT_SIZE="0.18713922427948398" NO="2" P_CHI2="0.2789709035049529" P_Z="0.09263857253198318" STUDIES="2" TAU2="0.0" TOTAL_1="193" TOTAL_2="198" WEIGHT="12.327985103891885" Z="1.6816404981845463">
<NAME>Hypertension + proteinuria</NAME>
<DICH_DATA CI_END="4.361184783035946" CI_START="0.9766596928528737" EFFECT_SIZE="2.0638297872340425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6396044880842814" LOG_CI_START="-0.01025673542322659" LOG_EFFECT_SIZE="0.3146738763305274" ORDER="7155" O_E="0.0" SE="0.3817316995532475" STUDY_ID="STD-USA-1987" TOTAL_1="94" TOTAL_2="97" VAR="0.1457190904438108" WEIGHT="5.026047317527974"/>
<DICH_DATA CI_END="2.3446304512096257" CI_START="0.5910085594521073" EFFECT_SIZE="1.1771561771561772" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.3700744011458413" LOG_CI_START="-0.228406229277967" LOG_EFFECT_SIZE="0.07083408593393713" ORDER="7156" O_E="0.0" SE="0.35155048483784457" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.12358774338972357" WEIGHT="7.301937786363911"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.038606035481737" CI_END="1.2315748733682395" CI_START="0.5252470371876329" DF="4" EFFECT_SIZE="0.8042891602597924" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="39" I2="20.612963747669486" ID="CMP-002.05.03" LOG_CI_END="0.09046081983099907" LOG_CI_START="-0.27963638868248775" LOG_EFFECT_SIZE="-0.09458778442574434" NO="3" P_CHI2="0.28335924057330564" P_Z="0.31642204426036247" STUDIES="5" TAU2="0.0" TOTAL_1="354" TOTAL_2="274" WEIGHT="23.617996004589877" Z="1.0018376069169501">
<NAME>Chronic hypertension</NAME>
<DICH_DATA CI_END="1.3270725639350585" CI_START="0.105966323034376" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12289467060744537" LOG_CI_START="-0.9748321351520076" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="7157" O_E="0.0" SE="0.644810159538427" STUDY_ID="STD-Brazil-1985" TOTAL_1="47" TOTAL_2="47" VAR="0.41578014184397166" WEIGHT="4.5388890668928745"/>
<DICH_DATA CI_END="1.2793318917912602" CI_START="0.3401282872818949" EFFECT_SIZE="0.6596491228070176" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.10698322632013381" LOG_CI_START="-0.4683572478097944" LOG_EFFECT_SIZE="-0.18068701074483032" ORDER="7158" O_E="0.0" SE="0.33795784248519845" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.11421550329725019" WEIGHT="10.545516717916868"/>
<DICH_DATA CI_END="170.95704985397572" CI_START="0.6220723646134377" EFFECT_SIZE="10.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.232887014752679" LOG_CI_START="-0.20615909163671586" LOG_EFFECT_SIZE="1.0133639615579815" ORDER="7159" O_E="0.0" SE="1.4327077563660757" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.052651515151515" WEIGHT="0.29283155270276606"/>
<DICH_DATA CI_END="3.6211056113868096" CI_START="0.27615875020475317" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5588411914211685" LOG_CI_START="-0.5588411914211685" LOG_EFFECT_SIZE="0.0" ORDER="7160" O_E="0.0" SE="0.6565321642986127" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.43103448275862066" WEIGHT="2.2694445334464373"/>
<DICH_DATA CI_END="1.9642496501313342" CI_START="0.36383364620577213" EFFECT_SIZE="0.8453757225433526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.29319668446117586" LOG_CI_START="-0.4390971412103305" LOG_EFFECT_SIZE="-0.07295022837457736" ORDER="7161" O_E="0.0" SE="0.43015301811234175" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18503161899115658" WEIGHT="5.97131413363093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3536365123944734" CI_END="1.2976767277468968" CI_START="0.7114093377204215" DF="6" EFFECT_SIZE="0.9608222215694345" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="68" I2="0.0" ID="CMP-002.05.04" LOG_CI_END="0.11316651616111492" LOG_CI_START="-0.14788043870908288" LOG_EFFECT_SIZE="-0.017356961273983968" NO="4" P_CHI2="0.7633298179475505" P_Z="0.7943738047878928" STUDIES="7" TAU2="0.0" TOTAL_1="484" TOTAL_2="460" WEIGHT="40.02250136463218" Z="0.26063524851290104">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="1.932006735256676" CI_START="0.29726269049790127" EFFECT_SIZE="0.7578347578347578" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.28600863609588756" LOG_CI_START="-0.5268595957654018" LOG_EFFECT_SIZE="-0.12042547983475708" ORDER="7162" O_E="0.0" SE="0.4774828231579635" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.22798984641089903" WEIGHT="5.1725651379201265"/>
<DICH_DATA CI_END="3.229845760329288" CI_START="0.21500854714921266" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5091817833102721" LOG_CI_START="-0.6675442754055219" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7163" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.4777777777777777" WEIGHT="2.150000084317677"/>
<DICH_DATA CI_END="3.4840772775713136" CI_START="0.5263279815622796" EFFECT_SIZE="1.3541666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.542087779185969" LOG_CI_START="-0.2787435406514321" LOG_EFFECT_SIZE="0.13167211926726838" ORDER="7164" O_E="0.0" SE="0.48216038045305265" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.23247863247863249" WEIGHT="3.2039216942773234"/>
<DICH_DATA CI_END="1.261814257395252" CI_START="0.5070833261549874" EFFECT_SIZE="0.7999031007751938" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.1009954302447171" LOG_CI_START="-0.2949206696294774" LOG_EFFECT_SIZE="-0.09696261969238013" ORDER="7165" O_E="0.0" SE="0.23256307688240377" STUDY_ID="STD-Italy-1998" TOTAL_1="129" TOTAL_2="127" VAR="0.054085584729010844" WEIGHT="18.297396550911902"/>
<DICH_DATA CI_END="136.45123367761124" CI_START="0.3734653508694201" EFFECT_SIZE="7.138613861386139" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1349774665501218" LOG_CI_START="-0.42774968467654884" LOG_EFFECT_SIZE="0.8536138909367865" ORDER="7166" O_E="0.0" SE="1.5053586143345372" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="2.266104557751198" WEIGHT="0.28089938465452224"/>
<DICH_DATA CI_END="2.2146684810856616" CI_START="0.5043033207724097" EFFECT_SIZE="1.0568181818181819" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.34530872486576064" LOG_CI_START="-0.29730817205822757" LOG_EFFECT_SIZE="0.024000276403766514" ORDER="7167" O_E="0.0" SE="0.37747634625809307" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.14248839198435975" WEIGHT="6.340035522009094"/>
<DICH_DATA CI_END="2.668214881201066" CI_START="0.45839113150591804" EFFECT_SIZE="1.1059322033898304" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4262208019918935" LOG_CI_START="-0.33876379325554473" LOG_EFFECT_SIZE="0.04372850436817436" ORDER="7168" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="0.20192057925839338" WEIGHT="4.577682990541532"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-05-20 18:41:10 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3">
<NAME>Any antihypertensive drug versus none (subgrouped by gestation at trial entry)</NAME>
<DICH_OUTCOME CHI2="26.96459309950352" CI_END="0.5957844050099786" CI_START="0.40104809405533387" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4888130522982616" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="242" I2="29.53722709670767" I2_Q="63.587361222894785" ID="CMP-003.01" LOG_CI_END="-0.22491086887316047" LOG_CI_START="-0.3968035432641052" LOG_EFFECT_SIZE="-0.3108572060686328" METHOD="MH" MODIFIED="2013-05-20 18:37:41 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.10548055639747844" P_Q="0.06416492328296919" P_Z="1.3513741021767654E-12" Q="5.492598359165111" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1336" TOTAL_2="1222" WEIGHT="100.0" Z="7.088945824922979">
<NAME>Severe hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.665188602563374" CI_END="0.8326642795830729" CI_START="0.47281544996064795" DF="6" EFFECT_SIZE="0.6274524173331627" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="101" I2="21.724039536437573" ID="CMP-003.01.01" LOG_CI_END="-0.07953006571603567" LOG_CI_START="-0.32530834066523834" LOG_EFFECT_SIZE="-0.202419203190637" NO="1" P_CHI2="0.2636728386489131" P_Z="0.0012448811494339494" STUDIES="7" TAU2="0.0" TOTAL_1="569" TOTAL_2="502" WEIGHT="41.17025456786852" Z="3.2283923232428955">
<NAME>Entry &lt; 32 weeks</NAME>
<DICH_DATA CI_END="1.4733985973056012" CI_START="0.30597037852147974" EFFECT_SIZE="0.6714285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.16832025206513437" LOG_CI_START="-0.5143206162222133" LOG_EFFECT_SIZE="-0.1730001820785394" ORDER="7169" O_E="0.0" SE="0.40098662515878386" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.16079027355623102" WEIGHT="5.529465567645235"/>
<DICH_DATA CI_END="1.3224589374430262" CI_START="0.6153541723895645" EFFECT_SIZE="0.9020979020979021" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" LOG_CI_END="0.12138219600494272" LOG_CI_START="-0.2108748503365684" LOG_EFFECT_SIZE="-0.04474632716581285" ORDER="7170" O_E="0.0" SE="0.1951694337199084" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.038091107858549716" WEIGHT="15.926797812357027"/>
<DICH_DATA CI_END="1.0938657367258307" CI_START="0.004509539483088448" EFFECT_SIZE="0.07023411371237458" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="0.0389640190929527" LOG_CI_START="-2.345867806273973" LOG_EFFECT_SIZE="-1.1534518935905105" ORDER="7171" O_E="0.0" SE="1.4008620193284582" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.9624143971970056" WEIGHT="3.550526116591623"/>
<DICH_DATA CI_END="0.8951643039341957" CI_START="0.20662144808217364" EFFECT_SIZE="0.43006993006993005" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.04809724430085871" LOG_CI_START="-0.6848245990784315" LOG_EFFECT_SIZE="-0.3664609216896451" ORDER="7172" O_E="0.0" SE="0.3740168000475848" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="123" VAR="0.13988856671783503" WEIGHT="8.660196310469132"/>
<DICH_DATA CI_END="4.099426132832591" CI_START="0.010939162996078491" EFFECT_SIZE="0.21176470588235294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6127230653081122" LOG_CI_START="-1.9610159065300856" LOG_EFFECT_SIZE="-0.6741464206109866" ORDER="7173" O_E="0.0" SE="1.5118270122711395" STUDY_ID="STD-UK-1990" TOTAL_1="16" TOTAL_2="17" VAR="2.28562091503268" WEIGHT="0.9805084067797218"/>
<DICH_DATA CI_END="3.699119357300525" CI_START="0.1201487169013067" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5680983446651372" LOG_CI_START="-0.9202808627764997" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7174" O_E="0.0" SE="0.8742813140471173" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.764367816091954" WEIGHT="1.21121626719848"/>
<DICH_DATA CI_END="1.2034709849825036" CI_START="0.22488329113438102" EFFECT_SIZE="0.5202312138728323" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.08043562413835074" LOG_CI_START="-0.6480428115172918" LOG_EFFECT_SIZE="-0.28380359368947056" ORDER="7175" O_E="0.0" SE="0.42791183913053826" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18310854206807967" WEIGHT="5.311544086827301"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3197208380365466" CI_START="0.061856000684717416" DF="0" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.12048207414354987" LOG_CI_START="-1.2086181628441013" LOG_EFFECT_SIZE="-0.5440680443502757" NO="2" P_CHI2="1.0" P_Z="0.10857634358020678" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="2.826171290129787" Z="1.6046250574486791">
<NAME>Entry &gt; 32 weeks</NAME>
<DICH_DATA CI_END="1.3197208380365462" CI_START="0.061856000684717444" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12048207414354972" LOG_CI_START="-1.208618162844101" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="7176" O_E="0.0" SE="0.7807200583588264" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="0.6095238095238094" WEIGHT="2.826171290129787"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.77728860534431" CI_END="0.527932731852978" CI_START="0.2987556950415268" DF="11" EFFECT_SIZE="0.3971434378658527" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="134" I2="13.909747679964982" ID="CMP-003.01.03" LOG_CI_END="-0.2774214108869972" LOG_CI_START="-0.5246838072102151" LOG_EFFECT_SIZE="-0.40105260904860623" MODIFIED="2013-05-20 18:37:41 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.30813081404931986" P_Z="2.0438120550844232E-10" STUDIES="12" TAU2="0.0" TOTAL_1="707" TOTAL_2="660" WEIGHT="56.003574142001696" Z="6.358012227735421">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="1.214567931047986" CI_START="0.16149936071047388" EFFECT_SIZE="0.4428904428904429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.08442181000508182" LOG_CI_START="-0.7918291924688724" LOG_EFFECT_SIZE="-0.35370369123189527" ORDER="7177" O_E="0.0" SE="0.5147141763656174" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.264930683351736" WEIGHT="4.4988032781657825"/>
<DICH_DATA CI_END="1.4103128933907758" CI_START="0.28142691019844857" EFFECT_SIZE="0.63" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.14931547634177364" LOG_CI_START="-0.5506343774346102" LOG_EFFECT_SIZE="-0.2006594505464183" ORDER="7178" O_E="0.0" SE="0.41115400891590376" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="20" TOTAL_2="21" VAR="0.16904761904761906" WEIGHT="3.938914690076358"/>
<DICH_DATA CI_END="0.7537090344788961" CI_START="0.17266719228262" EFFECT_SIZE="0.36075036075036077" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="-0.12279627894233291" LOG_CI_START="-0.7627901729372053" LOG_EFFECT_SIZE="-0.4427932259397691" MODIFIED="2013-05-20 18:37:41 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="742" O_E="0.0" SE="0.3759355813534565" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.14132756132756133" WEIGHT="7.511166650277823"/>
<DICH_DATA CI_END="0.890351646543475" CI_START="0.1797042782154134" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="7179" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.16666666666666669" WEIGHT="6.056081335992401"/>
<DICH_DATA CI_END="1.191211707520663" CI_START="0.13431701433913634" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.07598895311772173" LOG_CI_START="-0.871868970461797" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="7180" O_E="0.0" SE="0.5567764362830021" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.30999999999999994" WEIGHT="4.037387557328267"/>
<DICH_DATA CI_END="0.5456419852342921" CI_START="0.05707381278355769" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.2630922196308351" LOG_CI_START="-1.2435631136863878" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="7181" O_E="0.0" SE="0.575933456577432" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3316993464052287" WEIGHT="7.059660528813997"/>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7182" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="0.20186937786641335"/>
<DICH_DATA CI_END="1.2823063840978146" CI_START="0.00419990213254197" EFFECT_SIZE="0.07338638373121131" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10799180445385774" LOG_CI_START="-2.376760829552621" LOG_EFFECT_SIZE="-1.1343845125493814" ORDER="7183" O_E="0.0" SE="1.459555996939311" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="2.130303708201506" WEIGHT="2.6860501925519236"/>
<DICH_DATA CI_END="2.761015458222625" CI_START="0.4743339859607909" EFFECT_SIZE="1.144396551724138" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4410688381503073" LOG_CI_START="-0.32391575709713094" LOG_EFFECT_SIZE="0.058576540526588186" ORDER="7184" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-Sweden-1995" TOTAL_1="58" TOTAL_2="59" VAR="0.20192057925839338" WEIGHT="3.202303977094557"/>
<DICH_DATA CI_END="0.7465699182036291" CI_START="0.06694355152990397" EFFECT_SIZE="0.22355769230769232" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.1269295132328718" LOG_CI_START="-1.1742912509127434" LOG_EFFECT_SIZE="-0.6506103820728076" ORDER="7185" O_E="0.0" SE="0.615225469237373" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.37850237799834574" WEIGHT="5.331914996344632"/>
<DICH_DATA CI_END="0.9183944157552488" CI_START="0.13520589135855415" EFFECT_SIZE="0.3523809523809524" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.03697076564084711" LOG_CI_START="-0.8690043843650392" LOG_EFFECT_SIZE="-0.45298757500294307" ORDER="7186" O_E="0.0" SE="0.4887406662714275" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.23886743886743886" WEIGHT="5.887856854437056"/>
<DICH_DATA CI_END="0.97210968055073" CI_START="0.13697733797118744" EFFECT_SIZE="0.36490683229813664" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.012284732017487168" LOG_CI_START="-0.8633512781586645" LOG_EFFECT_SIZE="-0.43781800508807583" ORDER="7187" O_E="0.0" SE="0.49992070205067496" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.24992070833883975" WEIGHT="5.591564703052482"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.76131289125792" CI_END="1.0814358835551692" CI_START="0.7966725673334994" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9281973398790087" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="255" I2="34.83665735731317" I2_Q="55.27189411037513" ID="CMP-003.02" LOG_CI_END="0.034000775977027914" LOG_CI_START="-0.0987201370967698" LOG_EFFECT_SIZE="-0.032359680559870964" METHOD="MH" MODIFIED="2013-05-20 18:38:36 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.051937478310078" P_Q="0.10691409019067988" P_Z="0.33920007359547166" Q="4.4714614227917036" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1476" TOTAL_2="1375" WEIGHT="100.0" Z="0.9557470180046462">
<NAME>Proteinuria/pre-eclampsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.479405389747289" CI_END="1.3621454825508652" CI_START="0.8087144025049386" DF="7" EFFECT_SIZE="1.0495649908633216" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="86" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.134223494430566" LOG_CI_START="-0.09220482241093364" LOG_EFFECT_SIZE="0.02100933600981618" NO="1" P_CHI2="0.48501375059091667" P_Z="0.7160718029943671" STUDIES="8" TAU2="0.0" TOTAL_1="609" TOTAL_2="538" WEIGHT="34.39154995963687" Z="0.36371371295547394">
<NAME>Entry &lt; 32 weeks</NAME>
<DICH_DATA CI_END="1.3583113580225423" CI_START="0.184052057375089" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13299933222130308" LOG_CI_START="-0.7350593235492654" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7188" O_E="0.0" SE="0.5099019513592785" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.26" WEIGHT="3.8601194029451373"/>
<DICH_DATA CI_END="1.5842961150946966" CI_START="0.6384891163205925" EFFECT_SIZE="1.005761316872428" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.1998363572614902" LOG_CI_START="-0.19484650131708134" LOG_EFFECT_SIZE="0.002494927972204436" ORDER="7189" O_E="0.0" SE="0.23183866484071194" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.05374916651512396" WEIGHT="10.195750162126831"/>
<DICH_DATA CI_END="2.5880090016834325" CI_START="0.8937770351034582" EFFECT_SIZE="1.520888888888889" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" LOG_CI_END="0.41296578257419125" LOG_CI_START="-0.048770808386753274" LOG_EFFECT_SIZE="0.182097487093719" ORDER="7190" O_E="0.0" SE="0.2712263591634463" STUDY_ID="STD-Italy-1998" TOTAL_1="125" TOTAL_2="118" VAR="0.07356373790505877" WEIGHT="7.148369264713217"/>
<DICH_DATA CI_END="2.5234570593395587" CI_START="0.04403130645709946" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.4019959189169215" LOG_CI_START="-1.3562384283562463" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7191" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="1.4475447761044264"/>
<DICH_DATA CI_END="4.0885479522838075" CI_START="0.40201448264565726" EFFECT_SIZE="1.2820512820512822" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6115690957141797" LOG_CI_START="-0.3957583010951405" LOG_EFFECT_SIZE="0.10790539730951963" ORDER="7192" O_E="0.0" SE="0.5917090992368278" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="0.3501196581196581" WEIGHT="1.8662560749776076"/>
<DICH_DATA CI_END="3.0199847904557613" CI_START="0.03679194394033447" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48000475572610146" LOG_CI_START="-1.4342472651654263" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7193" O_E="0.0" SE="1.124441112772009" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="1.2643678160919538" WEIGHT="1.1580358208835413"/>
<DICH_DATA CI_END="3.3138380098347344" CI_START="0.40175800470462913" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5203312750083746" LOG_CI_START="-0.3960354615106857" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="7194" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.28974358974358977" WEIGHT="1.6058096716251773"/>
<DICH_DATA CI_END="1.9930163928537483" CI_START="0.6235458309350601" EFFECT_SIZE="1.1147811725846408" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.29951087085133893" LOG_CI_START="-0.2051316201474312" LOG_EFFECT_SIZE="0.04718962535195388" ORDER="7195" O_E="0.0" SE="0.2964294972332956" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.08787044682998439" WEIGHT="7.109664786260931"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06897111152687391" CI_END="0.9649155696634765" CI_START="0.11729841669574545" DF="1" EFFECT_SIZE="0.3364269141531323" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="-0.015510685861827803" LOG_CI_START="-0.9307078499896855" LOG_EFFECT_SIZE="-0.47310926792575664" NO="2" P_CHI2="0.7928407773088939" P_Z="0.04272395434985187" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="62" WEIGHT="4.799167680776984" Z="2.0263985996290717">
<NAME>Entry &gt; 32 weeks</NAME>
<DICH_DATA CI_END="3.283656704405851" CI_START="0.055935649162505596" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.516357746749645" LOG_CI_START="-1.252311317338834" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="7196" O_E="0.0" SE="1.0389249632986395" STUDY_ID="STD-Australia-2001" TOTAL_1="7" TOTAL_2="9" VAR="1.0793650793650793" WEIGHT="1.0132813432730985"/>
<DICH_DATA CI_END="1.06832246368607" CI_START="0.09098117388503381" EFFECT_SIZE="0.31176470588235294" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.028702360428301738" LOG_CI_START="-1.0410484639832713" LOG_EFFECT_SIZE="-0.5061730517774848" ORDER="7197" O_E="0.0" SE="0.6283769296113413" STUDY_ID="STD-UK-1983" TOTAL_1="51" TOTAL_2="53" VAR="0.3948575656677766" WEIGHT="3.785886337503885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.438286447300023" CI_END="1.0982715706944162" CI_START="0.7478173402105776" DF="12" EFFECT_SIZE="0.906259634335322" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="156" I2="46.51998035507766" ID="CMP-003.02.03" LOG_CI_END="0.040709741818130474" LOG_CI_START="-0.1262044687479165" LOG_EFFECT_SIZE="-0.04274736346489303" MODIFIED="2013-05-20 18:38:36 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.03289140055668027" P_Z="0.31542275897899197" STUDIES="13" TAU2="0.0" TOTAL_1="809" TOTAL_2="775" WEIGHT="60.80928235958615" Z="1.0039084454355809">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="2.645622079552134" CI_START="0.35884770476159167" EFFECT_SIZE="0.9743589743589743" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42252780640959303" LOG_CI_START="-0.44508982722897117" LOG_EFFECT_SIZE="-0.011281010409689058" ORDER="7198" O_E="0.0" SE="0.5096428927758443" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.2597358781569308" WEIGHT="2.737175576633825"/>
<DICH_DATA CI_END="0.8648180115377374" CI_START="0.21669620926622504" EFFECT_SIZE="0.4329004329004329" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="-0.06307527392293309" LOG_CI_START="-0.6641486858613557" LOG_EFFECT_SIZE="-0.36361197989214433" MODIFIED="2013-05-20 18:38:36 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="743" O_E="0.0" SE="0.35307349753400447" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.12466089466089465" WEIGHT="7.181376499975786"/>
<DICH_DATA CI_END="1.394881675466763" CI_START="0.024875366572638044" EFFECT_SIZE="0.18627450980392157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14453736899216438" LOG_CI_START="-1.6042305106103416" LOG_EFFECT_SIZE="-0.7298465708090885" ORDER="7199" O_E="0.0" SE="1.0272349090191268" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.0552115583075337" WEIGHT="2.187400995002245"/>
<DICH_DATA CI_END="2.9127186917646344" CI_START="0.03556141346709918" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4642985428103939" LOG_CI_START="-1.4490209853631926" LOG_EFFECT_SIZE="-0.4923612212763993" ORDER="7200" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Israel-1992" TOTAL_1="29" TOTAL_2="28" VAR="1.2631362889983577" WEIGHT="1.1783522387937788"/>
<DICH_DATA CI_END="2.6978801705038147" CI_START="0.37066138479132504" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.43102265606802675" LOG_CI_START="-0.43102265606802675" LOG_EFFECT_SIZE="0.0" ORDER="7201" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.2564102564102564" WEIGHT="2.3160716417670826"/>
<DICH_DATA CI_END="4.174737638310471" CI_START="0.6049216305326484" EFFECT_SIZE="1.5891472868217054" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6206291874090091" LOG_CI_START="-0.21830088589599841" LOG_EFFECT_SIZE="0.20116415075650532" ORDER="7202" O_E="0.0" SE="0.4927916778301993" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.24284363773870293" WEIGHT="2.371216204666299"/>
<DICH_DATA CI_END="4.028818448809723" CI_START="1.061595617073956" EFFECT_SIZE="2.068085106382979" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.605177697158387" LOG_CI_START="0.025959116822727186" LOG_EFFECT_SIZE="0.31556840699055716" ORDER="7203" O_E="0.0" SE="0.3402358612673805" STUDY_ID="STD-Sweden-1995" TOTAL_1="47" TOTAL_2="54" VAR="0.11576044129235619" WEIGHT="3.5925863750182465"/>
<DICH_DATA CI_END="1.44433264431343" CI_START="0.4592966054898607" EFFECT_SIZE="0.8144796380090498" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.15966722713427386" LOG_CI_START="-0.3379067642978832" LOG_EFFECT_SIZE="-0.08911976858180463" ORDER="7204" O_E="0.0" SE="0.2922774255982299" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="0.08542609351432881" WEIGHT="6.824691104407003"/>
<DICH_DATA CI_END="1.325960843975488" CI_START="0.139806606855715" EFFECT_SIZE="0.4305555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.12253069941078948" LOG_CI_START="-0.854472304604781" LOG_EFFECT_SIZE="-0.36597080259699577" ORDER="7205" O_E="0.0" SE="0.5738964008016139" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.3293570788530466" WEIGHT="3.5292520255498396"/>
<DICH_DATA CI_END="1.0030463333503243" CI_START="0.5287431144942136" EFFECT_SIZE="0.7282539682539683" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="45" LOG_CI_END="0.0013209946890276583" LOG_CI_START="-0.276755275137731" LOG_EFFECT_SIZE="-0.13771714022435164" ORDER="7206" O_E="0.0" SE="0.1633433773959736" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.02668105893912346" WEIGHT="16.888022387884977"/>
<DICH_DATA CI_END="1.7570972141948125" CI_START="0.5078480840975841" EFFECT_SIZE="0.9446366782006921" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.24479579019217332" LOG_CI_START="-0.29426618162375695" LOG_EFFECT_SIZE="-0.024735195715791802" ORDER="7207" O_E="0.0" SE="0.31664767064447336" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.10026574732457087" WEIGHT="5.871444776058657"/>
<DICH_DATA CI_END="4.49416039642105" CI_START="0.6452514414860213" EFFECT_SIZE="1.7028985507246377" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6526485683139724" LOG_CI_START="-0.190271016572973" LOG_EFFECT_SIZE="0.23118877587049977" ORDER="7208" O_E="0.0" SE="0.49513513668183046" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.24515880357693495" WEIGHT="2.2911676456190495"/>
<DICH_DATA CI_END="3.384593215279071" CI_START="0.7718834398672652" EFFECT_SIZE="1.616326530612245" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5295064795276351" LOG_CI_START="-0.11244827640567534" LOG_EFFECT_SIZE="0.20852910156097987" ORDER="7209" O_E="0.0" SE="0.3770874013625181" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.14219490826633682" WEIGHT="3.8405248882093757"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.239345396230442" CI_END="1.0218516327002856" CI_START="0.49463043485945174" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="0.710942274340458" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.009387843179175827" LOG_CI_START="-0.30571916479464983" LOG_EFFECT_SIZE="-0.148165660807737" METHOD="MH" MODIFIED="2013-05-20 18:39:25 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.9238133124655088" P_Q="0.8860110195636306" P_Z="0.06530283454220243" Q="0.2420517909296233" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1682" TOTAL_2="1548" WEIGHT="100.0" Z="1.8431793110286163">
<NAME>Total reported fetal or neonatal death (including miscarriage)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.193151221321117" CI_END="1.1404046151203242" CI_START="0.3865398387170217" DF="7" EFFECT_SIZE="0.6639366054080444" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.05705896619374863" LOG_CI_START="-0.4128057388909691" LOG_EFFECT_SIZE="-0.17787338634861025" NO="1" P_CHI2="0.6364051784227164" P_Z="0.1378249339609769" STUDIES="10" TAU2="0.0" TOTAL_1="689" TOTAL_2="587" WEIGHT="47.531853317589615" Z="1.4839396416830102">
<NAME>Entry &lt; 32 weeks</NAME>
<DICH_DATA CI_END="4.384751004320472" CI_START="0.35634862697115655" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6419449362379852" LOG_CI_START="-0.44812491022187245" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="7210" O_E="0.0" SE="0.6403124237432849" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.41" WEIGHT="6.250105774212234"/>
<DICH_DATA CI_END="8.432346492507785" CI_START="0.014360629336101962" EFFECT_SIZE="0.34798534798534797" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9259484437760184" LOG_CI_START="-1.8428265272798348" LOG_EFFECT_SIZE="-0.4584390417519083" ORDER="7211" O_E="0.0" SE="1.626392123655357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="2.645151339888182" WEIGHT="2.2933855865052957"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7212" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.425266203926439" CI_START="0.28932007166963136" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.38475941491815685" LOG_CI_START="-0.5386214359925852" LOG_EFFECT_SIZE="-0.0769310105372141" ORDER="7213" O_E="0.0" SE="0.5423984826338988" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.2941961139635558" WEIGHT="11.063405623318209"/>
<DICH_DATA CI_END="2.730529574091466" CI_START="0.25432591942371036" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.4362468846969332" LOG_CI_START="-0.5946093767921828" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7214" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.3666666666666667" WEIGHT="7.031368995988764"/>
<DICH_DATA CI_END="0.9226155353964339" CI_START="0.015273638959593142" EFFECT_SIZE="0.11870845204178537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.034979236829268255" LOG_CI_START="-1.816057479525592" LOG_EFFECT_SIZE="-0.9255183581774301" ORDER="7215" O_E="0.0" SE="1.0462141762393122" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="1.0945641025641026" WEIGHT="13.597854091416286"/>
<DICH_DATA CI_END="63.82881484401465" CI_START="0.12392766917779852" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050167806434498" LOG_CI_START="-0.9068317184046119" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="7216" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.5374999999999996" WEIGHT="0.8064652611886753"/>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7217" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="2.343789665329588"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7218" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.483281901280379" CI_START="0.12935631556800872" EFFECT_SIZE="0.7615384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6515960474362559" LOG_CI_START="-0.8882123628548295" LOG_EFFECT_SIZE="-0.11830815770928688" ORDER="7219" O_E="0.0" SE="0.9044910823795435" STUDY_ID="STD-USA-1990" TOTAL_1="195" TOTAL_2="99" VAR="0.8181041181041181" WEIGHT="4.145478319630564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.368170063591446" CI_START="0.046570804769315265" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.7298262658251345" LOG_CI_START="-1.3318862571530972" LOG_EFFECT_SIZE="-0.3010299956639812" NO="2" P_CHI2="1.0" P_Z="0.5670866141370015" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="3.125052887106117" Z="0.572347447271999">
<NAME>Entry &gt; 32 weeks</NAME>
<DICH_DATA CI_END="5.368170063591449" CI_START="0.046570804769315244" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7298262658251348" LOG_CI_START="-1.3318862571530974" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7220" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="3.125052887106117"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.121280553580408" CI_END="1.2693514273542688" CI_START="0.4665821106348441" DF="9" EFFECT_SIZE="0.7695821386390843" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.10358187570504351" LOG_CI_START="-0.33107191663851926" LOG_EFFECT_SIZE="-0.11374502046673783" MODIFIED="2013-05-20 18:39:25 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.8236103518220419" P_Z="0.3049810787439209" STUDIES="16" TAU2="0.0" TOTAL_1="933" TOTAL_2="901" WEIGHT="49.34309379530427" Z="1.0258101848533392">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="3.7796994558212216" CI_START="0.11163443866495346" EFFECT_SIZE="0.6495726495726496" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5774572681262113" LOG_CI_START="-0.952201807056952" LOG_EFFECT_SIZE="-0.18737226946537028" ORDER="7221" O_E="0.0" SE="0.8985293126971309" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.8073549257759783" WEIGHT="4.7484569843041"/>
<DICH_DATA CI_END="1.6635268505992704" CI_START="0.15333447281592205" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.22102981510744976" LOG_CI_START="-0.8143601956305119" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:39:25 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="744" O_E="0.0" SE="0.608193217570691" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.3698989898989899" WEIGHT="10.381887108171329"/>
<DICH_DATA CI_END="22.509252726006434" CI_START="0.22197715105018606" EFFECT_SIZE="2.235294117647059" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3523610773035457" LOG_CI_START="-0.6536917268264734" LOG_EFFECT_SIZE="0.34933467523853623" ORDER="7222" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.388544891640867" WEIGHT="1.475719418911222"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7223" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1986a" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7224" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.7812632217765293"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7225" O_E="0.0" SE="0.0" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.286031560619402" CI_START="0.21796282465092698" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.359082221907135" LOG_CI_START="-0.6616175725684332" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="7226" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="9.107296985280684"/>
<DICH_DATA CI_END="7.824262991946792" CI_START="0.01420084054248603" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8934434396874849" LOG_CI_START="-1.84768594912681" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7227" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="2.343789665329588"/>
<DICH_DATA CI_END="26.946306300069608" CI_START="0.30365054825448545" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.430499242122451" LOG_CI_START="-0.517625930402828" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="7228" O_E="0.0" SE="1.1443383697164793" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="1.3095103044053695" WEIGHT="1.5997294541138456"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7229" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1995" TOTAL_1="54" TOTAL_2="57" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6001382903696388" CI_START="0.23666593514526177" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.20415751774911287" LOG_CI_START="-0.6258642483788992" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="7230" O_E="0.0" SE="0.4875588940976005" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="0.23771367521367523" WEIGHT="14.625247511656628"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7231" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7232" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.0150081559399045" CI_START="0.012082077255360984" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7002716436529105" LOG_CI_START="-1.9178583916267722" LOG_EFFECT_SIZE="-0.6087933739869308" ORDER="7233" O_E="0.0" SE="1.5379025426759756" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="2.3651442307692307" WEIGHT="3.5022144424465105"/>
<DICH_DATA CI_END="73.49844303024413" CI_START="0.1248408162074388" EFFECT_SIZE="3.029126213592233" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8662781392129644" LOG_CI_START="-0.9036434005864231" LOG_EFFECT_SIZE="0.48131736931327057" ORDER="7234" O_E="0.0" SE="1.6270656238109158" STUDY_ID="STD-USA-1987" TOTAL_1="102" TOTAL_2="103" VAR="2.6473425441872043" WEIGHT="0.7774890033138407"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7235" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.53368752102263" CI_END="1.1005465123782894" CI_START="0.8456150020125109" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9646961393514691" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="279" I2="9.873299684617722" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.0416084018574428" LOG_CI_START="-0.07282732083608795" LOG_EFFECT_SIZE="-0.015609459489322554" METHOD="MH" MODIFIED="2013-05-20 18:40:16 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" P_CHI2="0.34267231643694795" P_Q="0.7307200055042984" P_Z="0.5928623042363097" Q="0.11845160784043976" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1135" TOTAL_2="1006" WEIGHT="100.0" Z="0.5346927986664206">
<NAME>Preterm birth (&lt; 37 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.0593070658981123" CI_END="1.2020875567194207" CI_START="0.8159385155807278" DF="5" EFFECT_SIZE="0.9903683843033905" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="120" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.0799361016228206" LOG_CI_START="-0.08834256593983365" LOG_EFFECT_SIZE="-0.004203232158506522" NO="1" P_CHI2="0.6908427664484974" P_Z="0.9220028015874094" STUDIES="6" TAU2="0.0" TOTAL_1="543" TOTAL_2="450" WEIGHT="42.75756222280144" Z="0.09791120608042675">
<NAME>Entry &lt; 32 weeks</NAME>
<DICH_DATA CI_END="2.059747840257095" CI_START="0.5978806659848787" EFFECT_SIZE="1.1097222222222223" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.31381405615168917" LOG_CI_START="-0.22338549038624325" LOG_EFFECT_SIZE="0.04521428288272295" ORDER="7236" O_E="0.0" SE="0.31555367281702357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.09957412042831316" WEIGHT="5.482800025869021"/>
<DICH_DATA CI_END="4.346977235005655" CI_START="0.44375947730871956" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.6381873658091225" LOG_CI_START="-0.3528523586716594" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="7237" O_E="0.0" SE="0.5821416398857661" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.3388888888888889" WEIGHT="1.4835811834704409"/>
<DICH_DATA CI_END="1.1143643270860302" CI_START="0.7286846217729761" EFFECT_SIZE="0.9011216056670602" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" LOG_CI_END="0.047027201049018336" LOG_CI_START="-0.13746039576903324" LOG_EFFECT_SIZE="-0.04521659736000748" ORDER="7238" O_E="0.0" SE="0.10836892759925609" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.011743824469012808" WEIGHT="27.28235691033318"/>
<DICH_DATA CI_END="1.6600512529016966" CI_START="0.26772935092671085" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7239" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.21666666666666667" WEIGHT="2.6271750123955724"/>
<DICH_DATA CI_END="4.819063550418095" CI_START="0.5526849712884415" EFFECT_SIZE="1.632" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6829626535089109" LOG_CI_START="-0.2575223446732263" LOG_EFFECT_SIZE="0.2127201544178423" ORDER="7240" O_E="0.0" SE="0.552445543408011" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.30519607843137253" WEIGHT="1.734108919072985"/>
<DICH_DATA CI_END="2.5395003843815207" CI_START="0.5802272219481015" EFFECT_SIZE="1.2138728323699421" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.4047482828999033" LOG_CI_START="-0.23640189968965558" LOG_EFFECT_SIZE="0.08417319160512383" ORDER="7241" O_E="0.0" SE="0.3766147909976962" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.14183870079823838" WEIGHT="4.147540171660235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Entry &gt; 32 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.735764201665274" CI_END="1.1310872202307984" CI_START="0.7903972958717741" DF="8" EFFECT_SIZE="0.9455201109788965" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="159" I2="37.184766667131335" ID="CMP-003.04.03" LOG_CI_END="0.05349609546872532" LOG_CI_START="-0.10215455423770535" LOG_EFFECT_SIZE="-0.02432922938449003" MODIFIED="2013-05-20 18:40:16 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.12127039433641229" P_Z="0.5400676148023464" STUDIES="9" TAU2="0.0" TOTAL_1="592" TOTAL_2="556" WEIGHT="57.24243777719857" Z="0.6127107526393318">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="1.5787217430117375" CI_START="0.3712459185862139" EFFECT_SIZE="0.7655677655677655" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.19830559034793077" LOG_CI_START="-0.43033831220733487" LOG_EFFECT_SIZE="-0.11601636092970206" ORDER="7242" O_E="0.0" SE="0.3692685401984678" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.13635925478030742" WEIGHT="4.967749114347991"/>
<DICH_DATA CI_END="0.722995814123863" CI_START="0.21342480718015033" EFFECT_SIZE="0.39281705948372614" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="-0.14086421710127925" LOG_CI_START="-0.6707551022719189" LOG_EFFECT_SIZE="-0.40580965968659916" MODIFIED="2013-05-20 18:40:16 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="745" O_E="0.0" SE="0.3112605289514186" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.09688311688311688" WEIGHT="8.37874876436494"/>
<DICH_DATA CI_END="1.6694078925301565" CI_START="0.7128770925027845" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22256246240243016" LOG_CI_START="-0.14698534062363067" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="7243" O_E="0.0" SE="0.2170742087886355" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.04712121212121212" WEIGHT="7.706380036360346"/>
<DICH_DATA CI_END="5.143571011393654" CI_START="0.49041635546458573" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7112647400184975" LOG_CI_START="-0.3094350544570707" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="7244" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="1.3611268635649443"/>
<DICH_DATA CI_END="1.8452362465144543" CI_START="0.4389681817328505" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.26605197699335337" LOG_CI_START="-0.3575669581147036" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="7245" O_E="0.0" SE="0.36631684944598736" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.13418803418803418" WEIGHT="3.50290001652743"/>
<DICH_DATA CI_END="1.839351437699459" CI_START="0.6536748364081058" EFFECT_SIZE="1.0965116279069766" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.2646647161177475" LOG_CI_START="-0.1846382331302263" LOG_EFFECT_SIZE="0.040013241493760614" ORDER="7246" O_E="0.0" SE="0.26392277647372825" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.06965523194160152" WEIGHT="7.172604795746642"/>
<DICH_DATA CI_END="1.4478220167842517" CI_START="0.38460668816655885" EFFECT_SIZE="0.746218487394958" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.16071517658529264" LOG_CI_START="-0.41498316781315214" LOG_EFFECT_SIZE="-0.12713399561392974" ORDER="7247" O_E="0.0" SE="0.33816805725241145" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.11435763494587023" WEIGHT="5.789515305093947"/>
<DICH_DATA CI_END="1.9858834006540402" CI_START="0.45467418436677676" EFFECT_SIZE="0.9502262443438914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2979537457005959" LOG_CI_START="-0.34229970360297884" LOG_EFFECT_SIZE="-0.02217297895119145" ORDER="7248" O_E="0.0" SE="0.37608804542660773" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.14144221791280615" WEIGHT="4.074425808697695"/>
<DICH_DATA CI_END="1.640730612375623" CI_START="0.8883935633157071" EFFECT_SIZE="1.2073170731707317" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="41" LOG_CI_END="0.2150372811367737" LOG_CI_START="-0.0513945967091073" LOG_EFFECT_SIZE="0.0818213422138332" ORDER="7249" O_E="0.0" SE="0.15650340390573614" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.024493315434081987" WEIGHT="14.288987072494633"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.442388292206317" CI_END="1.1702163995951986" CI_START="0.7986677038366341" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9667543870377162" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="165" I2="22.26618866840305" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.06826618008797396" LOG_CI_START="-0.09763387701628536" LOG_EFFECT_SIZE="-0.014683848464155694" METHOD="MH" MODIFIED="2013-05-20 18:41:10 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.17972657327138897" P_Q="0.3933489784758446" P_Z="0.7286261501800338" Q="1.8661164513779334" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1360" TOTAL_2="1226" WEIGHT="100.0" Z="0.34695363758798903">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.211298723664425" CI_END="1.111733032154064" CI_START="0.6279403626717399" DF="9" EFFECT_SIZE="0.8355250106400023" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="81" I2="11.862337558074485" ID="CMP-003.05.01" LOG_CI_END="0.04600050974400386" LOG_CI_START="-0.20208160051829252" LOG_EFFECT_SIZE="-0.07804054538714436" NO="1" P_CHI2="0.33365194107518936" P_Z="0.2175335691971445" STUDIES="10" TAU2="0.0" TOTAL_1="642" TOTAL_2="543" WEIGHT="48.93959693659606" Z="1.233113166692639">
<NAME>Entry &lt; 32 weeks</NAME>
<DICH_DATA CI_END="1.3270725639350585" CI_START="0.105966323034376" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12289467060744537" LOG_CI_START="-0.9748321351520076" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="7250" O_E="0.0" SE="0.644810159538427" STUDY_ID="STD-Brazil-1985" TOTAL_1="47" TOTAL_2="47" VAR="0.41578014184397166" WEIGHT="4.5388890668928745"/>
<DICH_DATA CI_END="1.2793318917912602" CI_START="0.3401282872818949" EFFECT_SIZE="0.6596491228070176" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.10698322632013381" LOG_CI_START="-0.4683572478097944" LOG_EFFECT_SIZE="-0.18068701074483032" ORDER="7251" O_E="0.0" SE="0.33795784248519845" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.11421550329725019" WEIGHT="10.545516717916868"/>
<DICH_DATA CI_END="3.4840772775713136" CI_START="0.5263279815622796" EFFECT_SIZE="1.3541666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.542087779185969" LOG_CI_START="-0.2787435406514321" LOG_EFFECT_SIZE="0.13167211926726838" ORDER="7252" O_E="0.0" SE="0.48216038045305265" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.23247863247863249" WEIGHT="3.2039216942773234"/>
<DICH_DATA CI_END="1.261814257395252" CI_START="0.5070833261549874" EFFECT_SIZE="0.7999031007751938" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.1009954302447171" LOG_CI_START="-0.2949206696294774" LOG_EFFECT_SIZE="-0.09696261969238013" ORDER="7253" O_E="0.0" SE="0.23256307688240377" STUDY_ID="STD-Italy-1998" TOTAL_1="129" TOTAL_2="127" VAR="0.054085584729010844" WEIGHT="18.297396550911902"/>
<DICH_DATA CI_END="3.565944608602859" CI_START="0.05265863561782842" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.552174592803172" LOG_CI_START="-1.2785303976288234" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="7254" O_E="0.0" SE="1.0753651735156091" STUDY_ID="STD-South-Africa-1991" TOTAL_1="10" TOTAL_2="13" VAR="1.1564102564102563" WEIGHT="1.4800725218128938"/>
<DICH_DATA CI_END="136.45123367761124" CI_START="0.3734653508694201" EFFECT_SIZE="7.138613861386139" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1349774665501218" LOG_CI_START="-0.42774968467654884" LOG_EFFECT_SIZE="0.8536138909367865" ORDER="7255" O_E="0.0" SE="1.5053586143345372" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="2.266104557751198" WEIGHT="0.28089938465452224"/>
<DICH_DATA CI_END="170.95704985397572" CI_START="0.6220723646134377" EFFECT_SIZE="10.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.232887014752679" LOG_CI_START="-0.20615909163671586" LOG_EFFECT_SIZE="1.0133639615579815" ORDER="7256" O_E="0.0" SE="1.4327077563660757" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.052651515151515" WEIGHT="0.29283155270276606"/>
<DICH_DATA CI_END="3.6211056113868096" CI_START="0.27615875020475317" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5588411914211685" LOG_CI_START="-0.5588411914211685" LOG_EFFECT_SIZE="0.0" ORDER="7257" O_E="0.0" SE="0.6565321642986127" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.43103448275862066" WEIGHT="2.2694445334464373"/>
<DICH_DATA CI_END="2.328896816412874" CI_START="0.007555867021765305" EFFECT_SIZE="0.1326530612244898" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3671502472056924" LOG_CI_START="-2.1217156939770083" LOG_EFFECT_SIZE="-0.877282723385658" ORDER="7258" O_E="0.0" SE="1.4619721739358231" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="2.137362637362637" WEIGHT="2.059310780349545"/>
<DICH_DATA CI_END="1.9642496501313342" CI_START="0.36383364620577213" EFFECT_SIZE="0.8453757225433526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.29319668446117586" LOG_CI_START="-0.4390971412103305" LOG_EFFECT_SIZE="-0.07295022837457736" ORDER="7259" O_E="0.0" SE="0.43015301811234175" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18503161899115658" WEIGHT="5.97131413363093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6682148812010666" CI_START="0.458391131505918" DF="0" EFFECT_SIZE="1.1059322033898304" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.42622080199189355" LOG_CI_START="-0.3387637932555448" LOG_EFFECT_SIZE="0.04372850436817436" NO="2" P_CHI2="1.0" P_Z="0.8227003039431082" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="58" WEIGHT="4.577682990541532" Z="0.22407325374101691">
<NAME>Entry &gt; 32 weeks</NAME>
<DICH_DATA CI_END="2.668214881201066" CI_START="0.45839113150591804" EFFECT_SIZE="1.1059322033898304" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4262208019918935" LOG_CI_START="-0.33876379325554473" LOG_EFFECT_SIZE="0.04372850436817436" ORDER="7260" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="0.20192057925839338" WEIGHT="4.577682990541532"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.040467606595278" CI_END="1.428978821727548" CI_START="0.8332852900865977" DF="8" EFFECT_SIZE="1.0912135592957248" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="76" I2="38.65250663286061" ID="CMP-003.05.03" LOG_CI_END="0.15502579234938965" LOG_CI_START="-0.0792062846697338" LOG_EFFECT_SIZE="0.03790975383982792" MODIFIED="2013-05-20 18:41:10 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.11046492513921702" P_Z="0.525801221196543" STUDIES="9" TAU2="0.0" TOTAL_1="659" TOTAL_2="625" WEIGHT="46.482720072862406" Z="0.6344284961685713">
<NAME>Unclassified/mixed</NAME>
<DICH_DATA CI_END="1.932006735256676" CI_START="0.29726269049790127" EFFECT_SIZE="0.7578347578347578" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.28600863609588756" LOG_CI_START="-0.5268595957654018" LOG_EFFECT_SIZE="-0.12042547983475708" ORDER="7261" O_E="0.0" SE="0.4774828231579635" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.22798984641089903" WEIGHT="5.1725651379201265"/>
<DICH_DATA CI_END="3.229845760329288" CI_START="0.21500854714921266" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5091817833102721" LOG_CI_START="-0.6675442754055219" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7262" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.4777777777777777" WEIGHT="2.150000084317677"/>
<DICH_DATA CI_END="0.9513082570593288" CI_START="0.3546043295942168" EFFECT_SIZE="0.5808080808080808" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.02167873369607392" LOG_CI_START="-0.4502559661197649" LOG_EFFECT_SIZE="-0.23596734990791945" MODIFIED="2013-05-20 18:41:10 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="746" O_E="0.0" SE="0.2517483878171916" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.06337725076855512" WEIGHT="15.078859651758208"/>
<DICH_DATA CI_END="4.885581830333628" CI_START="0.4186942807224805" EFFECT_SIZE="1.430232558139535" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6889162918329629" LOG_CI_START="-0.3781029714413025" LOG_EFFECT_SIZE="0.15540666019583024" ORDER="7263" O_E="0.0" SE="0.626772397077841" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.3928436377387029" WEIGHT="2.3234789270999237"/>
<DICH_DATA CI_END="2.2146684810856616" CI_START="0.5043033207724097" EFFECT_SIZE="1.0568181818181819" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.34530872486576064" LOG_CI_START="-0.29730817205822757" LOG_EFFECT_SIZE="0.024000276403766514" ORDER="7264" O_E="0.0" SE="0.37747634625809307" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.14248839198435975" WEIGHT="6.340035522009094"/>
<DICH_DATA CI_END="51.36507355693613" CI_START="0.7832527814858183" EFFECT_SIZE="6.3428571428571425" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7106679143784898" LOG_CI_START="-0.10609805417776379" LOG_EFFECT_SIZE="0.802284930100363" ORDER="7265" O_E="0.0" SE="1.0671773230665271" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="1.138867438867439" WEIGHT="0.5516011018793424"/>
<DICH_DATA CI_END="4.579387842528569" CI_START="0.4798392968177218" EFFECT_SIZE="1.4823529411764707" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6608074268290822" LOG_CI_START="-0.3189041880225419" LOG_EFFECT_SIZE="0.1709516194032702" ORDER="7266" O_E="0.0" SE="0.5754874522145517" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.33118580765639594" WEIGHT="2.538194543986147"/>
<DICH_DATA CI_END="4.361184783035946" CI_START="0.9766596928528737" EFFECT_SIZE="2.0638297872340425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6396044880842814" LOG_CI_START="-0.01025673542322659" LOG_EFFECT_SIZE="0.3146738763305274" ORDER="7267" O_E="0.0" SE="0.3817316995532475" STUDY_ID="STD-USA-1987" TOTAL_1="94" TOTAL_2="97" VAR="0.1457190904438108" WEIGHT="5.026047317527974"/>
<DICH_DATA CI_END="2.3446304512096257" CI_START="0.5910085594521073" EFFECT_SIZE="1.1771561771561772" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.3700744011458413" LOG_CI_START="-0.228406229277967" LOG_EFFECT_SIZE="0.07083408593393713" ORDER="7268" O_E="0.0" SE="0.35155048483784457" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.12358774338972357" WEIGHT="7.301937786363911"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-05-20 18:45:34 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4">
<NAME>Any antihypertensive drug versus none (subgrouped by use of placebo)</NAME>
<DICH_OUTCOME CHI2="26.964593099503524" CI_END="0.5957844050099788" CI_START="0.40104809405533387" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48881305229826166" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="242" I2="29.53722709670768" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.2249108688731604" LOG_CI_START="-0.3968035432641052" LOG_EFFECT_SIZE="-0.31085720606863276" METHOD="MH" MODIFIED="2013-05-20 18:42:20 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.10548055639747833" P_Q="0.9028378347115484" P_Z="1.3513741021767751E-12" Q="0.014902857222699184" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1336" TOTAL_2="1222" WEIGHT="100.0" Z="7.088945824922978">
<NAME>Severe hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.189722305162189" CI_END="0.6912099721215081" CI_START="0.357059402223931" DF="9" EFFECT_SIZE="0.4967927328946406" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="93" I2="2.064505312153066" ID="CMP-004.01.01" LOG_CI_END="-0.16039000489533342" LOG_CI_START="-0.44725952643122774" LOG_EFFECT_SIZE="-0.3038247656632806" NO="1" P_CHI2="0.4199490171975305" P_Z="3.301403798736202E-5" STUDIES="10" TAU2="0.0" TOTAL_1="460" TOTAL_2="477" WEIGHT="36.672500894778935" Z="4.151612866526441">
<NAME>Placebo</NAME>
<DICH_DATA CI_END="1.4733985973056012" CI_START="0.30597037852147974" EFFECT_SIZE="0.6714285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.16832025206513437" LOG_CI_START="-0.5143206162222133" LOG_EFFECT_SIZE="-0.1730001820785394" ORDER="7269" O_E="0.0" SE="0.40098662515878386" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.16079027355623102" WEIGHT="5.529465567645235"/>
<DICH_DATA CI_END="1.214567931047986" CI_START="0.16149936071047388" EFFECT_SIZE="0.4428904428904429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.08442181000508182" LOG_CI_START="-0.7918291924688724" LOG_EFFECT_SIZE="-0.35370369123189527" ORDER="7270" O_E="0.0" SE="0.5147141763656174" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.264930683351736" WEIGHT="4.4988032781657825"/>
<DICH_DATA CI_END="1.4103128933907758" CI_START="0.28142691019844857" EFFECT_SIZE="0.63" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.14931547634177364" LOG_CI_START="-0.5506343774346102" LOG_EFFECT_SIZE="-0.2006594505464183" ORDER="7271" O_E="0.0" SE="0.41115400891590376" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="20" TOTAL_2="21" VAR="0.16904761904761906" WEIGHT="3.938914690076358"/>
<DICH_DATA CI_END="0.890351646543475" CI_START="0.1797042782154134" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="7272" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.16666666666666669" WEIGHT="6.056081335992401"/>
<DICH_DATA CI_END="1.0938657367258307" CI_START="0.004509539483088448" EFFECT_SIZE="0.07023411371237458" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="0.0389640190929527" LOG_CI_START="-2.345867806273973" LOG_EFFECT_SIZE="-1.1534518935905105" ORDER="7273" O_E="0.0" SE="1.4008620193284582" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.9624143971970056" WEIGHT="3.550526116591623"/>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7274" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="0.20186937786641335"/>
<DICH_DATA CI_END="2.761015458222625" CI_START="0.4743339859607909" EFFECT_SIZE="1.144396551724138" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4410688381503073" LOG_CI_START="-0.32391575709713094" LOG_EFFECT_SIZE="0.058576540526588186" ORDER="7275" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-Sweden-1995" TOTAL_1="58" TOTAL_2="59" VAR="0.20192057925839338" WEIGHT="3.202303977094557"/>
<DICH_DATA CI_END="1.3197208380365462" CI_START="0.061856000684717444" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12048207414354972" LOG_CI_START="-1.208618162844101" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="7276" O_E="0.0" SE="0.7807200583588264" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="0.6095238095238094" WEIGHT="2.826171290129787"/>
<DICH_DATA CI_END="0.9183944157552488" CI_START="0.13520589135855415" EFFECT_SIZE="0.3523809523809524" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.03697076564084711" LOG_CI_START="-0.8690043843650392" LOG_EFFECT_SIZE="-0.45298757500294307" ORDER="7277" O_E="0.0" SE="0.4887406662714275" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.23886743886743886" WEIGHT="5.887856854437056"/>
<DICH_DATA CI_END="4.099426132832591" CI_START="0.010939162996078491" EFFECT_SIZE="0.21176470588235294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6127230653081122" LOG_CI_START="-1.9610159065300856" LOG_EFFECT_SIZE="-0.6741464206109866" ORDER="7278" O_E="0.0" SE="1.5118270122711395" STUDY_ID="STD-UK-1990" TOTAL_1="16" TOTAL_2="17" VAR="2.28562091503268" WEIGHT="0.9805084067797218"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.797920248753805" CI_END="0.6199130824653825" CI_START="0.37818522229906076" DF="9" EFFECT_SIZE="0.4841920764513466" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="149" I2="49.432293918553924" ID="CMP-004.01.02" LOG_CI_END="-0.2076691983272892" LOG_CI_START="-0.4222954453465097" LOG_EFFECT_SIZE="-0.31498232183689945" MODIFIED="2013-05-20 18:42:20 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.037591775646896086" P_Z="8.776245246957016E-9" STUDIES="10" TAU2="0.0" TOTAL_1="876" TOTAL_2="745" WEIGHT="63.32749910522107" Z="5.7528286045260915">
<NAME>No placebo</NAME>
<DICH_DATA CI_END="0.7537090344788961" CI_START="0.17266719228262" EFFECT_SIZE="0.36075036075036077" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="-0.12279627894233291" LOG_CI_START="-0.7627901729372053" LOG_EFFECT_SIZE="-0.4427932259397691" MODIFIED="2013-05-20 18:42:20 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="747" O_E="0.0" SE="0.3759355813534565" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.14132756132756133" WEIGHT="7.511166650277823"/>
<DICH_DATA CI_END="1.191211707520663" CI_START="0.13431701433913634" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.07598895311772173" LOG_CI_START="-0.871868970461797" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="7279" O_E="0.0" SE="0.5567764362830021" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.30999999999999994" WEIGHT="4.037387557328267"/>
<DICH_DATA CI_END="1.3224589374430262" CI_START="0.6153541723895645" EFFECT_SIZE="0.9020979020979021" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" LOG_CI_END="0.12138219600494272" LOG_CI_START="-0.2108748503365684" LOG_EFFECT_SIZE="-0.04474632716581285" ORDER="7280" O_E="0.0" SE="0.1951694337199084" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.038091107858549716" WEIGHT="15.926797812357027"/>
<DICH_DATA CI_END="0.5456419852342921" CI_START="0.05707381278355769" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.2630922196308351" LOG_CI_START="-1.2435631136863878" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="7281" O_E="0.0" SE="0.575933456577432" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3316993464052287" WEIGHT="7.059660528813997"/>
<DICH_DATA CI_END="1.2823063840978146" CI_START="0.00419990213254197" EFFECT_SIZE="0.07338638373121131" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10799180445385774" LOG_CI_START="-2.376760829552621" LOG_EFFECT_SIZE="-1.1343845125493814" ORDER="7282" O_E="0.0" SE="1.459555996939311" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="2.130303708201506" WEIGHT="2.6860501925519236"/>
<DICH_DATA CI_END="0.8951643039341957" CI_START="0.20662144808217364" EFFECT_SIZE="0.43006993006993005" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.04809724430085871" LOG_CI_START="-0.6848245990784315" LOG_EFFECT_SIZE="-0.3664609216896451" ORDER="7283" O_E="0.0" SE="0.3740168000475848" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="123" VAR="0.13988856671783503" WEIGHT="8.660196310469132"/>
<DICH_DATA CI_END="0.7465699182036291" CI_START="0.06694355152990397" EFFECT_SIZE="0.22355769230769232" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.1269295132328718" LOG_CI_START="-1.1742912509127434" LOG_EFFECT_SIZE="-0.6506103820728076" ORDER="7284" O_E="0.0" SE="0.615225469237373" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.37850237799834574" WEIGHT="5.331914996344632"/>
<DICH_DATA CI_END="3.699119357300525" CI_START="0.1201487169013067" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5680983446651372" LOG_CI_START="-0.9202808627764997" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7285" O_E="0.0" SE="0.8742813140471173" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.764367816091954" WEIGHT="1.21121626719848"/>
<DICH_DATA CI_END="0.97210968055073" CI_START="0.13697733797118744" EFFECT_SIZE="0.36490683229813664" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.012284732017487168" LOG_CI_START="-0.8633512781586645" LOG_EFFECT_SIZE="-0.43781800508807583" ORDER="7286" O_E="0.0" SE="0.49992070205067496" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.24992070833883975" WEIGHT="5.591564703052482"/>
<DICH_DATA CI_END="1.2034709849825036" CI_START="0.22488329113438102" EFFECT_SIZE="0.5202312138728323" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.08043562413835074" LOG_CI_START="-0.6480428115172918" LOG_EFFECT_SIZE="-0.28380359368947056" ORDER="7287" O_E="0.0" SE="0.42791183913053826" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18310854206807967" WEIGHT="5.311544086827301"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.761312891257916" CI_END="1.0814358835551692" CI_START="0.7966725673334996" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9281973398790088" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="255" I2="34.83665735731316" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.034000775977027914" LOG_CI_START="-0.09872013709676974" LOG_EFFECT_SIZE="-0.03235968055987091" METHOD="MH" MODIFIED="2013-05-20 18:43:05 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.051937478310078555" P_Q="0.5252760693028071" P_Z="0.33920007359547233" Q="0.40352175900671083" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1476" TOTAL_2="1375" WEIGHT="100.0" Z="0.9557470180046448">
<NAME>Proteinuria/pre-eclampsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.228212318073378" CI_END="1.092696706224856" CI_START="0.7053288443052517" DF="9" EFFECT_SIZE="0.8779011931747973" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="120" I2="31.9635958087585" ID="CMP-004.02.01" LOG_CI_END="0.03849963396115716" LOG_CI_START="-0.15160835539195225" LOG_EFFECT_SIZE="-0.056554360715397545" NO="1" P_CHI2="0.15254894486827275" P_Z="0.24356533122747592" STUDIES="10" TAU2="0.0" TOTAL_1="423" TOTAL_2="446" WEIGHT="44.76048051073132" Z="1.1661215349027956">
<NAME>Placebo</NAME>
<DICH_DATA CI_END="3.283656704405851" CI_START="0.055935649162505596" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.516357746749645" LOG_CI_START="-1.252311317338834" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="7288" O_E="0.0" SE="1.0389249632986395" STUDY_ID="STD-Australia-2001" TOTAL_1="7" TOTAL_2="9" VAR="1.0793650793650793" WEIGHT="1.0132813432730985"/>
<DICH_DATA CI_END="1.5842961150946966" CI_START="0.6384891163205925" EFFECT_SIZE="1.005761316872428" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.1998363572614902" LOG_CI_START="-0.19484650131708134" LOG_EFFECT_SIZE="0.002494927972204436" ORDER="7289" O_E="0.0" SE="0.23183866484071194" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.05374916651512396" WEIGHT="10.195750162126831"/>
<DICH_DATA CI_END="2.645622079552134" CI_START="0.35884770476159167" EFFECT_SIZE="0.9743589743589743" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42252780640959303" LOG_CI_START="-0.44508982722897117" LOG_EFFECT_SIZE="-0.011281010409689058" ORDER="7290" O_E="0.0" SE="0.5096428927758443" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.2597358781569308" WEIGHT="2.737175576633825"/>
<DICH_DATA CI_END="2.9127186917646344" CI_START="0.03556141346709918" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4642985428103939" LOG_CI_START="-1.4490209853631926" LOG_EFFECT_SIZE="-0.4923612212763993" ORDER="7291" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Israel-1992" TOTAL_1="29" TOTAL_2="28" VAR="1.2631362889983577" WEIGHT="1.1783522387937788"/>
<DICH_DATA CI_END="2.5234570593395587" CI_START="0.04403130645709946" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.4019959189169215" LOG_CI_START="-1.3562384283562463" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7292" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="1.4475447761044264"/>
<DICH_DATA CI_END="2.6978801705038147" CI_START="0.37066138479132504" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.43102265606802675" LOG_CI_START="-0.43102265606802675" LOG_EFFECT_SIZE="0.0" ORDER="7293" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.2564102564102564" WEIGHT="2.3160716417670826"/>
<DICH_DATA CI_END="4.028818448809723" CI_START="1.061595617073956" EFFECT_SIZE="2.068085106382979" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.605177697158387" LOG_CI_START="0.025959116822727186" LOG_EFFECT_SIZE="0.31556840699055716" ORDER="7294" O_E="0.0" SE="0.3402358612673805" STUDY_ID="STD-Sweden-1995" TOTAL_1="47" TOTAL_2="54" VAR="0.11576044129235619" WEIGHT="3.5925863750182465"/>
<DICH_DATA CI_END="1.06832246368607" CI_START="0.09098117388503381" EFFECT_SIZE="0.31176470588235294" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.028702360428301738" LOG_CI_START="-1.0410484639832713" LOG_EFFECT_SIZE="-0.5061730517774848" ORDER="7295" O_E="0.0" SE="0.6283769296113413" STUDY_ID="STD-UK-1983" TOTAL_1="51" TOTAL_2="53" VAR="0.3948575656677766" WEIGHT="3.785886337503885"/>
<DICH_DATA CI_END="1.0030463333503243" CI_START="0.5287431144942136" EFFECT_SIZE="0.7282539682539683" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="45" LOG_CI_END="0.0013209946890276583" LOG_CI_START="-0.276755275137731" LOG_EFFECT_SIZE="-0.13771714022435164" ORDER="7296" O_E="0.0" SE="0.1633433773959736" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.02668105893912346" WEIGHT="16.888022387884977"/>
<DICH_DATA CI_END="3.3138380098347344" CI_START="0.40175800470462913" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5203312750083746" LOG_CI_START="-0.3960354615106857" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="7297" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.28974358974358977" WEIGHT="1.6058096716251773"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.082380921232943" CI_END="1.1973610735402802" CI_START="0.7841146792321303" DF="12" EFFECT_SIZE="0.9689522145617274" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="135" I2="40.246128947228094" ID="CMP-004.02.02" LOG_CI_END="0.07822513503444073" LOG_CI_START="-0.1056204157396826" LOG_EFFECT_SIZE="-0.013697640352620968" MODIFIED="2013-05-20 18:43:05 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.06554363959260834" P_Z="0.7702414485098383" STUDIES="13" TAU2="0.0" TOTAL_1="1053" TOTAL_2="929" WEIGHT="55.23951948926868" Z="0.2920590860238363">
<NAME>No placebo</NAME>
<DICH_DATA CI_END="1.3583113580225423" CI_START="0.184052057375089" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13299933222130308" LOG_CI_START="-0.7350593235492654" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7298" O_E="0.0" SE="0.5099019513592785" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.26" WEIGHT="3.8601194029451373"/>
<DICH_DATA CI_END="0.8648180115377374" CI_START="0.21669620926622504" EFFECT_SIZE="0.4329004329004329" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="-0.06307527392293309" LOG_CI_START="-0.6641486858613557" LOG_EFFECT_SIZE="-0.36361197989214433" MODIFIED="2013-05-20 18:43:05 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="748" O_E="0.0" SE="0.35307349753400447" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.12466089466089465" WEIGHT="7.181376499975786"/>
<DICH_DATA CI_END="1.394881675466763" CI_START="0.024875366572638044" EFFECT_SIZE="0.18627450980392157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14453736899216438" LOG_CI_START="-1.6042305106103416" LOG_EFFECT_SIZE="-0.7298465708090885" ORDER="7299" O_E="0.0" SE="1.0272349090191268" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.0552115583075337" WEIGHT="2.187400995002245"/>
<DICH_DATA CI_END="2.5880090016834325" CI_START="0.8937770351034582" EFFECT_SIZE="1.520888888888889" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" LOG_CI_END="0.41296578257419125" LOG_CI_START="-0.048770808386753274" LOG_EFFECT_SIZE="0.182097487093719" ORDER="7300" O_E="0.0" SE="0.2712263591634463" STUDY_ID="STD-Italy-1998" TOTAL_1="125" TOTAL_2="118" VAR="0.07356373790505877" WEIGHT="7.148369264713217"/>
<DICH_DATA CI_END="4.174737638310471" CI_START="0.6049216305326484" EFFECT_SIZE="1.5891472868217054" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6206291874090091" LOG_CI_START="-0.21830088589599841" LOG_EFFECT_SIZE="0.20116415075650532" ORDER="7301" O_E="0.0" SE="0.4927916778301993" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.24284363773870293" WEIGHT="2.371216204666299"/>
<DICH_DATA CI_END="1.44433264431343" CI_START="0.4592966054898607" EFFECT_SIZE="0.8144796380090498" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.15966722713427386" LOG_CI_START="-0.3379067642978832" LOG_EFFECT_SIZE="-0.08911976858180463" ORDER="7302" O_E="0.0" SE="0.2922774255982299" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="0.08542609351432881" WEIGHT="6.824691104407003"/>
<DICH_DATA CI_END="4.0885479522838075" CI_START="0.40201448264565726" EFFECT_SIZE="1.2820512820512822" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6115690957141797" LOG_CI_START="-0.3957583010951405" LOG_EFFECT_SIZE="0.10790539730951963" ORDER="7303" O_E="0.0" SE="0.5917090992368278" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="0.3501196581196581" WEIGHT="1.8662560749776076"/>
<DICH_DATA CI_END="1.325960843975488" CI_START="0.139806606855715" EFFECT_SIZE="0.4305555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.12253069941078948" LOG_CI_START="-0.854472304604781" LOG_EFFECT_SIZE="-0.36597080259699577" ORDER="7304" O_E="0.0" SE="0.5738964008016139" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.3293570788530466" WEIGHT="3.5292520255498396"/>
<DICH_DATA CI_END="1.7570972141948125" CI_START="0.5078480840975841" EFFECT_SIZE="0.9446366782006921" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.24479579019217332" LOG_CI_START="-0.29426618162375695" LOG_EFFECT_SIZE="-0.024735195715791802" ORDER="7305" O_E="0.0" SE="0.31664767064447336" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.10026574732457087" WEIGHT="5.871444776058657"/>
<DICH_DATA CI_END="3.0199847904557613" CI_START="0.03679194394033447" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48000475572610146" LOG_CI_START="-1.4342472651654263" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7306" O_E="0.0" SE="1.124441112772009" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="1.2643678160919538" WEIGHT="1.1580358208835413"/>
<DICH_DATA CI_END="4.49416039642105" CI_START="0.6452514414860213" EFFECT_SIZE="1.7028985507246377" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6526485683139724" LOG_CI_START="-0.190271016572973" LOG_EFFECT_SIZE="0.23118877587049977" ORDER="7307" O_E="0.0" SE="0.49513513668183046" STUDY_ID="STD-USA-1987" TOTAL_1="92" TOTAL_2="94" VAR="0.24515880357693495" WEIGHT="2.2911676456190495"/>
<DICH_DATA CI_END="1.9930163928537483" CI_START="0.6235458309350601" EFFECT_SIZE="1.1147811725846408" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.29951087085133893" LOG_CI_START="-0.2051316201474312" LOG_EFFECT_SIZE="0.04718962535195388" ORDER="7308" O_E="0.0" SE="0.2964294972332956" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.08787044682998439" WEIGHT="7.109664786260931"/>
<DICH_DATA CI_END="3.384593215279071" CI_START="0.7718834398672652" EFFECT_SIZE="1.616326530612245" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5295064795276351" LOG_CI_START="-0.11244827640567534" LOG_EFFECT_SIZE="0.20852910156097987" ORDER="7309" O_E="0.0" SE="0.3770874013625181" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.14219490826633682" WEIGHT="3.8405248882093757"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.239345396230446" CI_END="1.0218516327002851" CI_START="0.49463043485945146" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7109422743404576" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.009387843179175638" LOG_CI_START="-0.3057191647946501" LOG_EFFECT_SIZE="-0.14816566080773722" METHOD="MH" MODIFIED="2013-05-20 18:44:00 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.9238133124655086" P_Q="0.757852630533367" P_Z="0.06530283454220204" Q="0.0950500699137393" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1682" TOTAL_2="1548" WEIGHT="100.0" Z="1.843179311028619">
<NAME>Total reported fetal or neonatal death (including miscarriage)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.058869970872146" CI_END="1.6902353292679746" CI_START="0.36947042988354195" DF="6" EFFECT_SIZE="0.7902480456850169" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.2279471750796153" LOG_CI_START="-0.4324203141089274" LOG_EFFECT_SIZE="-0.10223656951465604" NO="1" P_CHI2="0.9142054564370165" P_Z="0.5439344078968613" STUDIES="10" TAU2="0.0" TOTAL_1="448" TOTAL_2="463" WEIGHT="21.129782602199064" Z="0.6068741948452907">
<NAME>Placebo</NAME>
<DICH_DATA CI_END="8.432346492507785" CI_START="0.014360629336101962" EFFECT_SIZE="0.34798534798534797" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9259484437760184" LOG_CI_START="-1.8428265272798348" LOG_EFFECT_SIZE="-0.4584390417519083" ORDER="7310" O_E="0.0" SE="1.626392123655357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="2.645151339888182" WEIGHT="2.2933855865052952"/>
<DICH_DATA CI_END="3.7796994558212216" CI_START="0.11163443866495346" EFFECT_SIZE="0.6495726495726496" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5774572681262113" LOG_CI_START="-0.952201807056952" LOG_EFFECT_SIZE="-0.18737226946537028" ORDER="7311" O_E="0.0" SE="0.8985293126971309" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.8073549257759783" WEIGHT="4.7484569843041"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7312" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Israel-1992" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.7812632217765292"/>
<DICH_DATA CI_END="2.730529574091466" CI_START="0.25432591942371036" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.4362468846969332" LOG_CI_START="-0.5946093767921828" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7313" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.3666666666666667" WEIGHT="7.031368995988762"/>
<DICH_DATA CI_END="7.824262991946792" CI_START="0.01420084054248603" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8934434396874849" LOG_CI_START="-1.84768594912681" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7314" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="2.3437896653295875"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7315" O_E="0.0" SE="0.0" STUDY_ID="STD-Sweden-1995" TOTAL_1="54" TOTAL_2="57" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.368170063591449" CI_START="0.046570804769315244" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7298262658251348" LOG_CI_START="-1.3318862571530974" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7316" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-UK-1983" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="3.1250528871061167"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7317" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="63.82881484401465" CI_START="0.12392766917779852" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050167806434498" LOG_CI_START="-0.9068317184046119" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="7318" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.5374999999999996" WEIGHT="0.8064652611886752"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7319" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.170446023386301" CI_END="1.0423523266225183" CI_START="0.4563527037638987" DF="11" EFFECT_SIZE="0.6896958043433182" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="47" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.018014540119881454" LOG_CI_START="-0.3406993720511974" LOG_EFFECT_SIZE="-0.16134241596565796" MODIFIED="2013-05-20 18:44:00 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.6979592012301394" P_Z="0.07788261436048569" STUDIES="17" TAU2="0.0" TOTAL_1="1234" TOTAL_2="1085" WEIGHT="78.87021739780093" Z="1.763105994732397">
<NAME>No placebo</NAME>
<DICH_DATA CI_END="4.384751004320472" CI_START="0.35634862697115655" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6419449362379852" LOG_CI_START="-0.44812491022187245" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="7320" O_E="0.0" SE="0.6403124237432849" STUDY_ID="STD-Brazil-1985" TOTAL_1="50" TOTAL_2="50" VAR="0.41" WEIGHT="6.2501057742122335"/>
<DICH_DATA CI_END="1.6635268505992704" CI_START="0.15333447281592205" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.22102981510744976" LOG_CI_START="-0.8143601956305119" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2013-05-20 18:44:00 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="749" O_E="0.0" SE="0.608193217570691" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.3698989898989899" WEIGHT="10.381887108171327"/>
<DICH_DATA CI_END="22.509252726006434" CI_START="0.22197715105018606" EFFECT_SIZE="2.235294117647059" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3523610773035457" LOG_CI_START="-0.6536917268264734" LOG_EFFECT_SIZE="0.34933467523853623" ORDER="7321" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Ireland-1991" TOTAL_1="17" TOTAL_2="19" VAR="1.388544891640867" WEIGHT="1.4757194189112217"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7322" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1986a" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7323" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7324" O_E="0.0" SE="0.0" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.425266203926439" CI_START="0.28932007166963136" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.38475941491815685" LOG_CI_START="-0.5386214359925852" LOG_EFFECT_SIZE="-0.0769310105372141" ORDER="7325" O_E="0.0" SE="0.5423984826338988" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.2941961139635558" WEIGHT="11.063405623318207"/>
<DICH_DATA CI_END="2.286031560619402" CI_START="0.21796282465092698" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.359082221907135" LOG_CI_START="-0.6616175725684332" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="7326" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="9.107296985280682"/>
<DICH_DATA CI_END="26.946306300069608" CI_START="0.30365054825448545" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.430499242122451" LOG_CI_START="-0.517625930402828" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="7327" O_E="0.0" SE="1.1443383697164793" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="1.3095103044053695" WEIGHT="1.5997294541138454"/>
<DICH_DATA CI_END="1.6001382903696388" CI_START="0.23666593514526177" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.20415751774911287" LOG_CI_START="-0.6258642483788992" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="7328" O_E="0.0" SE="0.4875588940976005" STUDY_ID="STD-UK-1968" TOTAL_1="52" TOTAL_2="48" VAR="0.23771367521367523" WEIGHT="14.625247511656625"/>
<DICH_DATA CI_END="0.9226155353964339" CI_START="0.015273638959593142" EFFECT_SIZE="0.11870845204178537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.034979236829268255" LOG_CI_START="-1.816057479525592" LOG_EFFECT_SIZE="-0.9255183581774301" ORDER="7329" O_E="0.0" SE="1.0462141762393122" STUDY_ID="STD-UK-1976" TOTAL_1="117" TOTAL_2="125" VAR="1.0945641025641026" WEIGHT="13.597854091416284"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7330" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.0150081559399045" CI_START="0.012082077255360984" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7002716436529105" LOG_CI_START="-1.9178583916267722" LOG_EFFECT_SIZE="-0.6087933739869308" ORDER="7331" O_E="0.0" SE="1.5379025426759756" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="2.3651442307692307" WEIGHT="3.50221444244651"/>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7332" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="2.3437896653295875"/>
<DICH_DATA CI_END="73.49844303024413" CI_START="0.1248408162074388" EFFECT_SIZE="3.029126213592233" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8662781392129644" LOG_CI_START="-0.9036434005864231" LOG_EFFECT_SIZE="0.48131736931327057" ORDER="7333" O_E="0.0" SE="1.6270656238109158" STUDY_ID="STD-USA-1987" TOTAL_1="102" TOTAL_2="103" VAR="2.6473425441872043" WEIGHT="0.7774890033138406"/>
<DICH_DATA CI_END="4.483281901280379" CI_START="0.12935631556800872" EFFECT_SIZE="0.7615384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6515960474362559" LOG_CI_START="-0.8882123628548295" LOG_EFFECT_SIZE="-0.11830815770928688" ORDER="7334" O_E="0.0" SE="0.9044910823795435" STUDY_ID="STD-USA-1990" TOTAL_1="195" TOTAL_2="99" VAR="0.8181041181041181" WEIGHT="4.145478319630563"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7335" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.533687521022623" CI_END="1.1005465123782896" CI_START="0.8456150020125112" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9646961393514694" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="279" I2="9.873299684617681" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.04160840185744289" LOG_CI_START="-0.07282732083608784" LOG_EFFECT_SIZE="-0.015609459489322453" METHOD="MH" MODIFIED="2013-05-20 18:44:51 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" P_CHI2="0.3426723164369483" P_Q="0.3871327704493879" P_Z="0.5928623042363121" Q="0.7479289256186579" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1135" TOTAL_2="1006" WEIGHT="100.0" Z="0.5346927986664172">
<NAME>Preterm birth (&lt; 37 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2394669134608851" CI_END="1.1739035858533935" CI_START="0.6217775715722245" DF="4" EFFECT_SIZE="0.8543459023556264" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="67" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.0696324292358662" LOG_CI_START="-0.20636494764840174" LOG_EFFECT_SIZE="-0.06836625920626774" NO="1" P_CHI2="0.8715589019388585" P_Z="0.3315530566542588" STUDIES="5" TAU2="0.0" TOTAL_1="276" TOTAL_2="290" WEIGHT="22.370139474233962" Z="0.9709904297981938">
<NAME>Placebo</NAME>
<DICH_DATA CI_END="2.059747840257095" CI_START="0.5978806659848787" EFFECT_SIZE="1.1097222222222223" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.31381405615168917" LOG_CI_START="-0.22338549038624325" LOG_EFFECT_SIZE="0.04521428288272295" ORDER="7336" O_E="0.0" SE="0.31555367281702357" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.09957412042831316" WEIGHT="5.482800025869021"/>
<DICH_DATA CI_END="1.5787217430117375" CI_START="0.3712459185862139" EFFECT_SIZE="0.7655677655677655" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.19830559034793077" LOG_CI_START="-0.43033831220733487" LOG_EFFECT_SIZE="-0.11601636092970206" ORDER="7337" O_E="0.0" SE="0.3692685401984678" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.13635925478030742" WEIGHT="4.967749114347991"/>
<DICH_DATA CI_END="1.6600512529016966" CI_START="0.26772935092671085" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7338" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-South-Africa-1991" TOTAL_1="12" TOTAL_2="20" VAR="0.21666666666666667" WEIGHT="2.6271750123955724"/>
<DICH_DATA CI_END="1.8452362465144543" CI_START="0.4389681817328505" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.26605197699335337" LOG_CI_START="-0.3575669581147036" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="7339" O_E="0.0" SE="0.36631684944598736" STUDY_ID="STD-Sweden-1984" TOTAL_1="26" TOTAL_2="26" VAR="0.13418803418803418" WEIGHT="3.50290001652743"/>
<DICH_DATA CI_END="1.4478220167842517" CI_START="0.38460668816655885" EFFECT_SIZE="0.746218487394958" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.16071517658529264" LOG_CI_START="-0.41498316781315214" LOG_EFFECT_SIZE="-0.12713399561392974" ORDER="7340" O_E="0.0" SE="0.33816805725241145" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="0.11435763494587023" WEIGHT="5.789515305093947"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.632899295837602" CI_END="1.1506750113171782" CI_START="0.8629739137949396" DF="9" EFFECT_SIZE="0.9964951169084681" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="212" I2="33.983228330984" ID="CMP-004.04.02" LOG_CI_END="0.060952681821652525" LOG_CI_START="-0.06400233205551956" LOG_EFFECT_SIZE="-0.0015248251169335315" MODIFIED="2013-05-20 18:44:51 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.1359961361259996" P_Z="0.9618478602754432" STUDIES="10" TAU2="0.0" TOTAL_1="859" TOTAL_2="716" WEIGHT="77.62986052576603" Z="0.04783485222689065">
<NAME>No placebo</NAME>
<DICH_DATA CI_END="0.722995814123863" CI_START="0.21342480718015033" EFFECT_SIZE="0.39281705948372614" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="-0.14086421710127925" LOG_CI_START="-0.6707551022719189" LOG_EFFECT_SIZE="-0.40580965968659916" MODIFIED="2013-05-20 18:44:51 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="750" O_E="0.0" SE="0.3112605289514186" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.09688311688311688" WEIGHT="8.37874876436494"/>
<DICH_DATA CI_END="4.346977235005655" CI_START="0.44375947730871956" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.6381873658091225" LOG_CI_START="-0.3528523586716594" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="7341" O_E="0.0" SE="0.5821416398857661" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.3388888888888889" WEIGHT="1.4835811834704409"/>
<DICH_DATA CI_END="1.6694078925301565" CI_START="0.7128770925027845" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.22256246240243016" LOG_CI_START="-0.14698534062363067" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="7342" O_E="0.0" SE="0.2170742087886355" STUDY_ID="STD-Italy-1997" TOTAL_1="50" TOTAL_2="50" VAR="0.04712121212121212" WEIGHT="7.706380036360346"/>
<DICH_DATA CI_END="1.1143643270860302" CI_START="0.7286846217729761" EFFECT_SIZE="0.9011216056670602" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" LOG_CI_END="0.047027201049018336" LOG_CI_START="-0.13746039576903324" LOG_EFFECT_SIZE="-0.04521659736000748" ORDER="7343" O_E="0.0" SE="0.10836892759925609" STUDY_ID="STD-Italy-1998" TOTAL_1="132" TOTAL_2="129" VAR="0.011743824469012808" WEIGHT="27.28235691033318"/>
<DICH_DATA CI_END="5.143571011393654" CI_START="0.49041635546458573" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7112647400184975" LOG_CI_START="-0.3094350544570707" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="7344" O_E="0.0" SE="0.5995641118204178" STUDY_ID="STD-Sudan-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.3594771241830065" WEIGHT="1.3611268635649443"/>
<DICH_DATA CI_END="1.839351437699459" CI_START="0.6536748364081058" EFFECT_SIZE="1.0965116279069766" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.2646647161177475" LOG_CI_START="-0.1846382331302263" LOG_EFFECT_SIZE="0.040013241493760614" ORDER="7345" O_E="0.0" SE="0.26392277647372825" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.06965523194160152" WEIGHT="7.172604795746642"/>
<DICH_DATA CI_END="4.819063550418095" CI_START="0.5526849712884415" EFFECT_SIZE="1.632" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6829626535089109" LOG_CI_START="-0.2575223446732263" LOG_EFFECT_SIZE="0.2127201544178423" ORDER="7346" O_E="0.0" SE="0.552445543408011" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="0.30519607843137253" WEIGHT="1.734108919072985"/>
<DICH_DATA CI_END="1.9858834006540402" CI_START="0.45467418436677676" EFFECT_SIZE="0.9502262443438914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2979537457005959" LOG_CI_START="-0.34229970360297884" LOG_EFFECT_SIZE="-0.02217297895119145" ORDER="7347" O_E="0.0" SE="0.37608804542660773" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.14144221791280615" WEIGHT="4.074425808697695"/>
<DICH_DATA CI_END="2.5395003843815207" CI_START="0.5802272219481015" EFFECT_SIZE="1.2138728323699421" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.4047482828999033" LOG_CI_START="-0.23640189968965558" LOG_EFFECT_SIZE="0.08417319160512383" ORDER="7348" O_E="0.0" SE="0.3766147909976962" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.14183870079823838" WEIGHT="4.147540171660235"/>
<DICH_DATA CI_END="1.640730612375623" CI_START="0.8883935633157071" EFFECT_SIZE="1.2073170731707317" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="41" LOG_CI_END="0.2150372811367737" LOG_CI_START="-0.0513945967091073" LOG_EFFECT_SIZE="0.0818213422138332" ORDER="7349" O_E="0.0" SE="0.15650340390573614" STUDY_ID="STD-USA-1992" TOTAL_1="98" TOTAL_2="99" VAR="0.024493315434081987" WEIGHT="14.288987072494633"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.442388292206317" CI_END="1.1702163995951986" CI_START="0.7986677038366341" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9667543870377162" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="165" I2="22.26618866840305" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.06826618008797396" LOG_CI_START="-0.09763387701628536" LOG_EFFECT_SIZE="-0.014683848464155694" METHOD="MH" MODIFIED="2013-05-20 18:45:34 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.17972657327138897" P_Q="0.8551493198487402" P_Z="0.7286261501800338" Q="0.03332536326245398" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1360" TOTAL_2="1226" WEIGHT="100.0" Z="0.34695363758798903">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.761267902553824" CI_END="1.3761612210556449" CI_START="0.6392200104369417" DF="7" EFFECT_SIZE="0.9379071329753835" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="47" I2="28.28800448998432" ID="CMP-004.05.01" LOG_CI_END="0.13866931566788426" LOG_CI_START="-0.1943496381272341" LOG_EFFECT_SIZE="-0.027840161229674896" NO="1" P_CHI2="0.20251078877744721" P_Z="0.7431359709867299" STUDIES="8" TAU2="0.0" TOTAL_1="353" TOTAL_2="361" WEIGHT="26.829580887440752" Z="0.3277033496869451">
<NAME>Placebo</NAME>
<DICH_DATA CI_END="1.2793318917912602" CI_START="0.3401282872818949" EFFECT_SIZE="0.6596491228070176" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.10698322632013381" LOG_CI_START="-0.4683572478097944" LOG_EFFECT_SIZE="-0.18068701074483032" ORDER="7350" O_E="0.0" SE="0.33795784248519845" STUDY_ID="STD-Brazil-2000a" TOTAL_1="90" TOTAL_2="94" VAR="0.11421550329725019" WEIGHT="10.545516717916868"/>
<DICH_DATA CI_END="1.932006735256676" CI_START="0.29726269049790127" EFFECT_SIZE="0.7578347578347578" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.28600863609588756" LOG_CI_START="-0.5268595957654018" LOG_EFFECT_SIZE="-0.12042547983475708" ORDER="7351" O_E="0.0" SE="0.4774828231579635" STUDY_ID="STD-Caribbean-Is.1990" TOTAL_1="78" TOTAL_2="76" VAR="0.22798984641089903" WEIGHT="5.1725651379201265"/>
<DICH_DATA CI_END="3.229845760329288" CI_START="0.21500854714921266" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5091817833102721" LOG_CI_START="-0.6675442754055219" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7352" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Hong-Kong-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.4777777777777777" WEIGHT="2.150000084317677"/>
<DICH_DATA CI_END="3.565944608602859" CI_START="0.05265863561782842" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.552174592803172" LOG_CI_START="-1.2785303976288234" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="7353" O_E="0.0" SE="1.0753651735156091" STUDY_ID="STD-South-Africa-1991" TOTAL_1="10" TOTAL_2="13" VAR="1.1564102564102563" WEIGHT="1.4800725218128938"/>
<DICH_DATA CI_END="2.668214881201066" CI_START="0.45839113150591804" EFFECT_SIZE="1.1059322033898304" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4262208019918935" LOG_CI_START="-0.33876379325554473" LOG_EFFECT_SIZE="0.04372850436817436" ORDER="7354" O_E="0.0" SE="0.44935573798316336" STUDY_ID="STD-UK-1983" TOTAL_1="59" TOTAL_2="58" VAR="0.20192057925839338" WEIGHT="4.577682990541532"/>
<DICH_DATA CI_END="51.36507355693613" CI_START="0.7832527814858183" EFFECT_SIZE="6.3428571428571425" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7106679143784898" LOG_CI_START="-0.10609805417776379" LOG_EFFECT_SIZE="0.802284930100363" ORDER="7355" O_E="0.0" SE="1.0671773230665271" STUDY_ID="STD-UK-1989" TOTAL_1="70" TOTAL_2="74" VAR="1.138867438867439" WEIGHT="0.5516011018793424"/>
<DICH_DATA CI_END="170.95704985397572" CI_START="0.6220723646134377" EFFECT_SIZE="10.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.232887014752679" LOG_CI_START="-0.20615909163671586" LOG_EFFECT_SIZE="1.0133639615579815" ORDER="7356" O_E="0.0" SE="1.4327077563660757" STUDY_ID="STD-UK-1990" TOTAL_1="15" TOTAL_2="14" VAR="2.052651515151515" WEIGHT="0.29283155270276606"/>
<DICH_DATA CI_END="2.328896816412874" CI_START="0.007555867021765305" EFFECT_SIZE="0.1326530612244898" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3671502472056924" LOG_CI_START="-2.1217156939770083" LOG_EFFECT_SIZE="-0.877282723385658" ORDER="7357" O_E="0.0" SE="1.4619721739358231" STUDY_ID="STD-USA-1987a" TOTAL_1="13" TOTAL_2="12" VAR="2.137362637362637" WEIGHT="2.059310780349545"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.589628249085653" CI_END="1.2179268873738436" CI_START="0.784265145459565" DF="11" EFFECT_SIZE="0.9773318819548265" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="118" I2="24.603973369305134" ID="CMP-004.05.02" LOG_CI_END="0.08562121821218258" LOG_CI_START="-0.10553708560311821" LOG_EFFECT_SIZE="-0.009957933695467793" MODIFIED="2013-05-20 18:45:34 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.20206519457364758" P_Z="0.8381977953525517" STUDIES="12" TAU2="0.0" TOTAL_1="1007" TOTAL_2="865" WEIGHT="73.17041911255924" Z="0.20419925280789736">
<NAME>No placebo</NAME>
<DICH_DATA CI_END="1.3270725639350585" CI_START="0.105966323034376" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12289467060744537" LOG_CI_START="-0.9748321351520076" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="7358" O_E="0.0" SE="0.644810159538427" STUDY_ID="STD-Brazil-1985" TOTAL_1="47" TOTAL_2="47" VAR="0.41578014184397166" WEIGHT="4.5388890668928745"/>
<DICH_DATA CI_END="0.9513082570593288" CI_START="0.3546043295942168" EFFECT_SIZE="0.5808080808080808" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.02167873369607392" LOG_CI_START="-0.4502559661197649" LOG_EFFECT_SIZE="-0.23596734990791945" MODIFIED="2013-05-20 18:45:34 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="751" O_E="0.0" SE="0.2517483878171916" STUDY_ID="STD-India-2012" TOTAL_1="99" TOTAL_2="50" VAR="0.06337725076855512" WEIGHT="15.078859651758208"/>
<DICH_DATA CI_END="3.4840772775713136" CI_START="0.5263279815622796" EFFECT_SIZE="1.3541666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.542087779185969" LOG_CI_START="-0.2787435406514321" LOG_EFFECT_SIZE="0.13167211926726838" ORDER="7359" O_E="0.0" SE="0.48216038045305265" STUDY_ID="STD-Israel-1995" TOTAL_1="36" TOTAL_2="15" VAR="0.23247863247863249" WEIGHT="3.2039216942773234"/>
<DICH_DATA CI_END="1.261814257395252" CI_START="0.5070833261549874" EFFECT_SIZE="0.7999031007751938" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.1009954302447171" LOG_CI_START="-0.2949206696294774" LOG_EFFECT_SIZE="-0.09696261969238013" ORDER="7360" O_E="0.0" SE="0.23256307688240377" STUDY_ID="STD-Italy-1998" TOTAL_1="129" TOTAL_2="127" VAR="0.054085584729010844" WEIGHT="18.297396550911902"/>
<DICH_DATA CI_END="4.885581830333628" CI_START="0.4186942807224805" EFFECT_SIZE="1.430232558139535" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6889162918329629" LOG_CI_START="-0.3781029714413025" LOG_EFFECT_SIZE="0.15540666019583024" ORDER="7361" O_E="0.0" SE="0.626772397077841" STUDY_ID="STD-Sweden-1985" TOTAL_1="86" TOTAL_2="82" VAR="0.3928436377387029" WEIGHT="2.3234789270999237"/>
<DICH_DATA CI_END="136.45123367761124" CI_START="0.3734653508694201" EFFECT_SIZE="7.138613861386139" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1349774665501218" LOG_CI_START="-0.42774968467654884" LOG_EFFECT_SIZE="0.8536138909367865" ORDER="7362" O_E="0.0" SE="1.5053586143345372" STUDY_ID="STD-UK-1976" TOTAL_1="100" TOTAL_2="102" VAR="2.266104557751198" WEIGHT="0.28089938465452224"/>
<DICH_DATA CI_END="2.2146684810856616" CI_START="0.5043033207724097" EFFECT_SIZE="1.0568181818181819" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.34530872486576064" LOG_CI_START="-0.29730817205822757" LOG_EFFECT_SIZE="0.024000276403766514" ORDER="7363" O_E="0.0" SE="0.37747634625809307" STUDY_ID="STD-UK-1982" TOTAL_1="64" TOTAL_2="62" VAR="0.14248839198435975" WEIGHT="6.340035522009094"/>
<DICH_DATA CI_END="4.579387842528569" CI_START="0.4798392968177218" EFFECT_SIZE="1.4823529411764707" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6608074268290822" LOG_CI_START="-0.3189041880225419" LOG_EFFECT_SIZE="0.1709516194032702" ORDER="7364" O_E="0.0" SE="0.5754874522145517" STUDY_ID="STD-UK-1992" TOTAL_1="51" TOTAL_2="63" VAR="0.33118580765639594" WEIGHT="2.538194543986147"/>
<DICH_DATA CI_END="3.6211056113868096" CI_START="0.27615875020475317" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5588411914211685" LOG_CI_START="-0.5588411914211685" LOG_EFFECT_SIZE="0.0" ORDER="7365" O_E="0.0" SE="0.6565321642986127" STUDY_ID="STD-USA-1979" TOTAL_1="29" TOTAL_2="29" VAR="0.43103448275862066" WEIGHT="2.2694445334464373"/>
<DICH_DATA CI_END="4.361184783035946" CI_START="0.9766596928528737" EFFECT_SIZE="2.0638297872340425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6396044880842814" LOG_CI_START="-0.01025673542322659" LOG_EFFECT_SIZE="0.3146738763305274" ORDER="7366" O_E="0.0" SE="0.3817316995532475" STUDY_ID="STD-USA-1987" TOTAL_1="94" TOTAL_2="97" VAR="0.1457190904438108" WEIGHT="5.026047317527974"/>
<DICH_DATA CI_END="1.9642496501313342" CI_START="0.36383364620577213" EFFECT_SIZE="0.8453757225433526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.29319668446117586" LOG_CI_START="-0.4390971412103305" LOG_EFFECT_SIZE="-0.07295022837457736" ORDER="7367" O_E="0.0" SE="0.43015301811234175" STUDY_ID="STD-USA-1990" TOTAL_1="173" TOTAL_2="90" VAR="0.18503161899115658" WEIGHT="5.97131413363093"/>
<DICH_DATA CI_END="2.3446304512096257" CI_START="0.5910085594521073" EFFECT_SIZE="1.1771561771561772" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.3700744011458413" LOG_CI_START="-0.228406229277967" LOG_EFFECT_SIZE="0.07083408593393713" ORDER="7368" O_E="0.0" SE="0.35155048483784457" STUDY_ID="STD-USA-1992" TOTAL_1="99" TOTAL_2="101" VAR="0.12358774338972357" WEIGHT="7.301937786363911"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-09-09 17:12:36 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5">
<NAME>Any antihypertensive versus methyldopa (subgrouped by class of drug)</NAME>
<DICH_OUTCOME CHI2="25.346064742973702" CI_END="0.9476428672249567" CI_START="0.3033341831078119" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5361459456226698" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="89" I2="60.546143547699465" I2_Q="5.566690809233022" ID="CMP-005.01" LOG_CI_END="-0.02335530191912163" LOG_CI_START="-0.5180786457441184" LOG_EFFECT_SIZE="-0.2707169738316201" METHOD="MH" MODIFIED="2013-09-09 17:12:36 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.0047267527351912975" P_Q="0.3034555368278501" P_Z="0.03195131736176626" Q="1.0589483822703663" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.400681991037688" TOTALS="YES" TOTAL_1="331" TOTAL_2="307" WEIGHT="100.0" Z="2.1450191317486733">
<NAME>Severe hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.208674358403474" CI_END="1.0481713748032777" CI_START="0.3278251823299463" DF="8" EFFECT_SIZE="0.5861885123899265" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="83" I2="62.27958492450438" ID="CMP-005.01.01" LOG_CI_END="0.020432295096843668" LOG_CI_START="-0.48435768857249456" LOG_EFFECT_SIZE="-0.2319626967378254" MODIFIED="2013-05-20 18:46:46 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.00661329242424491" P_Z="0.07165596201104861" STUDIES="9" TAU2="0.3665530733418978" TOTAL_1="308" TOTAL_2="284" WEIGHT="91.00118242496208" Z="1.801297751822012">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="1.2099661875687906" CI_START="0.16325321007063315" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.08277323415325047" LOG_CI_START="-0.7871382703759754" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="7369" O_E="0.0" SE="0.510990323891863" STUDY_ID="STD-Brazil-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.2611111111111111" WEIGHT="12.76079625064072"/>
<DICH_DATA CI_END="16.792357344735667" CI_START="0.23820360166727778" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2251116675464473" LOG_CI_START="-0.6230516762184848" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="7370" O_E="0.0" SE="1.0856202966836188" STUDY_ID="STD-France-1988" TOTAL_1="42" TOTAL_2="21" VAR="1.1785714285714286" WEIGHT="5.347467880544798"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7371" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-India-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="7.672522132063415"/>
<DICH_DATA CI_END="1.0964350618752745" CI_START="0.05474560426527857" EFFECT_SIZE="0.245" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.03998291498811603" LOG_CI_START="-1.2616507462590512" LOG_EFFECT_SIZE="-0.6108339156354675" MODIFIED="2013-05-20 18:46:46 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="752" O_E="0.0" SE="0.7645860558071236" STUDY_ID="STD-India-2012" TOTAL_1="50" TOTAL_2="49" VAR="0.5845918367346938" WEIGHT="8.571228321058431"/>
<DICH_DATA CI_END="0.8284745859967708" CI_START="0.22170078900702814" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.08172080930939987" LOG_CI_START="-0.654232761279789" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="7372" O_E="0.0" SE="0.33629635456727464" STUDY_ID="STD-Israel-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.11309523809523808" WEIGHT="16.437098527804483"/>
<DICH_DATA CI_END="3.2923190646397895" CI_START="0.009125617491672728" EFFECT_SIZE="0.17333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5175019168493984" LOG_CI_START="-2.0397377390191247" LOG_EFFECT_SIZE="-0.7611179110848633" ORDER="7373" O_E="0.0" SE="1.5021352323976214" STUDY_ID="STD-UK-1980" TOTAL_1="14" TOTAL_2="12" VAR="2.256410256410256" WEIGHT="3.1782889527871903"/>
<DICH_DATA CI_END="1.3499529532340937" CI_START="0.8693718609226202" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" LOG_CI_END="0.13031863330474133" LOG_CI_START="-0.060794420786317534" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="7374" O_E="0.0" SE="0.11226075399796302" STUDY_ID="STD-UK-1983a" TOTAL_1="49" TOTAL_2="49" VAR="0.012602476888191171" WEIGHT="20.43388414518124"/>
<DICH_DATA CI_END="3.3695867262928925" CI_START="0.30371410659610737" EFFECT_SIZE="1.0116279069767442" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5275766387061566" LOG_CI_START="-0.517535035956055" LOG_EFFECT_SIZE="0.005020801375050812" ORDER="7375" O_E="0.0" SE="0.6139037710828079" STUDY_ID="STD-USA-1990" TOTAL_1="86" TOTAL_2="87" VAR="0.3768778401496926" WEIGHT="10.860909473299634"/>
<DICH_DATA CI_END="1.4250621258752751" CI_START="0.02466997709198606" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15383379791413418" LOG_CI_START="-1.607831253786659" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="7376" O_E="0.0" SE="1.0348107717516923" STUDY_ID="STD-Venezuela-1988" TOTAL_1="16" TOTAL_2="15" VAR="1.0708333333333333" WEIGHT="5.738986741582176"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01517421350087278" CI_END="1.2239061247145897" CI_START="0.044319525039380886" DF="1" EFFECT_SIZE="0.23290113383180402" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.08774810810207513" LOG_CI_START="-1.353404902473699" LOG_EFFECT_SIZE="-0.6328283971858119" NO="2" P_CHI2="0.9019616695960653" P_Z="0.08519828012011006" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="8.998817575037924" Z="1.7212896309779946">
<NAME>Calcium channel blockers versus methyldopa</NAME>
<DICH_DATA CI_END="1.8627820278251161" CI_START="0.03355196639564513" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2701620391951836" LOG_CI_START="-1.4742820218511086" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="7377" O_E="0.0" SE="1.0246950765959597" STUDY_ID="STD-Italy-2000" TOTAL_1="10" TOTAL_2="10" VAR="1.0499999999999998" WEIGHT="5.821404683296224"/>
<DICH_DATA CI_END="3.8006456018408334" CI_START="0.01052452772250749" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5798573749067983" LOG_CI_START="-1.9777973835788358" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="7378" O_E="0.0" SE="1.5023790657297034" STUDY_ID="STD-South-Africa-1993" TOTAL_1="13" TOTAL_2="13" VAR="2.2571428571428567" WEIGHT="3.177412891741699"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.769483553805365" CI_END="0.9866128298386933" CI_START="0.5414823822216622" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.73091276184748" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.005853241304528737" LOG_CI_START="-0.26641566910031605" LOG_EFFECT_SIZE="-0.13613445520242243" METHOD="MH" MODIFIED="2013-05-20 18:47:55 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.6513420901604117" P_Q="0.7351070051465446" P_Z="0.040557966368018526" Q="0.11447397826942597" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="513" TOTAL_2="484" WEIGHT="100.0" Z="2.0480207488766973">
<NAME>Proteinuria/pre-eclampsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.516724156361778" CI_END="1.0482006071476337" CI_START="0.5346036186459215" DF="9" EFFECT_SIZE="0.7485798806059224" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="64" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.020444406922375633" LOG_CI_START="-0.2719681059000262" LOG_EFFECT_SIZE="-0.12576184948882527" MODIFIED="2013-05-20 18:47:55 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.583482766780663" P_Z="0.09181563123404214" STUDIES="10" TAU2="0.0" TOTAL_1="470" TOTAL_2="433" WEIGHT="80.29656072688549" Z="1.6858970448843327">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="4.183096553588057" CI_START="0.5378790499277525" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6214978890144232" LOG_CI_START="-0.2693153709030606" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="7379" O_E="0.0" SE="0.5232681184722836" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="0.27380952380952384" WEIGHT="4.785848298896031"/>
<DICH_DATA CI_END="2.6137650764263043" CI_START="0.20109879221382276" EFFECT_SIZE="0.725" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.41726655088163156" LOG_CI_START="-0.6965905377396442" LOG_EFFECT_SIZE="-0.13966199342900631" ORDER="7380" O_E="0.0" SE="0.6542851675376495" STUDY_ID="STD-Australia-1985" TOTAL_1="96" TOTAL_2="87" VAR="0.4280890804597701" WEIGHT="6.27652235920791"/>
<DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="7381" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Brazil-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="4.785848298896031"/>
<DICH_DATA CI_END="2.377652263320506" CI_START="0.36694986169424393" EFFECT_SIZE="0.9340659340659341" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3761483384390952" LOG_CI_START="-0.435393271652697" LOG_EFFECT_SIZE="-0.02962246660680086" ORDER="7382" O_E="0.0" SE="0.4767035589636772" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="85" VAR="0.2272462831286361" WEIGHT="9.898004436353157"/>
<DICH_DATA CI_END="2.658238642988837" CI_START="0.28801966370451826" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.4245939670810792" LOG_CI_START="-0.5405778610364528" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="7383" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-France-1988" TOTAL_1="42" TOTAL_2="21" VAR="0.32142857142857145" WEIGHT="6.381131065194708"/>
<DICH_DATA CI_END="1.1354323892172955" CI_START="0.09398279644345173" EFFECT_SIZE="0.32666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.055161278701895015" LOG_CI_START="-1.0269516367562301" LOG_EFFECT_SIZE="-0.4858951790271676" MODIFIED="2013-05-20 18:47:55 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="753" O_E="0.0" SE="0.6356384830854235" STUDY_ID="STD-India-2012" TOTAL_1="50" TOTAL_2="49" VAR="0.40403628117913826" WEIGHT="10.876927952036436"/>
<DICH_DATA CI_END="4.03767303864423" CI_START="0.012230489090311394" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6061311478761283" LOG_CI_START="-1.9125561754268157" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="7384" O_E="0.0" SE="1.4794894014114763" STUDY_ID="STD-Israel-1986" TOTAL_1="8" TOTAL_2="9" VAR="2.1888888888888887" WEIGHT="2.8337259664515972"/>
<DICH_DATA CI_END="1.2932735129283135" CI_START="0.0047998584845660285" EFFECT_SIZE="0.07878787878787878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.11169038303487368" LOG_CI_START="-2.318771566849013" LOG_EFFECT_SIZE="-1.1035405919070695" ORDER="7385" O_E="0.0" SE="1.42766538034248" STUDY_ID="STD-UK-1980" TOTAL_1="14" TOTAL_2="12" VAR="2.0382284382284377" WEIGHT="7.0505800831950465"/>
<DICH_DATA CI_END="2.6377614694052958" CI_START="0.379109336306083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42123552009404736" LOG_CI_START="-0.42123552009404736" LOG_EFFECT_SIZE="0.0" ORDER="7386" O_E="0.0" SE="0.49487165930539345" STUDY_ID="STD-UK-1983a" TOTAL_1="49" TOTAL_2="49" VAR="0.24489795918367344" WEIGHT="8.375234523068055"/>
<DICH_DATA CI_END="1.6997043816774" CI_START="0.46098236834503564" EFFECT_SIZE="0.8851744186046512" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.23037339398402742" LOG_CI_START="-0.33631568518929933" LOG_EFFECT_SIZE="-0.052971145602635945" ORDER="7387" O_E="0.0" SE="0.332875970262595" STUDY_ID="STD-USA-1990" TOTAL_1="86" TOTAL_2="87" VAR="0.11080641157826403" WEIGHT="19.032737743586527"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2722553561180499" CI_START="0.3412590228734025" DF="0" EFFECT_SIZE="0.6589147286821705" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.10457428790266537" LOG_CI_START="-0.4669158570725779" LOG_EFFECT_SIZE="-0.18117078458495625" MODIFIED="2013-05-20 15:10:39 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="1.0" P_Z="0.2139877021148" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="51" WEIGHT="19.703439273114512" Z="1.2426748421103955">
<NAME>Calcium channel blockers versus methyldopa</NAME>
<DICH_DATA CI_END="1.27225535611805" CI_START="0.3412590228734024" EFFECT_SIZE="0.6589147286821705" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.10457428790266544" LOG_CI_START="-0.466915857072578" LOG_EFFECT_SIZE="-0.18117078458495625" MODIFIED="2013-05-20 15:10:39 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="719" O_E="0.0" SE="0.33569614008029985" STUDY_ID="STD-India-2002" TOTAL_1="43" TOTAL_2="51" VAR="0.1126918984648123" WEIGHT="19.703439273114512"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.67832352073362" CI_END="1.0636920274949897" CI_START="0.6640907163067242" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8404689170153168" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="105" I2="53.870971662380704" I2_Q="3.3695319743110397" ID="CMP-005.03" LOG_CI_END="0.02681590416187304" LOG_CI_START="-0.17777259096269635" LOG_EFFECT_SIZE="-0.07547834340041168" METHOD="MH" MODIFIED="2013-05-20 15:11:47 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" P_CHI2="0.016829898992859693" P_Q="0.3090178392615759" P_Z="0.14812962820981884" Q="1.0348702851508" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="512" TOTAL_2="477" WEIGHT="100.0" Z="1.4461696351740514">
<NAME>Additional antihypertensive</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="20.16638824726172" CI_END="1.1339246519866528" CI_START="0.6887585716146272" DF="8" EFFECT_SIZE="0.883742226908356" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="89" I2="60.33003083193999" ID="CMP-005.03.01" LOG_CI_END="0.054584197137482394" LOG_CI_START="-0.1619329833027436" LOG_EFFECT_SIZE="-0.0536743930826306" NO="1" P_CHI2="0.009724558247382054" P_Z="0.33117682216923816" STUDIES="10" TAU2="0.0" TOTAL_1="445" TOTAL_2="408" WEIGHT="85.02086192635085" Z="0.9717462339026202">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="2.3951894492294183" CI_START="0.10437587727368712" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3793398699430588" LOG_CI_START="-0.9813998612710212" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7388" O_E="0.0" SE="0.7993052538854533" STUDY_ID="STD-Argentina-1988" TOTAL_1="18" TOTAL_2="18" VAR="0.6388888888888888" WEIGHT="3.6882041143847935"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7389" O_E="0.0" SE="0.0" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9855967277198625" CI_START="0.9724743263931308" EFFECT_SIZE="1.3895833333333334" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="30" LOG_CI_END="0.29789104843427894" LOG_CI_START="-0.012121855352355361" LOG_EFFECT_SIZE="0.14288459654096178" ORDER="7390" O_E="0.0" SE="0.18210311427289227" STUDY_ID="STD-Australia-1985" TOTAL_1="96" TOTAL_2="87" VAR="0.03316154422788606" WEIGHT="29.02193401483116"/>
<DICH_DATA CI_END="1.2099661875687906" CI_START="0.16325321007063315" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.08277323415325047" LOG_CI_START="-0.7871382703759754" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="7391" O_E="0.0" SE="0.510990323891863" STUDY_ID="STD-Brazil-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.2611111111111111" WEIGHT="8.298459257365785"/>
<DICH_DATA CI_END="0.9645214636354213" CI_START="0.26912887794378576" EFFECT_SIZE="0.5094905094905094" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.01568810349473895" LOG_CI_START="-0.5700396992680257" LOG_EFFECT_SIZE="-0.2928639013813823" ORDER="7392" O_E="0.0" SE="0.32562887144188374" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="85" VAR="0.10603416191651485" WEIGHT="20.976660900563513"/>
<DICH_DATA CI_END="16.792357344735667" CI_START="0.23820360166727778" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2251116675464473" LOG_CI_START="-0.6230516762184848" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="7393" O_E="0.0" SE="1.0856202966836188" STUDY_ID="STD-France-1988" TOTAL_1="42" TOTAL_2="21" VAR="1.1785714285714286" WEIGHT="1.2294013714615977"/>
<DICH_DATA CI_END="0.8284745859967708" CI_START="0.22170078900702814" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.08172080930939987" LOG_CI_START="-0.654232761279789" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="7394" O_E="0.0" SE="0.33629635456727464" STUDY_ID="STD-Israel-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.11309523809523808" WEIGHT="12.908714400346778"/>
<DICH_DATA CI_END="3.2923190646397895" CI_START="0.009125617491672728" EFFECT_SIZE="0.17333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5175019168493984" LOG_CI_START="-2.0397377390191247" LOG_EFFECT_SIZE="-0.7611179110848633" ORDER="7395" O_E="0.0" SE="1.5021352323976214" STUDY_ID="STD-UK-1980" TOTAL_1="14" TOTAL_2="12" VAR="2.256410256410256" WEIGHT="2.469779540882674"/>
<DICH_DATA CI_END="14.127169659225064" CI_START="0.6370702849259677" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1500551608219594" LOG_CI_START="-0.19581265138263457" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7396" O_E="0.0" SE="0.7905694150420948" STUDY_ID="STD-UK-1983a" TOTAL_1="48" TOTAL_2="48" VAR="0.6249999999999999" WEIGHT="1.8441020571923967"/>
<DICH_DATA CI_END="3.3695867262928925" CI_START="0.30371410659610737" EFFECT_SIZE="1.0116279069767442" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5275766387061566" LOG_CI_START="-0.517535035956055" LOG_EFFECT_SIZE="0.005020801375050812" ORDER="7397" O_E="0.0" SE="0.6139037710828079" STUDY_ID="STD-USA-1990" TOTAL_1="86" TOTAL_2="87" VAR="0.3768778401496926" WEIGHT="4.583606269322142"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6152479123351244" CI_END="1.2230461685217628" CI_START="0.28931741266660427" DF="1" EFFECT_SIZE="0.5948517067711248" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.08744285144003765" LOG_CI_START="-0.5386254274047327" LOG_EFFECT_SIZE="-0.2255912879823475" MODIFIED="2013-05-20 15:11:47 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.4328188854283008" P_Z="0.15781211735241552" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="69" WEIGHT="14.979138073649152" Z="1.4124683029373963">
<NAME>Calcium channel blocker versus methyldopa</NAME>
<DICH_DATA CI_END="1.4103764164436696" CI_START="0.31512469952179994" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.1493350373130964" LOG_CI_START="-0.501517555424459" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-05-20 15:11:47 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="720" O_E="0.0" SE="0.38231403474633413" STUDY_ID="STD-India-2002" TOTAL_1="54" TOTAL_2="56" VAR="0.14616402116402116" WEIGHT="12.674010502158655"/>
<DICH_DATA CI_END="3.8006456018408334" CI_START="0.01052452772250749" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5798573749067983" LOG_CI_START="-1.9777973835788358" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="7398" O_E="0.0" SE="1.5023790657297034" STUDY_ID="STD-South-Africa-1993" TOTAL_1="13" TOTAL_2="13" VAR="2.2571428571428567" WEIGHT="2.305127571490496"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.885567712516142" CI_END="1.0307893934782282" CI_START="0.5825114072271318" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7748848818694325" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" I2="74.26373508358091" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.013169941138493997" LOG_CI_START="-0.2346955654997302" LOG_EFFECT_SIZE="-0.11076281218061809" METHOD="MH" MODIFIED="2013-05-20 18:48:59 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" P_CHI2="0.04870285019837828" P_Q="1.0" P_Z="0.07982801851462094" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="134" WEIGHT="100.00000000000001" Z="1.7516848200846635">
<NAME>Antenatal hospital admission</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.885567712516142" CI_END="1.0307893934782282" CI_START="0.5825114072271318" DF="1" EFFECT_SIZE="0.7748848818694325" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" I2="74.26373508358091" ID="CMP-005.04.01" LOG_CI_END="0.013169941138493997" LOG_CI_START="-0.2346955654997302" LOG_EFFECT_SIZE="-0.11076281218061809" MODIFIED="2013-05-20 18:48:59 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.04870285019837828" P_Z="0.07982801851462094" STUDIES="2" TAU2="0.0" TOTAL_1="141" TOTAL_2="134" WEIGHT="100.00000000000001" Z="1.7516848200846635">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="1.1926110882057055" CI_START="0.6693386655813064" EFFECT_SIZE="0.8934543717152413" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="46" LOG_CI_END="0.07649884284651896" LOG_CI_START="-0.17435408645089395" LOG_EFFECT_SIZE="-0.04892762180218748" ORDER="7399" O_E="0.0" SE="0.14735225241132693" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="85" VAR="0.021712686290691403" WEIGHT="81.06468132719371"/>
<DICH_DATA CI_END="0.9001421654626139" CI_START="0.07935936509216729" EFFECT_SIZE="0.2672727272727273" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.045688894116190475" LOG_CI_START="-1.1004018153759452" LOG_EFFECT_SIZE="-0.5730453547460678" MODIFIED="2013-05-20 18:48:59 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="754" O_E="0.0" SE="0.619543590861142" STUDY_ID="STD-India-2012" TOTAL_1="50" TOTAL_2="49" VAR="0.38383426097711804" WEIGHT="18.9353186728063"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.540769161347352" CI_END="1.182641587555084" CI_START="0.8599334453283738" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0084607354651252" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="111" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.07285314688372233" LOG_CI_START="-0.0655351597391422" LOG_EFFECT_SIZE="0.0036589935722900965" METHOD="MH" MODIFIED="2013-05-22 17:12:28 +0100" MODIFIED_BY="Edgardo J Abalos" NO="5" P_CHI2="0.4717064942171346" P_Q="0.35179586181997247" P_Z="0.9174525936424264" Q="0.8669690604087484" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="225" TOTAL_2="218" WEIGHT="100.00000000000001" Z="0.10364308656360521">
<NAME>Elective delivery (induction of labour + elective caesarean section)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.793196759245558" CI_END="1.1450343293230372" CI_START="0.8362479622908716" DF="3" EFFECT_SIZE="0.9785359598141934" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="105" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.05881850747247105" LOG_CI_START="-0.07766492748051317" LOG_EFFECT_SIZE="-0.00942321000402105" MODIFIED="2013-05-22 17:12:28 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.4246211712069573" P_Z="0.7866655183073765" STUDIES="4" TAU2="0.0" TOTAL_1="171" TOTAL_2="162" WEIGHT="94.81390651690366" Z="0.2706431331099053">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="1.2288068393165141" CI_START="0.7387062787853074" EFFECT_SIZE="0.9527472527472527" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="50" LOG_CI_END="0.08948361989866403" LOG_CI_START="-0.13152820958843076" LOG_EFFECT_SIZE="-0.02102229484488333" ORDER="7400" O_E="0.0" SE="0.12982344266691964" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="85" VAR="0.016854126265890973" WEIGHT="45.518374514059424"/>
<DICH_DATA CI_END="1.1527433799863243" CI_START="0.4079000493919397" EFFECT_SIZE="0.6857142857142857" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.061732636817565405" LOG_CI_START="-0.3894462420949045" LOG_EFFECT_SIZE="-0.1638568026386696" ORDER="7401" O_E="0.0" SE="0.26502470684465484" STUDY_ID="STD-UK-1980" TOTAL_1="14" TOTAL_2="12" VAR="0.07023809523809525" WEIGHT="9.480750194644331"/>
<DICH_DATA CI_END="1.3215209514069968" CI_START="0.8808997107335238" EFFECT_SIZE="1.0789473684210527" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="38" LOG_CI_END="0.12107405283157173" LOG_CI_START="-0.05507353262572108" LOG_EFFECT_SIZE="0.033000260102925345" ORDER="7402" O_E="0.0" SE="0.10346996364222437" STUDY_ID="STD-UK-1983a" TOTAL_1="50" TOTAL_2="50" VAR="0.010706033376123233" WEIGHT="33.45350425824499"/>
<DICH_DATA CI_END="2.2231083981437054" CI_START="0.5163757127776653" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3469606392927456" LOG_CI_START="-0.28703419253785917" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="7403" O_E="0.0" SE="0.3724117025423291" STUDY_ID="STD-Venezuela-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.1386904761904762" WEIGHT="6.361277549954905"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.074775969720382" CI_START="0.5938370856216177" DF="0" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="0.6101037363180076" LOG_CI_START="-0.22633268384018135" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2013-05-20 15:13:37 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="1.0" P_Z="0.3685118894973546" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="56" WEIGHT="5.186093483096353" Z="0.8992643350265845">
<NAME>Calcium channel blocker versus methyldopa</NAME>
<DICH_DATA CI_END="4.074775969720383" CI_START="0.5938370856216177" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6101037363180077" LOG_CI_START="-0.22633268384018135" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2013-05-20 15:13:37 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="721" O_E="0.0" SE="0.491326893627976" STUDY_ID="STD-India-2002" TOTAL_1="54" TOTAL_2="56" VAR="0.24140211640211645" WEIGHT="5.186093483096353"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3759168402161106" CI_END="1.118395732663321" CI_START="0.7755761085532697" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9313436584642649" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="150" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.04859550131620936" LOG_CI_START="-0.11037557773063493" LOG_EFFECT_SIZE="-0.030890038207212814" METHOD="MH" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="6" P_CHI2="0.9475114209228699" P_Q="0.6819441775816192" P_Z="0.4462448878816281" Q="0.16794581077045462" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="448" TOTAL_2="430" WEIGHT="100.0" Z="0.7616902738562017">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.196307858778" CI_END="1.126012657689156" CI_START="0.7791012742905515" DF="8" EFFECT_SIZE="0.9366311421647863" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="147" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.05154327251679878" LOG_CI_START="-0.108406085322576" LOG_EFFECT_SIZE="-0.028431406402888614" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.9214407637245783" P_Z="0.48594224383556806" STUDIES="9" TAU2="0.0" TOTAL_1="435" TOTAL_2="417" WEIGHT="98.04141500811718" Z="0.6967771966354899">
<NAME>Beta blocker veresus methyldopa</NAME>
<DICH_DATA CI_END="1.683996986298216" CI_START="0.5938252907436687" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.22634130994556298" LOG_CI_START="-0.22634130994556295" LOG_EFFECT_SIZE="0.0" ORDER="7404" O_E="0.0" SE="0.26590801173915524" STUDY_ID="STD-Argentina-1988" TOTAL_1="18" TOTAL_2="18" VAR="0.07070707070707072" WEIGHT="7.181478303570344"/>
<DICH_DATA CI_END="3.2261920626934746" CI_START="0.30996294720442735" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5086902183799912" LOG_CI_START="-0.5086902183799912" LOG_EFFECT_SIZE="0.0" ORDER="7405" O_E="0.0" SE="0.5976143046671969" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="0.3571428571428572" WEIGHT="2.6114466558437615"/>
<DICH_DATA CI_END="1.3174671058609424" CI_START="0.6575367088780936" EFFECT_SIZE="0.9307432432432432" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="37" LOG_CI_END="0.11973978068047086" LOG_CI_START="-0.18207999642274036" LOG_EFFECT_SIZE="-0.03117010787113475" ORDER="7406" O_E="0.0" SE="0.17729043110241838" STUDY_ID="STD-Australia-1985" TOTAL_1="96" TOTAL_2="87" VAR="0.031431896960481355" WEIGHT="25.343875741959128"/>
<DICH_DATA CI_END="1.710757736046539" CI_START="0.725008746554982" EFFECT_SIZE="1.113693998309383" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" LOG_CI_END="0.23318851255245046" LOG_CI_START="-0.1396567540391427" LOG_EFFECT_SIZE="0.04676587925665387" ORDER="7407" O_E="0.0" SE="0.21901115520973713" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="85" VAR="0.04796588610630356" WEIGHT="17.553076101495282"/>
<DICH_DATA CI_END="1.4407048413834183" CI_START="0.3195033749797015" EFFECT_SIZE="0.6784615384615384" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.15857501558960194" LOG_CI_START="-0.495524549939636" LOG_EFFECT_SIZE="-0.16847476717501705" MODIFIED="2013-05-20 18:49:55 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="755" O_E="0.0" SE="0.3842213226369431" STUDY_ID="STD-India-2012" TOTAL_1="50" TOTAL_2="49" VAR="0.14762602476888192" WEIGHT="8.572930940901237"/>
<DICH_DATA CI_END="1.9890720084146771" CI_START="0.23639369497106014" EFFECT_SIZE="0.6857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.2986505057443792" LOG_CI_START="-0.6263641110217183" LOG_EFFECT_SIZE="-0.1638568026386696" ORDER="7408" O_E="0.0" SE="0.5433581647846062" STUDY_ID="STD-UK-1980" TOTAL_1="14" TOTAL_2="12" VAR="0.29523809523809524" WEIGHT="3.515408959789679"/>
<DICH_DATA CI_END="1.3302265160564297" CI_START="0.3553201235239467" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.1239256005889555" LOG_CI_START="-0.4493801955843551" LOG_EFFECT_SIZE="-0.16272729749769974" ORDER="7409" O_E="0.0" SE="0.3367626625816629" STUDY_ID="STD-UK-1983a" TOTAL_1="50" TOTAL_2="50" VAR="0.11340909090909092" WEIGHT="10.445786623375046"/>
<DICH_DATA CI_END="1.4662112153747413" CI_START="0.6536784795443666" EFFECT_SIZE="0.9789947486871718" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" LOG_CI_END="0.16619653719757646" LOG_CI_START="-0.1846358126766953" LOG_EFFECT_SIZE="-0.009219637739559416" ORDER="7410" O_E="0.0" SE="0.20608065896428746" STUDY_ID="STD-USA-1990" TOTAL_1="86" TOTAL_2="87" VAR="0.04246923799915495" WEIGHT="20.1217248106343"/>
<DICH_DATA CI_END="4.0222449608053426" CI_START="0.49165057866193523" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.604468516257359" LOG_CI_START="-0.30834344534648367" LOG_EFFECT_SIZE="0.1480625354554377" ORDER="7411" O_E="0.0" SE="0.5361902647381804" STUDY_ID="STD-Venezuela-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.2875" WEIGHT="2.695686870548399"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3539979285169768" CI_START="0.13251184226013002" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="0.5255627900428981" LOG_CI_START="-0.8777453081542606" LOG_EFFECT_SIZE="-0.17609125905568127" NO="2" P_CHI2="1.0" P_Z="0.6228012251566366" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="1.958584991882821" Z="0.49188417879843">
<NAME>Calcium channel blocker versus methyldopa</NAME>
<DICH_DATA CI_END="3.353997928516977" CI_START="0.13251184226012996" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5255627900428982" LOG_CI_START="-0.8777453081542608" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7412" O_E="0.0" SE="0.8243101233681287" STUDY_ID="STD-South-Africa-1993" TOTAL_1="13" TOTAL_2="13" VAR="0.6794871794871795" WEIGHT="1.958584991882821"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.279805196169441" CI_END="0.9140867502724975" CI_START="0.5175732126449154" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6878276062900406" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="65" I2="82.26919733791867" I2_Q="100.00000000000001" ID="CMP-005.07" LOG_CI_END="-0.03901258612958732" LOG_CI_START="-0.28602820896521636" LOG_EFFECT_SIZE="-0.16252039754740183" METHOD="MH" MODIFIED="2013-05-20 20:34:24 +0100" MODIFIED_BY="Edgardo J Abalos" NO="7" P_CHI2="0.0035532223881593605" P_Q="0.0" P_Z="0.00990694153828444" Q="1.4636472494233058E-31" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="206" TOTAL_2="206" WEIGHT="99.99999999999997" Z="2.579060565395904">
<NAME>Maternal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.279805196169441" CI_END="0.9140867502724975" CI_START="0.5175732126449154" DF="2" EFFECT_SIZE="0.6878276062900406" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="65" I2="82.26919733791867" ID="CMP-005.07.01" LOG_CI_END="-0.03901258612958732" LOG_CI_START="-0.28602820896521636" LOG_EFFECT_SIZE="-0.16252039754740183" MODIFIED="2013-05-20 20:34:24 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.0035532223881593605" P_Z="0.00990694153828444" STUDIES="5" TAU2="0.0" TOTAL_1="152" TOTAL_2="150" WEIGHT="99.99999999999997" Z="2.579060565395904">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7413" O_E="0.0" SE="0.0" STUDY_ID="STD-Argentina-1988" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6729986466858204" CI_START="0.0028088602815934836" EFFECT_SIZE="0.043478260869565216" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.17198580908578748" LOG_CI_START="-2.551469862949398" LOG_EFFECT_SIZE="-1.3617278360175928" ORDER="7414" O_E="0.0" SE="1.397720711875515" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="1.9536231884057969" WEIGHT="17.414094350611528"/>
<DICH_DATA CI_END="1.2502023297562521" CI_START="0.7010182643325659" EFFECT_SIZE="0.9361702127659575" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="47" LOG_CI_END="0.09698030387676823" LOG_CI_START="-0.15427066677582832" LOG_EFFECT_SIZE="-0.028645181449530023" MODIFIED="2013-05-20 20:34:24 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="760" O_E="0.0" SE="0.14758606387369827" STUDY_ID="STD-India-2013" TOTAL_1="90" TOTAL_2="90" VAR="0.02178164624973135" WEIGHT="71.17064647641233"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7415" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8591616193494213" CI_START="0.01745160894691234" EFFECT_SIZE="0.12244897959183673" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.06592513210664969" LOG_CI_START="-1.7581645271830901" LOG_EFFECT_SIZE="-0.91204482964487" ORDER="7416" O_E="0.0" SE="0.9940297973880049" STUDY_ID="STD-UK-1980" TOTAL_1="14" TOTAL_2="12" VAR="0.988095238095238" WEIGHT="11.41525917297612"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-20 15:14:55 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Calcium channel blockers versus methyldopa</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-20 15:14:55 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="722" O_E="0.0" SE="0.0" STUDY_ID="STD-India-2002" TOTAL_1="54" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.91447198942267" CI_START="0.1157980986865873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8043478260869565" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="1.831962328558115" LOG_CI_START="-0.9362985713227655" LOG_EFFECT_SIZE="0.4478318786176749" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.5259885824346688" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="139" TOTAL_2="133" WEIGHT="100.0" Z="0.6341413508078846">
<NAME>Changed/stopped drugs due to maternal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.91447198942267" CI_START="0.1157980986865873" DF="0" EFFECT_SIZE="2.8043478260869565" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-005.08.01" LOG_CI_END="1.831962328558115" LOG_CI_START="-0.9362985713227655" LOG_EFFECT_SIZE="0.4478318786176749" NO="1" P_CHI2="1.0" P_Z="0.5259885824346688" STUDIES="4" TAU2="0.0" TOTAL_1="139" TOTAL_2="133" WEIGHT="100.0" Z="0.6341413508078846">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7417" O_E="0.0" SE="0.0" STUDY_ID="STD-Argentina-1988" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7418" O_E="0.0" SE="0.0" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.91447198942267" CI_START="0.1157980986865873" EFFECT_SIZE="2.8043478260869565" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.831962328558115" LOG_CI_START="-0.9362985713227655" LOG_EFFECT_SIZE="0.4478318786176749" ORDER="7419" O_E="0.0" SE="1.6260901557024847" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="85" VAR="2.644169194472531" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7420" O_E="0.0" SE="0.0" STUDY_ID="STD-Israel-1986" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.902280130567465" CI_START="0.18690127531441325" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0232558139534884" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="1.340489329295686" LOG_CI_START="-0.728387735217622" LOG_EFFECT_SIZE="0.306050797039032" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.5619966396350728" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="87" WEIGHT="100.0" Z="0.57987837936363">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.902280130567465" CI_START="0.18690127531441325" DF="0" EFFECT_SIZE="2.0232558139534884" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="1.340489329295686" LOG_CI_START="-0.728387735217622" LOG_EFFECT_SIZE="0.306050797039032" NO="1" P_CHI2="1.0" P_Z="0.5619966396350728" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="87" WEIGHT="100.0" Z="0.57987837936363">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="21.902280130567465" CI_START="0.18690127531441325" EFFECT_SIZE="2.0232558139534884" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.340489329295686" LOG_CI_START="-0.728387735217622" LOG_EFFECT_SIZE="0.306050797039032" ORDER="7421" O_E="0.0" SE="1.215268628801753" STUDY_ID="STD-USA-1990" TOTAL_1="86" TOTAL_2="87" VAR="1.4768778401496925" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.430971525360261" CI_END="1.2691430748207595" CI_START="0.41782571899061655" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7282036924782418" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="0.10351058435048727" LOG_CI_START="-0.3790048308183033" LOG_EFFECT_SIZE="-0.137747123233908" METHOD="MH" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="10" P_CHI2="0.8785984947011363" P_Q="0.4934900387327399" P_Z="0.2631188927024345" Q="1.4125054696186456" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="689" TOTAL_2="650" WEIGHT="100.0" Z="1.119049845974424">
<NAME>Total reported fetal or neonatal death (including miscarriage)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.00619352557598" CI_END="1.3335999530287037" CI_START="0.40493673206328" DF="11" EFFECT_SIZE="0.7348629850925865" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" ID="CMP-005.10.01" LOG_CI_END="0.12502557152347685" LOG_CI_START="-0.39261282632163974" LOG_EFFECT_SIZE="-0.13379362739908143" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.8729507359150767" P_Z="0.31097373485186874" STUDIES="15" TAU2="0.0" TOTAL_1="600" TOTAL_2="560" WEIGHT="86.85297263911845" Z="1.013180985625543">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="7422" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Argentina-1985" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="3.648457353737465"/>
<DICH_DATA CI_END="14.786473993825217" CI_START="0.06762937536140103" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" ORDER="7423" O_E="0.0" SE="1.3743685418725535" STUDY_ID="STD-Argentina-1988" TOTAL_1="18" TOTAL_2="18" VAR="1.8888888888888888" WEIGHT="3.648457353737465"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7424" O_E="0.0" SE="0.0" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9883031671645162" CI_START="0.025816267485733378" EFFECT_SIZE="0.2265625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.29848260430092793" LOG_CI_START="-1.5881065477987526" LOG_EFFECT_SIZE="-0.6448119717489122" ORDER="7425" O_E="0.0" SE="1.108191806710269" STUDY_ID="STD-Australia-1985" TOTAL_1="96" TOTAL_2="87" VAR="1.22808908045977" WEIGHT="15.311558730439199"/>
<DICH_DATA CI_END="9.711596264208866" CI_START="0.41187873663381236" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9872906193787466" LOG_CI_START="-0.3852306280507843" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="7426" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Brazil-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="7.29691470747493"/>
<DICH_DATA CI_END="2.047803997619256" CI_START="0.026628499669548333" EFFECT_SIZE="0.23351648351648352" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31128838647080337" LOG_CI_START="-1.57465330234033" LOG_EFFECT_SIZE="-0.6316824579347633" ORDER="7427" O_E="0.0" SE="1.1078114835695811" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="85" VAR="1.2272462831286362" WEIGHT="15.091346326823153"/>
<DICH_DATA CI_END="7.604300153978122" CI_START="0.03287613520479129" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8810592508346102" LOG_CI_START="-1.4831192421625727" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7428" O_E="0.0" SE="1.3887301496588271" STUDY_ID="STD-France-1988" TOTAL_1="42" TOTAL_2="21" VAR="1.9285714285714286" WEIGHT="4.864609804983287"/>
<DICH_DATA CI_END="2.6848004915933457" CI_START="0.03637374557468292" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4289120186689645" LOG_CI_START="-1.4392119753087764" LOG_EFFECT_SIZE="-0.5051499783199059" ORDER="7429" O_E="0.0" SE="1.0973452814254347" STUDY_ID="STD-India-1992" TOTAL_1="16" TOTAL_2="15" VAR="1.2041666666666666" WEIGHT="11.298448579316021"/>
<DICH_DATA CI_END="8.41940118924036" CI_START="0.2566572077312978" EFFECT_SIZE="1.47" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9252812043908025" LOG_CI_START="-0.5906465348944505" LOG_EFFECT_SIZE="0.1673173347481761" MODIFIED="2013-05-20 18:50:55 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="756" O_E="0.0" SE="0.8904634580194895" STUDY_ID="STD-India-2012" TOTAL_1="50" TOTAL_2="49" VAR="0.7929251700680271" WEIGHT="7.370620916641344"/>
<DICH_DATA CI_END="14.640493479420055" CI_START="0.06830370857414654" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1655557155049627" LOG_CI_START="-1.1655557155049627" LOG_EFFECT_SIZE="0.0" ORDER="7430" O_E="0.0" SE="1.3693063937629153" STUDY_ID="STD-Israel-1986" TOTAL_1="16" TOTAL_2="16" VAR="1.875" WEIGHT="3.648457353737465"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7431" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1980" TOTAL_1="14" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.548273108710726" CI_START="0.06431582420814068" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1916821605007981" LOG_CI_START="-1.1916821605007981" LOG_EFFECT_SIZE="0.0" ORDER="7432" O_E="0.0" SE="1.4" STUDY_ID="STD-UK-1983a" TOTAL_1="50" TOTAL_2="50" VAR="1.96" WEIGHT="3.648457353737465"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7433" O_E="0.0" SE="0.0" STUDY_ID="STD-UK-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.4799438184416145" CI_START="0.04656639154246898" EFFECT_SIZE="0.5051546391752577" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7387761060270945" LOG_CI_START="-1.331927414502557" LOG_EFFECT_SIZE="-0.2965756542377312" ORDER="7434" O_E="0.0" SE="1.2163414981068563" STUDY_ID="STD-USA-1990" TOTAL_1="97" TOTAL_2="98" VAR="1.4794866400168316" WEIGHT="7.259494632051982"/>
<DICH_DATA CI_END="13.684571710013993" CI_START="0.0642260692277889" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1362312097192329" LOG_CI_START="-1.19228865691972" LOG_EFFECT_SIZE="-0.028028723600243537" ORDER="7435" O_E="0.0" SE="1.3677840960229555" STUDY_ID="STD-Venezuela-1988" TOTAL_1="16" TOTAL_2="15" VAR="1.8708333333333333" WEIGHT="3.7661495264386735"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6516009553217734" CI_START="0.0365025224713892" DF="0" EFFECT_SIZE="0.3111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-005.10.02" LOG_CI_END="0.4235081668136251" LOG_CI_START="-1.4376771230078365" LOG_EFFECT_SIZE="-0.5070844780971057" MODIFIED="2013-05-20 15:16:56 +0100" MODIFIED_BY="Edgardo J Abalos" NO="2" P_CHI2="1.0" P_Z="0.2855232571069155" STUDIES="3" TAU2="0.0" TOTAL_1="79" TOTAL_2="80" WEIGHT="11.322798684012822" Z="1.0679939494739465">
<NAME>Calcium channel blocker versus methyldopa</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-20 15:16:56 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="723" O_E="0.0" SE="0.0" STUDY_ID="STD-India-2002" TOTAL_1="54" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7436" O_E="0.0" SE="0.0" STUDY_ID="STD-Italy-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.6516009553217748" CI_START="0.03650252247138919" EFFECT_SIZE="0.3111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42350816681362524" LOG_CI_START="-1.4376771230078367" LOG_EFFECT_SIZE="-0.5070844780971057" ORDER="7437" O_E="0.0" SE="1.0932694522568969" STUDY_ID="STD-South-Africa-1993" TOTAL_1="15" TOTAL_2="14" VAR="1.1952380952380952" WEIGHT="11.322798684012822"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="65.90289327402995" CI_START="0.13656456572516806" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-005.10.03" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" NO="3" P_CHI2="1.0" P_Z="0.48584124712227683" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.8242286768687326" Z="0.6969385642065118">
<NAME>Ketanserin versus methyldopa</NAME>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7438" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Argentina-1987" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.8242286768687326"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.530655537198955" CI_END="1.054132175827074" CI_START="0.5536568873702409" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.763955194592744" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="65" I2="6.22057161826506" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.02289506973169135" LOG_CI_START="-0.2567592931869606" LOG_EFFECT_SIZE="-0.11693211172763462" METHOD="MH" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="11" P_CHI2="0.38342068765748083" P_Q="0.3385075850462623" P_Z="0.10120435734169339" Q="0.916075816292959" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="315" TOTAL_2="308" WEIGHT="100.0" Z="1.6390427471288478">
<NAME>Preterm birth (&lt; 37 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.074699758669323" CI_END="1.1531245352481234" CI_START="0.5697572733409207" DF="6" EFFECT_SIZE="0.8105560381771807" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="54" I2="15.190747244819653" ID="CMP-005.11.01" LOG_CI_END="0.0618762128024358" LOG_CI_START="-0.244310122046376" LOG_EFFECT_SIZE="-0.09121695462197012" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.3139944732077813" P_Z="0.24288814068508557" STUDIES="7" TAU2="0.0" TOTAL_1="290" TOTAL_2="284" WEIGHT="83.33850444948598" Z="1.1677983338267828">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="4.183096553588057" CI_START="0.5378790499277525" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6214978890144232" LOG_CI_START="-0.2693153709030606" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="7439" O_E="0.0" SE="0.5232681184722836" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="0.27380952380952384" WEIGHT="5.96522680203588"/>
<DICH_DATA CI_END="21.316560117637714" CI_START="0.20907642222110503" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3287171233160748" LOG_CI_START="-0.6796949402890666" LOG_EFFECT_SIZE="0.3245110915135041" ORDER="7440" O_E="0.0" SE="1.1797511879617142" STUDY_ID="STD-Brazil-1988" TOTAL_1="18" TOTAL_2="19" VAR="1.391812865497076" WEIGHT="1.4510011140087276"/>
<DICH_DATA CI_END="1.6455142668348035" CI_START="0.5819158505666867" EFFECT_SIZE="0.97854526425955" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" LOG_CI_END="0.2163016520395502" LOG_CI_START="-0.23513981307657797" LOG_EFFECT_SIZE="-0.00941908051851388" ORDER="7441" O_E="0.0" SE="0.26517895128050634" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="85" VAR="0.07031987620222914" WEIGHT="32.38508073491638"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="7442" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-India-1992" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="5.219573451781395"/>
<DICH_DATA CI_END="1.509476149232115" CI_START="0.19637259802827045" EFFECT_SIZE="0.5444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.17882625525993467" LOG_CI_START="-0.7069191140815572" LOG_EFFECT_SIZE="-0.26404642941081125" MODIFIED="2013-05-20 18:51:58 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="757" O_E="0.0" SE="0.5202912144614831" STUDY_ID="STD-India-2012" TOTAL_1="50" TOTAL_2="49" VAR="0.27070294784580495" WEIGHT="13.557333640990636"/>
<DICH_DATA CI_END="2.0525588415128095" CI_START="0.41206015007725033" EFFECT_SIZE="0.919661733615222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3122956160609183" LOG_CI_START="-0.38503938362726686" LOG_EFFECT_SIZE="-0.03637188378317425" ORDER="7443" O_E="0.0" SE="0.40961803068075936" STUDY_ID="STD-USA-1990" TOTAL_1="86" TOTAL_2="87" VAR="0.1677869310587835" WEIGHT="16.309550736202144"/>
<DICH_DATA CI_END="1.426031417062145" CI_START="0.005133666577826066" EFFECT_SIZE="0.0855614973262032" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1541290936129204" LOG_CI_START="-2.2895723413740687" LOG_EFFECT_SIZE="-1.0677216238805742" ORDER="7444" O_E="0.0" SE="1.4354423194285506" STUDY_ID="STD-Venezuela-1988" TOTAL_1="16" TOTAL_2="15" VAR="2.060494652406417" WEIGHT="8.450737969550831"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.46002205274605146" CI_END="1.1717138784448324" CI_START="0.24051673484838487" DF="1" EFFECT_SIZE="0.5308641975308642" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-005.11.02" LOG_CI_END="0.06882157398325289" LOG_CI_START="-0.6188547005813793" LOG_EFFECT_SIZE="-0.2750165632990632" NO="2" P_CHI2="0.49761369808138967" P_Z="0.11695964240986848" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="16.66149555051401" Z="1.567663678841906">
<NAME>Calcium channel blocker versus methyldopa</NAME>
<DICH_DATA CI_END="1.6600512529016966" CI_START="0.26772935092671085" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="7445" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-Italy-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.21666666666666665" WEIGHT="8.94784020305382"/>
<DICH_DATA CI_END="1.6224079194028156" CI_START="0.0859079742590758" EFFECT_SIZE="0.37333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.21016005756482267" LOG_CI_START="-1.0659665216637841" LOG_EFFECT_SIZE="-0.42790323204948083" ORDER="7446" O_E="0.0" SE="0.749603069567329" STUDY_ID="STD-South-Africa-1993" TOTAL_1="15" TOTAL_2="14" VAR="0.5619047619047619" WEIGHT="7.71365534746019"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3459085036523804" CI_END="1.2086633222790755" CI_START="0.5284626028741811" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7992079612279619" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="41" I2="0.0" I2_Q="4.103931982173509" ID="CMP-005.12" LOG_CI_END="0.08230534334284534" LOG_CI_START="-0.2769857405042105" LOG_EFFECT_SIZE="-0.09734019858068257" METHOD="MH" MODIFIED="2013-05-20 18:52:49 +0100" MODIFIED_BY="Edgardo J Abalos" NO="12" P_CHI2="0.6468208558482508" P_Q="0.30717251491674546" P_Z="0.28823641373830755" Q="1.042795623084469" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="303" TOTAL_2="294" WEIGHT="100.0" Z="1.0619984299266831">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.333281756620189" CI_END="1.318666025231852" CI_START="0.5514076103514088" DF="4" EFFECT_SIZE="0.8527147716702732" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" I2="0.0" ID="CMP-005.12.01" LOG_CI_END="0.12013481695295036" LOG_CI_START="-0.25852724419539946" LOG_EFFECT_SIZE="-0.06919621362122452" MODIFIED="2013-05-20 18:52:49 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.6747164012193293" P_Z="0.4737922113167998" STUDIES="6" TAU2="0.0" TOTAL_1="293" TOTAL_2="284" WEIGHT="88.18090025096816" Z="0.7163225497312593">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="7.676698731922972" CI_START="0.014473814199463616" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8851744972786274" LOG_CI_START="-1.8394170067179525" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7447" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Argentina-1988" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="3.5457299247095513"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7448" O_E="0.0" SE="0.0" STUDY_ID="STD-Brazil-1988" TOTAL_1="18" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7471090250744319" CI_START="0.3810571580805232" EFFECT_SIZE="0.8159340659340659" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.24232000716428273" LOG_CI_START="-0.41900987582797006" LOG_EFFECT_SIZE="-0.08834493433184365" ORDER="7449" O_E="0.0" SE="0.3884684469053666" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="81" VAR="0.1509077342410676" WEIGHT="30.015016106843643"/>
<DICH_DATA CI_END="1.3190047978282313" CI_START="0.300908685588941" EFFECT_SIZE="0.63" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.12024637527838679" LOG_CI_START="-0.5215652763712234" LOG_EFFECT_SIZE="-0.2006594505464183" MODIFIED="2013-05-20 18:52:49 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="758" O_E="0.0" SE="0.37700334119789497" STUDY_ID="STD-India-2012" TOTAL_1="50" TOTAL_2="49" VAR="0.14213151927437642" WEIGHT="33.42775686594864"/>
<DICH_DATA CI_END="6.35814024707232" CI_START="0.43688526358896196" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8033301032984537" LOG_CI_START="-0.35963260406574094" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="7450" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-UK-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.4666666666666667" WEIGHT="7.091459849419103"/>
<DICH_DATA CI_END="3.368999313587678" CI_START="0.4134607227952287" EFFECT_SIZE="1.180232558139535" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5275009224963728" LOG_CI_START="-0.3835657404850447" LOG_EFFECT_SIZE="0.07196759100566404" ORDER="7451" O_E="0.0" SE="0.5351650676880004" STUDY_ID="STD-USA-1990" TOTAL_1="86" TOTAL_2="87" VAR="0.2864016496735021" WEIGHT="14.100937504047234"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5993752631669527" CI_START="0.10003906130396256" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-005.12.02" LOG_CI_END="0.20395037469164112" LOG_CI_START="-0.9998303920357162" LOG_EFFECT_SIZE="-0.3979400086720376" NO="2" P_CHI2="1.0" P_Z="0.19503379114580333" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.819099749031839" Z="1.2958307800931992">
<NAME>Calcium channel blocker versus methyldopa</NAME>
<DICH_DATA CI_END="1.5993752631669527" CI_START="0.10003906130396256" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.20395037469164112" LOG_CI_START="-0.9998303920357162" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="7452" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Italy-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.5" WEIGHT="11.819099749031839"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2558986215749923" CI_END="1.2623676968181663" CI_START="0.6737133341191532" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9222114453354411" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="0.10118587268955728" LOG_CI_START="-0.17152485701564305" LOG_EFFECT_SIZE="-0.035169492163042874" METHOD="MH" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="13" P_CHI2="0.7396311425884455" P_Q="0.6405659155623682" P_Z="0.6131907010770659" Q="0.21800282194552545" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="231" WEIGHT="100.0" Z="0.5055242092501597">
<NAME>Admission to special care baby unit</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methyldopa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0680014386245538" CI_END="1.250199287542149" CI_START="0.6559262335902043" DF="2" EFFECT_SIZE="0.9055597771073308" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" I2="0.0" ID="CMP-005.13.01" LOG_CI_END="0.0969792470731023" LOG_CI_START="-0.18314499926166186" LOG_EFFECT_SIZE="-0.043082876094279764" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.5862549328303532" P_Z="0.5465874197987803" STUDIES="3" TAU2="0.0" TOTAL_1="236" TOTAL_2="217" WEIGHT="95.46483051284406" Z="0.6028816612631127">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="1.3323480784017052" CI_START="0.39232764464644765" EFFECT_SIZE="0.7229916897506925" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.12461769989500406" LOG_CI_START="-0.40635108902975803" LOG_EFFECT_SIZE="-0.14086669456737697" ORDER="7453" O_E="0.0" SE="0.3118936949522997" STUDY_ID="STD-Australia-1985" TOTAL_1="95" TOTAL_2="87" VAR="0.09727767695099818" WEIGHT="34.07417967164698"/>
<DICH_DATA CI_END="1.5486455977845757" CI_START="0.7032294486102981" EFFECT_SIZE="1.0435771125426299" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" LOG_CI_END="0.18995204233206564" LOG_CI_START="-0.15290295093035525" LOG_EFFECT_SIZE="0.018524545700855218" ORDER="7454" O_E="0.0" SE="0.2013947202019341" STUDY_ID="STD-France-1987" TOTAL_1="91" TOTAL_2="81" VAR="0.04055983332521533" WEIGHT="52.714553720069254"/>
<DICH_DATA CI_END="2.7483979867057533" CI_START="0.2236415551798342" EFFECT_SIZE="0.784" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.43907962173362775" LOG_CI_START="-0.6504474963647509" LOG_EFFECT_SIZE="-0.10568393731556154" MODIFIED="2013-05-20 18:53:38 +0100" MODIFIED_BY="Edgardo J Abalos" ORDER="759" O_E="0.0" SE="0.6399936224172034" STUDY_ID="STD-India-2012" TOTAL_1="50" TOTAL_2="49" VAR="0.40959183673469385" WEIGHT="8.676097121127828"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1194782759177055" CI_START="0.3164062084926874" DF="0" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-005.13.02" LOG_CI_END="0.7092257044455453" LOG_CI_START="-0.4997550034055194" LOG_EFFECT_SIZE="0.10473535052001298" NO="2" P_CHI2="1.0" P_Z="0.7341670104716429" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="14" WEIGHT="4.535169487155939" Z="0.3395877429546083">
<NAME>Calcium channel blocker versus methyldopa</NAME>
<DICH_DATA CI_END="5.119478275917704" CI_START="0.31640620849268747" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7092257044455452" LOG_CI_START="-0.4997550034055193" LOG_EFFECT_SIZE="0.10473535052001298" ORDER="7455" O_E="0.0" SE="0.7101612523427367" STUDY_ID="STD-South-Africa-1993" TOTAL_1="11" TOTAL_2="14" VAR="0.5043290043290043" WEIGHT="4.535169487155939"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.255271387845047" CI_END="2.1824961036725528" CI_START="0.5013308121515042" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.046017468387433" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="0.0" I2_Q="100.0" ID="CMP-005.14" LOG_CI_END="0.33895347704884654" LOG_CI_START="-0.29987560251611906" LOG_EFFECT_SIZE="0.01953893726636375" METHOD="MH" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="14" P_CHI2="0.5211439396043893" P_Q="0.0" P_Z="0.9045677958020506" Q="3.419290000303437E-34" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="151" WEIGHT="99.99999999999999" Z="0.11989314376339685">
<NAME>Neonatal hypoglycaemia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.255271387845047" CI_END="2.1824961036725528" CI_START="0.5013308121515042" DF="3" EFFECT_SIZE="1.046017468387433" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="0.0" ID="CMP-005.14.01" LOG_CI_END="0.33895347704884654" LOG_CI_START="-0.29987560251611906" LOG_EFFECT_SIZE="0.01953893726636375" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.5211439396043893" P_Z="0.9045677958020506" STUDIES="4" TAU2="0.0" TOTAL_1="170" TOTAL_2="151" WEIGHT="99.99999999999999" Z="0.11989314376339685">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="95.60761657277001" CI_START="0.26148544327503137" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9804924916878397" LOG_CI_START="-0.5825524830158021" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="7456" O_E="0.0" SE="1.5055453054181618" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="2.266666666666666" WEIGHT="4.274214574371007"/>
<DICH_DATA CI_END="2.6714459733062204" CI_START="0.43111312409131874" EFFECT_SIZE="1.0731707317073171" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.4267463955384859" LOG_CI_START="-0.36540875600558204" LOG_EFFECT_SIZE="0.030668819766451964" ORDER="7457" O_E="0.0" SE="0.46531585724822644" STUDY_ID="STD-France-1988" TOTAL_1="41" TOTAL_2="20" VAR="0.21651884700665186" WEIGHT="57.45665493416764"/>
<DICH_DATA CI_END="3.9981665126016623" CI_START="0.010004585820506876" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6018608773254143" LOG_CI_START="-1.9998008859974516" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="7458" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-UK-1984" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="21.371072871855038"/>
<DICH_DATA CI_END="7.101410202434033" CI_START="0.14752174946721597" EFFECT_SIZE="1.0235294117647058" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8513445997503108" LOG_CI_START="-0.8311439459416593" LOG_EFFECT_SIZE="0.010100326904325756" ORDER="7459" O_E="0.0" SE="0.988302100192084" STUDY_ID="STD-USA-1990" TOTAL_1="85" TOTAL_2="87" VAR="0.9767410412440839" WEIGHT="16.89805761960631"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal bradycardia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7460" O_E="0.0" SE="0.0" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.032997302148902" CI_START="0.47477787038575636" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-005.16" LOG_CI_END="0.48187202400589396" LOG_CI_START="-0.3235095319106443" LOG_EFFECT_SIZE="0.07918124604762482" METHOD="MH" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.6999496104323366" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.38538848913106166">
<NAME>Neonatal jaundice</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.032997302148902" CI_START="0.47477787038575636" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-005.16.01" LOG_CI_END="0.48187202400589396" LOG_CI_START="-0.3235095319106443" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2013-05-22 17:56:03 +0100" MODIFIED_BY="Edgardo J Abalos" NO="1" P_CHI2="1.0" P_Z="0.6999496104323366" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.38538848913106166">
<NAME>Beta blocker versus methyldopa</NAME>
<DICH_DATA CI_END="3.032997302148902" CI_START="0.4747778703857563" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.48187202400589396" LOG_CI_START="-0.32350953191064435" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="7461" O_E="0.0" SE="0.4730851126483731" STUDY_ID="STD-Australia-1983" TOTAL_1="14" TOTAL_2="14" VAR="0.22380952380952387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Any antihypertensive versus calcium channel blocker (subgrouped by class of drug)</NAME>
<DICH_OUTCOME CHI2="0.03715388189608771" CI_END="4.573069240375952" CI_START="0.9577250133845074" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0927835051546393" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.6602077770390137" LOG_CI_START="-0.01875916974507746" LOG_EFFECT_SIZE="0.3207243036469681" METHOD="MH" NO="1" P_CHI2="0.8471521568051148" P_Q="0.8473421606219298" P_Z="0.0640746123191028" Q="0.03706041879909746" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="62" WEIGHT="100.0" Z="1.8516603410287684">
<NAME>Severe hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="35.67106857035189" CI_START="0.06822335572034682" DF="0" EFFECT_SIZE="1.56" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="1.5523161193539505" LOG_CI_START="-1.1660669226450273" LOG_EFFECT_SIZE="0.1931245983544616" NO="1" P_CHI2="1.0" P_Z="0.7806384935239457" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="8.59106529209622" Z="0.2784870648877823">
<NAME>Glyceryl trinitrate versus calcium channel blockers</NAME>
<DICH_DATA CI_END="35.67106857035189" CI_START="0.06822335572034682" EFFECT_SIZE="1.56" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5523161193539505" LOG_CI_START="-1.1660669226450273" LOG_EFFECT_SIZE="0.1931245983544616" ORDER="7462" O_E="0.0" SE="1.5967916550832766" STUDY_ID="STD-Italy-1999" TOTAL_1="24" TOTAL_2="12" VAR="2.5497435897435894" WEIGHT="8.59106529209622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.802426443725981" CI_START="0.9561493108744592" DF="0" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.681460721721434" LOG_CI_START="-0.01947428363858525" LOG_EFFECT_SIZE="0.3309932190414244" NO="2" P_CHI2="1.0" P_Z="0.06416157319166786" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="91.40893470790378" Z="1.8510554715838774">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="4.802426443725981" CI_START="0.9561493108744592" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.681460721721434" LOG_CI_START="-0.01947428363858525" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="7463" O_E="0.0" SE="0.4117326918327102" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.16952380952380952" WEIGHT="91.40893470790378"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5380826511796625" CI_END="6.37603663623366" CI_START="0.7275763172493581" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.8045508038191106" LOG_CI_START="-0.13812144574834556" LOG_EFFECT_SIZE="0.33321467903538254" METHOD="MH" NO="2" P_CHI2="0.46322850923891323" P_Q="0.4634756388699558" P_Z="0.16586555494451832" Q="0.537488223691371" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="58" WEIGHT="100.00000000000001" Z="1.3856115321716376">
<NAME>Proteinuria/pre-eclampsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.956857307626873" CI_START="0.10043329628054506" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.9981222832702461" LOG_CI_START="-0.9981222832702461" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="30.769230769230774" Z="0.0">
<NAME>Glyceryl trinitrate versus calcium channel blockers</NAME>
<DICH_DATA CI_END="9.956857307626873" CI_START="0.10043329628054506" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9981222832702461" LOG_CI_START="-0.9981222832702461" LOG_EFFECT_SIZE="0.0" ORDER="7464" O_E="0.0" SE="1.1726039399558574" STUDY_ID="STD-Italy-1999" TOTAL_1="24" TOTAL_2="12" VAR="1.375" WEIGHT="30.769230769230774"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.423694790238036" CI_START="0.7545990473373014" DF="0" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.9742212119653189" LOG_CI_START="-0.12228374742075647" LOG_EFFECT_SIZE="0.4259687322722811" NO="2" P_CHI2="1.0" P_Z="0.127806696921162" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="69.23076923076924" Z="1.5228082037336166">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="9.423694790238036" CI_START="0.7545990473373014" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9742212119653189" LOG_CI_START="-0.12228374742075647" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="7465" O_E="0.0" SE="0.6440924409304678" STUDY_ID="STD-France-1994" TOTAL_1="46" TOTAL_2="46" VAR="0.4148550724637681" WEIGHT="69.23076923076924"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.59508521794332" CI_START="0.2617775092331654" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.9342501869566456" LOG_CI_START="-0.5820676688452829" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6489477312144929" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.4552245090577255">
<NAME>HELLP syndrome</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.59508521794332" CI_START="0.2617775092331654" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.9342501869566456" LOG_CI_START="-0.5820676688452829" LOG_EFFECT_SIZE="0.17609125905568124" NO="1" P_CHI2="1.0" P_Z="0.6489477312144929" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.4552245090577255">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="8.59508521794332" CI_START="0.2617775092331654" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9342501869566456" LOG_CI_START="-0.5820676688452829" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="7466" O_E="0.0" SE="0.8906926143924925" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.7933333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.802426443725981" CI_START="0.9561493108744592" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.681460721721434" LOG_CI_START="-0.01947428363858525" LOG_EFFECT_SIZE="0.3309932190414244" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.06416157319166786" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.8510554715838774">
<NAME>Additional antihypertensive</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.802426443725981" CI_START="0.9561493108744592" DF="0" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.681460721721434" LOG_CI_START="-0.01947428363858525" LOG_EFFECT_SIZE="0.3309932190414244" NO="1" P_CHI2="1.0" P_Z="0.06416157319166786" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.8510554715838774">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="4.802426443725981" CI_START="0.9561493108744592" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.681460721721434" LOG_CI_START="-0.01947428363858525" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="7467" O_E="0.0" SE="0.4117326918327102" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.16952380952380952" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="50.248889076868295" CI_START="0.1345303373704219" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="1.7011264646374185" LOG_CI_START="-0.8711797686957826" LOG_EFFECT_SIZE="0.414973347970818" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5271409861361448" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="62" WEIGHT="100.0" Z="0.6323763524165565">
<NAME>Changed/stopped drug due to side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="50.248889076868295" CI_START="0.1345303373704219" DF="0" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="1.7011264646374185" LOG_CI_START="-0.8711797686957826" LOG_EFFECT_SIZE="0.414973347970818" NO="1" P_CHI2="1.0" P_Z="0.5271409861361448" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="100.0" Z="0.6323763524165565">
<NAME>Glyceryl trinitrate versus calcium channel blockers</NAME>
<DICH_DATA CI_END="50.248889076868295" CI_START="0.1345303373704219" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7011264646374185" LOG_CI_START="-0.8711797686957826" LOG_EFFECT_SIZE="0.414973347970818" ORDER="7468" O_E="0.0" SE="1.5109854145811346" STUDY_ID="STD-Italy-1999" TOTAL_1="24" TOTAL_2="12" VAR="2.283076923076923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7469" O_E="0.0" SE="0.0" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6786074906021247" CI_START="0.391452473165137" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="100.0" ID="CMP-006.06" LOG_CI_END="0.5656834508483587" LOG_CI_START="-0.407320958753109" LOG_EFFECT_SIZE="0.07918124604762482" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.7497293389041237" Q="2.3582815645557982E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.31899627375360884">
<NAME>Maternal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6786074906021247" CI_START="0.391452473165137" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-006.06.01" LOG_CI_END="0.5656834508483587" LOG_CI_START="-0.407320958753109" LOG_EFFECT_SIZE="0.07918124604762482" NO="1" P_CHI2="1.0" P_Z="0.7497293389041237" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.31899627375360884">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="3.6786074906021238" CI_START="0.39145247316513704" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5656834508483586" LOG_CI_START="-0.4073209587531089" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="7470" O_E="0.0" SE="0.5715476066494082" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.32666666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1544297646798325" CI_START="0.6890598035152989" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="0.0623675156508931" LOG_CI_START="-0.16174308402910814" LOG_EFFECT_SIZE="-0.04968778418910752" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.38479729542384666" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.869091132871926">
<NAME>Elective delivery (induction of labour + elective caesarean section)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1544297646798325" CI_START="0.6890598035152989" DF="0" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="0.0623675156508931" LOG_CI_START="-0.16174308402910814" LOG_EFFECT_SIZE="-0.04968778418910752" NO="1" P_CHI2="1.0" P_Z="0.38479729542384666" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.869091132871926">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="1.1544297646798325" CI_START="0.6890598035152989" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" LOG_CI_END="0.0623675156508931" LOG_CI_START="-0.16174308402910814" LOG_EFFECT_SIZE="-0.04968778418910752" ORDER="7471" O_E="0.0" SE="0.13164367561739276" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.017330057330057328" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7059149930031934" CI_START="0.9125888143150277" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="0.43231414900605153" LOG_CI_START="-0.03972485871811514" LOG_EFFECT_SIZE="0.1962946451439682" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.10308480321539414" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.630078991544118">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7059149930031934" CI_START="0.9125888143150277" DF="0" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="0.43231414900605153" LOG_CI_START="-0.03972485871811514" LOG_EFFECT_SIZE="0.1962946451439682" NO="1" P_CHI2="1.0" P_Z="0.10308480321539414" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.630078991544118">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="2.705914993003193" CI_START="0.9125888143150278" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" LOG_CI_END="0.4323141490060515" LOG_CI_START="-0.03972485871811508" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="7472" O_E="0.0" SE="0.2772780497679484" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.07688311688311687" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7473" O_E="0.0" SE="0.0" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.548273108710726" CI_START="0.06431582420814068" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="1.1916821605007981" LOG_CI_START="-1.1916821605007981" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="62" WEIGHT="100.0" Z="0.0">
<NAME>Total reported fetal or neonatal death (including miscarriage)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Glyceryl trinitrate versus calcium channel blockers</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7474" O_E="0.0" SE="0.0" STUDY_ID="STD-Italy-1999" TOTAL_1="24" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.548273108710726" CI_START="0.06431582420814068" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.10.02" LOG_CI_END="1.1916821605007981" LOG_CI_START="-1.1916821605007981" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.0">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="15.548273108710726" CI_START="0.06431582420814068" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1916821605007981" LOG_CI_START="-1.1916821605007981" LOG_EFFECT_SIZE="0.0" ORDER="7475" O_E="0.0" SE="1.4" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="50" VAR="1.96" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9104670775454689" CI_START="0.20446570610463882" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-006.11" LOG_CI_END="0.28113955803409546" LOG_CI_START="-0.689379523345945" LOG_EFFECT_SIZE="-0.2041199826559248" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.40968908890474953" Q="9.481501264675626E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="12" WEIGHT="100.0" Z="0.8244409042667604">
<NAME>Preterm birth (&lt; 37 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9104670775454689" CI_START="0.20446570610463882" DF="0" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-006.11.01" LOG_CI_END="0.28113955803409546" LOG_CI_START="-0.689379523345945" LOG_EFFECT_SIZE="-0.2041199826559248" NO="1" P_CHI2="1.0" P_Z="0.40968908890474953" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="100.0" Z="0.8244409042667604">
<NAME>Glyceryl trinitrate versus calcium channel blockers</NAME>
<DICH_DATA CI_END="1.9104670775454693" CI_START="0.2044657061046387" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.28113955803409557" LOG_CI_START="-0.6893795233459452" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="7476" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-Italy-1999" TOTAL_1="24" TOTAL_2="12" VAR="0.325" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.956857307626873" CI_START="0.10043329628054506" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.12" LOG_CI_END="0.9981222832702461" LOG_CI_START="-0.9981222832702461" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.956857307626873" CI_START="0.10043329628054506" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.12.01" LOG_CI_END="0.9981222832702461" LOG_CI_START="-0.9981222832702461" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Glyceryl trinitrate versus calcium channel blockers</NAME>
<DICH_DATA CI_END="9.956857307626873" CI_START="0.10043329628054506" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9981222832702461" LOG_CI_START="-0.9981222832702461" LOG_EFFECT_SIZE="0.0" ORDER="7477" O_E="0.0" SE="1.1726039399558574" STUDY_ID="STD-Italy-1999" TOTAL_1="24" TOTAL_2="12" VAR="1.375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.89151768742508" CI_START="0.4417647319471329" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.47" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-006.13" LOG_CI_END="0.6894436282464329" LOG_CI_START="-0.3548089587500808" LOG_EFFECT_SIZE="0.1673173347481761" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.529952958360976" Q="8.189815999274594E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="49" WEIGHT="100.0" Z="0.6280778313202342">
<NAME>Admission to special care baby unit</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ca-blockers</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.89151768742508" CI_START="0.4417647319471329" DF="0" EFFECT_SIZE="1.47" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-006.13.01" LOG_CI_END="0.6894436282464329" LOG_CI_START="-0.3548089587500808" LOG_EFFECT_SIZE="0.1673173347481761" NO="1" P_CHI2="1.0" P_Z="0.529952958360976" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="49" WEIGHT="100.0" Z="0.6280778313202342">
<NAME>Beta blockers versus calcium channel blockers</NAME>
<DICH_DATA CI_END="4.891517687425079" CI_START="0.441764731947133" EFFECT_SIZE="1.47" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6894436282464328" LOG_CI_START="-0.35480895875008067" LOG_EFFECT_SIZE="0.1673173347481761" ORDER="7478" O_E="0.0" SE="0.6133991387354244" STUDY_ID="STD-France-1994" TOTAL_1="50" TOTAL_2="49" VAR="0.37625850340136047" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-01-05 11:44:39 +0000" MODIFIED_BY="Edgardo J Abalos">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-01-05 11:44:39 +0000" MODIFIED_BY="Edgardo J Abalos" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAc7klEQVR42u1da3Ab13U+fOwLgEjukqxFqdWYopp2Rv2ROpViyaJr
g1EStUmcZJqZjOO8PFO5idNkOsk0qTvjOv1RO07s1vU4SWXPKH6lzdjjqZ2HZUuCY0PKg+qo02mU
ZhxSVOWIoCtyl5RILoAFwd7XvvAgQRAAAfp8fAB77zn3nF2cvffu4n57ABCIuqENdDwIiDrBasdj
gKgfMLwQGF4IDC8EAsMLgeGFwPBCIDC8EBuGTjwEtYWFhyBwpx7Dq9nGg1YdT5a8d8s4OCJw7oXA
8EIgMLwQGF4IDK+WgdlwRUSdwitOIEdSJas2at+2l7Gtx1bxsIxivLT0soFhVPfeK5FITElDTbVv
+4hXpfom+3+rU3T3tGA7Z2Nv14jB0ZjIAfRrskJO53iPKpOX0YhCb+E6UTnq0EJFPmqrUpKJ25Ki
JmmdFHOopKrHeddA/syIEjWZgmKTOpU2KcqAtdpDhJwYb7X7kGx77cS7VeFDnP3Qci7l2n3G7gVb
VjRmW6Y64LXlqCO+YkSJ+D4wuxprCaBPk1WyX0lZVvtAWhzCOGrE3GunBHA1mo0ukPf5yRh5iasp
eje39/ms3EsLUyc/OzB5ZYRJd8Uyx99F6sYcWhd/aTLQCeyYyxzTmcJsN8DN2gXbLwPYI6fytFUr
q9BW4emTXV470DEJ89Hs7ALpZVg/0/s8LwfX7l+dYrZfprZnuV+sLfquR/uvRVdRVzLqDs8HZvfS
GJdeMLORRYCRWPb4PMCpLMZRvcOLzr1yswDpaTBvINsXDPqSGzNmyEbmOhhPk9cZY3jfeUM7wDQU
J7k7Q+oGwCQvzm4jFxhwJBjWWCtUODc+YPtlANp53qrENGHCGB722oExA+xp0G5wm/qosD3h2l3a
TWxnuW3RAntnZail6bTnwziM5TwfKCxjgEvbGttJKdO3m4jvzmEclUGtmELxBNjGFdJ7zezM5fcl
6Db9k7PshW6Rt6KQ/ZGA6vnY412X2XBIzn/J8STpCy90txLulJp3FIePeELysRIqMzuXlrgPQlnJ
BOxSn6jtLdMBnYA2BBQDTkOgJXNwKbc/ATM7nLYLA9wfFxZ+57is1+xgBKApXyT/b4PpK4HoNYHO
bU6bJS72pYX7IlfJh0ouCsgHfiOXFLcFTvNCgdNM2S97gstSzWOe0Clf5Ta47F8cniK2l4N2h01u
ez7YpNBuC7hJnR4OeeyA+UlxaSm/RkfUhSntNuLw49hNNeBcmX2MzJZPHrd7/aL0EPTRcXAXDKmF
4mrSeIGEvNoPehTgjMYkT9smjX3Slx3VPMnOXSmNldm8EXsn9JIJlOrAiYjfHG+H4uS0nfGiUi20
/bNzpNBmtpWUq0Pa0klbPxvqV1lEUh802PXzkMfdoP0be5P/1di7+B58n+zyOVx20pCueO6gCXM3
DgTaPJNV2+icKyNnZwqltxyU2Uhmy2kSPBf6FCo52731O/Tiv1v+jN8Jzi4Okg880SPrV3mfm1Go
jZke6YGoJyTaYX5sYT50boVStmUyk9picNu/6+qQtq4nbb1iXyFBJl/DbkD0ynb4JsSc2s9bitzO
DMQOKiNzAAdkjKM6z71qNYGr+CaIbVdrxfzYU7219Nr5wNMGzr1Kz706QGseDyeXKpP70n90LL36
aLVWvjaz8JNaet2d+mpgK9227hO+NRGY32qBg4HPmKgpcDF0YDG0hbPSeh1aBOCCHASGFwLDC4HA
8EI0Eji1xyvHOl7eYHi1znjQKiNNDgdHBM69EBheCASGFwLDC4HhVWeYG980EstaN7yMOF2pFS9L
r92+PuLtSrp38xf7oVV07l4TjTZmYxg1T3hlR/tWrF+Zw7ou/JL3Tfq+1eXWQKO9qGNv1zThZTpW
zvs4TM5UdTTKg01psnrC5bCaEVkzPTYuMHqu7fNxuzU56eqJsn5NUbhoXFcO27Yq2QGmLZWP847n
rLIXDEXWbMbHjXBnzKhM36U0xfb5t7Lg5cqcfwv9EeaTZ8uWJS0Jhow02nJo+GrVe2JL6t9KMDhB
fx9R5rd8Iwvd8mx3Dn55tn3LE7mJwQStuW/LQhepGbz0xrcX2BrWdiajSwtRLQODqYuH4nmhp1uw
5fM/gXzs6nz7Emv40m8+29lz8U++twRfPg4xUsfladMEz/3oKOQjC10Hx+BfX/n2lQfamL1FSPxe
G3wjFmlbEi4QWxFm6w1qi2DwjYtH7mbSwlY0snj1mRyceNzx9y9dv9WmrbKONe+vVm1473VEBtmj
BTpjMEY+mux5KQ3wogbWfrdGHWc1go1LcCuTyYzDeZ85y/UoF/Zhxt916a4zxvS+88Yw2XpYAuth
T57j1t0AnaY99iKxvxc0ziLSOEf3jvOXM65c2Bawd5e5tLD19ZxtUxqtg91U2TOiscsrzY8sA5xO
GUVMVVJ17aeO7E+sxGGFguIQvdbpy92YSQSouOXouJRGa/720nL35QIabdJZnUbLC4St0ZtykDjA
uLUeLPzOMac34GCUhvbTRCLRcU5sUaZqm0tI3N7+1FVPTtRAsAA4J7aojDNgu2H6hSJzp0J0XP++
g7GYil0J0mjpO8dlOArdIu5vn+uTsLV3cSo6gvcxmuiMoCxVUM+KrfvPwS4JQNrpkOK8NEbXbyRH
aQ3lsEpBRS6j7oKdamEZZ9PmQvxdd4x1PG4tDRg2islkEDxksKsAaRQMMdxx3q485Ciu3OdDttgd
DXgbfwKFsKUZxiTpjDVcdtIs4ZUbI//GvixO+I+/R0lfBPh1JnYcIDr/FfqZK2wCdbGX1fjgMhOZ
w85MQdlMj/R+EkJzTww8V2Rupudw2idyS+zRAP9+DcAZW1qYJVZuVm4VzNxuhfJ2LfvOWVfu3ozk
hLm/Y5rNl3MJWy/bcg8RveZ5jKMmmXs1AcyB5N5atufEUrWk0W6quddbkedoZBZq2dxDXw1OvjC8
3urhVVfgYmik0Tbi0CIAF+QgMLwQGF4IBIYXopHAqT1eOdbx8gbDqynGA6a0tEmOAGajReDcC4Hh
hUBgeCEwvBAYXhXDrJEMYnOEF01qpvaXoLjGV2Sn2vKXSpYH+bDl1Lev7N06+LRCVV8uUZeUu9bR
ZBGNFr/Frqz3SiSmNL54s4hFugKttGvuGyXLg3zYcur76rx7ZrpUMryRk1fW0Wbhvlhp7IMrHBwN
K+/1VzpjsJoayycb9/K5OlGWChbcPK/x4T9lGgZjpCY1ieZpJbIuGZVlkqXqScZo7VMVnq1WEYRV
wWiFoC63Iwi0ELeZ5mhUjowyv1wdM5Qv1tXjzFmOIUminmmjwdy18QN/F8hRy9RFjtxkRFZ7eH7b
JGPuHg2156giG62QS0qK1geShDTaSudehs+q5flkv6el3LvJyyyfa6+Uupdv8zyvIncrzKTU7wG8
23RonlbomBTl39QuLHLxA1PP9wLMH8/M/hmwHK89THc+kjX58OLqcjud8pS70r1/imaK3TObnaF5
yGASFrjODiWjPum25elZ2Rc9TkeWZpPKpdQ9fnnH09Sqm6O2Y5KqnxA5ct/9UpaH+tMnSbv297s/
E2rvsUmNvxNyT8YyL38YQL4H46iS8CKTr7ff721NMAbrszyfLAVPy5o5b7yDb6dFnleOnDH2rJen
leaE5XhhfEDInDG6MkRpGLQx3hjnx0oO46KCr8vtqOPGGXc4MqgdVQKNEgrHDejkOu8ch7EX/LaE
ngQ3erzD61+ngW+Mq34598z1nW75OXLtYbBuYLs+THzMXnc5HWrvHYbIVSvkvuvYu48AvP7XGEdl
EFwMTWmi/VcyARZpKJ+sKKCc0cLsrOBxTM3BWW1/IsBbDRJTqYDT/9Wv7AsKjN60BPOMcxbWLbYD
HtN19I/zVKeYVFuYV1bkuKWvxYzaQI5a8Td60E1jWyoJrq8j5JyebPuWaU7M9WZi+J3jCtloLxde
abUXkUm9gnCOWYdxTLe39b4Wkj7tiYwyge78deF59d7FVOROfhkZ1vVbN70MtWIStNdORWIluLYU
IeZsu8nVOwoZtacLc9Qy3NgmB5w7ZRa01+96JOSkhTdpTluzDbupCudeekfhbYchuDZUoOwE/RQf
HH8BQ4pX3ge7yMiR/x+Wp9X/dDqHUof49rvgLJG+bWZ3b+gT1Gyj7Tt8sufrUjtnPcM6s5N2vJkh
1SEv9xdybSlUB17zqI2dlA8+CENyQTnzXS0+7ziTV0A+26+G9BbgnBKUozltPwFw7n6Mo8rmXnL6
1QKBM1klzE6dcdxHkOQOBfO8tskZMleK3u4lo/0Llgz2FftakTH46/IHifS+LcFstUQm+mFpYY5t
RG/fGqiauUVxH/NmMDtWt7Io+haqM0va6pXTRbc8Znqkez1i9oOUk9umZC8UlBf47iL6R1sDWde1
B65YIb0fq++dCcpt0eWRj5NrFpzaVzL3qhh6tpgouGom2XjVD4WrXhPM7VekeKK+h9DpurRuGu1m
nXutPbxiznJn9HJRsZxdRU+q+jFFqza90pngzAefX1OXo9m7fhothheiIuBiaKTRNuLQIgAX5CAw
vBAYXggEhheikcCpPV451vHyBsOrOcYDX6v1734hjRaBcy8EhhcCgeGFwPBCYHjVAeYG2zE3yB8M
r/KgpNtIas2kW0N5qKhsW4N2Vtgxoq6fZexvW1M22ocMDKM69F6JxJR8O39XVFVeaz76haKy/Q3a
WW7HXHxjFfv715SNdt8i9nZ1GRyN2ZNef3WC5Wx1oodd0m0P48+amnKCn+6c8xo/8Ha6QeQEI1Xk
fuVsWzPKebG6oryWZHRb8yE5yj+9Pk2hbRsyY9AmD8tqH6n+ImvHlt/7uSS47Nr4CUWxbeaPqI/3
HDpse9loZcP1k9uj5cKOox023Gy0M8LHHvWwyJad0iI8G63rC7O3Vz6LcVSXuZfucyOOTc4x7ut9
7l3n/GR0gUj8U+rDQlbJqLpLuu18/ojc6XcHCejRuhaJjJx5hH7sS6nZe9+XYvr7stP8O4b5lzP7
iMhCNGuSFkf2ZY/Pk+r7jkz3AnRHj73jIDB2LbV2LHXCGGD+iHrIP72v27V9y5uen/ps5pFrWbmw
06M8sujKGRL3cXny493c0QcuRXZ4vix49t78IMZR7cOLTL7+0L//fxfjod4xblwQBTyPrPYRl4Wr
jcOYx8254zoYV4KN5cYpZZXI3KIxXS3DWbzqXtA4PSg9DJ++geaRNewXAeS/7NtNFO6QQPsogHRP
8pa0V0d8cXmxop40+OkDrinH9vzUJPg0X2kt7Dgsv63w8Tz3cYLltaW415h2PF8OePZszEZbDtUv
hqYMieTBdEmObRELF3w2ayEDt4Bt68qESbE0KvpzlLoq8sgKBiutPp0BR8+2kS1zex66Lheqn86E
ebHUR9dPcJm5IfKt71KAaRvKRtufy+1PuPZqQKPdXN851iob7XC++Bo/PM9tD5FuPWt045PBmwCc
bRuS4eUeibVr+cXzwPLIRj/EGKzaPK8mkSLNT/2QbBl2KvKhIvVCJscnTShm5go7u8K5boWPLlKu
d13LlyfAs4cz+7LoAK1KzUFygHuWHfrKf+lf9J/T39oWLHAeTX9rnAWhdpf06NU2Vk7GwsfsI6fa
4NL81X9ITcBkukP9ZiyfC8qIv9yZRw1gD1Fqn/vH+4nsof9+MHJmCdRXft+S8xCd79DbHVCvPvjn
jy+5dQF1US+2iB3S0K++abt+5nIdR1/O0XJh54bbr0bZNjXNfXRbI/+/7LzvCCton1sI+PIoBHqv
dFuVo4h37rd+UHkhlV7X3Et2xgvKZnJKeImPlVGe4zYuGkr6jDfVyshZEjQnuwYeA5b9dXbxaoTL
hBdMWTfJgjt7cguTvctgDNrYQbnrCuW4yulxymdVRk7yumjYH14vwLPMPp/z/DzDc9CScmHnb1h+
Wy5HfHTCTweLaO+xCn0h9nISdlM1n3tVjKN3LjbVLpvbrtY0HkZvnFx/NtpNOveqd3h1ffTxjrkm
O7vtI1+oZXOxy8H5BYYX0mjrCFwMjTTaRhxaBOCCHASGFwLDC4HA8EI0Eji1xyvHOl7eYHjheLAO
LK9SiIMjAs81BIYXAoHhhcDwQmB4NQRmVVVrVTGDVbj8tFZo8IqJilMY+IJquqyQyAO5ltbCKrqX
DoiURxZdWbJRylFRVlhVi+fatypK35jQW+hgrMCxrSKXbUglkKuWlF/P3yXCeXSLUViVs7G3a57B
UeSOHWW8WUfkk/0XecRI8pyy9gjNOQuMdxvlHFeRhxZ8eXDpt/2HZJtlruWMV0U+muR8Xi+HLKk7
Ciy1rMIZsjQfLj+/aK5ar5y116OIdomF0VCuW4pRTXB/+zR5RKc5uSmXV1rEbLRNNPfKp2a7AW7W
LticW0uZqYenfpB5HyuHa55R9jC5HXOZY5x3u+cNkYfWkxfdSALsny700Ly4WZZbNp86+dn3T56k
OXOtrMIzr/XKU58C+vCB7OwCT397PDPLcyLRXLVeOSPPPpsS7dL4Fba4vxR7Lk3zNhfM7H8S70di
jMvbn8U4ap7w4kljc+MDNv0PY7STOWNo75xg5SJ3LDCGxDBfZqwaoPGP0JX34JyXMn5uWZ5XlrJe
MxKYnIGWGTfo94D2NIj0tzQfLufF5l4PllNcF1g179ri/rKphKHxNmneXDJoS5kk5fK+nsM4apqp
fTjVayifrFsuFTBbBdu1SD7UTDi3rE+/FYzZmZ25PE80K/LhAs+i5ZfHC5LoFvgWtGIOLlEa7cwO
p+3CQDgbF07tm2Jq7/Nmh8MVDssdC0EGbZvPdvXk+VzMzRhblFs2kEPWZLK/A9Mxvt2V7xJpIWmu
Wr+8hIcFvjnuLYvtINO8ub0LU9ptUMj8RTTBfa/OXSky8kka7Pp5uKKX5Y7lfctRInLKgROjbh5a
IX/KMN/Fo0re6Shk9NxVmFtWJVr8+SrKWaCyuWk7w2NmaeYWkQ+X5qr1y5PeBSCP2fuLfOsGjT8Y
I/+rMTo/1JLG98llxDlcdtJ04TW7OEg+xESvbBdc6Lez3LF0ht0tf+ZVwXFVbN7hCPnYwgDt4eSt
YKVjJ8gIlynMLTvTIz3AGbUzH1So7BzPgittpRxYsdfygWC5stVVltm74ly3c2o/dy16+wAdAKIH
lZE5gAMyxlFzzL0qmp01DOa2S73rb2Vmew1otJt07tV04VXv3LEhGNn59TcSk4IrVDG8guHVdNOG
RkZXbb5cLIjQPA6JgRk2HoLaAmm0TTG1R2B4IRAYXggMLwRO7RHrBdJokUbbTOPB5hs/cjg4InDu
hcDwQiAwvBAYXggMr42C2QCN9ekhmjm8nIhyuMtftl6Y9XXbilluS+HuMhp6rCq9MtloYzaGUSuE
V5eSug/+pmz1yjliS+GXpTXM662q9AQKqy7q2Nu1Qnjlxw3jysM0R6wc4Z8YZdKOMgqsLcitmgOO
5pbTrqRbdeXjNmPO0qy3o4z9Kuiw8R5VNigHVunhHc/QaakqPeiPaJzD26+xVLmGLGlJMJSdGEct
EF6dgyccupxQn82+xL9X2PHjzPQeAFtZcPPYSr8FT0luOUXHpCffPyX1Eh01o7BwSAk6LOQnYwsA
e9SUWOmX/WF1epD5TYz7dTWamZ0HmI845kGAH2C60FYIrzf+/gNRLcVyxAr+rLMXNJXEg58j9of3
wOcUt5xizPDkLxrnSXA6YzBOP+/z3gJ4nhdXHTcm+HZud3V6MGFc5lbT04yJ+/WcbRPHdmN4lUOT
rbU3B/e/uGKOWHNbWk0HSLKM5OrJu7TXIqZtKC8uZb1WoxfIRtuXuzGTgNGbcpA4EOYHWPidY645
n5CjmGDMnSyRI/a0P3c2Onq+FmTYulIOu59gfoqzX0ul7PTz4rab1elBvyvRDdMvkJe9i1PREbyP
0SLnTnrQMbsl8sr5s7Sf4fxZaaejukEmX9fllbt6Qv5a2EnrzsEukeHvVHDUsofg2iSf452rTg8W
4W2cRps7blMGm2YYk8vkBZedtEJ4WffFtuYukleeI5bOim5Wbo0B/JrliL1/gBb936lbvHJXT8h3
HM7dRereo6Qv8gopeH/Lz4sr/6I6PRjT7AvszdwTA8/RaZot9xDRa57HOGqNudd6sDoBV+TFNT/2
glSNXhmsMxvtpp57VZ+qvelwaeU8rl3LnT969VH67mszmbZq9MrgD555MDjCt635BN9syGuBg4HE
vNqO8HgIMBttAw4tAnBBDgLDC4HhhUBgeCEaCZza45VjHS9vMLw2z3iwsSORf/cQs9EicO6FwPBC
IDC8EBheCAyvtwZwBSqGVx1gHJJZwtpynN0yVFoEhlcFSC3elTX1vhVz4FIk8FBheK0dW7Vh0LQ0
59HqiuTntY13H2ISjioy0iYjstIDYEuKlsQDh+FVCdRx8m88yzm7+dQVntf2Rcrb6HiaSTw2eYzn
IXr3S9kIGUa/EMu8/CQeuDLA1arhqRUb9XhO0PizBn2hJEZa8CxbUB+/b6/LhuTiMbhsB5babyS1
r2m+FGpOnmMTgGVydK8aedTcEI/Hl70t2Ouujje7Y3RNubXcNdCHBw4Hx0qQGSL/hqRQxIUou5RK
y99sa5Mpi01aeDMyjwcOw6sSTNlJSNq/BjjtMWkzDrwW8SUW4Byn0i5LY3S5iWobL3wCD1wZbCIi
Wi3wwNXpi09bD5Go6VwanAAgf7metkvTi/QdxeBTT37X6qBb8yN3fuvcBOjt7U88cNRvIb1xxLKN
pbQFluEgEa1uwKk9Tu0RDQKuVq018m9ByxhejQLONfDKEYHhhcDwQiAwvBAYXggMLwQCwwuB4YXA
8EKsCdYG6zdXAxheCOy9EBheCEQBcL1Xk829NgPwweMNOLZVhud6T/cmaAAHRwTOvRAYXggETu0R
G3Gdg1P7elw76uxFr3ya7Omw1zWp+tNpvTrb/nRcr9gDXuV7Xc4ohlfNo4sfZPZbcXS5H4wutipX
DV2wVmPbV7egUg+sgj0taxTnXk10M6P6WwKWXrPzoqbWsPeqc0dWzbhahapVeMNt7bb1ij3QK95h
DK96dUgW/bUqvnJyx0byulZV8DSrtF3UTlUelNLB8KrngCdmJmscI6tQ1ddte70elNbBuVdzjI3W
Ooe29Y/L+vpnc8U6GF5NFInVfx1eqy/Sa/2FPN5WrX2oBO8SVHZ4A3ed1qoaNrqOBvS1OF/qvlcJ
HQvDC1HHMw0HR0QdgeGFwPBCYHghEBheCAwvxKZA4Esh5LggagS9RHjhHTBEbWDh4IjAuRcCwwuB
wPBCYHghNhc6V575t941Jfre9OFV2KflW3iPcq3ke0HKvGUcHBEIDC9Ek4eXVWFtkZxl+aUb9MWT
VdK41RL74/lezqVmPvS1IqKt9jiCVpurNuH+6C146Nc+OFqWOJO8M8NiP6ImeMZxSavgTBJivnRD
uzHXeHBv3BerqfeH24KQ/81+6Nfce5V6EoGlh2uC2+5TLTyCZfjBFw2PL93/LXbG97U594faCRlv
9kNf5eCoW+KnoN/Vi/rkor5Z39D+Wi9pWw+/Ntf+WAVHvtjB5j30NXwIgB54SNXqh0u3mmImtsK8
t1n2pwKGbdMe+s7aHgd69qzyaAIr8JCyjY8vPeRTy+5Ps7pa7X0vnT1HRa/mzkXgoqBhR98qGjis
Ve5aNOv+WOu5adTwQ9+5xh3Ty/esfg2Pu7CkbnmVvKahg2OBtaAz9J3wqen3p6SfzXzoAw8B8M/u
Qu52vpW+Fi78zrGVfC/8zlFf7WZWk+6HXubDQDT35wYttooCw6uV0HILdEqHV76FP4JcC/u+vNnO
h85NcZKg700KXJCDwPBCYHghEBheCAwvBIYXArEygjcm8AlMiPqFFz5/CYGDIwLDC4HA8EJgeCEw
vBAIDC8EhhcCgUCsjv8HoqkhLJKlrYcAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-01-05 11:44:39 +0000" MODIFIED_BY="Edgardo J Abalos" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVEAAAcTCAIAAABjVJdIAABZsElEQVR42u3dsW4lx7W+fQIGDAcM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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-05-25 23:01:10 +0100" MODIFIED_BY="Edgardo J Abalos" NO="3" REF_ID="CMP-001.04" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Any antihypertensive drug versus none (subgrouped by class of drug), outcome: 1.4 Proteinuria/pre-eclampsia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAwRElEQVR42u19C3wV5Zn3G3LuuZycSaJgKiuQpQt0tUCNKIFq8LKA
VfQnxUrxA+1HarssbLe2YLay0EUJyifUdtuAEpDqVw21CF66YuJKDhUil3ohFAwXg5Bgkjm5ntsE
zs7MO9dzyzk5t7k8fw1nZs7MO/M+8z/P+7zv/Od5sxwIAEg+RoAJAEAsABALoG8YYt3RRf858Ae7
gFwOlyNkH4fwPb/AbIM4DogVkVcO7h+HdEMw+O9d4oIDmAVN4TDgcrnwB+eiAID4mkK+BZQ7LOaD
/mP+j3YcuCwgVkRu8KFVEMNkO0i/j7QjAIgV7K2kMVaU/bB/ckSIwwAQYwV1CmPmoCt4AQDEGnYU
D7YEDNkUukKavOAYi4vHHXhPh0vmnYRgnVuAJhGIJe3rhesROoI2BW928P86EATvQKxhQDaE4JJE
96HODxwWxFjxMEu6TIP9CLObQ1tuqxE4kzixXDzATjwaHqwBI8SCLMcQMRa0Y1IU5358Q18n2CGN
ww26gNO0csILZicYYmhkW8Ns9FrxH78M4HBpaWXebwxffA6WGJ7HctBhFbSAYbCzEmUh104wxDBj
rOB4C8CA6iP4xabJRrAHxFjJQfv4OmG5bzwFBhlGjBUcbwFof/XZ4h8JKy9VUyezwSbgsZLhryYu
YxdK2H8r7wGfBR4rGZg3ZjVeuGBmP96pfmIbWAWC9+Sh5ALYAJrCZMVXflJYDoibt0BrCMRKBOSc
xyUuXlw8PocE40BTOHxeLSpdTYT9Znnz2zCeBcH7cPHZ6LXheYXeab7qUDVwCDzWMKIrQ/mbdqI7
ojM7NgsoBB4rfhQPmvv8H75oviT6pZI+yffVLwGDIHgfhr/qzqlExhntvnHithNB+3h+BhE8ECtO
GLKXNJ9CiMiZL26bEEysY2vBUECs+FBeeXwdE7eflAyyB4L2IV49/jOwFMRYcWEwa10Z87lgvWiE
/L6gnapPmtfsBiKFeHswQWR89STLKzS5eFDYFvpEx/hMKZgKmsLY0YRyZzWxS4XRh0HLCAQBPDSF
saLmz4d9lpq8c1X/6XAPDCW+8m4ErQN4rJiw5XsLERrI903OslB/kXgsRo/1dMje86u2g8mAWLHw
6sFPyukPl6/dcdlTJvmCGccaF9p/fKYWmAXEiiG+qmN5FQbMONbpMHHWutomMBsQayiUvRqBV+w4
1rgw28v/VAZmA2JFh5NERGgfESOr/+n+0/RfSJxFdw3hFWkgVlReXd8Suu0fONZcyF2VO47+WxV6
XPP1j4LxYLghIrZvXD83ZGNeBzokrEypD3vgth0//QhGHcBjRfJX969bHLKxeM9LvxQHQekYi1+R
jYwu/dcqiODBY0XA7167J3Tj9MUP3r2EHSVl9FhT6smBf9/ArHW5fyGVkDauaXsTOAUeKyxMi8O0
jr6FaPXttHeiAidGZNtXIcJm6mJ5ZROi/Kdf638NFSx87WkwIdvJAWmyrB08XhlmK7ngLRNCY1ZW
Ftk6iHMHbx9xgWA4Vcj8yXZ87bsI1efBuAM0hUGgzl2/N8zmsc3H6AaveteBpwP9ee7ajvU1XrTh
301HrUG8QrU0/144fxhesABiyf3VuX1vh3NYD1cyw6UvvfLn1n5Gj1X9bwcuI7Sh76J7fNCefppY
2X/7+A9bgVgQY0kIVLXPFG57bukDzAex71gO1mNtv8zEV55vfKMraM/n2SDtrSpJX/E1IJYuuST7
XBiWV03ehThCz/rbOrzlVAcbtxf73UHMwqOmJolEPtxzRSCW9nllxMzoMjLMIpaG3enQ97h+onHu
HrwQKGZjd1SI+4YhWCp5IDQOYiwdxljV/W5mPOrQSH9hk+Hd8DG3c8X7Yy/g/wzvf7SNGce6cvQS
7g9u6JePY4lezvBfXJwVYZQeiKXt4J3u2/Vv6KJ5RW403xd+l219ZuE/4rOeMwMrtjb2P/sL3B/c
8Ivwb99vnf7pITq+qt1du2xKZe3uOv0RS/fjWF3uC5Nof1U1MULiDzmIgaLPbujsiaaB789lP+aO
Zt8cQ0+vghhLlyi0TPIWopdj4xUifQFHqzuWFDNvmdboOsbSPbEOWbzeLrQwNl4hWX6s6Fg9H3qF
OkbXRH8x3bcri5VXKOZMkUQ5O4gBvUJdBu9MfxD5bp+CtQoJ47Upb2xcVuvfWImjde/330F1OiWW
voN30kjzannzqwETRSSrTC54Z4tf8EAlAmLpsVdIEgyvCOYzRgyZNVlCLESN/8kyIJY+hxsa18aX
R7Q3f4gdZOML1By9ZinVfa9wxqvx3fkJQ+0gc1HGV/Wa/VbnHqu4I94jrrkY7xGULrmlb4/lz407
TUxWvAeQcxrAY+nMY9WsP5V0bxLqn6g5x3Q4i7SePZY/Bbz6YuBc8Cbj6rxG8Fh68lj+rGHxKlrM
dPHDb1y9/acdxTk90q1FF03gsXQE03B4VRLGJ4n+yja1J7dvz+d9Xov0zdVO/fFKRiyXyyUuuTRe
8Xp5Bg8yd7TLkB/DcScO1xcMGsPvec7enX9L0aJbrrL2D94p/8pZpF9iuRwOB08nelHb9W54WJZX
m7rq8snP+3yWITuJX0y4d9Hh/t0+a5g9vyjovm60sfu6noJzRptX/t1xs1O3xNJHTxDD8+hLM6T+
yprrsZZZLw6OHeK4i4cDRe7b3dPPUkfDfNd9HfLShPs7d8HFrqnyLyufXFSs1+CdoROmFOO3HFom
WcOinRXS9dzLHvYz3++N7q/sWzddYD937AnWslMDB+bS5vqceQ/6relec7Dd/F8/ZdQ9sbglIc7S
Grma+uSzdo0+icVB1K0Hoh127sjU0j52z3MFy3/FfE47iJCd/5ZuCZGB+Z7er8RyOfjomslleieW
1FPpIncD9jN0k1h0Jdo4A+2TXAGsgzh5dRZHqB676M+6r7N7+43MZyDHjXQNidCPkfSJsj5+SXtC
v+L/eyh4U94m3Er9pzEQzVbt48ktT7J7XjzqOGTBW30W/vtN7QXkU+YRz/X/qmSE+UI46eDyd3ST
1iF88K7lGhfnhua/yrkbzxtuMEc99Loe28ZSZs8vbGd2hf/+nJvqvdduyfmiMGwJC9p12BQyfBKD
K60G78W5KyWqTspgCGTl9iArRQ325RnMX4yKfvS5ghEEddVHBVuq3O6QppD9/tJnU6+LfDyrKtRb
U4isVmbFKixpsim8Wsqroqup+hrnNtNX6+woa4PRmjfU3IObLu15xXWkePxv87y+kKaQ/b7wV1F4
hQ5957dn9Oexwse1GvNY0id9lDWXme6ZLM6PvfG/ppnzST3hPBZCXYVRDye/3qEPYunrWSEdH0nH
klYZ2WnEiX+NoweX1XO1tK27oYf+/4aenhv4DdF5hYgOpI+pwnTlscgFK2XjV9kOLJQq6h6M3+cx
+gVmGAuPY93wcczH1+9ZrYM4S08ei1owcbJsQ2cb/jwVV/PE+Tw7jRP2mXZ7vJeR17yGBGJpCOSc
cb/JkikY7j6IPwNpfYxX9qpfB8zS0ZvQ3vetL/7mydvavxIGKXtf9LK5268cpWIupUQ+J/TIS/LP
WFD97m+z9oLH0gqaDnvemUFY6yS6hB7jrflFZFv+pp7YizmRhEsh1j0AwbtGgney+a4A7vvlT39H
cosHBjuHyHcV7LHkb0LzQXscwTuGsxw8lhZ4tajO99940fyudLvvcoz5rngEknRF/+EHYmmAV2tH
L+yYhpdPJvYuVvB7hT03sP/tj5tYXm0zSxdNIblo9DrCkI+7YkNortIGZ9VDWk5Fow+PVbqEQLYB
3PVz/FUZ11S+bpeWBx10NPJu8w1edTLvhX9x6zVPR1qhg3GsLTvwwBVVMP3Ez/Mb+hLjVdA4VmKg
du6GplCt8AvJGl31lx2XBxL0VyeSeW2HarcDsdTKqzuS+8h3QjILK19y/3Yglkp59UxyRyIDSS1t
8SfbNPoiq0HjxHKakvzOVVZyiyvXqseCqXsB0BTG3R+sUUdzrcXWUMtN4fZt9aoYstr+hAbTlGrY
Y225/6kU3K+S5Be59D2PE4ilnrD995+kQplyIgVlmv5QpbmnOxoO3lOjeCq5kIpSty8GYqkDZKpe
hIk/zzv0CrXUDt7XlKpfYqqu+DFttYba9FjOJx5RXduywrdOS68batJjOavUxyu0ybxASz5Lk7IZ
891qjIUPfqfjTfBYisa6FPKqJHVFr54MMZaC0VSa0lClNz+VpVN9WomzNOexmh7fldLyJ6S09MfX
QFOoUF5V7Vua0hMEUlr6k83PA7GU6a/eSvG8NVkpLZ3YuUcjrxtqrFe4+6+png+pL7XFP3v4RHM2
BO8AgA48FjlWG+NA5J0vQYylpPtRtTcNQ9clqT+F/wc16r8b2mkKyarWnWkYBErtOBYGNf6FWdAU
KgW959PBKzS2Lw035c0lG9Se8k87mveb0iMOCKTjJOWU6m8H9ArjjbEugA10FLwvT9vbCGnj1fZi
IFbmedU8UXM/+dG5qn51RxPBuybn1NrR1n5SxWPwWvBYNc0708erkrSdybpqPAXEyiTmvz0yfSc7
kb5TVfT1qfemqL9XSKa3FYReoU48Vs2i9J4vkN5fzVwKiJURbFm7Ks0uPq1nI+6do1JmqbwprFnr
60SaRs2ut1WZiiaCx1LJPPbt618N4pXmkmtUPjBPQx7LJUxir3CPFRy5U4MGzaWaIgnNEMvlcKmB
WM6JwSanBq/907TUMisTvcIUv9GWvqZQHc+d6xfkBfPqoKFz2sFo0S6ZcIt5IgM1PbZIfS18hOAd
+ymXkpnW+PCLFeHaQepgZJ9F3tHagaYeQcWj92EfQHp8PrPlGoV7LPRY6061+awIzwrxE0IrDa+D
/keJ/mqK9XfB/mobw6jsLQe3RHrGVr3bOehuMRWPbl3NrndZV5rsWVeWra6O+bx5mRgNf/fTFz/X
ksdScozld1ZEituj+azi0cuebx29bDH2V5ZuxllR5+PwWRkaeX/spsUa8ljyJYVd+I6gVu6X3c/x
X725b2MkF+Ruveg73sbpfv9lJftIOfvngf8X83kz9PjusNpmc1KnNNnZEvL7JQwtfFJr6vWIHmvq
/pn7Z6Jp+2ceYdZ83I+mmLKpoNLqylMaYYBU2f1CapEvdKNxItcf7IrSEh7JaaWZ1ZrD8gqNNGfU
C8UH8uUtGiCWotE+/p5wk94W4pEGyhZtJIuOsWZuHr2dK8gX/8lLMlVrYt3LakrroEIFKbX7J6vD
14XpD3J9w0i8Ote2t+X3rRcH3czaz71PbsCxVuwx1gVzpuq9te501V4gVupwpPRHkSqz5eDe7mi8
IvdkedHNbdmDo48z0f3GFd6fr+/5+XLfNbFrgMdmrt3cWvfFO9AUpg5lkSd/N048H/VZIbGvA1Hv
O1EHNz46xnKFslgC9jieAgUyWfNl6rlLapPNtD8afQw6+hNbymDonJT1wOYELiDDClJn81J1EEtl
Hot8dIjnsVG/LbbZ/mecee4vE9HOZVqZ/OAWIFYKeLWodHUCUX+3zTNj6k9+8A8/RapF+ScqYZa6
iLWmNJGZww2GHrTdt7DsoTpS1czaDr3CpEcY/53IQ35DvptcOe0edOrzCcPP0FaS6dHUbR+VPQse
K7kNITImJB7pbEN1ppUIncpdry49VpDPGqmGm6WiXuGKDQkmrjW8P2nqyko61rKULxx230oR7xU+
trBc6cRSj8fyH/9rgiXkzMotnU9/Fpr2HRt2IQEl2OKbVU1ArGTxau66sgSL6DF6J4wnqYD7g6w9
DcN28UowRuW+x5WeikYtwbvzYsK8QuhHJbYPf5ZvGdiW/dSHh4ZZhjKUENlPbD5WDcRKRl/ocGni
5Fz7vuv8pPOj28ZeOPnHj7ciNePNl78OwXvioDT3smBSeslKfsFCFTHWljnKGdEsUcyVpG7ea714
rO0vJyG+ShbSkec9ff0ZXXusLbWrFWS/Ccq5FNNEBY86qIBYx59R0mhgQEHXsnniMSBWAuZTlL/P
UpRp5gOxhhuhKi3bubIyRRKoiARiDYdX1/8JhhWiYuECEogVP6+qXi8H7kTFatMaEogVt79auFhp
11SisOshdjZXkUCs+HDTJ8p7c+CE0i6IeNWkxHsHs3/F67Egz3tMUO5D6CbbISUaLE+JiR4UOBu2
YpvCpqpJiryuLEWyff3z4LFi5dV8Zb6ZqcjMNNkdp6rfBGLFgnPzVfLGr1KYdUJhzFJqU7gOeBUX
jKcUFjkosleoZAUb9ArV67HIBQp+U+CEci/NXwPEihq3L5ik4BmeJyj30prW1kNTGMVfrUGrFdwU
XnNRuddWlNesmIQIyvNYuYrmlTLHsTh07pzYDh5LlaG70qGc15mU5rGoIXKnAaKPOihmxkaFDZAu
n34Q2JHYL/Pjk9lKuA5leazlzU8q/caVKPz6jPPHKyLOUlSMtbxF+bOnKei9wgioWX9KAZGWkjwW
laWCWfkmKP4KK08qIceqkiZpMm7apPwYJqD8SzSt3pz5i1COx6qhkBqQpYJrJFATCcTiebVLHb0u
dTyDzvws0koJ3rc8fQpSFSWzH5Tp5xcK8Vg1dcCrpGJzaYZfN1QIscw71cKrEpVc5zLUDE2hmqD8
cSxlQAmPdLZ8Rz3zO2ZyvsJ4QY7bkbkEuIaw3smF0jgtNKGquD2gnktFx44rI8ZyiYsOR9p41WDd
qaa4PUs9l0osaV6RsQheEmO5HLzHksZVqY6xinNfmAURSaoawyrT5swTSySRtCVMefAOqbZTiKa/
LlUUsRzcn9AypuwnBao+jSLsOJZDjLQc+J8UwTm1XW0GK1HbBW/ZohxipQvUohdGqu0+nVDbBX+z
brtiiOVKE6/Gr1Rf3D5BbRdctvr+TPis0BiLC67SELwvn1ipvthBye8VRorgf/pU+jO5jgiJrRwo
XcNYq1XIKzWNYwk+69kMvFmesWeFVB90CNOItHe/MxW8U3OOwd1OI9KeZyVDxCLn3APj7enE6iec
eiAWueCeZSq9QyXqvOzyR65PL7MyI5v5jl2tvEIXzOq87t0fvXxYF8G7WqHejH7pjd8z0BSSW9RM
rIBqr5xAZBrfsMtAU+i98F8qnkE+v0+91z5uoG6rdom1wr+uVMUeS8W8Qns/P384XWLltDeFK3xL
YGQ0UzBNXkBplVgTFDzzuvax4a390CuEXqGakV6P5S9WvcFOqL4G9aTmiOWf+5bqb8sE1dfgubTM
Ip1OYm2Z+6r646uA6mvwkikdc/2mcbjBP7C+VPV3RdXjWBjVh7Z/+k7KRx3S6LGy/qSF/qAGYndi
ZxpmCktbrxBe9IJeYSqwvQpsrSQ4l5OaINaW+xdq5I6UaKMapc1rtNAUOqvWlWuEWFrJj0XNmZjS
tA5p8VikdnilgXEsDOPOZr/6PZaGIncVvlcYyWcdK1M3sZwTtdQh1NSzwhT+4FPfFDqfaNFSd0pT
z6AX1aiXWM6qR0Ano1SsWpsymXiqm0LnE0+Vww1ULIryUpVPMdUe69gjGuNViaZq07nzBymSlILQ
L05oLc97quL3lBKrqb9Cc8TSoII0JVlgU9kUNlW1aO4maECPFcKr8cXqIhZVNXmp9oiVpbkaGV80
pSCtQ+qEfk3nH1ilwRirT3tV2rF7idGtHo9VOr8SAVSBWauSHzhCrxCQEqTIY5GPNWnUYCUardf2
YjUQi6wyafU5zgmN1suXSymfWGTV+dVadfETNFqvynvGJ5VZKekVerM3a/bVibw+jVbs0C+vnMxW
uMdauFq7r+RkabZmy+5JZiLrFPQK4UUvQCqawuV3Z4NZVQoysDfGV6RdXgZWyUKqm8LnW/rhBqkW
fYtifd2QmW3Q4ZIupNZjPb9n77OaNn1Jn4YrV/3ukQNvx+SzMC3of4WF1Hqs4j2vanwm3hOarh2x
LrBWkTGW+7DWI/exfZquXvU7xdti8lgsHJKFVPYK9TBvuHbeK0wI/LTh4kIKm8Ln55Dat2iW9qv4
fIyvSAshe5jYPZnEqtnztg5GsHSQ23bh3CS8FJY8YtWsX62DllAPINa9HBuzorms5AXv4/bugHui
DWw9tualIUJ4K/+vVbI6dPCensnGhxEvZh7MWzrat0n83bDgKxkRfqdwY6nRUO/Uy6/5hC5qSfMq
QaVmWGLF/TNofFg3zcQEndSTfHx75oP3+rV/0E2ChoBO6kmsuz8hZkUaIMWDXzEWkj3+hF54hb7x
mW5884gr8dxWRxzEijU8TI8CC7oRab6SuG6rKzZiibvB7YQrSVqvEF4mBCQKQ1heSQeyAIAkBu8A
QPI9lnTonV/KZOuotAcByogU8FVkvG2RXYZ4NYaIO7sc0iVXhi+du5cuRdxRpJyriCSHysxlSK5m
hJp+o+Cv1HNHYiSWQiIxB1yEWu7ICAQApABALAAQCwDEAugc4YcbHHg8gg75HQoYgxevBhDBNgq5
DMnVwMg7AJpCABALAMQCAIBYACAWAIgFAACxAEAsABALAABiAYBYACBWFFD5S01Lc9v41YoKsBwg
GcQq+NbD/kVlj4C9ADEiO8aEfX/3rK/2bAuqGHOW+RuDugMWdzaVv+TMLWPOVoz5yjCI7AFDjo/f
oWJMNzJ+VV0cyM62FLjBzOCxIsCIplpkU3BezrlpFTLctAvPcWf+ANmn5ti+lS/ZwXLzaNR7c7/9
pgGwMhArEno+RLf8o3QOznMtqBdVopZWdq2lDC1Ap08jSR7nc2cQs3v+/98FDkuPCBH6hbyNiXcg
65bfgg4NVKAGRP+xH06/ebqwhthlp1+6QyPlcE9HB3LI8AUDtIRgHhmG3AODQOTRpyjUOAORD7BE
Q9IPxC2PQAemI+zXqD56zUVai6c7o5UL0AZcQ3ussASY7XvLWvyPhwZm+z71fYtxSIcN3zzcm/+t
v3bN4jyWfeoxNPlwr+WWNXdPZXfInlyfZb35k7a7zO+A3bVPLMfwYqw9TctN99W3otf/cp+Z3XDp
gQ/PorMH3Q50AO9x9sh89+FetK/0TpzJ+XX3QRe6cG/fjw9uA7NDjBXfuzCzjpzJu+tguOCcdWIA
HXushIhFeKkR2T3hcs0bR/jA2LomliGR0tjuXtg5DCgwtc4RMcZqs053TbcWg4UASSVWYLLxlOO5
bJIAE4XiaTDBcImVaznf24HK+nN7qciNoG4xDngzTGI15vbj0KnHWMh18yoqzJKG8WvyLqD0I3iz
BnFaZqscUz4VptbRqx+DcSpUbdzwxLrTzYfk7z7ILTQ0tFnuE3aYBh6Lj0Xv6Gw/W/Be6E46H28J
Tyy/WWDQi+LggmsH3d3LNeVQ9O+lAhVZTRauj9lkzeGe4+Qw36ImixnHZgX5qCnHZGuif2EFFnrd
QtHfcWWgCvts5DGZLY3490f/NZpMliL8g7TPNnmE8uiDTbX8uRXmsZ62WonC7llIYo/i2Uz1K4Rq
VTjMZqLWYsI2oWYzdUG1Zma9qNJsdjAVNJs9EepJWW14hrcmm9lGCsezxqXtk0vxxp1NIcoitTdh
Nlk8wlV4TMbZjdi4Bey1cOVx5+aOSzGxAh38krFT3OqgL7/Q5TcX0r/GBjRA+m3c2OiNFzpxi1n4
ht9EL91mPedhq+7qRTe+7++6kV7OYmZ/N32A7jQzZTB7oeyXUX6uL/d24QSzcv37+rnll+vzhfJQ
4GJ9JRKOyyT6X3v6tf5x/a/Rn3hDDcMyYxaS2MPzYb9cKkS25XhXXMzFGw3/Zn+M/ljexqz3f9/X
zWy+0tZdEKGehRdsN2I+mH2W0cLxyLGmFxW24D3bGOO+fRW62iS194DNbxM7XwVvU6/fgRevsNfC
lcec246E41JLrJuFaIoqQkKQNZk2n8+ISDz26bEicjo3OkZY8TbvFHTai9Dg6VEMsQp8LtpJlSEr
IyY8zVTRMAsNvsmU4WL2byGQ2d94ShxKNfoaJ3nx4llixgyhPGatHAnHZRK531313dzTud+lP7nf
IH/rRHv4zxjll+kiyGlnCe5b85QOpkrn2HXvDGQtZ9es0yPUs4votLALg6dRCyUcX+BZRO85Ct8N
D3MRxRTymaX2NlBEi0coJ3uWx8MZF5+bK485d7l4n5KFEAUpOwd01yDviou+f4T9HNNw9uwf/EfQ
t8eMGdN6GY05i8jfGUdce5b97oc0Zdht3/4hqqaX6A9mc/Mj92WzB5y7wu6D0IXNlxf/s1AGvWnA
EljkcDOHMn/tz9Vu/HIjX6RYHr+Gj8s8KuvE5Uf3VTM+qZq3B75qxF4wVy328nEVaHDf4nWqsPqD
a8/ya/J64t3HtNK//ivMykzaGNmCcX/43n9kSy2J0JfPDBp6pPa+tNHb2SoY99Kv/+nHhFtybq48
yUnp44aLkKnDw3usHq+dc+J9N4tbb6JjLGdDQwOW85Ug037erfHDD04SkQGEDuDVrDoD/Q99gBAw
EEZ7vrQMZBxYb8ONH9O+Fw60W78vvQ6uPH5NPE45MVYNE8kXXSO1h5OMNi4j/RblX8nvDd1DVs9i
RGazC7RVyRnC8csthqA9iWxHtszehLu9rle4CsL9So3sXFx5HGT3KWVNodE+YPG0IcpxlWWJJMbK
ZsPv92x0mE2iK39r4aMjO7LiaN9SisbRfttY2sYS2GVrQ+9RiBDZvHvqNrYMhw2vWzzEHtoHOQmS
KcvaSOxtlF4HVx6/Jh6nnF5hMd0MFQ+8iST2MI2lsDmcjeSYkINNR4vFKl3uujc0apTX043Gm9iF
DVZUekg8vttajCxt0j1Nk+nQWGJvq4fIYsZDPOR1zBpBPCibHpYrj4P8PqVsgJT8ylRwrcvi3tov
DJzQsV4P3UgWGDfm0A39SGR7ZBR/cI+l+ByOB3wmfxdNKPcY/LMi/x657GaP+EPJd7awZUzLwet5
hKmC7pfnDoxifpU5d5hn9UgvgyuPXxOPU47H6rR5TX0mmlKiPazeXDz8UF8xKtS+1o29+4SV+rxR
r4fsIa+nbbYHG/fmQpO3QXJ8rht1/b3JK17MV046opLY+13CONCNUIOdvYp3bzLZc2WBNC6PjwNl
9ylxJKRuAAAi0QbehAakcYA0UuAJACTeFHp8ZisYCJDsprBt90e7QTQT2YuDPx9eU9ho/fEdXzvj
AQvJ0GR+hf53Kv33irkJzDEMYrV9aSbRDHMkn0Um3wOoAmXH76WZtZ9m2L1vlAF74ieWx/pjJr6y
Cj4rVXqskij7VSiVWTPRK5PeeIjb4qhwyK61IkI19CNXi0Kstt2fYlcy49PdXFKsFOmxblabwRhm
7af9Fc8rRDXBmyOxEqvROo9/iDTja1Y+zkqCHkvyQ8XbmYKQYxanvRK1Rcwa6wjss3k9EWUz17AH
Z1h3VPbGvTNFf4VIf6sf/wgrCLONMQNhYs5TbDVxRkDFs23YPE029txYr4XNI9Gm4ZrNRqTNnEPi
mnF14WrG1ROJdbHxNmDqyR2nYGKRXx4QxxlmWHbzV5u4HkuCG81+SwVbELpSx2qvurG26Dl2x0JT
O3va7Jf5AwqNbUvZhYzqjqYOTL135v6ZT9GfeEOpjzCV4sWuNvaXNtjOnKc/x9/NqbJ8L+fgX+CN
FqbOgl7LQfVy9uTqeeAqdNVf0Oge358duGZ2sS40JPXE+i2uPK6e/HHKJRYxr1fsDXr+NI/ggqzE
9VhMjkkuzaSlBauBEK+94ku+l93Rd5r4iPlsERjjO0vgzBMZ1R0dyTnyxv6Z+5+gPzk2OZCRExgM
EpLzeDqRlTNPF9ExKK0zp9dyeM+LtWbr+ZYfUUY0aEQz+JqJdaEhqSfWb/E25OrJHacMhNVjGX89
bUUt1yrOuXUz85kcPRY6e5YuiF1idsU6oyAVEt7R8BTaKn7H/NFbqlmJUkZ1R3T7M+ON6uMzdv2R
8+6bbhoz6mwHc2VjWqXn6aoxGK4VFVWCeR49wpvn/JWfbJDXeuMzl0f0opn0pi/wpku/Nj9LiDXD
9UQyuRpdHl9PfFxmEKMea9S8L/FPo/HLr40Stiaux5Igi95VdvIDcrUViYJVTSTCsVFmdUdMf3Am
HWe9wrWERro8Yylvhixhv2tRJ68lKOK3M3XeISiq+i1jghVVxgKDzBCEu61GWjO+nhIb7ohkQGUO
N1hv3c0wy/Plj8Vbkgw9lvjyyqHjaJxR4CANcxtyiGIR81ghoRanJzKPQbfjVFuZ1B2x/cH96KHj
HLO6GK2UaZAjUKnYbg12enh5sQeN9/J1LjWKeq1uP8Xbk4NpCl0zI4Vq+ZrhunC6Lq6eIrjyOEiO
U/AA6ah5NLM8u+cJ9z05eiwRrXeafXQbYRzJb2C0RaJduigzr4Dj9ERdg2bufBnUHTWx/cGZTN+w
jvWfVkYOddrHVneEyfeRsGdPnmAem9X9EV9nb6tEr5Vr5+3J4dIBD1MP02MfcDXDdeF0XVw9ZTb0
too/WfE4BSDyQ+i2/ynqvHWUosZG9v9TxvOZijkHQrIPVOj5TcJ40hh5fJ/OUNClB25vNHYbFWxb
kx+INXRTyHj5K0riFcqq9w8omVdIz7yKpykEABLwWAawSZzo6kEj27LshWCJ4fQKe264oYf974Ye
sJEMF60Wq2205St48jy84YaPP7az/30cqXekV155vdeMQsZr7NRwLEAOuU0zdo0QY/XYBd+Fl6wW
F0IO8cGV1SPrXnPLmu9xU5SXG2U4ayrBC8TAdGePdai6428t3iAz0UsWr6zHpFLN7rBf/7p5PonI
+beI6/p0WOe7+dErc4DnVXfDewVFsR3O2U+kYIOwTWt2jfm9wnwrKq1BoToqrCFCrIKqVvgeVdSa
GBESl/+J/q02MSIqieaKy4UliKjYPFkIi4saxcxYQp6sXGUENcIzFQvHsIFuK5qZMyip42xJjiv6
+pmcYNwTBcZqTN0rBA1VhbAN67eYNUFXNbTNrKLNahVms5iJ9eJIdJmhCNYziToqRkPETk5RaGpf
jHidFULL2vcUivmfkOku9IFZms9JmgsLSfNkBS7Wz2JK87/B9lhxnqyWzGfGYjFSeBRBcMra6Qxp
SPZJi/lOpo44f5Wos7J8gO408f6pgdebcRoqbhttD6zfYtYEXRUuT6JTC7HZu6LNmLxaRpnNujNq
s5iJ9ZUP+ZnxSYmeidVRmentbzFrvtOsXorXCLmIKT4x/xO6RKE/vynN5yTJhcXYUMyTxeWIOo2m
WJCg1RrFq8AyjHZh9mJS8rSrAmvMjBSa187lrxJ1VnvnocFsSRFYb8ZpqDjQ9hD1W4Kuqn0QzXpT
qlMLsdkkuc3OyGxmzKjNYiaWMdB1hcnzN522Iif6YS3UcYUcnMStMhum0x+M3MmIiNtof1ywGbPQ
8xD69Qz24AA+shXNGtUmxn6BnaOKJKWyxdwmrnHHZb4lFJRc3kvi1gYcNHUuJCkPKiekV0ygGRT5
UIukCEL2Iax02XO43+st9KFXOJtZo9qsItRmSCk2iz13g5Fg3WyInslznYHgesrM835eZ9WEyPcl
+Z8IS4FHpj4Sc2Ex8YSYJ4sDo+wSY1zFZMay93I3lvRyGv4DrLwI63n+cJ2R4NRWkiv2OiwxvPgr
6rcEXRW22YHINrsUajORShmWZ8VBrEr2SR2nZxJ1VM4HcQRhPoqYFp/TWdHLR83S/E8vTaGtK8nn
ZGkk2hqZ+0Iy8QSXJ0uErxQdFR25PA9UBkFcZb9wkb5/F7vNXFPYXUA3YwWYE5f8u/n8VRKdVaHl
JcFWYaJpbhun36LtKuqqWJtJdGpc/rDYbCbXtymGWNzAe88NM/kte1r2sg4Y65lEHdWklq/Yz655
ZiaU4HRWKNs475w0/1NH42kkzeeUe4fZXk/fF/tIhnlcniwRgz7jvEFhTZ4HKpMo9GYFLG6Lz1rC
DzzlDFTYubdjPLfk8/mrJDqrluliquDcMD9YvI3Tb9F2FXVVZ3ibcY0klz+Mttn22GyWQd1f4g+h
iwY8EQcEdYbGO8OZovEuHcyKHUKb8MltuS7Qs7EUORhWJHXhsg6J9YornClaO3WQASPEOUbxWJRn
XAcChAFMXTW0x4oSvN+HFoLBwoGygrQhgV6h85XXj4IBw/HqYPdgF5hh2MH7HZM2zS3dDBYK4dWg
wcj8gSWG1xQ2tjyDVu6J6LIS1w2pVHlEHaQ5ZTQMJsWZk0m1k6IsGtFj3XHPMvqfyRu4zcnXY1m8
kXdX7mAF76sEn8U8JXRmf1A2rIpgG0TfSa7XilZ00D1Rpsfa7mMi99WH+F9B8vVYt6jWXzGgfRYX
ZzU0NLSbvj1sGzQM106hBypKyxVpZoraaUyXurxVmI4oQT0WkmTGYvNVVXAZn2TaJUk5nG6JzYyV
Yy4QMmNlNH8UNTiNj62MBps4RdDZy4L+ia5dgThVIRLmMeTyfjXONpkLeM0UVmNxcxdi3RZnN6GO
ZmYPMRcYUw9Oh1Uh12uhCLnGuDxduFxeG5aGeSMjEKvOtJL9XLmLvxUJ6rGkPpzNV8WWcLlNOj8f
zoXFlcPrlhCbGQsnMMp0/ijy95LBYGP3oEDT0mxB/3SjqU2ey4bPI4brc+frfhtLfkYz1cC5HXbu
Qk63he3GX+uuNmafG8/7u24X6iHosOR6LVmuMVH3xufpYsulz3EXm2wi9fNGhicWuf4BfIfm+3dx
mxLUY0kyY/H5qlDw/HwthKQcXrfEbDmDc2VlPH8U8f0WycynLQY+cZjJ94Ggf7KeIeRjEXweMVwf
es01nbcdD/b6ON0Wtht/rVPYgywEsvqFegg6LLleS3JPpLo3XufFlkufg2pHaZk3Mjyx6krnc6Zc
yLeFCeqxGM0SJ1u6hd4jIClBqjgSy5EIlm4jEI6NJw2iwU5Br0Tv8GVOwUgx4+75K/0ri2UF00X9
H2FN0DkNH8aJBymhVZxo5Cq2ZsT5MqEWDxNIPhJB2nMt4iXRa/8srx2/wum2sN0kdZTYHK8JOiy5
XiuCRXmdF1sucw7mp9diQQ/JlF4SPRyS6b5weeW0IbNQXEqvsMRq+t5CvuIPNDt5oyakx5JAnq8K
hait+DxYQhf6/SauJ535/FGF0zhm0VG80BrM+O1osfiXSETJev+SPGI0rskyPRehbKzbwnaTX6vc
5oIOK0SvFc6ivM4Ll8tpw9Iwb2RYYn3ze4uFX8DKNXx9EtNjid0YLl+VqE2Sz8/HlcMWjfNC0bGE
gw3jFJA/yoiZJYniaSxBom7KMxYVOgXNFJLOY8ggYGyRvHwu02dh3Ra2G32tHouwz3tN0pxeog4r
SK8l3hOJfo3P04XL5bVhqZ83MhyxqDGrxJUf/pFzWQnqsSS9YpyvStQmyefn48phwOWF6qJMXNup
gPxRLLOEUQd+BOkmktc/uXxsGi9OZ4ak8xgyyOkfKWkFZfosrNvCdmsoMDn6hH1ct0pzeok6rCC9
ljzXGKdf4/N04XJ5bVjq540MN0C6wvdbyQb/49Gf66RFj0X4BhQzQtPVXFrgjtYrIrzDEmCxuq1U
jXBy5Ra5U6QNi0WP5XyQvDBW/K+94/OouqzU67ECluwrPdmKIdaGLdfvjmyRnx7OvvzB1uGUy+q2
UqVj48q9OVXasHj0WICI41mgxxrSYwGxACkhVoSR964wSwBA7Igw8m7q5JY6T8KEj4CkEYvwmTGz
Os3jw8YTqWIbsFgriBRjdZr7rqH/PTWeG+ivQOjAiFzh5QqbO7QrG9xTHk7PmS5Xj2m39BNjoSJf
Xifjr4QHSCmarzAI0+AWabopZJjlN1/4rF+aUCwZ8xVSwtyBrCcqMJtqG3E+LKFcPN8f1hoxZdtm
OcSSmTkBm1iN0yycdotClDVo7kJrlLkLqeTOXQiIn1iosDd/knxiiiTMV+jg5g7chR+eX2mr/9F3
cD4soVw835+ZzafFlP2bOmZsj8+X1dXGKKzocx9jz+C5Cl1tFPRKeO5CqxgV2oPnLnSIcxcyei3u
OEA6idX5Ra9FMnllcuYr5LVYWGeEuogZN5/hNT68qoid78/oZ3JN0bDeS5xDYr4sPCcgc25WssvN
XcjplULmLjREmbtwuqhzAiQfEV+x7zRvGtln6+NfpkjSfIWSuQMRnskvaLZCfopC95J9G1zMLICP
fJedppAp+Y4Wfk5A4dxh5i70yeYuZOf7Q6mauxAQTJshPVYnE1/RcZZ0wt0kzFcYosXiEaLxYXNN
IUHfxOfLwnMCCucOM3dhm2zuwrZUzl0IiLsp7DR/g4mvCpm+oRhjJT5foVE2d6AEYrkc2FxTTIs7
DjE9CD73E54TkD43N68znrtQ1CtZCTx3YWP4uQvl55frnACpJxZ1ylfEjTqYKT7GSsZ8hQ2FJk/Y
QSmxXA5srimGnD4Lcxo+9xOeEzDnkVFchxTPXSjqld71GAfochpmsTqwkLkL5eeX65wAaRgg7RL0
Rl0ZyrwbPtcUDJWqZYBUseoGc3e4RsoEnTiVEGuEUq/UFzb4AV6pfxwLAABiAYBYACAWAADEAigK
oXNCu8AogMSRBS/lAKApBACxAEAsAACIBQBiAYBYAAAQCwDEAgCxAAAgFgCIBQBiAQBALAAQCwDE
AgCSgv8FknOxvn8Ezf4AAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-05-25 23:02:50 +0100" MODIFIED_BY="Edgardo J Abalos" NO="4" REF_ID="CMP-002.02" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Any antihypertensive drug versus none (subgrouped by type of hypertensive disorder at trial entry), outcome: 2.2 Proteinuria/pre-eclampsia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-11-25 12:03:24 +0000" MODIFIED_BY="Denise Atherton">
<APPENDIX ID="APP-01" MODIFIED="2013-06-17 11:32:47 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-06-17 11:31:34 +0100" MODIFIED_BY="[Empty name]">Additional author searching</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-17 11:32:07 +0100" MODIFIED_BY="[Empty name]">
<P>Additional searching carried out for the previous version (<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>), </P>
<P>The Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> 2005, Issue 3), MEDLINE (1966 to November 2005), LILACS (1984 to November 2005) and EMBASE (1974 to November 2005) using the terms hypertens*, pre-eclamp*, preeclamp*, pre eclamp* and pregnan*.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>